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Abstract 
The structural characterisation of aggregation-prone proteins, and the development 
of methods which allow such investigations, is of paramount importance to the 
prevention and treatment of illnesses such as Alzheimer’s disease, and to the 
development of the next generation of biotherapeutic medicines. 
This thesis outlines the development of several structural mass spectrometry based 
techniques, including hydrogen deuterium exchange (HDX) and fast photochemical 
oxidation of proteins (FPOP) to study the structure and dynamics of two protein 
systems: β2 – microglobulin (β2m), along with two of its variants (ΔN6 and D76N), as 
well as WFL and STT, two biotherapeutic antibody variants. 
The first aggregation-prone variant of β2m studied, missing the six N-terminal residues 
(ΔN6), showed significant structural changes compared with the wild-type protein 
close to the truncation site when examined by FPOP-LC-MS/MS, consistent with 
experiments performed using more well-established structural MS methods, such as 
HDX. A thorough examination of the data revealed the presence of positional isomers, 
generated from the oxidation of aromatic amino acids within peptides, which showed 
oxidation patterns consistent with known structural changes observed by NMR, 
indicating sub-amino acid level resolution may be achievable using FPOP. The second 
aggregation-prone variant, D76N, showed significant structural changes proximal to 
the site of the amino acid substitution when using HDX, but only minimal changes 
when analysed by FPOP-LC-MS/MS. We hypothesise that these changes may be due 
to a disruption of hydrogen bonding networks within the loop containing the amino 
acid substitution, and that these differences may lead, or contribute, to the increased 
aggregation propensity of the D76N variant, relative to the wild-type protein. 
FPOP-LC-MS/MS analysis of the antibody variants WFL and STT, so called due to 
their different amino acid sequences in the heavy chain complementarity determining 
regions (CDRs), revealed long-range conformational changes at the interface between 
the two constant domains of the Fab arm, a considerable distance from the site of the 
xxvi 
 
amino acid substitutions. Although the relationship between these observed changes 
and the propensity of WFL to undergo reversible self-association cannot be 
determined from these data, these experiments strongly indicate that conformational 
changes can be transmitted between the antigen binding region and the constant 
domains of the Fab arm – two regions often considered to be functionally 
independent. The large data set obtained from these experiments allowed further 
development of the FPOP experimental technique, where trends in the altered 
hydrophobicity of modified peptides, probed by relative retention time shifts of 
peptides following separation by reverse-phase chromatography, highlight the 
possibility of using such analyses to aid in the assignment of modified species, when 
coupled to tandem MS analysis. 
Overall, the data presented in this thesis shed new light on the changes in protein 
structure and dynamics associated with the two aggregation-prone variants of β2m, as 
well as the aggregation-prone mAb, WFL which may provide key insights into the 
causes of aggregation or reversible self-association in these proteins. Similarly, the 
work presented here contributes significantly to a greater understanding of FPOP, the 
application of both FPOP and HDX towards the study of aggregation-prone proteins, 
and provides a foundation for the further advancement of these methods in future 
research.
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1 Introduction I: Mass Spectrometry Theory 
 
“I feel sure that there are many problems in chemistry which could be solved with 
far greater ease by this than any other method.” 
- J.J Thomson, from the Preface of “Rays of positive electricity and their 
application to chemical analysis”, 1913, [1]. 
 
1.1 Overview and history of mass spectrometry 
Mass spectrometry (MS) is an analytical technique used to determine molecular mass 
by measuring the mass to charge ratio (m/z) of ions in the gas phase. The earliest work 
in the field of mass spectrometry was done by J.J Thomson in 1897, where he observed 
that cathode rays under vacuum could be deflected by electromagnetic fields [2]. This 
lead to the discovery of the electron, and determination of its mass to charge ratio, 
winning Thomson the Nobel Prize in physics in 1906. Later, in April 1912, Thomson, 
along with his assistant F.W. Aston, constructed the first mass spectrometer, called a 
parabola ion spectrograph at the time, using the same principle of deflecting ion beams 
with electromagnetic fields to study ions of neon. They discovered that the neon ion 
beam generated two different parabolas when deflected by the magnetic field, 
suggesting the presence of two different atomic masses, 20Ne and 22Ne – the first 
evidence of isotopes in a stable element [3]. Aston would later go on to study isotopes 
of other stable elements using a refined version of the spectrograph instrument, an 
early version of what would later be called a magnetic sector mass spectrometer, 
winning his own Nobel Prize in chemistry in 1922. 
Since then, MS has advanced from the electromagnets and photographic detector 
plates used by Thomson and Aston, to a diverse range of intricate mass analysers and 
detector systems. New ionisation methods, as well as advances in MS instrument 
technology and chemical labelling techniques, have allowed MS to evolve from the 
Introduction I: Mass spectrometry theory 
3 
 
study of elementary particles, to the investigation of complex biological systems such 
as proteins - the structure, dynamics and aggregation of which will be the main focus 
of this thesis. 
Although many of today’s modern mass spectrometers, and the analysis methods used, 
would be unrecognisable to Thomson and Aston, the essential principle of 
determining the m/z of a gas phase ion, by manipulating electric or magnetic fields 
has remained the same. As such, MS can be broken down into three fundamental 
components: ionisation, m/z separation, and detection (Figure 1.1).  
 
 
Figure 1.1 Overview of a mass spectrometer.  Samples are ionised and introduced into the gas phase 
before m/z separation by a mass analyser. This is followed by detection of the ions and data analysis. 
 
1.2 Ionisation 
For a molecule to be analysed by MS, it must first be ionised. Although dozens of 
ionisation methods have been developed to suit specific experiments or types of 
analyte, historically, one of the most practical, and thus widely used, ionisation 
methods was electron ionisation (EI) [4]. In an EI source, a heated filament is used to 
generate electrons which are then accelerated towards an orthogonal path of gaseous 
molecules. With the appropriate wavelength and kinetic energy, these electrons can 
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ionise the nearby gaseous sample, before the product ions are directed towards a mass 
analyser. However, EI frequently induces fragmentation of the analyte, a property not 
always experimentally useful, so complementary ionisation methods, such as chemical 
ionisation (CI) were developed to reduce fragmentation and study intact molecular 
ions [5]. Chemical ionisation uses EI to ionise gas reagents in the source region, such as 
methane or isobutane, which in turn undergo ion-molecule collisions with the 
gaseous analyte, ionising the sample by proton transfer. 
These, and other similar ionisation methods are, however, limiting in the sense that 
they require the analyte to be in the gas phase prior to ionisation. For years, this made 
MS analysis of large biomolecules, such as proteins, problematic, effectively limiting 
MS to the analysis of thermally stable, volatile compounds that could be introduced 
into the gas phase by heating.  
 
1.2.1 Electrospray ionisation 
The development of electrospray ionisation-MS (ESI-MS) in 1984 by John Fenn 
revolutionised the study of large biomolecules by mass spectrometry [6, 7]. During ESI, 
an atmospheric pressure ionisation technique, a voltage is applied across a thin, metal 
coated glass capillary containing a low µM concentration of analyte in a volatile buffer 
solution. The applied voltage forms a unique solvent formation at the capillary tip 
know as a Taylor cone, which generates a fine spray of charged droplets containing 
the analyte of interest [8] (Figure 1.2). Gradual desolvation of these droplets reduces 
their size until Coulombic repulsion from charges on the droplet surface overcomes 
the force of surface tension – a point known as the Rayleigh limit [9, 10]. When the 
Rayleigh limit is reached, droplet fission creates smaller progeny droplets, and the 
desolvation process continues. 
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Figure 1.2 Overview of the Electrospray ionisation (ESI) source.  A voltage is applied across a capillary 
containing the analyte in a solution of volatile buffer. The applied voltage causes the solution to form 
a Taylor cone at the end of the capillary, where charged droplets containing the analyte are ejected. 
 
Three main models exist to explain the formation of ions from this point forward: the 
charge residue model [11], the ion evaporation model [12] and the chain ejection model 
[13] (Figure 1.3). The charge residue model (CRM) suggests that continued droplet 
desolvation and Coulombic fission of progeny droplets eventually results in 
completely desolvated ions. The ion evaporation model (IEM) differs slightly in that 
ions are proposed to be ejected from the droplet surface once the droplet radii have 
been sufficiently reduced. It has been suggested, however, that both models may 
occur, depending on the size of the sample being ionised [13]. Larger, globular species 
are proposed to ionise via the CRM, whereas the IEM has been suggested as the most 
likely ionisation mechanism for small, inorganic ions [13, 14]. The chain ejection model 
(CEM) was proposed recently as a possible ionisation mechanism, primarily for 
unfolded proteins, where the extended hydrophobic nature of the unfolded chain 
leads to rapid migration to the droplet surface, followed by stepwise ejection starting 
at the chain terminus [13].  
While small, volatile molecules could still be ionised by ESI, usually accepting a single 
charge forming [MH]+ ions, this newly developed ‘soft’ ionisation technique allowed 
far larger, non-volatile biomolecules such as peptides and proteins to be ionised 
without fragmentation, typically adopting multiple charges such that [M+nH]n+, 
where M is the molecular weight and n is an integer.  
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Figure 1.3 ESI ionisation mechanisms.  Desolvation of ESI droplets decreases their size until reaching 
the Rayleigh limit, where Coulombic fission generates smaller progeny droplets. Three models explain 
how ions are generated from the ESI droplets: the charge residue model (CRM), the ion evaporation 
model (IEM) and the chain ejection model (CEM). 
 
In the years since its development, ESI-MS technology has advanced significantly. 
With the development of nano-ESI (nESI), smaller capillaries (1-2 µm orifice) with 
lower flow rates (20 nl min-1), allowed for lower sample consumption and decreased 
initial droplet size, aiding the desolvation process [15]. Several different variations of 
the ESI/nESI source have since been developed to suit a variety of specific applications 
including 3D imaging MS of tissue samples [16], real time analysis of human breath [17], 
ionisation of electrosurgical aerosols [18] and numerous others [19-22].  
As a result of this unparalleled versatility, and the unique capability of ESI to maintain 
non-covalent interactions during ionisation - a feature particularly useful in the study 
of protein complexes [23] - ESI, today, is one of the most widely used ionisation sources 
in biological MS. Along with Koichi Tanaka for the development of soft laser 
desorption ionisation techniques, for his efforts in developing ESI, and providing 
“electrospray wings for molecular elephants”, Fenn was awarded the Nobel Prize in 
chemistry in 2002.  
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1.3 Mass analysers 
After ionisation, ions are separated according to their m/z using a mass analyser. Like 
most other regions of the mass spectrometer, mass analysers are kept at a constant 
high vacuum (low pressure) to prevent unwanted ion-molecule collisions and increase 
ion transmission and resolution. While all mass analysers use some combination of 
static or dynamic electric fields to achieve m/z separation, the basic difference 
between different analysers is the manner in which these fields are applied. There are 
three main features by which different mass analysers are often characterised: mass 
range limit (the m/z range over which an analyser can measure ions), scan speed (the 
rate at which mass spectra can be acquired) and resolution. Although different 
definitions have been proposed [24, 25] resolution is typically defined using Equation 1.1, 
where Δm/z is either the peak width at half height for a given m/z, also known as its 
full width half maximum (FWHM) (Figure 1.4a), or the difference in m/z, between 
two peaks of equal intensity, with an overlap of <10% relative intensity between them 
(Figure 1.4b). It is useful to note, however, that for some mass analysers, resolution is 
dependent on m/z and thus changes across the m/z range.  
 
 
𝑅 = 
𝑚/𝑧
∆𝑚/𝑧
 
(1.1) 
Equation 1.1 Definition of resolution.  Resolution (R) is equal to the mass to charge ratio of the ion 
(m/z) divided by Δm/z, which is defined as either the peak width at half height (Figure 1.4a), or the 
distance between two peaks of equal intensity, with 10% relative overlap (Figure 1.4b). 
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Figure 1.4 Different definitions of m/z resolution.  a) Resolution defined by the peak width at half 
height (FWHM) and b) the difference in m/z between two peaks that overlap at 10% relative intensity.  
 
Although an extensive review of mass analysers is beyond the scope of this thesis, 
certain types of mass analyser have been shown to be particularly useful in the field 
of biological mass spectrometry. 
 
1.3.1 Quadrupole analysers 
First described by Wolfgang Paul and co-workers in 1953 [26], a quadrupole mass 
analyser is a tuneable m/z filter, frequently used in combination with other mass 
analysers, where ions of different m/z are separated by the differential stability of their 
trajectories as they pass through the instrument. Ions with a stable trajectory are able 
to pass through the length of the quadrupole and reach the detector, where ions with 
unstable trajectories are filtered out. The quadrupole itself is made from two pairs of 
parallel metal rods arranged perpendicular to one another, where opposite direct 
current (DC) polarities are applied to each rod pair, such that opposite rods have the 
same charge, and adjacent rods have opposite charge (Figure 1.5). 
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Figure 1.5 Schematic diagram of a quadrupole mass analyser. Voltages applied to each rod pair are seen 
on the right where DC (dashed red line) and RF-AC (solid black line) potentials are superimposed, 
resulting in changing rod polarities which generate spiral-like trajectories for ions passing through the 
analyser. Separation occurs by differential stability of these ion trajectories for a given AC and DC 
potential.  
 
A radio frequency (RF) alternating current (AC), with a zero-to-peak amplitude 
greater than that of the applied DC voltage is also applied to the rods, such that the 
waveforms of adjacent rods are 180° out of phase, resulting in a dynamic potential on 
each rod defined by: 
 
 𝛷0 = 𝑈 − 𝑉 cos(2𝜋𝑣)𝑡 (1.2) 
Equation 1.2 Dynamic potential on quadrupolar rods generated by superimposed AC and DC potentials. 
The potential applied to the rod (Φ0) is a combination of the DC potential (U), and the AC potential 
where V is the 0-to-peak amplitude, v is the frequency and t is time. 
 
The combined effect of these potentials is to periodically change the polarity on each 
rod pair simultaneously, where ions are attracted to, and then repelled by, each of the 
four rods, resulting in a spiral-like trajectory for ions passing through the quadrupole. 
It is convenient to conceptualise the quadrupole as filtering ions separately in the two 
lateral planes of the analyser: X-Z (left to right, and along) and Y-Z (up and down, 
and along). In the X-Z axis, the average polarity on the rods is positive, hence 
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positively charged ions will be repelled by the rods and focused into the centre of the 
analyser. The brief change to negative polarity in the X-Z plane will have a negligible 
effect on the trajectory of higher m/z ions, as they respond less significantly to the  
polarity change than to the average polarity on the rod, allowing these ions to pass 
through to the detector unhindered. Conversely, the trajectories of lower m/z ions, 
which respond more significantly to the polarity change, are more likely to be 
destabilised, and therefore less likely to reach the detector. Thus the X-Z plane of the 
quadrupole acts as a ‘high pass m/z filter’ allowing only high m/z ions to pass through 
to the analyser (Figure 1.6) [27, 28]. In the Y-Z axis, the average polarity on the electrodes 
is negative, hence positively charged ions are pulled from a stable trajectory in the 
centre of the analyser, towards the rods. Lower m/z ions, responding more 
significantly to the temporary change to positive polarity, are repelled back towards 
the centre of the analyser and are able to pass through to the detector with stable 
trajectories. Higher m/z ions, being more affected by the average polarity on the rod, 
have unstable trajectories in this plane, and depolarise on the rods before exiting the 
quadrupole. The Y-Z plane, then, acts as a ‘low pass m/z filter’ (Figure 1.6). 
For an ion to be able to pass through the quadrupole and reach the detector, it must 
lie in the overlapped stability region between the two planes of the quadrupole, where 
the m/z of the ion is high enough to be stable in the X-Z plane, but low enough to be 
stable in the Y-Z plane. The main determinants of an ion’s stability through the 
quadrupole are the frequency of the polarity changes (i.e. AC frequency – typically 
maintained constant) and the magnitude of the applied DC and AC voltages (U and V 
as per Equation 1.2) [29]. While a fixed value of U and V can be maintained to allow 
consistently only ions of a particular m/z to have stable trajectories through the 
analyser, maintaining a fixed ratio of U and V while changing their absolute values, 
allows the quadrupole to sequentially stabilise the trajectory of different m/z ions. 
Thus, a quadrupole can behave as a scanning mass analyser, building up a mass 
spectrum by rapidly ramping up the AC and DC voltages, sequentially allowing ions 
of different m/z through to the detector (Figure 1.6). 
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Figure 1.6 The m/z separation of ions in the two lateral planes of a quadrupole.  The low pass m/z filter 
(Y-Z) and the high pass m/z filter (X-Z) work together to stabilise the trajectory of ions in the 
quadrupole (m/z values with stable trajectories in each plane are in the grey shaded area of each plot). 
A mass spectrum is acquired by sequentially stabilising the trajectories of different m/z ions by 
increasing U and V. 
 
The effect of U and V on the stability of different m/z ions in the quadrupole can be 
readily visualised using stability areas calculated from a complex series of equations 
known as the Mathieu and Paul equations [26, 30] (Figure 1.7). The increase in DC and 
AC voltage necessary for scanning m/z analysis is visualised as the scan line in Figure 
1.7, where an intersection between this line and a stability area highlights conditions 
at which an ion will have a stable trajectory in both planes of the quadrupole, and 
successfully reach the detector. The green m/z value in Figure 1.7, for example, at 
position 1 on the scan line has an m/z too high for the applied voltages to have a stable 
trajectory, so is stable in the X-Z plane (high pass) but unstable in the Y-Z plane (low 
pass). The reverse is true for this ion at position 3 on the scan line. Only at position 2, 
where the scan line intersects the stability region, will the green m/z ion have a stable 
trajectory through the quadrupole. 
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Figure 1.7 Stability diagrams for ions in a quadrupole.  Each lateral plane of the quadrupole acts as an 
m/z filter, allowing either low m/z ions (Y-Z), or high m/z ions (X-Z) to pass through to the detector. 
The combined stability area for both lateral planes as a function of DC and AC voltage for high (blue), 
low (purple) and intermediate (green) m/z values is shown, where an ion will have a stable trajectory 
in the quadrupole at voltages where the scan line intersects the stability area. The stability of the green 
ion is shown, in each plane of the quadrupole, at U:V ratios at positions 1,2 and 3 on the scan line. 
 
The gradient of the scan line (i.e. the ratio of U and V) determines the m/z resolution 
of the quadrupole, visually represented in Figure 1.7 as the stability area above the 
scan line (the smaller this area, the higher the resolution). Although the resolution 
can be increased by adjusting to a higher U/V ratio (steeper scan line gradient), 
quadrupoles are inherently low resolution mass analysers, and are usually operated at 
unit resolution (two peaks one m/z unit apart) [29]. Similarly, quadrupoles are limited 
in their detectable m/z range, which is typically no more than 3000-4000 m/z [29, 31], 
although this can be increased by lowering the frequency of the AC potential, 
typically at the cost of sensitivity and resolution [31]. Their advantage, however, is their 
fast scan speed, and the independence of ion kinetic energy and initial lateral ion 
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positioning on m/z separation, allowing ions to be continually infused into the 
analyser – a characteristic ideal for coupling to continuous ionisation sources such as 
ESI. Additionally, by removing the DC potential entirely, a quadrupole can function 
in RF-only mode (Y=0 in Figure 1.7), allowing a very wide range of m/z ions to be 
transmitted through the analyser simultaneously, effectively acting solely as an ion 
guide – a characteristic ideal for using quadrupoles in conjunction with other mass 
analysers.  
 
1.3.2 Linear ion traps 
Conceptually very similar to a quadrupole mass analyser, the most common variant of 
the linear ion trap (LIT), sometimes referred to as the 2D ion trap or Paul trap, after 
Wolfgang Paul, consists of four parallel rods, each of which is cut into three separate 
sections, usually referred to as a segmented quadrupole. A quadrupolar RF field is 
applied (i.e. waveforms of adjacent rods are 180° out of phase) to the centre section, 
confining ions in the X and Y dimensions, and DC potentials are applied to the two 
end sections, repelling ions back and forth axially along the trap, thus confining ions 
to the centre of the device in all three dimensions (Figure 1.8) [32]. 
 
 
Figure 1.8 Basic design of the linear ion trap.  DC confinement potentials are applied to the front and 
back sections of the segmented quadrupole. RF-AC quadrupolar potentials are applied to the centre 
section to radially confine ions. Slots are cut into the x axis centre rods for radial ion ejection. 
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Although, in principle, LITs can operate in a similar fashion to quadrupole mass 
analysers, manipulating DC and RF amplitudes in the centre section to select or scan 
through different m/z ions to generate a mass spectrum [33], the most common mode 
of operation for separating ions according to their m/z in LITs involves dipolar 
resonance ejection [32]. In this mode of operation, supplemental AC potentials are 
applied to both x axis rods, such that the waveform on each rod is out of phase by 180° 
[32]. When the oscillation of an ion in the trap resonates with the waveform of the AC 
field, it is pushed and pulled further away from the centre of the trap, with each 
oscillation, linearly increasing the amplitude of its oscillation until it is ejected 
through slots in the x axis rods, and analysed by one of two detectors – either side of 
the trap (Figure 1.9).  
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Figure 1.9 Dipolar resonance ejection in linear ion traps. Ions trapped in the centre section of the ion 
trap are subjected to supplemental AC fields, the amplitude of which is ramped to sequentially eject 
ions of increasing m/z. Ions are ejected through slots in the x axis rods to detectors either side of the 
trap.   
 
The resonance frequency of an ion is positively correlated with m/z, but is similarly 
correlated with the applied AC amplitude. Thus, by maintaining a high, fixed AC 
frequency and ramping the AC amplitude, the resonance frequency for all ions in the 
trap is increased, until ions of increasing m/z sequentially reach a resonance frequency 
matching the AC waveform and are ejected from the trap, thus achieving m/z 
separation (Figure 1.10) [29, 33]. 
While LITs are often used as standalone mass analysers, with scan speeds and 
resolutions similar to quadrupole mass analysers [33], in many commercial mass 
spectrometers, LITs are also used as ion storage devices and collision cells, before m/z 
separation is achieved by other means [34]. Indeed, fragmentation of trapped ions can 
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be readily achieved by filling the device with a collision gas, and exciting ions to 
elevated energies, below the energy required for resonance ejection [33]. This 
versatility, coupled with the ability to eject ions both axially, and laterally after 
storage or fragmentation, makes the 2D ion trap a valuable multi-use component in 
many commercial instruments [34]. Indeed, the RF ion confinement technology that 
underpins both the quadrupole and the LIT, as well as other mass analysers such as 
the 3D ion trap, is now widely considered to be an essential tool in MS instruments 
for a wide variety of applications. For his work in the development of the ion trap 
technique, Paul was awarded the Nobel Prize in physics in 1989. 
 
 
Figure 1.10 The relationship between dipolar resonance ejection frequency and applied AC amplitude.  
Increasing AC amplitude increases the resonance frequency for ions in the trap, until the resonance 
frequency of increasing m/z ions approaches the AC waveform frequency, and ions are ejected from 
the trap. 
 
1.3.3 Time-of-flight (ToF) analysers 
Initially proposed by Stephens in 1946 [35], then later developed by Cameron and 
Eggers in 1948 [36], a time-of-flight (ToF) mass spectrometer, or ‘Velocitron’ as 
Cameron and Eggers called it, separates ions of different m/z according to their flight 
time through a high vacuum, field free region of the instrument called a flight tube 
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(Figure 1.11). The aptly named “pusher” voltage provides the initial kinetic energy 
needed to accelerate ions through the flight tube towards the detector, where the 
relationship between the applied pusher voltage and ion kinetic energy is defined as: 
 
 1
2
𝑚 (
𝐿
𝑡
)
2
= 𝑧𝑒𝑉 
(1.3) 
Equation 1.3 The relationship between potential and kinetic energy for ions accelerated in ToF-MS.  
Potential energy, given by zeV (where z is the number of charges on the ion, e is the elementary charge 
on an electron and V is the pusher voltage), is converted into kinetic energy, where m is the ion mass, 
L is the length of the flight tube, and t is the flight time. 
 
Rearranging this formula, we can show that the time taken for an ion to traverse the 
flight tube, for a given acceleration voltage, is proportional to the square root of its 
m/z: 
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(1.4) 
Equation 1.4 The relationship between flight time and m/z for ions accelerated in ToF-MS.  All terms 
inside the brackets are constant, therefore, flight time is shown to be proportional to the square root of 
the m/z. 
 
Thus, ions of different m/z have different flight times within the instrument, and 
reach the detector at different times. This also demonstrates a positive correlation 
between m/z and flight time, where higher m/z ions take longer to traverse the flight 
tube. As there is, in principle, no limit to how long an ion can take to reach the 
detector, ToF-MS has a particularly high detectable mass range, making this type of 
mass analyser ideally suited to the study of large biomolecules. Indeed, conventional 
ToF-MS instruments have been used to study intact bacteriophage capsids up to 18 
MDa [37]. Similarly, as flight tubes are classically no more than 1-2 m in length (to 
maintain sensitivity), flight times are typically on the order of µs, meaning ToF-MS 
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instruments are also capable of fast scanning speeds, usually acquiring multiple scans 
in order to build up a mass spectrum. 
 
 
Figure 1.11 m/z separation by time-of-flight mass spectrometry (ToF-MS).  An acceleration voltage 
pushes ions through a field free flight tube under high vacuum. Ions of different m/z are accelerated to 
different velocities such that ions of lower m/z reach the detector first.  
 
However, unlike quadrupole or LIT mass analysers, ToF-MS is a pulsed analysis 
technique, requiring ions to start from approximately the same position relative to the 
pusher voltage, in order to ensure a minimal kinetic energy distribution is delivered 
to ions of the same m/z. Spatial distribution of ions in the pusher region results in 
uneven exposure to the acceleration voltage, where some ions of the same m/z receive 
a greater accelerative force towards the detector than others. The result is that ions 
with the same m/z reach the detector at slightly different times, broadening the 
resulting m/z peaks and lowering instrument resolution. This complicates the 
effective coupling of ToF-MS to continuous ionisation sources, such as ESI, as a 
continuous stream of ions directed towards the detector would generate a large spatial 
distribution of ions in the ToF direction. This problem was addressed by Dawson and 
Guilhaus in 1989, with the development of orthogonal acceleration ToF-MS [38]. 
 
1.3.3.1 Orthogonal acceleration Time-of-flight (oa-ToF) 
In orthogonally accelerated ToF instruments, the ion beam from the ionisation source 
is orientated orthogonally to the direction of the ToF m/z separation. Ions generated 
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in the source are allowed to accumulate in the pusher region before the acceleration 
voltage is applied to direct ions towards the detector (Figure 1.12). Successive ‘pushes’ 
from the acceleration voltage allow a continuous stream of ions to be effectively 
analysed by pulsed ToF separation, and permits continuous ionisation sources, such as 
ESI, to be effectively coupled to ToF mass analysers. With this orientation, ions are 
not initially travelling in the direction of the detector, minimising their spatial and 
velocity distributions in the ToF direction, thus also minimising kinetic energy 
dispersion of ions of the same m/z. While this has a favourable effect on instrument 
resolution, some variations in kinetic energy will remain. It is therefore useful to 
minimise this distribution further by other methods. 
 
 
Figure 1.12 Schematic diagram of an orthogonal acceleration time-of-flight mass spectrometer (oa-
ToF).  The beam of ions from the source region is accelerated orthogonally towards the detector, 
allowing effective coupling to continuous ionisation sources. 
 
1.3.3.2 Reflectrons 
A reflectron, or electrostatic reflector, is an ion mirror device developed by Mamyrin 
and colleagues in the 1970’s, used to further minimise differences in the flight time of 
ions of the same m/z in ToF mass analysers [39]. Ions directed into the reflectron by the 
pusher acceleration voltage are reflected ~180° back towards the detector by the 
increasing electric field gradient of the device. Ions with higher kinetic energy 
penetrate more deeply into the reflectron before changing trajectory, effectively 
lengthening their flight path relative to those of lower kinetic energy. This has the 
effect of normalising the overall flight time of ions of the same m/z with different 
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velocities, increasing the resolution of the instrument (typical commercial ToF-MS 
instruments equipped with reflectrons can attain resolutions of ~20,000 at m/z 400 
[40]). Usually, ToF mass analysers with reflectrons are operated in ‘V-mode’ where ions 
are passed through a single reflectron device before reaching the detector (Figure 
1.13). However, many modern ToF instruments are equipped with multiple reflectron 
devices and can operate in ‘W-mode’, where ions are passed through two reflectrons, 
further increasing resolution at the cost of sensitivity.  
 
 
Figure 1.13 Schematic diagram of an electrostatic reflector.  Ions of the same m/z with higher kinetic 
energies (pink) penetrate further into the reflectron than those with lower kinetic energy (purple). The 
resulting longer flight path for higher kinetic energy ions normalises their flight time with lower 
energy ions allowing them to reach the detector simultaneously.  
 
1.3.4 Orbital trapping analysers 
Orbitral ion traps work by holding ions in stable orbits around a central electrode. 
The simplest and earliest example of an orbital ion trap is the Kingdon trap, developed 
by K.H Kingdon in 1923 (Figure 1.14) [41]. In a Kingdon trap, a DC voltage is applied 
to a length of wire running lengthwise at the centre of an outer cylindrical electrode. 
When injected orthogonally into the trap, the logarithmic electric field generated by 
the DC voltage on the wire is able to trap ions with appropriate initial conditions (i.e. 
kinetic energy, starting position) in stable orbits around the central electrode, until 
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collisions with residual gas molecules in the trap cause ions to collide with the wire. 
DC voltages are applied to flat, end cap electrodes at either end of the cylinder to trap 
ions laterally. However, as ions in a Kingdon trap are free to move both around, and 
along the central electrode, no m/z separation of ions can occur. As such, Kingdon 
traps can only function as orbital trapping devices, rather than mass analysers.  
 
 
Figure 1.14 The Kingdon trap and the Knight trap: early orbital ion traps. Ions are kept in stable orbits 
around a central electrode and are contained axially by either end cap electrodes (Kingdon trap) or by 
a quadrupolar field (Knight trap). 
 
An important step forward in the use of orbital ion traps for m/z separation of ions 
was the development of the Knight trap in 1981 (Figure 1.14) [42]. Like Kingdon’s 
device, ions in a Knight trap form stable orbits around a central wire from which an 
applied DC potential generates a logarithmic electric field. However, this 
configuration differs from the Kingdon trap in that the outer cylinder is replaced by 
a split electrode, where an RF-AC potential is applied to generate a quadrupolar 
electric field. Together, the inner and outer electrodes produce a combined 
quadrupolar and logarithmic field, or quadro-logarithmic field, directing ions to 
oscillate back and forth along the axis of the central wire, whilst maintaining stable 
orbits around the wire. In principle, the effect of this field should induce harmonic 
oscillations of ions, such that ions of different m/z oscillate along the central electrode 
at different frequencies, thus achieving m/z separation. In practice, Knight noted that 
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the resonance frequencies observed for ions trapped in this manner were broad, 
shifted and weak when compared to what theory would suggest [42]. He proposed that 
interference between the DC potential on the central wire, and the RF potential on 
the outer electrodes, creates a non-ideal quadro-logarithmic field, disturbing the 
harmonic oscillation of ions and detrimentally effecting m/z separation [42]. His 
suspicions were confirmed in 1996, where calculations by Gillig, Bluhm and Russell 
showed that in order to achieve purely harmonic oscillations of ions along the central 
electrode, and thus achieve useful m/z separation in an orbital ion trap, the central 
electrode and trapping volume must have spindle-like geometries [43]. 
 
1.3.4.1 Orbitrap mass analysers 
The orbitrap, developed in 2000 by Alexander Makarov [44], is an orbital ion trap device 
approximating the ‘ideal Kingdon trap’, where a DC potential applied to a central, 
spindle-shaped electrode, provides the quadro-logarithmic field necessary for m/z 
separation [44] (Figure 1.15). Unlike the Knight trap, where ions are ‘pushed’ back and 
forth along the central electrode by the quadrupolar field applied to the outer 
electrodes, the unique field generated by the central electrode of the orbitrap is such 
that ions are ‘pulled’ towards the equator of the spindle (r in Figure 1.15) and can 
undergo harmonic oscillations along the z axis without the need for an applied field 
on the outer electrodes - typically held at virtual ground potential in orbitrap mass 
analysers [44].  
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Figure 1.15 The orbitrap mass analyser: an ‘ideal’ Kingdon trap. Ions injected into the trap undergo 
harmonic oscillations in the z axis, where the oscillation frequency is proportional to the m/z of the 
ion. Analysis of the different frequencies and intensities produced by each different m/z ion is used to 
generate a mass spectrum.     
 
Upon injection into the orbitrap, as with both Knight and Kingdon’s devices, ions 
rapidly form stable orbits around the centre electrode. The frequency of these radial 
orbits is dependent on the  kinetic energy of the ion, as well as other factors such as 
initial ion position [44]. As such, upon injection of an ion packet into the orbitrap, ion 
orbits in the radial dimension rapidly go out of phase, as ions with more initial kinetic 
energy orbit with a higher frequency than those with lower initial kinetic energies. 
Typically, ions are injected into the orbitrap tangentially at one end of the central 
electrode, a so called ‘excitation by injection’ method [44], to ensure ions are drawn 
immediately towards the equator of the spindle, and begin to oscillate along the z axis 
without any additional energy input (Figure 1.16) [44]. If the dimensions of the injected 
ion packet are small enough, radial de-phasing, coupled with the tangential off-
equator ion injection, causes ions of the same m/z to form ‘rings’ around the centre 
electrode, where each ring oscillates back and forth along the spindle with a frequency 
inversely proportional to its m/z (Figure 1.16, Equation 1.5). The different oscillation 
frequencies observed can then be used to generate a mass spectrum. 
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Figure 1.16 Excitation by injection, and radial de-phasing of ions in an orbitrap.  Ions are injected 
tangentially at one end of the electrode, to initiate z axis oscillations. Differences in the initial kinetic 
energy and position of ions cause rapid de-phasing of ion orbits in the radial dimension. Together, these 
properties cause ions of the same m/z to form a ‘ring’ of ions orbiting the centre electrode, which 
oscillates back and forth at a frequency proportional to m/z. 
 
Crucially, the relationship between oscillation frequency and m/z shown in Equation 
1.5 also demonstrates that, unlike the frequency of the radial ion orbits, z axis 
oscillation frequency is independent of ion kinetic energy, and only dependent on the 
m/z of the ion and the properties of the static electric field in the trapping volume.  
 
 
2𝜋𝑣 =  √
𝑘
𝑚 𝑧⁄
 
(1.5) 
Equation 1.5 The relationship between z axis oscillation frequency and m/z in an orbitrap mass 
analyser.  Where v is the oscillation frequency, m/z is the mass to charge ratio of an ion and k is the 
field curvature. 
 
As a reliable measurement of oscillation frequency, and thus the m/z of an ion, 
requires multiple oscillations along the centre electrode to occur, the scanning speed 
of orbitraps is significantly slower than quadrupole, LIT, or ToF mass analysers, 
typically on the order of 10 Hz [45], where scan times are longer if higher resolution 
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measurements are required. Similarly, unlike quadrupoles where resolution is largely 
independent of m/z, the resolution of orbitrap mass analysers decreases as a function 
of (m/z)0.5 [46]. Nevertheless, orbitrap mass analysers are, due to the unique ion motions 
around the central electrode, inherently high resolution instruments, where 
continued development has thus far enabled orbitraps to achieve up to 1,000,000 
resolution (FWHM) at m/z 200 [47]. Similar to ToF instruments, orbitrap mass analysers 
require pulses of ion packets for analysis, and as such are often coupled to continuous 
ionisation sources via a curved linear ion trap, usually called the C-trap. The purpose 
of this is twofold: to accumulate and store ions from the ionisation source, cooling 
them with collisions with gas molecules, and to rapidly (100-200 ns) inject ion packets 
into the orbitrap with minimal spatial and temporal spread [48], crucial for maintaining 
the coherence of the harmonic oscillations of ions. This linear ion trap, rather than 
the orbitrap itself, is often the limiting factor in the detectable mass range limit [29]. 
However, recent advances in instrument technology upstream of the mass analyser, 
have enabled orbitrap instruments to study high molecular weight intact protein 
complexes up to several MDa [49]. 
 
1.4 Ion Detectors 
Ion detection is the final fundamental component in a mass spectrometer. Far from 
the photographic plates used as detectors by Thomson and Aston in the early 20th 
century, today, the purpose of an ion detector in mass spectrometry is to produce a 
signal from the separated ions, which can interpreted by a computer in order to 
generate a mass spectrum.  
 
1.4.1 Electron multipliers 
One of the most commonly used detector systems in modern mass spectrometers is 
the electron multiplier. In this type of detector, ions collide with a conversion dynode, 
causing the emission of secondary particles, including electrons.  This sets off a cascade 
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effect, where electrons are further amplified, generating a current which can then be 
detected by a computer. For ToF instruments, the microchannel plate detector (Figure 
1.17), a type of continuous dynode electron multiplier, is the favoured detector system 
due its fast response time – a characteristic useful for a mass analyser where narrow 
pulse width and precise time measurements are critical.  
 
 
Figure 1.17 Schematic diagram of a microchannel plate continuous dynode electron multiplier.  Ions 
striking the detector set off a cascade of electrons which generate a current detected by a computer. 
 
1.4.2 Image current detection 
Clearly, for some mass analysers such as orbitraps, the path of the ion must remain 
undisturbed in order to measure its m/z. For this type of separation, a non-destructive 
method of ion detection is required. In image current detection, the presence of ions 
is detected by the induced current produced on metal surfaces as the ions approach. 
The magnitude of the induced current is proportional to distance, so as ions move 
closer to the surface, the induced current increases. In orbitrap mass analysers, the 
outer electrodes function as the image current detector surfaces, where the detected 
waveform of induced current is used to determine the m/z of the ion (Figure 1.18). 
Typically for orbitrap mass analysers, a short delay after ion injection into the trap is 
allowed before image current detection begins. This allows time for ions to radially 
de-phase and form orbital rings around the electrode, reducing the presence of 
interfering harmonic signals from in-phase radial oscillations [44]. Overlapping and 
interfering image current signals generated from multiple different m/z ions in the 
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trap are then processed by fast Fourier transform algorithms to generate a mass 
spectrum [50].  
 
 
Figure 1.18 Image current detection in orbitrap mass analysers.  The induced current on the outer 
electrodes of the orbitrap oscillates with the z axis oscillation of ions along the spindle electrode. The 
oscillation of this signal is then used to determine the m/z of the detected ion. 
 
1.5 Analysis of mass spectrometry data 
Once a mass spectrum (i.e. m/z vs intensity) has been generated, the mass can then be 
determined, for positively charged ions, using Equation 1.6. However, this equation 
demonstrates that, before the mass can be calculated, the number of charges on the 
analyte (n), also known as the charge state, must be determined. 
 
 𝑀𝑎𝑠𝑠 =  𝑚 𝑧⁄ − 1.0072𝑛 (1.6) 
Equation 1.6 Calculating mass from a mass spectrum.  The mass, for positively charged ions, is equal to 
m/z multiplied by the charge state (n), where the mass of the additional protons is subtracted. Mass of 
a proton = 1.0072 Da. 
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For analysis of biomolecules ionised by ESI, where a distribution of different charge 
states is often observed, n for a given charge state is typically determined in one of 
two ways. If the resolution is sufficient to observe the naturally abundant isotopes of 
13C, then the mass difference between two adjacent isotopic peaks will be 
approximately 1 Da, due to the additional neutron in the atomic nuclei of carbon. The 
charge state, then, is equal to the reciprocal of the difference in m/z between two 
adjacent peaks in the isotope distribution (Figure 1.19a).  
 
 
Figure 1.19 Determination of charge states in a mass spectrum.  a) Example peptide isotope distribution. 
With isotopic resolution, the charge state can be determined from the natural abundance of 13C, where 
the mass difference between two adjacent peaks is known. b) Example protein charge state distribution. 
Without isotopic resolution, the charge state of a peak can be determined from the charge state 
distribution using a set of simultaneous equations (Equation 1.7). 
 
For larger species, where 13C isotopes are less easily resolved, the charge state can be 
determined using adjacent peaks in the charge state distribution. Knowing that n must 
be an integer, and that adjacent peaks in the charge state distribution must be either 
n+1 (lower m/z) or n-1 (higher m/z), n can be calculated for a given m/z peak using a 
set of simultaneous equations (Equation 1.7, Figure 1.19b). As isotopes are typically 
not resolved in these spectra, the mass calculated is the average mass, rather than the 
monoisotopic mass. 
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 𝑀𝑎𝑠𝑠 =  𝑚 𝑧(1)⁄ 𝑛 − 1.0072𝑛 =
𝑚
𝑧(2)⁄ (𝑛 + 1) −  1.0072(𝑛 + 1) (1.7) 
Equation 1.7 Determination of charge states in non-isotopically resolved mass spectra. Adjacent peaks 
in a charge state distribution have a different number of charges but are ionised from the same 
molecule, and have the same mass, after correcting for the different number of additional protons. This 
can be used to calculate n for a given peak and, subsequently, to calculate mass. 
 
1.5.1 Mass error and mass accuracy 
Mass accuracy is typically quoted in parts per million (ppm) and is a measure of how 
close the calculated mass is to the theoretical mass of the molecule (Equation 1.8) [51]. 
 
 
𝑀𝑎𝑠𝑠 𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠 − 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑚𝑎𝑠𝑠
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠
 × 106 
(1.8) 
Equation 1.8 The definition of mass accuracy. Measured in ppm, mass accuracy is a measure of how 
close the calculated mass is to the theoretical mass of the molecule being studied. 
 
1.6 Tandem mass spectrometry (MS/MS) 
For many applications in mass spectrometry, such as experiments where 
fragmentation of specific ions is required, one stage of mass analysis is not enough. 
For this reason, many modern mass spectrometers are equipped with multiple mass 
analysers, frequently separated by collision cells for ion fragmentation, enabling m/z 
separation to be performed in tandem, usually referred to as MS/MS. While the use of 
multiple mass analysers allows a variety of different MS/MS workflows, a commonly 
used workflow in biological mass spectrometry, particularly for the structural analysis 
of proteins, is the product ion scan (Figure 1.20). 
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Figure 1.20 The workflow of a product ion scan.  Ions are selected in the first mass analyser (usually a 
quadrupole) which are then fragmented in the collision cell. A second mass analyser separates the 
product ions produced from the fragmented precursor ion. 
 
In a product ion scan, the first mass analyser, usually a quadrupole, selects ions of a 
particular m/z to pass through to the fragmentation cell. The selected ion is then 
fragmented, and the product ions resulting from the fragmentation are then examined 
by the second mass analyser. 
 
1.6.1.1 Fragmentation methods 
A variety of different fragmentation methods are available for MS/MS experiments, 
each of which causes different fragmentation properties of biological molecules, 
discussed later in Section 2.4.2. One of the most commonly used methods of ion 
fragmentation in biological mass spectrometry is collision induced dissociation (CID) 
[52]. In CID, a collision gas, typically argon, nitrogen or helium, is introduced into the 
fragmentation cell, where ions suffer collisions with the gas molecules effectively 
‘heating’ the ions by transferring kinetic energy into internal energy. CID is a slow, 
or ergodic, fragmentation technique where the added internal energy is redistributed 
throughout the molecule and breaks the weakest bonds first, usually non-covalent 
interactions, before breaking the weakest covalent bonds. An alternative, but similar, 
method of fragmentation is higher energy C-trap dissociation (HCD), characterised 
by the rapid injection of ions into a gas filled region of the instrument where, similar 
to CID, collisions with the buffer gas cause the ions to fragment. However, HCD 
typically generates fragment ions faster than CID which often uses a slower resonance 
excitation method to initiate buffer gas collisions and fragmentation [53]. The 
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terminology behind these two fragmentation techniques, however, is often confusing, 
where HCD on some instrument geometries is often more similar to CID in others 
(i.e. HCD on the Thermo Q Exactive is more similar to CID on the Waters Synapt 
instruments, discussed later in section 1.10). 
Alternatively, fast acting fragmentation techniques such as electron capture 
dissociation and electron transfer dissociation (ECD and ETD respectively), use the 
addition of low energy electrons, either by use of electron emitters (ECD) or anionic 
gas phase reagents (ETD) to fragment ions. Although less common than either CID or 
HCD, fragmentation techniques such as ETD or ECD are useful for applications where 
the maintenance of non-covalent interactions is prioritised, or to get complementary 
or additional fragmentation data. The utility of various fragmentation methods for 
experiments in structural mass spectrometry is discussed later in Section 2.4.2. 
 
1.7 Liquid chromatography – mass spectrometry (LC-MS) 
The analysis of biological samples by mass spectrometry is often complicated by the 
complexity of the sample, where many different species occupying a single mass 
spectrum can make data analysis significantly more challenging. Liquid 
chromatography (LC) is a separation technique often used prior to ionisation and MS 
analysis, where the aqueous sample is passed through an analytical column which 
separates the components of the solution by certain physical properties (size/charge 
etc…) depending on the type of LC employed (Figure 1.21). 
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Figure 1.21 Separating and analysing complex mixtures by liquid chromatography-mass spectrometry 
(LC-MS).  The sample is injected into an analytical column, which separates components of the solution 
by a set a physical properties such as size, charge or polarity. Following separation and elution from 
the column, the separated components are ionised by ESI and analysed by MS. 
 
The most common form of liquid chromatography employed in biological mass 
spectrometry is reverse-phase LC (RP-LC), which separates molecules according to 
their polarity [54]. Generally, the inner surface of the analytical column is coated with 
silica bound alkyl chains of varying lengths, although for analysis of biological 
samples, an 18 carbon length alkyl chain, frequently short-handed to “C18”, is the 
most commonly used. As alkyl chains are highly non-polar (hydrophobic), any non-
polar (or hydrophobic) components of the injected sample will interact with the inner 
surface of the column to a greater extent than the more polar, or hydrophilic, 
molecules in the solution. Thus, the most polar compounds in the sample have the 
shortest retention time on the column and elute first, where the least polar 
compounds have the longest retention time and elute later. Typically, the least polar 
molecules are eluted from the column by gradually making the solvent less polar, 
weakening their interaction with the column surface. This is usually achieved by 
increasing the concentration of non-polar solvents in the solution, such as acetonitrile 
(MeCN) [54]. Advances in LC separation technology led to the development of high-
performance LC (HPLC) and later ultra-performance LC (UPLC) – systems that 
operate at higher pressure and offer increased speed and resolution [55]. Usefully, many 
of these LC systems have been developed to operate using solution conditions and 
flow rates compatible with ESI sources, so they can be effectively coupled directly to 
a mass spectrometer [55]. 
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1.8 LC-MS/MS data acquisition methods 
As discussed earlier in Section 1.6, tandem mass spectrometry experiments are useful 
for acquiring fragment ion spectra of the ion of interest which, for biomolecules, is 
typically used for peptide sequencing, discussed later in Section 2.4.2. When 
continually infusing a pure analyte into the mass spectrometer, the intact and 
fragment ion spectra can be easily acquired separately by activating and deactivating 
fragmentation in the collision cell, to obtain both the intact mass measurement, and 
the fragment ion spectra necessary to analyse the sample. However, when LC is used 
to separate complex mixtures prior to MS analysis, the ion is only introduced into the 
mass spectrometer for the brief period that it elutes off the LC column, making rapid 
acquisition of both the intact, and the fragment ion spectra for each molecule 
challenging. To tackle this issue, instrument methods have been developed to allow 
rapid automated switching between high and low energies in the collision cell, 
allowing acquisition of both MS, and tandem MS data of ions as they are introduced 
into the mass spectrometer from online LC separation. Generally, there are two main 
acquisition modes that achieve this: data dependent, and data independent, 
acquisition. 
 
1.8.1 Data dependent acquisition (DDA) 
In data dependent acquisition modes (DDA), the spectra for intact molecular ions are 
first acquired by deactivating the fragmentation, and allowing a full m/z scan of all 
ions eluting from the LC column at that time. A user-defined number of the most 
intense m/z ions from the initial scan, sometimes called the MS1 or precursor ion scan, 
are then sequentially selected by the first mass analyser for fragmentation and spectral 
analysis by the second mass analyser. When complete, another full m/z scan is 
acquired at the new, now longer, LC retention time, and the cycle is repeated for as 
long as the LC elution takes place (Figure 1.22). Typically, a dynamic exclusion time 
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is applied such that the same m/z value is not repeatedly selected if it remains at high 
intensity after the DDA cycle finishes. This is to prevent continual fragmentation of 
the same ions, and to more effectively utilise the available MS/MS time to fragment 
ions of different m/z. 
However, DDA modes for LC-MS/MS present a trade-off between the speed, and 
depth of the analysis. Whilst sequentially selecting and fragmenting ions, full scan 
intact MS data cannot usually be acquired, thus some ions eluting from the LC column 
may be missed if the DDA cycle takes too long. Conversely, making the cycle shorter 
by reducing the number of different m/z ions to select and fragment, allows the DDA 
cycle to repeat more frequently, but at the cost of narrowing the analysis to only a 
few of the most intense ions. That said, the use of product ion scans and m/z selection 
in DDA make it a very popular MS/MS method, as only ions fragmented from the 
precursor are present in the tandem MS spectra, drastically simplifying data analysis. 
 
 
Figure 1.22 Operating procedure of data dependent acquisition (DDA) in LC-MS experiments.  A full 
MS scan is first performed to determine the most abundant ions in the spectra at the current LC 
retention time. The top x most intense ions, x being a parameter tuneable by the operator, are then 
sequentially selected by the first mass analyser (usually a quadrupole) where product ion scans are used 
to obtain tandem MS spectra for each ion selected. When x is reached, a full scan is performed again. 
This process is repeated across the entire LC gradient elution. 
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1.8.2 Data independent acquisition (DIA) 
Data independent acquisitions (DIA) involve rapid switching between high and low 
energy modes without any m/z selection (Figure 1.23). The result is that co-eluting 
precursor ions are fragmented together, generating complex tandem MS spectra with 
fragment ions present from multiple precursors. Whilst this method allows both deep 
and rapid analysis of the sample, acquiring MS1 and MS2 spectra quickly for ions as 
they elute from the LC column, the data analysis is far more complicated, as assigning 
which fragment ions in the high energy spectra belong to which precursor ions in the 
MS1 spectra can be challenging. 
 
Figure 1.23 Operating procedure for data independent acquisition (DIA) in LC-MS experiments.  The 
instrument switches rapidly between high and low energy modes without any precursor m/z selection. 
Co-eluting precursors are fragmented together generating highly complex MS/MS data. 
 
One common method of DIA data analysis, termed MSE, matches precursor ions to 
their respective fragment ions by retention time alignment [56]. In this method, shown 
in Figure 1.24, the change in intensity of the precursor and fragment ions over the 
course of the LC separation is used to determine their respective retention times. 
Fragment ions will have the same retention time as the precursor ion from which they 
are produced, so these data can be used to reconstruct MS/MS data and assign fragment 
ions to their corresponding intact molecular ions. 
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Figure 1.24 Data analysis in DIA-MSE.  The retention times of precursor ions are matched to the 
retention times of the fragment ions. These data are then used to reconstruct the tandem MS spectra 
which correspond to particular precursor ions. 
 
1.9 Ion mobility spectrometry – mass spectrometry (IMS-MS) 
Although liquid phase separation techniques, such as LC, used prior to ionisation, are 
useful for separating complex biological mixtures, additional separation of the sample 
after ionisation is often helpful to further simplify the data analysis. Originally known 
as plasma chromatography [57] and conceptually very similar to LC separation, ion 
mobility spectrometry (IMS) separates gas phase ions based on the physical properties 
of size and charge [58]. Although commonly used independently in airport security for 
detecting nitro-organic explosives [59], IMS has been shown to be a useful research tool, 
when used in conjunction with MS analysis, for the separation and analysis of large 
biomolecules. For example, owing to the speed at which IMS can separate ions 
(typically on the order of milliseconds) IMS can be used in conjunction with LC as an 
orthogonal separation technique for further partitioning of complex biological 
samples, prior to MS analysis (LC-IMS-MS). Similarly, with appropriate instrument 
geometry, precursor, or fragment ions in MS/MS experiments can be separated by IMS 
by fragmenting the molecular ion before, or after, IMS separation. Although a variety 
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of different types of IMS are now available, two of the most commonly available IMS 
methods are summarised below. 
 
1.9.1 Drift tube IMS (DTIMS) 
The simplest form of IMS is drift tube IMS (DTIMS) where ions are drawn by a weak 
electric field through a drift tube filled with a neutral buffer gas, typically He or N2 [58, 
60]. Larger ions suffer more collisions with the buffer gas and are slowed down, eluting 
from the drift tube later than smaller ions, which suffer fewer buffer gas collisions 
(Figure 1.25). However, more highly charged ions are affected more by the electric 
field and are drawn through the drift tube faster than ions with fewer charges. Thus, 
IMS separation is dependent on both the size and the charge of an ion, as well as the 
properties of the buffer gas (i.e. polarizability)  which is usually kept constant. By 
using IMS-MS in tandem to determine the mass and charge of an ion, and with precise 
knowledge of the experimental conditions in the drift tube, the drift time of an ion 
through the IMS device can be used to calculate the rotationally averaged collision 
cross section, or CCS (Ω), a measurement of an ions’ size in a given buffer gas, using 
the Mason-Schamp equation (Equation 1.9) [61].   
 
 
Figure 1.25 The principle of drift cell ion mobility spectrometry.  Ions are drawn by a weak electric 
field through a drift tube filled with a neutral buffer gas. Larger ions suffer more collisions with the 
buffer gas and have longer drift times, separating them from smaller, more mobile ions which suffer 
fewer buffer gas collisions. 
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Equation 1.9 The Mason-Schamp equation.  The relationship between rotationally averaged collision 
cross section (Ω) and drift time (tD). Where E is electric field, L is the length of the drift region, T is 
temperature, P is pressure, z is the charge on the analyte, e is the elementary charge of an electron, kB 
is the Boltzmann constant, N is the buffer gas density and µ is the reduced mass of the ion-neutral pair. 
 
Although recent commercial developments have improved DTIMS technology [62], 
historically, many conventional drift tube IMS instruments were plagued by 
sensitivity issues, sampling only a small proportion of the total ion current [63].  As a 
result, many commercial instruments use an alternative form of IMS known as 
travelling wave IMS or TWIMS. 
 
1.9.2 Travelling wave IMS (TWIMS) 
First incorporated into a commercial instrument in 2006 by the Waters Corporation 
[64], TWIMS consists of a stacked ring ion guide (SRIG) of ringed electrodes where an 
applied RF voltage, operating such that adjacent electrodes are 180° out of phase with 
each other, serves to radially confine the ions during transit through the device 
(Figure 1.26) [65]. 
 
 
Figure 1.26 Schematic diagram of a stacked ring ion guide.  RF voltages are applied to ringed electrodes, 
such that adjacent rings are 180° out of phase with each other. The electric field generated serves to 
radially confine ions during their transit through the device. 
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A DC potential is superimposed over the RF-AC potential on adjacent pairs of 
electrodes and, after a short time, is switched off and moved to the next pair of 
electrodes. This generates a travelling DC potential or ‘wave’ which pushes ions 
through the IMS device. Ions with higher mobility are able to ‘surf’ this wave for 
longer as they suffer fewer buffer gas collisions, whereas lower mobility ions ‘roll over’ 
the wave and remain in the TWIMS cell until pushed by the next wave (Figure 1.27). 
Separation parameters in TWIMS can be easily changed and optimised by voltage 
manipulation of the wave height and velocity, or buffer gas pressure [66]. However, the 
complex nature of the dynamic electric field in TWIMS complicates the relationship 
between drift time and CCS. As such, despite several attempts to resolve and 
understand this issue [67, 68], TWIMS is currently unable to directly measure the CCS 
of separated ions, and instead must rely on a calibration approach, based on known 
CCS values from DTIMS measurements [69]. 
 
 
Figure 1.27 Separation of ions by travelling wave ion mobility spectrometry (TWIMS).  A travelling 
DC potential pushes ions through the SRIG towards the detector. High mobility ions that suffer fewer 
buffer gas collisions keep up with the wave for longer and have shorter drift times. Lower mobility ions 
are overtaken by the wave and undergo more ‘roll over’ events, having longer drift times. 
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1.10 Commercial instruments used in this thesis 
1.10.1 Waters Synapt high definition mass spectrometer 
The Synapt series of instruments from the Waters Corporation, follow standard Q-
ToF instrument geometry, where a quadrupole mass analyser is followed by an 
orthogonal acceleration, reflectron ToF mass analyser. Between these two mass 
analysers, is the ‘Tri-wave’ region, where three separate SRIG cells are situated. The 
first cell, typically filled with argon gas, can act as a collision cell, and serves to trap 
and accumulate ions before they pass into the next SRIG, equipped with TWIMS 
separation in a nitrogen buffer gas. The third and final SRIG in this region, known as 
the transfer cell, is typically used to maintain IMS separation prior to mass analysis, 
but can also be used as a second collision cell, allowing for post-IMS CID if necessary. 
For each ion packet released by the trap cell and subjected to TWIMS separation, 200 
acceleration pushes, or bins, in the ToF are initiated before the trap cell releases the 
next ion packet. By knowing when each ion packet was released and by which push 
the ions were accelerated for ToF separation, the drift time of each ion can be 
calculated. This drift time can be corrected for m/z independent flight time in the 
transfer cell, as well as m/z dependent flight time between the transfer exit lens and 
the pusher region [66]. In practice, however, these corrections only minimally change 
the drift time (typically ~0.2 ms) and, given that other sources of error, such as 
precisely determining the drift time apex, are usually much larger, these corrections 
are not routinely applied [63].  
The Z-spray source region, so called for its distinctive Z shape, is designed to remove 
neutral molecules in the electrospray, as the path of these molecules will not be 
directed by the voltages controlling the ion path. While this is present on the earlier 
version of this instrument (Syanpt G1), later versions of this instrument, such as the 
Synapt G2Si, were also equipped with a stepwave device, to further remove neutral 
molecules and increase ion transmission, as well as a short, helium filled SRIG 
immediately prior to the TWIMS cell, to cool ions and increase IMS resolution.  
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Figure 1.28 Schematic diagram of a Waters Synapt G2Si HDMS. A typical Q-ToF design, ions pass 
through a stepwave ion guide device to remove neutral molecules before entering the quadrupole. Ions 
then enter the tri-wave region, where they pass through three SRIG cells: Trap, IMS and transfer. 
Finally ions enter a high vacuum ToF region equipped with a dual stage reflectron and an MCP 
detector. 
 
1.10.2 Thermo Q Exactive hybrid quadrupole – orbitrap mass spectrometer 
Following ionisation, ions in a Q-Exactive orbitrap MS, developed by Thermo Fisher 
Scientific, traverse a bent flatpole ion guide, before passing through a quadrupole mass 
filter, where m/z selection can be applied if necessary, and finally into a curved linear 
ion trap called the C-trap. Here, ions are accumulated before either being injected 
laterally into the orbitrap for m/z analysis, or axially into the nitrogen filled HCD cell, 
if MS/MS fragmentation is required. Following fragmentation, fragment ions can be 
injected back into the C-trap and, subsequently, the orbitrap for fragment ion analysis. 
The scan time of the orbitrap mass analyser can be adjusted, allowing control of 
resolution and MS acquisition speed, and, although in principle ToF mass analysers 
have a faster scan speed than orbitraps, the DDA cycle of the Q-Exactive is 
considerably faster than the current commercially available ToF instruments, capable 
of acquiring tandem MS spectra at 12 Hz [70]. Similarly, the accumulation time of 
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quadrupole selected ions in the C trap can be adjusted based on their intensities as 
measured by MS1 scans in the orbitrap, a process known as predictive automatic gain 
control, allowing lower intensity ions to be accumulated for longer before 
fragmentation, generating better quality MS/MS data [70]. Although, with the default 
instrument setup, this instrument geometry cannot separate ions by IMS, and is not 
well suited to high mass ions, such as those generate by native MS (discussed later in 
Section 2.4.1), the above characteristics make this instrument ideally suited to 
biological mass spectrometry in proteomics workflows and peptide fragmentation. 
 
 
Figure 1.29 Schematic diagram of a Thermo Q Exactive mass spectrometer.  Ions pass through a series 
of focusing lenses in the source region, before traversing a bent flatpole ion guide, the quadrupole mass 
filter and into the C-trap, a curved linear ion trap. Ions are then injected, laterally out of the C-trap, 
into the orbitrap, where m/z is measured by image current detection, or axially into the HCD cell, a 
nitrogen filled collision cell, if MS/MS fragmentation is required. Adapted from [70]. 
 
1.10.3 Thermo orbitrap fusion tribrid mass spectrometer 
With a similar architecture to the Q Exactive instrument, ions in the orbitrap fusion 
tribrid MS are first accumulated in the nitrogen filled ion routing multipole (IRM). If 
a single MS analysis is required, these ions are typically passed back into the C-trap 
for m/z analysis in the orbitrap. However, if MS/MS experiments are required, this 
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instrument architecture lends itself to a diverse range of options for fragmentation 
and analysis. For example, quadrupole selected ions can be fragmented in either the 
high pressure cell of the linear ion trap, by CID with the helium collision gas, or 
fragmented more quickly (by ~10-30 ms) by HCD fragmentation simply by injection 
of ions into the IRM at elevated energies [71]. Fragment ions can then be analysed by 
the linear ion trap, by injecting ions into the low pressure cell, or by the orbitrap, via 
the C-trap and the IRM (Figure 1.30).  
 
 
Figure 1.30 Schematic diagram of a Thermo orbitrap fusion tribrid mass spectrometer.  Similar to the 
architecture of the Q Exactive instrument, ions are accumulated in the ion routing multipole before 
being passed, either back into the C-trap for injection into the orbitrap, or into the dual pressure linear 
ion trap mass analyser for an alternative route for mass analysis or MS/MS experiments. Adapted from 
[71]. 
 
Although m/z analysis for the precursor, and fragment ions, for a typical DDA 
workflow, can both be performed in the orbitrap (a workflow unimaginatively named 
orbitrap-orbitrap), the unique ‘T’ shaped geometry of the instrument is such that 
precursor and fragment ion analysis can be performed simultaneously by precursor 
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analysis in the orbitrap, and fragment ion analysis in the linear ion trap (orbitrap-
iontrap workflow). This parallelisation streamlines MS/MS acquisition, taking 
advantage of both the high resolution of the orbitrap and fast scan speeds of the linear 
ion trap, drastically increasing the DDA cycle speed, and allowing the orbitrap fusion 
instrument to achieve MS/MS fragmentation frequencies of up to 22 Hz [71]. 
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2 Introduction II: Protein aggregation, structure and 
dynamics studied by mass spectrometry 
 
 “…the most remarkable thing about proteins is that they can do almost anything.”  
-Francis Crick, Co-discoverer of the Structure of DNA, 1958 [72].  
 
Essential for nearly all biochemical processes, proteins can be thought of as the 
molecular machines that maintain life, where almost everything inside a cell is itself, 
or is synthesised by, a protein. Some of the more well-known roles proteins adopt are 
enzymes, biological catalysts for a cells’ metabolism, and antibodies, a vital component 
of the adaptive immune system. However, proteins have an almost uncountable 
number of other functions. Opsin proteins in the retina mediate the conversion of 
photons into electrochemical signals to enable sight [73]. Motor proteins like kinesins 
‘walk’ through cells moving cellular cargo from one place to another [74]. Even the air 
we breathe is transported around our bodies using the oxygen binding protein 
haemoglobin. 
The remarkable ability of these molecules to function in such a wide variety of roles, 
for most proteins, relies on adopting a specific three-dimensional shape, or 
conformation. These 3D shapes are formed by the folding of one or more polypeptide 
chains - long strings of peptide bond linked amino acids - the main structural 
components of proteins (Figure 2.1). In 1961, after demonstrating for the first time 
that protein folding could be reversible, work for which he would later be awarded 
the Nobel Prize in chemistry, C.B Anfinsen famously concluded that the specific 
sequence of amino acids in a polypeptide chain, contains all the information necessary 
for the protein to adopt its native fold [75]. Although varying significantly in length 
from just ~50 or so amino acids, up to several thousand for larger proteins, 
polypeptides are composed of only twenty different types of amino acids, sometimes 
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known as residues, each of which differ by the structural and chemical components 
of their side chain, varying in size, shape, hydrophobicity and charge (Table 2.1). 
Additionally, many proteins adopt post-translational modifications, such as 
acetylation or phosphorylation, altering the chemistries of the modified amino acids 
and allowing the protein to correctly fold and perform its biological function [76]. 
 
 
Figure 2.1 Transcribing, translating and folding polypeptide chains.  DNA is transcribed and translated 
into a chain of amino acids called a polypeptide. The sequence of those amino acids in the chain 
determines how the polypeptide folds, to generate the three-dimensional structure, or conformation, 
of a fully folded protein. 
 
Techniques such as X-ray crystallography [77], nuclear magnetic resonance 
spectroscopy (NMR) [78] and, more recently, cryo-electron microscopy [79] allow us to 
study the final folded structure of proteins, and observe some of the interactions 
which stabilise them: the hydrophobic effect, where hydrophobic side chains are 
buried in the protein core, away from solvent, disulphide bonds between cysteine 
residues, and hydrogen bonds formed between side chains, or the polypeptide 
backbone. Despite this, understanding the protein folding problem; exactly how 
proteins adopt their native fold from the sequence of a largely unstructured 
polypeptide, persists as one of the greatest challenges in modern structural biology [80, 
81].  
 
Introduction II: Protein aggregation, structure and dynamics studied by MS 
48 
 
Table 2.1 Summary of the twenty different naturally occurring amino acid structures, masses and 
abbreviations. 
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2.1 Protein folding, misfolding and aggregation 
In 1968, Cyrus Levinthal famously summarised the protein folding problem by 
demonstrating that even a relatively small polypeptide of 100 or so residues has such 
a large number of possible conformations physically available to it, that an exhaustive 
search of all of them, even when sampling at 10 trillion conformations per second, 
would take longer than the current lifetime of the universe to complete [82]. Knowing 
that proteins can find and adopt their native fold in as little as a few microseconds [80], 
this problem, now known as Levinthal’s paradox, effectively illustrated that the native 
state of a polypeptide could not possibly be found simply by searching conformations 
at random [83].  
 
2.1.1 Protein folding  
In the face of Levinthal’s paradox, many models have been proposed to explain how 
polypeptides fold into proteins on a biological timescale. The framework model 
proposed that smaller secondary structural elements, such as α-helices, folded first 
before these pre-formed structural elements dock together to create the overall native 
fold [84-87]. Conversely, the hydrophobic collapse model proposed that the need for 
hydrophobic side chains in the polypeptide to be free from solvent interaction, leads 
to a collapsed molten globule state with hydrophobic side chains at its core. This 
collapsed globule was proposed to aid protein folding by compacting the polypeptide 
into a confined volume, narrowing the conformational search necessary to find the 
native state [88, 89]. The nucleation-condensation model combines these two processes, 
suggesting that protein folding occurs by the formation of a small nucleus, that may 
involve weak secondary structure, followed by collapse of the polypeptide around it 
[90]. 
Today, protein folding is thought of in the context of energy landscapes or ‘folding 
funnels’ [81], where the internal free energy of the polypeptide (y axis) is plotted against 
entropy (x axis), a measure of the conformational freedom of the molecule (Figure 
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2.2). Native-like interactions formed by folding polypeptides, perhaps driven by 
hydrophobic interactions or partially folded secondary structure, are, on average, 
more stable than non-native interactions. These favourable contacts are therefore 
more persistent, forming partially folded intermediate structures with lower internal 
energy and restricted conformational freedom (i.e. reduced entropy). This further 
directs the polypeptide towards ever more stable, lower energy species, eventually 
adopting the fully folded native state, usually considered to be the lowest energy, most 
thermodynamically stable structure that is kinetically accessible under physiological 
conditions [91]. 
A thought experiment proposed by Dawkins [92] and discussed elsewhere [82] is useful 
for understanding this concept. Consider the, now infamous, infinite monkey 
theorem: a monkey randomly hitting keys on a typewriter will, given an infinite 
amount of time, produce the complete works of Shakespeare. To make it easier for the 
monkey, we reduce the number of typewriter keys to just 27, the 26 letters and a space 
key, and instead of having to produce the complete works of Shakespeare, the monkey 
only has to correctly type a single phrase from Hamlet: ‘Methinks it is like a weasel’. 
Randomly typing letters, it would take approximately 1040 key strokes for the monkey 
to correctly type out this statement [82]. However, if, with each attempt, the monkey 
cannot change those letters already in the correct positions, analogous to the 
polypeptide finding a stable native-like interaction, he need only attempt the 
statement a few thousand times before correctly reproducing Hamlet’s comment.  
This analogy simplifies the problem somewhat. In actuality, protein conformations 
are in constant dynamic equilibrium, where changing environmental or solution 
conditions (temperature, pH etc…) shifts the equilibrium to populate more unfolded 
or native forms of the molecule. Depending on their relative stabilities, partially 
folded states can often revert to more unfolded conformations rather than move 
towards the native state, analogous to the monkey merely finding it difficult to change 
correctly placed letters rather than impossible. Similarly, there is some debate as to 
whether folding intermediates are useful, on-pathway structures towards the native 
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state, or kinetically trapped stable conformers that result in less efficient folding [93]. 
Nevertheless, this simplification does effectively demonstrate that there can be several 
different ways of attaining the correct native fold and that a biased search, rather than 
a random search, is what solves Levinthal’s paradox, where the sequence of amino 
acids in a polypeptide chain, are selected by evolution to not only allow the protein 
to effectively perform its biological function, but to fold quickly and effectively into 
the native structural conformation.  
 
 
Figure 2.2 Idealised folding funnel/energy landscape for protein folding.  From the unfolded 
polypeptide, native-like interactions are favoured in the folding process which produce partially folded 
conformers of lower internal free energy (y axis) and reduced conformational entropy (x axis). This 
process continues until the native state is reached. 
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2.1.2 Misfolding, aggregation and disease 
Given the immense complexity of protein folding, and the sheer number of possible 
conformations a polypeptide chain may adopt, it would be remarkable if protein 
misfolding were never to occur. Frequently, protein misfolding is a result of amino 
acid substitutions in the polypeptide sequence, improper proteolysis, or destabilising 
solution conditions such as changes in temperature or pH [94]. A common, and 
expected, consequence of protein misfolding is the loss of biological function, and is 
associated with many diseases, collectively known as proteinopathies or 
conformational diseases [95].  Cystic fibrosis is one such example, usually caused by the 
deletion of a phenylalanine residue at position 508, shorthanded to ΔF508, in the 
polypeptide of a particular transmembrane conductance regulator protein [96]. 
On the other hand, some misfolded proteins experience a toxic gain of function. This, 
too, is associated with various diseases including bovine spongiform encephalopathy 
(BSE), commonly known as mad cow disease, where the misfolded prion protein 
‘replicates’ by misfolding other correctly folded proteins of the same type, eventually 
leading to large insoluble protein aggregates [97]. Indeed, protein aggregation is a 
common consequence of misfolding and, although the specific sequence of events 
leading to aggregation is difficult to elucidate and differs from protein to protein, 
aggregation is generally thought to be driven, at least in part, by hydrophobic side 
chains, normally buried in the native fold, becoming solvent exposed in the misfolded 
species. These misfolded species are then proposed to aggregate into small, initially 
soluble, oligomers, before assembling further into larger, insoluble species sometimes 
containing many thousands of protein molecules (Figure 2.3).  
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Figure 2.3 Generalised mechanism of protein aggregation.  A misfolded or partially folded species 
generated from the native state aggregates into oligomeric species, before proceeding to larger insoluble 
aggregates, such as amyloid fibrils. 
 
The size, composition and morphology of protein aggregates can vary significantly 
depending on the protein involved and the nature of aggregation. For example, the 
bovine serum albumin (BSA) protein as well as several therapeutic antibodies have 
been shown to form large, amorphous aggregates when stressed under extensional 
flow conditions [98]. Still, a wide variety of different proteins have been shown, with 
an equally wide variety of different stimuli, to aggregate into highly ordered, highly 
stable protein aggregates with rope-like morphologies. These types of protein 
aggregate, collectively known as amyloid, are associated with more than 60 human 
diseases [99], including well known afflictions such as Alzheimer’s disease [100], 
Parkinson’s disease [101] and type 2 diabetes mellitus [102].  
 
2.1.3 Structure and formation of amyloid 
Although the different proteins and peptides that form amyloid often share little 
structural or sequence homology, the resulting aggregate fibril structures are 
strikingly similar. First described in atomic detail by William Astbury in the 1930’s 
[103], mature amyloid fibrils are now known to consist of 2-6 protofilaments, 2-5 nm in 
diameter, that twist to form rope-like structures 7-13 nm wide [94]. The protofilaments 
are constructed from a core of stacked β-sheets running parallel to the long axis of the 
fibril, with the individual β-strands that make up those sheets, perpendicular to the 
fibril axis (Figure 2.4) [104]. This so called “cross-β” structure, named for the 
distinguishing “cross” pattern observed during analysis by X-ray fibre diffraction [105, 
106], is a defining characteristic of amyloid fibrils. Similarly, many fibrils are known to 
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share common non-amyloid components as part of the overall in vivo structure. Long 
unbranched polysaccharides known as glycosaminoglycans (GAGs), various metal 
ions and Serum Amyloid P (SAP), a pentameric protein (each subunit ~ 25 kDa) 
observed to make up approximately 14% of amyloid deposits by dry mass, are all 
known to associate with amyloid deposits in vivo [94].  
 
 
Figure 2.4 Structure of an amyloid fibril.  Twisted protofilaments forming the overall amyloid fibril 
consist of stacked β-sheets stabilised by extensive hydrogen bonding between strands, and steric zipper 
interactions. PDB: 5OQV [107].  
 
Generally, amyloid fibrils and protofilaments are extraordinarily stable structures, 
held together by extensive hydrogen bonding between β-strands, and interdigitated 
amino acid side chains in the fibril core that form solvent free ‘steric zipper’ interfaces 
[108]. Indeed, it has been suggested that the amyloid fibril state can be more 
thermodynamically stable than the native state under certain conditions (Figure 2.5) 
[109], where drastic changes in pH, or dissolution in strong organic solvents is often 
required to disaggregate fibril structures [110, 111]. 
 
Introduction II: Protein aggregation, structure and dynamics studied by MS 
55 
 
 
Figure 2.5 Energy landscape for protein folding, misfolding and aggregation. Protein aggregation, 
thought to be caused by misfolding, leads to oligomer formation and, ultimately, the formation of 
highly stable, rigid, amyloid fibrils. 
 
Needless to say, understanding the conformational changes that allow proteins to 
form amyloid from, initially stable, soluble protein monomers, is of paramount 
importance to the prevention and treatment of amyloid diseases. 
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2.2 Beta-2 microglobulin (β2m) 
Wild-type β2-microglobulin (β2m) is a small, 99 residue member of the 
immunoglobulin (Ig) superfamily of protein structures [112, 113]. As is typical for 
members of this group, β2m has a “β-sandwich” fold consisting of seven anti-parallel 
β strands, labelled A-G, organised into two β-sheets, where strands A, B, E and D form 
one sheet and strands C, F and G form the other (Figure 2.6b). These two β-sheets are 
stabilised by a single, central disulphide bond between strands B and F, at residues 25 
and 80 [77].  
 
2.2.1 Normal function and dialysis related amyloidosis 
β2m is part of a complex of proteins known as the class 1 major histocompatibility 
complex (MHC-1), formed by the non-covalent, 1:1 association of β2m, the light chain 
component of the complex, with the α1 protein, the heavy chain component (Figure 
2.6a) [114]. Present on the surface of all nucleated cells, the function of this complex is 
to bind short peptides (8-10 residues) from proteins processed in the cytosol [115]. These 
peptides are transported from the cytosol to an organelle in cells known as the 
endoplasmic reticulum, where assembly of the MHC-1 occurs. After binding, the 
MHC-1 is transported to the cell surface where the bound peptide is presented for 
recognition by T-cells [115]. These cells recognise the peptide as ‘self’ or ‘non-self’, 
where the identification of a ‘non-self’ antigen, perhaps indicative of viral infection 
in the cytosol, triggers pathways leading to an immune response [116]. Although not 
directly involved in interactions with the bound peptide, β2m is critical for the 
assembly and stability of the complex [117], and is essential for efficient transport of the 
MHC1 to the cell surface [118]. The binding of β2m to the α1 chain of the complex is 
stabilised by extensive intermolecular interactions between the two proteins 
including contacts made in the B-C loop (His31-Asp34), a continuous eleven residue 
stretch in the D-E loop and parts of the D and E strands (Ser52-Tyr63), as well as a 
network of hydrogen bonds in the A and B strands [115].  
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Figure 2.6 The structures of β2m and the class 1 major histocompatibility protein complex.  a) The class 
1 major histocompatibility complex (MHC1). The α1 chain (cyan) is bound to the β2m light chain 
component (blue) and a peptide antigen (red – shown as spheres). PDB: 2XPG [119]. b) NMR structure 
of monomeric β2m. β-strands A-G are coloured as in the sequence diagram below. The disulphide bond 
between residues 25 and 80 is shown as sticks. PDB: 2XKS [78]. 
 
Similar to many other proteins, β2m is being constantly turned over in the body. 
When the MHC-1 is degraded, the membrane bound α1 heavy chain is internalised 
back into the cell, leaving the non-covalently associated β2m protein to be released 
into the blood [120] where it is then cleared and degraded by the kidneys [115].  
Patients with abnormal kidney function have a reduced rate of β2m clearance [121]. 
Similarly, despite recent improvements in dialysis technology [122], filtration 
membranes used in kidney dialysis machines are typically ineffective at filtering out 
β2m [123] causing a sustained increase in serum β2m concentration up to 60 times normal 
levels [124]. The end result is protein aggregation, and the formation of β2m amyloid 
fibrils, typically localised to osteoarticular tissues, such as the bones and joints (Figure 
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2.7) [123, 124]. Whilst β2m fibril formation has been documented in long surviving non-
dialysed kidney disease patients [121], build-up of amyloid deposits typically takes years, 
and is usually beyond the life expectancy of most non-dialysed patients. As such, 
amyloid deposits of this kind are more commonly found in patients undergoing long-
term hemodialysis, with an estimated incidence of >95% after 15 years of treatment 
[123]. Even with kidney transplantation, this condition, known as dialysis related 
amyloidosis (DRA), is difficult to reverse, eventually leading to pathological 
destruction of the bones and joints with symptoms including bone cysts, restricted 
movement, joint pain and carpal tunnel syndrome [115]. 
 
 
Figure 2.7 β2m amyloid deposits in dialysis related amyloidosis (DRA).  Indium labelled β2m amyloid 
fibrils are localised to the bones and joints of DRA patients. Zoomed images are shown of the arms (a), 
chest (b) and knees (c). Taken, with permission, from [125].  
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2.2.2 β2m aggregation in vitro 
In an effort to understand how amyloid fibril deposits in DRA are formed, the 
structure, folding pathway, and amyloidogenic properties of β2m have been studied 
extensively [115, 126]. Despite its fibrillogenic properties in vivo, however, β2m does not 
readily form amyloid fibrils in vitro under physiological conditions, even after 100 
days, and when incubated at concentrations 20 times higher than those found in DRA 
patients [78, 113]. Whilst strongly acidic conditions (pH < 4) do permit aggregation of β2m 
into amyloid fibrils in vitro, and considerable research has been targeted at the 
aggregation of this acid unfolded state [127-131], unlike amyloid deposits associated with 
DRA, β2m fibrils generated under acidic conditions rapidly depolymerise when 
returned to physiological pH, highlighting the differences between in vitro 
fibrillation from the acid unfolded state, and in vivo fibrillation from native 
conditions [110]. This, combined with the observation that many dialysis patients with 
similarly increased levels of serum β2m do not display symptoms of DRA [132], suggests 
that additional factors must be important for β2m amyloid formation in vivo. 
Several studies have shown that the addition of accessory molecules such as pre-
formed amyloid fibril seeds [133-135], or molecules commonly associated with fibrils such 
as SAP [136] and GAGs [137], permit β2m fibril formation in vitro at, or near, 
pathophysiological conditions. In one such case, the addition of collagen was shown 
to cause fibrillation of β2m under neutral pH conditions in vitro [138]. β2m has been 
shown to bind collagen proteins with µM affinity [139], and ex vivo fibrils from DRA 
patients are also associated with collagen, leading to the hypothesis that this property 
may be responsible for the specificity of DRA amyloid deposits to the bones and joints, 
tissues typically high in collagen fibres [138]. Copper ions have also been implicated in 
the amyloidogenic properties of β2m [140]. In the presence of Cu2+, β2m readily forms 
amyloid fibrils at neutral pH in vitro [141] and the symptoms of DRA patients were 
shown to improve after switching to Cu2+ free dialysis membranes [142, 143]. Binding of 
Cu2+ ions has also been shown to destabilise the native state of β2m and delay refolding 
[144]. Nevertheless, while understanding the solution conditions and additional factors 
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which favour β2m amyloid formation is useful, insights into the structure and folding 
pathway of β2m are essential to determine how these accessory molecules affect the 
protein’s structure, and change its amyloidogenic properties. 
 
2.2.3 β2m folding pathway and the IT state 
Changes in tryptophan fluorescence observed during stopped-flow refolding 
experiments have shown that β2m folds in two stages: a fast phase (~2.1 s-1) which 
generates a stable partially folded intermediate, followed by a very slow folding phase 
(0.02 s-1) into the final native state of the protein (Figure 2.8a) [136]. Further probing of 
this folding pathway revealed that an engineered variant in which the Pro 32 amino 
acid was changed to a much smaller glycine residue (P32G), was able to fold into the 
protein’s native state without this slow folding phase [136]. Given that the native, fully 
folded structure of β2m is known to contain a relatively uncommon cis peptide bond 
between residues His 31 and Pro 32 (Figure 2.8b) [145], it was suggested that trans-cis 
isomerisation of this bond is responsible for the slow phase in the refolding of β2m [136].  
Whilst only representing ~5% of the protein at equilibrium in wild-type β2m, the 
folding intermediate structure found between the fast and flow folding phases of β2m, 
usually referred to as the IT state (IntermediateTrans) due to the non-native trans His 
31-Pro 32 peptide bond, was significantly more populated in the P32G variant (~30% 
at equilibrium). Interestingly, this variant was also shown to elongate existing wild-
type β2m fibrils faster than the wild-type protein, with an increasing elongation rate 
occurring under solution conditions favouring a higher relative population of the IT 
state folding intermediate[136]. Another engineered proline variant, P5G, found to 
populate ~60% IT state at equilibrium, was also able to form amyloid fibrils de novo 
under physiological conditions without the addition of any accessory molecules [146].  
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Figure 2.8 The folding pathway of β2m.  a) Folding funnel of β2m under physiological conditions. 
Parallel folding pathways with (IT), and without (IC) a trans His-Pro 32 peptide bond form intermediate 
states (I) while folding into the native state (N) from the unfolded state (U). The folding intermediate 
IT is proposed as a link between the folding and aggregation pathways. Taken from [136]. b) Cis/trans 
isomerisation of proline residues in a polypeptide. 
 
With the His-Pro 32 peptide bond in the trans configuration, β2m has been shown to 
bind Cu2+ ions with 10,000 fold greater affinity than the native structure, and it has 
been suggested that Cu2+ binding to His 31 may induce cis-trans isomerisation, and 
generation of the IT state folding intermediate, consistent with earlier work showing 
increased β2m amyloidogenicity in the presence of copper [147]. Similarly, cis-trans 
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isomerisation of proline residues has been linked to aggregation in several other Ig 
domains [148-150]. As a result, the IT state folding intermediate of β2m has been 
highlighted as a leading candidate for the amyloidogenic precursor of β2m fibril 
formation. 
 
2.2.4 ΔN6 β2-microglobulin 
Considered to be a structural mimic of the IT state, ΔN6 is a proteolytically cleaved 
truncation variant of β2m lacking the six N-terminal amino acids. This variant readily 
forms amyloid fibrils in vitro under physiological conditions in the absence of 
accessory molecules and, at equilibrium, is approximately 90% in the trans His-Pro 32 
conformer [78, 146]. ΔN6 has a higher affinity for collagen relative to full length β2m [139] 
and has been detected in the amyloid deposits of DRA patients [151, 152] constituting 
~30% of protein extracted from ex vivo fibrils [153]. Although not detected in the blood 
plasma of DRA patients [154], leading to the inevitable question of whether formation 
of ΔN6 is a cause, or result of amyloid formation in DRA, it has been shown that ΔN6 
can initiate fibrillation of full length β2m in vitro, even when added at ~1% 
concentration relative to the full length protein [78]. This, coupled with their known 
association in vivo, led to the suggestion that that ΔN6 promotes aggregation of the 
wild-type protein [155]. Some have suggested a prion-like mechanism whereby a ΔN6-
β2m collision initiates amyloidogenesis by triggering cis-trans isomerisation of full 
length β2m, causing it to adopt the non-native, IT state precursor to amyloid formation 
[78]. Others suggest a secondary nucleation mechanism where formation of ΔN6 
amyloid fibrils seed the growth of amyloid fibrils made from the wild-type protein 
[156]. In spite of recent efforts, an exact mechanism of how β2m forms amyloid fibrils in 
DRA, and indeed how the IT state is involved in amyloid formation, has yet to be 
elucidated. 
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2.2.5 D76N β2-microglobulin 
In 2012, a study published in the New England Journal of Medicine reported a unique, 
hereditary, systemic amyloidosis discovered in several members of a French family 
experiencing progressive bowel dysfunction [157]. With disease onset in middle age and 
slow disease progression over many years, amyloid deposits were identified in various 
tissues of the affected family members including the spleen, heart, liver and nerves. 
Proteomic analysis of these amyloid deposits found them to be composed of a variant 
of β2m, with an aspartic acid to asparagine amino acid substitution at position 76, 
shown by DNA sequencing, to be caused by a single guanine to adenine base 
substitution at position 286 in the β2m gene [157]. Interestingly, despite affected family 
members being heterozygous for this mutation, indicating that wild-type β2m is also 
present in patients, amyloid deposits contained only the D76N variant, and were not 
localised to the bones and joints, as in DRA. Similarly distinct from DRA, affected 
individuals had normal renal function, and normal concentrations of β2m in the blood 
[157]. Patients were not immune-deficient, and the D76N containing MHC-1 was 
shown to have comparable structure, dissociation patterns and stability compared 
with the wild-type complex [158], suggesting the D76N variant may retain its biological 
function.  
Structurally, the D76N variant is almost indistinguishable from the wild-type protein 
[78, 157] (Figure 2.9), and has been shown to fold via a similar pathway involving the IT 
state [156]. Unlike wild-type β2m, however, D76N is highly amyloidogenic in vitro in 
the absence of accessory molecules and readily forms amyloid fibrils under neutral pH 
conditions [159]. While this amino acid substitution has been shown to significantly 
destabilise the native state of the protein [156], as has the N-terminal truncation in ΔN6 
[146], the native state of murine β2m is also less stable than that of D76N, and yet does 
not form amyloid fibrils [160], suggesting that thermodynamic stability of the native 
state is not necessarily correlated with the propensity to form amyloid in β2m. 
While some evidence suggests D76N has an increased population of IT state at 
equilibrium relative to the wild-type protein (~25% compared to ~4% for the wild-
Introduction II: Protein aggregation, structure and dynamics studied by MS 
64 
 
type protein) [156], others have shown no significant difference [161]. Similarly, the P32G 
variant of the wild-type protein, shown to populate ~30% IT state at equilibrium, is 
unable to form amyloid fibrils de novo at physiological pH, unlike the D76N variant 
[146]. Numerous in silico studies have suggested that the IT state in D76N is structurally 
different to that of the IT state in the wild-type protein, either by comparatively more 
unfolding close to the N and C-termini [162] or a more disordered D-strand [163], 
suggesting that this may be responsible for the increased aggregation propensity of the 
D76N variant. However, subsequent studies using CD and NMR have shown that the 
IT state structures of D76N and the wild-type protein are similar, instead suggesting 
there may be an alternative aggregation-prone conformation, distinct from the IT state 
present in the wild-type protein or ΔN6 [161]. Interestingly, no increase in aggregation 
propensity was observed for other D-N variants (D34N, D38N, D53N, D59N and 
D98N) in Asn-scan mutagenesis studies [159] suggesting the amino acid position, rather 
than the residue substitution itself, is the important factor in aggregation propensity. 
Indeed, several other D76 variants (D76H, D76E and D76A) have all been shown to 
form amyloid fibrils in vitro in the absence of additional factors, under the same 
experimental conditions as D76N [164]. 
The D76N variant of β2m, therefore, raises an important question: 
How does a single amino acid substitution in a solvent exposed loop of the protein 
increase amyloidogenicity so significantly, seemingly without significantly affecting 
the native conformation or folding pathway? 
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Figure 2.9 Wild-type, and aggregation-prone variants of β2m.  NMR structures of a) wild-type (PDB: 
2XKS, [78]), b) ΔN6 (PDB: 2XKU, [78]) and an X-ray crystallography structure of c) D76N (PDB: 4FXL, 
[157]) β2m are shown. Side chains of position 76 are highlighted in the wild-type and D76N structures. 
Side chains of His31 and Pro32 are shown as sticks at the top of all three structures. The N and C-
termini have been annotated –N and –C respectively. The amino acid sequence of wild-type β2m is 
shown. The site of the D76N amino acid substitution is highlighted with an *. 
 
2.3 Protein aggregation in biopharmaceuticals 
Small molecule drugs, such as aspirin, have been used to treat diseases for more than 
100 years [165]. However, a recent push for more targeted medicines, with reduced risk 
of off-target toxicity, often associated with small molecule treatments, has led to an 
increasing interest in therapies derived from biological sources, commonly referred to 
as biopharmaceuticals [166]. Perhaps the most striking surge in biopharmaceutical 
development of the last 20 years has been in therapeutic monoclonal antibodies 
(mAbs), where 112 therapeutic mAbs were approved in the United States and the 
European Union between 2015 and 2018, compared with less than 10, in the years 
leading up to 1989 [167]. 
Structurally, mAbs are ~150 kDa tetrameric proteins, made from two pairs of 
polypeptide chains, with each pair consisting of one heavy chain (~50 kDa each) and 
one light chain (~25 kDa each). This ‘dimer of dimers’ is arranged into a quaternary 
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structure with an overall ‘Y’ shape, characteristic of mAbs (Figure 2.10a), which can 
be broken down into three main sections: the FC region, and the two Fab arms. 
Typically, each of these sections is made from four distinct Ig domains (of similar 
structure to β2m) where each Fab arm comprises two Ig domains from the light chain 
and two from the heavy chain, and the FC region comprises the remaining two 
domains from each copy of the heavy chain (Figure 2.10a). 
 
 
Figure 2.10 The structure of an IgG1 antibody.  a) Schematic diagram of an antibody structure. 
Disulphide bonds are shown in yellow. Domains annotated Vx and CxN show variable and constant 
domains, respectively. Subscripts L and H denote the light and heavy chains, respectively. The crystal 
structure of Pembrolizumab (PDB: 5DK3) [168] is shown in b). Heavy and light chains are coloured dark 
and light blue, respectively. 
 
In nature, mAbs constitute an integral part of the adaptive immune system, where 
mAb binding to proteins on the surface of infecting bacteria or viruses, for example, 
can result in a variety of therapeutic outcomes, ranging from death or paralysis of the 
infectious agent, or complement activation; the recruitment of immune cells to the FC 
binding site of the antibody [169]. Despite the typically high specificity of mAbs to their 
respective targets (pM-nM affinities are common [170]), usually referred to as antigens, 
the vast array of different and constantly evolving infectious targets requires 
significant adaptability of the mAb antigen binding site to remain effective. While 
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most of the mAb structure is comprised of constant domains (denoted CH1-3 or CL in 
Figure 2.10a), so called due to their lack of variability among mAb variants, the 
capacity for mAbs to adapt to bind a wide range of different antigens arises from 
hypervariable loop structures in the antigen binding site in the variable domains of 
the Fab arms (denoted VL and VH in Figure 2.10a for the variable domains of the light 
and heavy chains, respectively). Typically, there are twelve of these loop structures 
for a given mAb protein, three for each of the variable domains, where the amino acid 
sequences in these loops, also known as the complementarity determining regions 
(CDRs), are readily substituted between antibody variants, adapting the structure, 
conformation and microenvironment of the antigen binding site to suit a multitude 
of different targets. 
In the development of biotherapeutic antibodies, this system is ‘hijacked’, and the 
structure and sequence of the CDR regions is purposefully changed to produce mAbs 
which bind a target chosen by the developer, typically one the natural immune system 
has failed to identify. For example, Pembrolizumab, the structure of which is shown 
in Figure 2.10b, is a biotherapeutic used to treat a variety of different cancers by 
binding to the PD-1 receptor protein on the surface of activated T cells. Cancerous 
cells often highly express the binding partner of this receptor, PD-L1, on their surface, 
such that activated immune cells recognise the tumour as ‘self’, hence preventing an 
anti-tumour immune response. Pembrolizumab binding to PD-1 receptors interferes 
with this interaction, allowing activated T cells and the natural immune system to 
attacked the tumour [171]. 
While the benefits of developing specifically targeted biotherapeutic antibodies are 
obvious, the development process for these products harbours numerous 
opportunities for protein aggregation. Coupled with the engineered amino acid 
sequence of the mAb, itself a possible cause of aggregation, biotherapeutics are 
subjected to an array of physical, chemical and mechanical stresses at various stages 
of production, storage or even during the administration of the drug to patients. For 
example, changes in pH or temperature during protein production in bioreactors [172], 
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or downstream purification [173], freeze-thaw cycles during storage [174], and interaction 
with siliconized surfaces on syringes prior to subcutaneous injection of the drug [175], 
are all possible causes of protein aggregation in biopharmaceuticals. Not only does 
protein aggregation decrease the yield of useful product, passing the increased cost on 
to consumers, but can also result in more insidious outcomes, such as reducing the 
efficacy of treatment, requiring higher doses to remain effective, or worse, the 
triggering of an immune response in patients, compromising patient safety. 
Consequently, mitigating protein aggregation in the early stages of biopharmaceutical 
development is of paramount importance. 
 
2.3.1 MEDI1912 and MEDI1912_STT 
Initially designed to bind the nerve growth factor (NGF) protein for the potential 
treatment of chronic pain, MEDI1912, developed by Medimmune (now AstraZeneca), 
is an IgG1 class mAb which, despite low pM affinity for its target antigen [170], 
displayed significant propensity to reversibly self-associate into protein aggregates 
during manufacture. Noting several other undesirable biophysical characteristics, 
such as adsorption to filter membranes during purification, resulting in decreased 
yield, and significant oligomerisation at low (<1 mg ml-1) concentrations, three surface 
exposed hydrophobic amino acids in CDR loops one and two of the VH domain were 
highlighted for their involvement in the reversible self-association dimer interface: 
W30, F31 and L57 [170]. These amino acids in MEDI1912, hereafter referred to as WFL, 
were substituted for three less hydrophobic groups (W30S, F31T, L57T) generating a 
triple substitution variant: STT. Despite these CDR substitutions, the STT variant 
maintained a low pM affinity for NGF, with significantly improved biophysical 
characteristics including  significantly reduced self-association, a 2-fold improved 
half-life in rat in vivo models, and less non-specific tissue association [170]. Although 
WFL and STT have been shown to behave differently under flow induced stress 
conditions [176], the exact mechanism of aggregation and the conformational changes 
associated with these amino acid substitutions remain unexplored. 
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2.4 Mass spectrometry in structural biology 
In recent years, mass spectrometry has evolved a plethora of different approaches 
aimed at the biophysical characterisation of proteins, revealing various different 
aspects of protein structure including protein dynamics, protein-protein and protein-
ligand interactions, as well as differences in conformation and shape [177]. These 
methods can be broadly split into two groups: those that require the protein sample 
to remain intact, and those that require the protein to be fragmented. While a 
complete review of structural MS methods is beyond the scope of this thesis, an 
overview of some of the most common techniques used in structural MS, as well as 
those used in this thesis, are shown Figure 2.11, and are discussed in the next section.  
 
 
Figure 2.11 A summary of structural MS methods.  Broadly, structural MS methods can be split into 
two categories: intact, where the polypeptide chain of the protein is analysed intact, or proteomic, 
where MS fragmentation and/or enzymatic digestion is used to study proteins at the peptide level.  
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2.4.1 Accurate mass determination, native MS and ion mobility 
As discussed earlier in Section 1.2.1, the advent of ESI has allowed large molecules 
such as proteins to be ionised and analysed intact by use of MS. By using volatile, but 
non-denaturing, solution conditions, such as ammonium acetate solutions, proteins 
can be ionised and introduced into the instrument from their native solution phase 
conformation. Typically, folded proteins have a lower solvent accessible surface area 
(SASA) than unfolded proteins and, as such, have fewer accessible ionisable groups, 
resulting in native proteins adopting narrower charge state distributions,  with fewer 
charges on average (i.e. higher m/z) when ionised by ESI (Figure 2.12b). Conversely, 
unfolded proteins, with a larger SASA and more accessible ionisable groups, adopt 
more charges from ESI (lower m/z) and have wider charge state distributions (Figure 
2.12a). Thus analysis of charge state distributions can yield information on the 
conformation of proteins [178-180].  
Typically for native MS experiments, considerable effort is made to optimise 
instrument conditions, aimed at striking a balance between effective transmission of 
high m/z ions, maintaining the intact molecule and any non-covalent interactions 
(particularly important for protein complexes), and aiding the desolvation process, 
usually achieved by voltage and pressure manipulation within the instrument [181-183]. 
That said, complete desolvation of native ions, particularly for larger complexes, 
remains challenging, and broader, less resolved, solvated charge state peaks are 
frequently observed in native MS spectra, decreasing the mass accuracy. This, coupled 
with the fewer charge states observed for native charge state distributions, equating 
to fewer data points from which to calculate a mass, means that denatured MS is the 
preferred technique to calculate an average mass of a protein, whilst native MS is more 
typically used for structural characterisation of the folded protein or native protein 
complex. 
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Figure 2.12 Idealised native and non-native charge state distributions.  a) Unfolded proteins have more 
accessible ionisable groups, and adopt higher charge states and wider charge state distributions. b) 
Natively folded proteins have fewer exposed ionisable groups, and so adopt lower charge states and a 
narrow charge state distribution, the latter indicating reduced flexibility of the structure. 
 
By introducing the protein into the instrument from its native conformation, IMS can 
be used as a gas phase separation technique to separate different co-populated 
conformations of a protein, with the same m/z but different sizes or shapes. This 
technique is now well established as a method to study the conformational 
distribution of proteins [184], including aggregation-prone samples [185, 186] and the early 
stage oligomers they form in the aggregation cascade, that would otherwise overlap 
in a 1D mass spectrum [187, 188]. The CCS values calculated from native IMS-MS data 
can then be compared with CCS values calculated in silico, using a variety of different 
algorithms [189-191], from structural data obtained from X-ray crystallography or NMR 
experiments. This information can be used for low resolution modelling of structures 
observed in IMS experiments, to determine the structure and conformation of 
proteins, oligomers or protein complexes [184, 192]. 
There is considerable debate, however, as to the extent to which proteins retain their 
native conformation in the gas phase. Some proteins have been shown to undergo 
significant gas phase collapse, where the lack of solvent, and subsequent loss of the 
hydrophobic effect, leads to self-solvation of side chains and conformational changes 
[192, 193]. Others however, have shown in ion trap-IMS experiments that, when sprayed 
under non-denaturing solution conditions, gas phase protein ions retain a CCS 
consistent with the native conformation for several hundred milliseconds [194, 195], 
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before adopting stable gas phase conformations. Similarly, gas phase spectroscopic 
approaches have shown that protein ions retain native secondary structure in the gas 
phase [196, 197], and that, when decelerated onto a surface and recovered after ionisation, 
some protein ions can retain biological activity [198]. As such, most proteins are 
considered to retain a native-like gas phase conformation on the timescale of an IMS 
experiment, providing the sample was introduced from non-denaturing solution 
conditions and that no collision induced unfolding has occurred, intentionally or 
otherwise, within the instrument. 
 
2.4.2 Fragmentation and peptide sequencing 
Many structural MS methods for protein characterisation require tandem MS 
experiments, and fragmentation of the protein sample. Although proteins can be 
introduced into the mass spectrometer intact and fragmented within the instrument, 
usually referred to as ‘top-down’ MS/MS, more commonly, proteins are first 
proteolytically digested into peptides using digestive enzymes, before MS/MS is used 
to analyse the resulting peptides, typically following prior LC separation. This is 
usually referred to as a ‘bottom-up’ approach which, in its simplest form, can be used 
to determine the sequence of amino acids from which the peptides are made, where 
multiple peptides can be used to determine the amino acid sequence of the protein. 
Typically, this is performed using a product ion scan and CID (Figure 2.13). 
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Figure 2.13 Peptide sequencing by product ion scan MS/MS.  Peptides with specific m/z are selected in 
the quadrupole. Fragmentation results in multiple fragment ions with different masses, typically 
including some remaining intact peptide. Ions exiting the fragmentation cell are separated by their m/z 
in the second mass analyser, where differences in mass from fragment ion peaks are used to determine 
the amino acid sequence of the peptide. 
 
Alternative fragmentation techniques, such as ETD and ECD, can be used for peptide 
and protein fragmentation in instances where maintaining non-covalent interactions 
is crucial. For example, mapping of non-covalent protein complexes in ‘top-down MS’ 
experiments [199], mapping post translational modifications [200] and localising sites of 
electrostatic interactions [201]. Importantly, these fragmentation techniques generate 
different fragment ions from peptides. Where CID and HCD generally cause 
fragmentation at the peptide bond, generating b and y ions, ETD and ECD generally 
cleave the N-Cα bond, resulting in the formation of c and z fragment ions (Figure 2.14) 
[202-204].  
 
 
Figure 2.14 Fragment ions generated from peptide ion dissociation.  Different fragmentation methods 
cleave peptides at different bonds. X, y and z ions are formed when the positive charge is retained at 
the C-terminal side of the peptide. A, b and c ions are formed when the positive charge is retained by 
the N-terminal side of the peptide. The subscript x defines the number of amino acids present in each 
ion. 
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2.4.3 Hydrogen deuterium exchange (HDX) 
Developed at the Carlsberg laboratory in the late 1950’s [205] (yes, that Carlsberg), 
hydrogen deuterium exchange (HDX) is a non-covalent labelling technique where 
labile protons, such as those involved in N-H, O-H or S-H bonds [206], are exchanged 
for deuterium, a heavy isotope of hydrogen with an additional neutron (+1 Da). 
Although deuterium exchange is detectable by other methods [207-209], the mass 
difference resulting from deuterium incorporation is readily detectable by MS, which 
has the advantage of lower sample requirements, and the ability to study larger 
proteins or protein complexes when compared with other analytical techniques used 
to measure HDX, such as NMR. Although many variations on this method exist, such 
as ‘exchange-out’ reactions (D→H exchange) [210], or rapid pulsed labelling techniques 
[211], HDX in structural MS is typically performed using the forward exchange reaction 
(H→D, ‘exchange-in’) in a continuous labelling approach, where the sample is first 
diluted into a deuterated buffer solution, and left to equilibrate for a fixed period of 
time, before quenching the reaction to limit further exchange (Figure 2.15). The 
deuterated protein sample is then either analysed at the intact level [212], or, more 
commonly, proteolytically cleaved into peptide fragments before LC-MS analysis is 
used to separate the labelled peptides, and localise differences in deuterium uptake to 
peptide level resolution [213].  
Although any labile proton in a protein can exchange for deuterium, in practice, 
many, such as those on amino acid side chains, undergo rapid back-exchange to the 
protonated form when the reaction is quenched [214], typically leaving only the 
deuterium incorporated at the amide nitrogen on the peptide backbone. As such, 
HDX-MS largely only probes deuterium uptake observed at these positions on the 
protein – with one backbone amide group for each amino acid in the sequence, except 
proline residues, which have no exchangeable amide group (Table 2.1). 
 
Introduction II: Protein aggregation, structure and dynamics studied by MS 
75 
 
 
Figure 2.15 General HDX-MS experimental workflow.  Protein samples are diluted into deuterated 
buffer solutions where solvent accessible and exchangeable (i.e. not hydrogen bonded) backbone amide 
hydrogens exchange for deuterium. After incubation, the reaction is quenched by dilution into low 
pH, low temperature protiated quench solution, which unfolds the proteins and minimises further 
deuterium exchange. The protein is then digested into peptides which are then analysed by LC-MS. 
 
Primarily, the two main factors affecting the rate of deuterium exchange in a protein 
structure are solvent accessibility and hydrogen bonding [211, 215]. Indeed, HDX is 
particularly sensitive to these factors; backbone amides in folded proteins can have a 
decreased rate of exchange by 6-8 orders of magnitude compared with unfolded 
proteins [206, 211]. Increased access to the deuterium buffer solution allows faster 
deuterium exchange, so exposed regions of the protein increase in mass faster than 
more buried regions. This makes HDX a useful technique for probing changes in 
protein conformation [212, 216], or sites of protein-protein [217] or protein-ligand [218] 
interactions, where changes in solvent accessibility of certain regions of the protein 
often occur. Additionally, backbone amides involved in hydrogen bonding are 
protected from exchange [214, 219], allowing HDX to probe changes in hydrogen bonding 
and secondary structure. Proteins, however, are dynamic entities, where local, or even 
global, structural fluctuations, as well as transient hydrogen bond separation can 
occur, resulting in many amide groups in protein structures fluctuating between 
exchange competent, and non-exchangeable states. These aspects of protein dynamics 
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give rise to two different exchange regimes in HDX, referred to as EX1 and EX2 
kinetics [211, 214].  
The exchange mechanism of an amide group in equilibrium between exchange 
competent (exposed to solvent, not H-bonded) and non-exchangeable (buried, H-
bonded) states, loosely defined as ‘open’ and ‘closed’, can be described as: 
 
 
 
Where kop and kcl are the rate constants for opening and reclosing respectively, and 
kch is the chemical rate constant of deuterium exchange, defined as the rate constant 
measured under conditions of maximal solvent exposure, for amides not involved in 
hydrogen bonding [206]. The EX1 and EX2 exchange regimes are the result of a kinetic 
competition between the reclosing of the exchangeable state (formation of a hydrogen 
bond or protein refolding) and the chemical deuterium exchange rate of the amide 
group in question. If reclosing is faster than deuterium exchange (kcl > kch), then the 
probability of successful HDX during a single opening event is small, and opening 
must occur multiple times before deuterium exchange is likely to take place – this is 
known as EX2 kinetics.  Alternatively, if deuterium exchange is faster than reclosing 
(kch > kcl) then deuterium labelling is likely to occur on the first available opening 
event – this is defined as EX1 kinetics, although in practice this is not commonly seen 
in proteins at physiological pH [206]. During peptide level MS analysis, the two regimes 
can be distinguished by their distinctive isotope patterns [220, 221] although mixed EX1-
EX2 kinetics are often observed [220]. Thus, HDX can be used to study changes in 
protein dynamics, as well as conformation, protein-protein, and protein-ligand 
interactions. 
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Solution pH is also an important factor in HDX where, at near physiological 
conditions, increases in pH increase the chemical exchange rate by approximately one 
order of magnitude per pH unit [206]. Consequently, this means that increasing pH 
above physiological conditions alters the limit of EX1 kinetics as kch increases [214]. 
However, as deuterium exchange can be catalysed under both acidic and basic 
conditions (Figure 2.16a), a complex relationship is observed where both the extremes 
of pH correlate with faster exchange rates, resulting in a ‘V’ shaped curve of exchange 
rate vs pH (Figure 2.16b). This curve has an exchange rate minima for backbone amide 
groups at ~pH 2.5-3.0, and, as deuterium exchange is also slower at lower 
temperatures, this pH, and temperatures around 0 °C, are typically used to quench the 
exchange reaction and minimise further deuterium exchange prior to MS analysis. 
This is a crucial step in the experimental workflow, not just to prevent further 
deuterium being incorporated on to the sample, but to reduce back exchange of 
deuterium from the sample into the protiated ESI solvents used in MS analysis. 
Although loss of some of the deuterium label during analysis is unavoidable, quench 
conditions decrease the exchange rate by ~5 orders of magnitude from typical 
labelling conditions (pH 7, 25 °C) [215], and increase the half-life of deuterium on 
peptides to between 30-120 minutes [222] (approximately 500x less than the half-life of 
teaspoons in an Australian research institute [223]). 
The final significant factor affecting the deuterium exchange rate is the primary 
sequence of amino acids in the protein. The backbone amide hydrogen of each amino 
acid residue has a different chemical exchange rate with deuterium (except proline, 
which has no backbone amide group), governed by inductive and steric effects of the 
side chain, and side chains of adjacent residues, affecting the acidity of the amide N-
H bond, and thus its propensity to exchange with deuterium by acid and base 
catalysed exchange [224].  
Fortunately, the effects of pH, temperature and nearby side chains have been well-
characterised [224, 225], and it is now possible to predict the unprotected chemical 
exchange rate of different amino acids under all conditions [214]. 
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Figure 2.16 Mechanisms of acid and base catalysed deuterium exchange.  a) Deuterium exchange onto 
the amide nitrogen of the peptide backbone can occur under acidic (D3O+) or basic (OD-) conditions. 
This generates a complex relationship between pH and deuterium exchange rate (b), with a ‘V’ shaped 
curve with a minimum exchange rate at approximately pH 2.5. 
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2.4.4 Fast photochemical oxidation of proteins (FPOP) 
Developed in the early 2000’s [226, 227], Fast Photochemical Oxidation of Proteins 
(FPOP) is a covalent labelling technique where hydroxyl radicals liberated from 
photolysis of hydrogen peroxide covalently label solvent accessible regions of the 
protein. Although hydroxyl radicals can attack almost any region of a protein, where 
attack on certain residues, or the α-carbon itself can result in fragmentation of the 
polypeptide backbone [228], more commonly, steric inaccessibility of the backbone 
leads to hydroxyl radical attack primarily on amino acid side chains, preferentially 
labelling large hydrophobic residues, or side chains containing sulfur atoms [228]. This 
hydroxyl radical labelling results in a variety of different covalent modifications of 
different masses. By far, the most common of these are +16 Da hydroxylations 
(addition of OH and abstraction of H), although many others are possible, including 
the formation of carbonyl groups (+14 Da, addition of O and abstraction of 2H), 
decarboxylation (-30 Da) and deguanidination (-43 Da). A summary of common 
oxidative modifications, and the side chains on which they are typically observed, are 
shown in Table 2.2. 
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Table 2.2 Reactivities and common mass additions in hydroxyl radical oxidation of amino acid side 
chains.  Taken from [228]. 
Side chain Reactivity rate (M-1 s-1) Common Δmasses (Da) 
Cys (most 
reactive) 
3.5 x 1010 +48, +32, -16 
Trp 1.3 x 1010 +16, +32, +48 etc 
Tyr 1.3 x 1010 +16, +32 
Met 8.5 x 109 +16, +32, -32 
Phe 6.9 x 109 +16, +32, +48 
His 4.8 x 109 +16, -22, -10, +5 
Arg 3.5 x 109 -43, +16, +14 
Ile 1.8 x 109 +16, +14 
Leu 1.7 x 109 +16, +14 
Val 8.5 x 108 +16, +14 
Pro 6.5 x 108 +16, +14 
Gln 5.4 x 108 +16, +14 
Thr 5.1 x 108 +16 
Lys 3.5 x 108 +16, +14 
Ser 3.2 x 108 +16 
Glu 2.3 x 108 -30, +16, +14 
Ala 7.7 x 107 +16 
Asp 7.5 x 107 -30, +16 
Asn 4.9 x 107 +16 
Gly 1.7 x 107 - 
 
A typical FPOP experiment involves a solution containing the protein of interest, 
hydrogen peroxide (typically <0.5% (v/v)), and a free amino acid of moderate 
hydroxyl radical reactivity, typically histidine or glutamine, known as the scavenger. 
The purpose of this scavenger amino acid is to control the degree of oxidative 
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modification on the protein analyte, and control the lifetime of hydroxyl radicals in 
solution [229]. If more labelling/longer labelling timescales are required, then a less 
reactive, or lower concentration of scavenger can be added to the solution, and vice 
versa [230]. This solution is irradiated with UV light, typically of 248 nm wavelength, 
causing photolysis of the solution hydrogen peroxide, generating the desired hydroxyl 
radicals [231]. Although it has been demonstrated that a considerable proportion of 
these radicals rapidly recombine back into hydrogen peroxide [230], the remaining 
radicals go on to covalently label the protein analyte and scavenger amino acid, before 
the reaction is quenched, typically with a mixture of catalase, an enzyme which 
degrades excess hydrogen peroxide, and methionine, a highly reactive free amino acid 
which removes any radicals left in solution (Figure 2.17) [231]. 
 
 
Figure 2.17 General theory of FPOP labelling.  Solution containing the protein sample, hydrogen 
peroxide and a scavenger amino acid is irradiated with 248 nm UV light, causing photolysis of the 
hydrogen peroxide, generating hydroxyl radicals. These hydroxyl radicals then covalently label the 
protein sample, before the reaction is quenched to prevent further radical oxidation. 
 
The rationale behind performing an FPOP experiment is that a side chain with greater 
access to solvent, such as those on the surface of proteins, will also have greater access 
to the hydroxyl radicals in solution, and will undergo more oxidative labelling than 
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side chains with less solvent accessible surface area. Although the target, and nature 
of the labelling is very different, these characteristics mean FPOP can be used to probe 
many of the same changes as HDX; changes in protein structure, conformation and 
dynamics, as well as protein-protein or protein ligand interactions, all of which can 
change a side chain’s accessibility to solvent, and thus its degree of oxidative 
modification in FPOP. Again similar to HDX, changes in FPOP oxidative labelling can 
be observed by introducing the protein sample into the mass spectrometer intact, and 
quantifying the observed distributions of different mass modifications. However, 
unlike HDX, quenching can be performed under neutral pH conditions, and the 
covalent nature of the label means that no back exchange occurs during the 
experiment. Combined, these properties make proteolytic digestion and LC-MS/MS 
analysis of the oxidised peptides a more attractive option, as choice of digestive 
enzyme is not restricted to acid proteases as in HDX, and lengthy analytical 
procedures can be used to analyse the resulting peptides, without the concern of losing 
the label. 
However, unlike the wealth of knowledge available concerning solution conditions 
and protein structure on deuterium labelling in HDX [224, 225], these parameters are not 
well understood with regards to oxidative labelling in FPOP. Work by Xie et al., has 
shown a positive correlation between the fraction of the side chain that is exposed to 
solvent and the extent of modification observed, normalised for the reactivity of each 
side chain [232]. However, this relationship was only observed for the most reactive side 
chains, while the correlation was less clear or absent for less reactive residues. The 
authors proposed that highly reactive side chains compete for hydroxyl radicals with 
nearby side chains that are less reactive, highlighting possible effects of sequence or 
local environment on the extent of oxidative modification, in addition to solvent 
accessible surface area [232]. Similarly, although it is not currently disputed that the 
primary radical generated by FPOP, the hydroxyl radical, labels the protein sample 
on the timescale of µs under typical FPOP solution conditions [230], Vahidi et al., have 
demonstrated that radicals in FPOP experiments can exist in such solutions for up to 
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a millisecond, suggesting that generation of secondary radicals, possibly with 
dissolved oxygen, can continue to label the protein long after the primary hydroxyl 
radicals have been exhausted [233]. Additionally, despite the covalent nature of the label 
making residue level assignment of modifications trivial in principle, in practice the 
complex, manual, and time intensive nature of the data analysis is such that FPOP 
oxidations are commonly quantified to peptide level resolution [231, 234]. 
Nevertheless, despite these shortcomings in our current understanding of the 
technique, FPOP holds great potential as a structural MS method of the future. Espino 
et al., have already shown that FPOP can be performed in live cells to probe protein 
structure in vivo [235]. Others have demonstrated that generation of hydroxyl radicals 
can be used, not just to label the proteins themselves, but to generate other radicals 
with different side chain labelling preferences [236, 237]. Numerous studies have also 
highlighted the role of FPOP in epitope mapping and antibody structure – a crucial 
step in assessing the role of FPOP for industrially relevant applications in biopharma 
and biotechnology [238-241].   
 
2.5 Aim of the thesis 
The aims of this thesis are threefold (Figure 2.18): 
1. Use the two well-characterised variants of β2m (wild-type and ΔN6) as a 
benchmark to develop FPOP, compare the results with existing structural MS 
methods, such as HDX, and gain insight on the usefulness and limitations of 
FPOP to study the structure of aggregation-prone proteins. This information 
will be used to guide the remaining two goals. 
2. Using what can be learned from this method development, examine the 
structure of D76N β2m and compare these results with the wild-type protein, 
with a view to understanding how such similar structures can be associated 
with significantly different aggregation propensities, as well as probing any 
similarities in structure to the, already aggregation-prone, ΔN6 variant.  
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3. Test the effectiveness of FPOP to characterise the mAbs WFL and STT, 
determine any structural changes caused by the amino acid substitutions that 
may be linked to the propensity of WFL to undergo reversible self-association, 
and assess the utility of FPOP, more generally, in characterising large, complex 
biopharmaceutical molecules, such as mAbs.  
 
 
 
Figure 2.18 Aims of this thesis.  I)  Use two well characterised variants of β2m to develop FPOP and 
compare these data with more well-established structural MS methods, including HDX. These 
developments will be used to compare the D76N β2m variant with both the wild-type protein (II) and 
the ΔN6 variant (III) to assess any structural changes caused by the amino acid substitution which affect 
the propensity of the protein to aggregate.  VI)  The method development from FPOP will be used to 
assess the utility of the technique to characterise WFL and STT, and gain insight on any 
structural/dynamical changes linked to reversible self-association in these mAbs. 
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3 Materials and methods 
3.1 Protein preparation and purification 
3.1.1 Wild-type, D76N and ΔN6 
The three variants of β2m were each overexpressed in BL21 [DE3] pLysS cells 
containing a pET23a plasmid containing either the wild-type β2m gene, the D76N 
gene (identical to wild-type with the exception of a G→A base substitution at 
positions 286), or the ΔN6 gene (missing the six N terminal amino acids) (Figure 3.1). 
 
 
Figure 3.1 The pINK plasmid containing the gene of one of three variants of β2m. Expression of the β2m 
protein is under control of the T7 promoter, and the plasmid contains an ampicillin resistance selection 
marker. 
 
Glycerol stocks (provided by Dr Hugh Smith) containing BL21 [DE3] pLysS 
Escherichia coli carrying the Pet23a plasmid with either the wild-type, D76N or ΔN6 
gene were used to grow starter cultures containing 100 ml lysogeny broth (LB – 
Melford Laboratories, Ipswich, UK), 50 µg ml-1 carbenicillin and 50 µg ml-1 
chloramphenicol. These were incubated overnight at 37 °C with aeration (200 rpm). 
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Large scale 1 L cultures were then set up containing 25 g LB, 5 ml of starter culture 
and 50 µg ml-1 carbenicillin. These were incubated at 37 °C with aeration (200 rpm) 
to an OD600 of 0.6 and then induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) before overnight incubation (37 °C, 200 rpm). 
After 16 hours, cells were harvested by centrifugation at 15,000 rpm for 20 minutes 
using a Beckman JLA 16.250 rotor (approximately 33,700 G) (4 °C). The cell pellets 
were incubated in 200 ml lysis buffer (100 µg ml-1 lysozyme, 50 µg ml-1 
phenylmethylsulfonyl fluoride (PMSF), 20 µg ml-1 DNase, 1 mM 
ethylenediaminetetraacetic acid (EDTA) in 25 mM Tris.HCl pH 8.0) for 30 min at 
room temperature before being further lysed using a cell disrupter (constant cell 
disruptor systems, Northhants, UK) at a pressure of 30 kpsi. 
This cell lysate was then centrifuged as above for 30 min. The resulting pellet 
(containing the inclusion bodies) was then washed with 200 ml, 25 mM Tris.HCl pH 
8.0 and any dark material on the pellet surface was removed. The pellet was then 
resuspended in 200 ml 25 mM Tris.HCl pH 8.0 and centrifuged again (as above). This 
process was repeated three times to remove any dark material left on the pellet surface 
following centrifugation.  
The resulting clean pellet was then solubilised in 200 ml, 25 mM Tris.HCl pH 8.0 
containing 8 M urea and incubated at room temperature overnight with gentle 
stirring, before a final centrifugation step (15,000 rpm for 1 hour) was used to remove 
any precipitate. 
The protein was then allowed to refold by dialysis into 5 L, 25 mM Tris.HCl pH 8.0, 
using 3500 molecular weight cut off (MWCO) dialysis tubing (Thermo Scientific, 
Hemel Hempstead, UK). The dialysis buffer was changed a total of 6 times with a two 
hour equilibration period between changes.  
Refolded protein was then purified by anion exchange chromatography using an 
XK50 fast-flow Q-Sepharose column (GE Healthcare, Buckinghamshire, UK). The 
column was equilibrated with 2 column volumes of buffer (25 mM Tris.HCl pH 8.0) 
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before the refolded protein was added. The bound protein was then eluted with a 0-
125 mM NaCl gradient at room temperature in 25 mM Tris.HCl pH 8.0 buffer. Eluted 
fractions containing the protein were then dialysed into purite 18 MΩ water using the 
above dialysis protocol, before being concentrated to ≈ 1 mM using Sartorius vivaspin 
2, 3,000 MWCO spin columns. 
The refolded, concentrated ion exchange product was then filtered (0.22 µm filter 
units, Fischer Scientific) and further purified by size exclusion chromatography using 
a Superdex 75 prep grade XK 26/60 column (Amersham Biosciences, 
Buckinghamshire, UK) equilibrated with 150 mM ammonium acetate (pH 7.4) at 
room temperature. The eluted fractions containing monomeric protein were collected 
and analysed by SDS-PAGE to confirm the presence of monomeric β2m (or 
D76N/ΔN6). These fractions were then pooled, and stored at ≈400 µM at -80 °C. 
Protein preparation and purification of all three variants of β2m was carried out with 
the help and supervision of Dr Hugh Smith (Radford research laboratory). 
 
3.1.1.1 SDS-PAGE 
Tris-tricine buffered SDS-PAGE gels were used to confirm the presence of β2m in the 
eluted gel filtration fractions. Samples were diluted 1:1 with 2X loading buffer (50 
mM Tris.HCl pH 6.8, 100 mM dithiotheritol (DTT), 2% w/v sodium dodecyl sulphate 
(SDS), 0.1% w/v bromophenol blue, 10% v/v glycerol) and boiled for 5 min prior to 
being loaded onto the gel. A 60 mA current was applied until the samples had entered 
the resolving gel, at which point the current was increased to 100 mA. The completed 
gels were then stained with Instant Blue (Expedeon protein solutions, 
Cambridgeshire, UK) overnight and then imaged using the Genesnap software 
(Syngene bioimaging). Molecular weight markers used for SDS-PAGE analysis were 
2-250 kDa precision plus protein standard ladders (Bio Rad, Hertfordshire, UK). 
Components of the resolving and stacking gels are listed in Table 3.1. The cathode 
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running buffer was 100 mM Tris 100mM tricine, 0.1 % (w/v) SDS, pH 8.25. The anode 
running buffer was 200 mM Tris.HCl, pH 8.9. 
 
Table 3.1 Solution components of Tris-tricine buffered SDS-PAGE gels used for analysis of β2m.
 Solution Component Volume added to stacking gel 
(ml) 
Volume added to 
Resolving gel (ml) 
30% w/v acrylamide: 
0.8% w/v bis-
acrylamide 
7.5 0.83 
3 M Tris.HCl, 0.3% 
w/v SDS pH 8.45 
5.0 1.55 
H20 0.44 3.72 
Glycerol 2.0 0 
10% w/v ammonium 
persulfate 
0.1 0.2 
TEMED 0.01 0.01 
 
3.1.1.2 Circular dichroism spectroscopy 
Circular dichroism (CD) experiments were performed in the far-UV range 
(wavelengths of 200 nm-260 nm with a 1 nm step size) on a Chirascan plus CD 
spectrometer (Applied PhotoPhysics, Surrey, UK) at 25°C. Each sample contained 20 
µM protein (≈0.2 mg ml-1 for β2m), in 25 mM sodium phosphate buffer (pH 7.4). The 
pathlength was 1 mm. Measured ellipticity at each wavelength was converted to mean 
residue ellipticity using Equation 3.1 [242]. 
 
 [𝜃] =
𝜃 ×𝑀𝑅𝑊
10 × 𝑑 × 𝑐
 
(3.1) 
Equation 3.1 Conversion of measured ellipticity to mean residue ellipticity.  Where 𝜃 is the measured 
ellipticity (degrees) MRW is the mean residue weight, d is the path length (cm) and c is the protein 
concentration (g ml-1). 
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CD experiments were carried out by Dr Hugh Smith (Radford research laboratory). 
3.1.2 WFL and STT 
The two mAb variants MEDI1912_WFL and MEDI1912_STT were provided by 
AstraZeneca (formerly Medimmune) in formulation buffer (125 mM L- arginine, 20 
mM sodium succinate, pH 6.0). 
 
3.2 Native MS 
3.2.1 Sample preparation 
Samples prepared for native MS were 2x buffer exchanged into 150 mM ammonium 
acetate (pH 7.4) using 7k MWCO zeba spin desalting columns (Thermo Scientific, 
Hemel Hempstead, UK). The final sample was diluted to a concentration of 10 µM, 
calculated based on the absorbance at 280 nm and the Beer-Lambert law, using an 
extinction coefficient of 20065 M-1 cm-1 for all β2m variants. 
Samples were then loaded into borosilicate glass capillaries pulled in-house (Sutter 
Intrument Company, Novato, CA, USA) and coated with palladium using a sputter 
coater (Polaron SC7620, Quorum Technologies Ltd, Kent, UK). 
 
3.2.2 Waters Synapt G1 HDMS 
The instrument was first calibrated using ~10 mg ml-1 caesium iodide clusters across 
the m/z acquisition range (usually 500-8000 m/z) before data were analysed using 
MassLynx v4.1 and Driftscope v3.0 (Waters, Wilmslow, UK), if IMS acquisition mode 
was active. All samples were analysed in positive ionisation mode. 
Ion mobility experiments were performed under two different sets of T-wave 
conditions. Source and T-wave conditions for the instrument in each case are listed 
in Table 3.2. 
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Table 3.2 Summary of instrument source and IMS conditions used in native IMS-MS experiments.
Instrument 
Parameter 
T-wave 1 (CCS 
calculations) 
T-wave 2 (detailed ATD 
analysis) 
Cone voltage (V) 70 70 
Backing Pressure 
(mbar) 
2.1 2.1 
IMS T-wave 
velocity (ms-1) 
200 300 
IMS T-wave height 
(V) 
4-20 V ramp (100% cycle) 4-10 V ramp (100% cycle) 
m/z acquisition 
range 
500-8000 500-8000 
Trap CE (V) 5 5 
Transfer T-wave 
velocity (ms-1) 
248 248 
Transfer T-wave 
height (V) 
3 3 
 
3.2.2.1 Calculating rotationally averaged collision cross sections 
The calibration approach used here is taken from Ruotolo et al [66]. CCS values were 
calculated by manual calibration using native calibrant proteins from the Bush 
database of known CCS values generated from drift cell measurements [69]. These CCS 
values were corrected for ion mass, charge state and the buffer gas mass, according to 
Equation 3.2. 
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𝛺′ =
𝛺𝐿𝑖𝑡
𝑧√(
1
𝑚 +
1
𝑚𝑔
)
 
(3.2) 
Equation 3.2 Correcting literature CCS for mass, charge and buffer gas mass. Where Ω’ is the corrected 
CCS, ΩLit is the published literature cross section for the calibrant protein, derived from DTIMS 
measurements, z is the ion charge state, m is the ion mass and mg is the buffer gas mass. The term in 
brackets is equivalent to the reciprocal of the reduced mass of the ion neutral pair (µ from Equation 
1.9). 
 
Drift time measurements of calibrant proteins were then corrected for m/z dependent 
flight time between the exit of the transfer cell and the pusher region [243] according 
to Equation 3.3. Flight time for ions to traverse the transfer cell is also included in the 
measured drift time. Although this can be corrected for, knowing the length of the 
transfer cell and the transfer T-wave velocity [66], this correction was not applied in 
our experiments for simplicity, as this flight time is independent of m/z and only made 
minimal changes to measured CCS values, well below other sources of error (i.e. 
calibration, precise determination of peak apex) [63]. 
 
 
𝑡′𝐷 = 𝑡𝐷 −
𝐶√
𝑚
𝑧
1000
 
(3.3) 
Equation 3.3 Correcting drift time for m/z dependent flight time. Where t’D is the corrected drift time, 
tD is the measured drift time, m/z is the mass to charge ratio of the ion and C is the enhanced duty cycle 
(EDC) delay coefficient. 
 
Corrected drift time and corrected CCS values from calibrant proteins were then used 
to generate a linear calibration plot (Equation 3.4). 
 
  Ω′ = 𝐴 𝑡𝐷
′ +  𝑁       (3.4) 
Equation 3.4 Linear calibration curve used to determine unknown CCS values from analyte proteins. 
Where Ω’ is the corrected CCS of the analyte protein, A is the fit determined slope of the curve, t’D is 
the corrected drift time of the analyte protein, and N is the fit determined y axis intercept. 
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Fit determined constants from the calibration plot were used to determine CCS 
values of analyte proteins, by combining Equation 3.2 and Equation 3.4 (Equation 
3.5). 
 
 
Ω = 𝐴 𝑡𝐷
′ +  𝑁 𝑧 √(
1
𝑚
+
1
𝑚𝑔
)   
(3.5) 
Equation 3.5 Calculation of CCS values for analyte proteins based on a linear calibration plot.  Where 
Ω is the calculated CCS of the analyte protein, A and N are fit determined constants from the calibration 
curve (Equation 3.4), t’D is the corrected drift time of the analyte protein, z is the charge state of the 
analyte protein, m is the ion mass and mg is the buffer gas mass. 
 
IMS data for calibrant proteins and analyte proteins were acquired on the same day 
under identical IMS conditions. Literature CCS values were taken from a database of 
published cross sections [69]. Although N2 was used as a separation gas in the IMS cell 
of the Synapt instrument, CCS values acquired in He separation gas were used for 
calibration [69] as these allow comparison to computationally derived CCS values, 
where He is the most commonly used in silico buffer gas [190]. Annotation for CCS 
values in this thesis follows recommendations by Gabelica et al., [244] and will be shown 
as: TWCCSN2>He. 
Peak top times from IMS arrival time distributions (ATDs) were determined by 
Gaussian curves fitted to ATD data using the multiple peak fit function from Origin 
2017 (Origin Lab Corporation). 
 
3.2.3 Calculation of in silico CCS 
To calculate CCS values from protein structures derived from X-ray crystallography 
or NMR data, gas phase molecular dynamics (MD) simulations (i.e. absent of solvent) 
were first performed on the analyte PDB structures using NAMD (v2.9) [245] and the 
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CHARMM force field [246]. A radial cut-off of 12 Å around each atom was used with a 
time-step of 2 fs. Simulations were run for 2 ps and kept at a constant temperature of 
300 K. 
The resulting post-MD structures were used as input data for IMPACT, a software 
developed by the Robinson group to determine in silico CCS values from protein 
structures [190]. 
 
3.3 Intact mass analysis 
Intact mass analysis for accurate mass determination was performed using a Waters 
Xevo G2-XS Q-TOF MS operating in MS mode. Prior to introduction into the mass 
spectrometer, protein samples at a concentration of 5 µM, were loaded onto a 
MassPREP micro desalting column (Waters corporation, Wilmslow, Manchester, UK) 
before being eluted with an MeCN gradient containing 0.1% v/v formic acid. 
 
3.4 Hydrogen Deuterium Exchange 
3.4.1 Experimental 
HDX-MS experiments were carried out using an automated sample handling robot 
(LEAP technologies, Fort Lauderdale, FL, USA) coupled to an M-Class Acquity LC 
system and HDX manager (Waters Ltd., Wilmslow, UK). 30 µl of protein stock 
solution containing 8 µM of either wild-type β2m, D76N or ΔN6 in equilibration buffer 
(10 mM potassium phosphate, pH 7.4) was added to 135 µl of deuterated label buffer 
(10 mM potassium phosphate, pD 7.4). This was incubated at 4 °C for 30, 60, 120, 1800 
or 7200 seconds, before 50 µl of the labelled solution was quenched by dilution into 
100 µl quench buffer (10 mM potassium phosphate, 2 M guanidine HCl, 200 mM 
tris(2-carboxyethyl)phosphine pH 2.2) at 1 °C, giving a final quench pH ~ 2.5. 50 µl of 
quenched sample (~ 24 pmol) was passed through an immobilised ethylene bridged 
hybrid (BEH) pepsin column (Waters Ltd., Wilmslow, UK) at 20 °C at a flow rate of 
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500 µl min-1 before the resulting peptides were trapped using a VanGuard pre-column 
Acquity UPLC BEH C18 trap column (1.7 µm, 2.1 µm x 5 µm, Waters Ltd., Wilmslow, 
UK). After valve switching, the resulting peptic peptides were transferred to a C18 
column (75 µm x 150 mm, Waters Ltd., Wilmslow, UK) and separated by gradient 
elution of 0-40% MeCN (0.1% v/v formic acid) in H20 (0.3% v/v formic acid) over 7 
minutes at 40 µl min-1. Peptides were analysed using a Synapt G2Si mass spectrometer 
(Waters Ltd., Wilmslow, UK) operating in DIA mode. Dynamic range extension, with 
an HDMSE workflow (with ion mobility separation) was used to separate peptides 
prior to fragmentation in the transfer cell (exact details of this type of workflow are 
described in [247]. 
 
3.4.2 Data processing and analysis 
HDX data were processed using Protein Lynx Global Server (PLGS v3.0.2) and 
DynamX (v3.0.0) software supplied with the mass spectrometer. Criteria for 
confidently identified peptides were as follows: min intensity = 1000, min products 
per amino acid = 0.3, max sequence length = 25, max ppm error = 5, file threshold = 
4/5 replicates. 
To visualise data and generate difference plots, data were further processed using an 
in-house developed algorithm originally written in R by the author, and later 
developed by Dr James Ault (MS facility manager) using R and Java. This processing 
method, named PAVED (positional averaging for visualising exchange data), 
combines the mean relative fractional uptake values per residue, along with their 
standard deviations from replicate measurements, per time point, for all peptides 
covering a given residue. 
Further details on the development and functioning of this algorithm can be found in 
Section 4.4. The original R code developed by the author for the first version of this 
algorithm (not the final version in PAVED) can be found in Section 8.1. 
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3.5 Fast Photochemical Oxidation of Proteins 
3.5.1 Experimental procedures for the analysis of β2m 
Immediately prior to UV irradiation, 1 µl of 5% v/v H2O2 was added to 100 µl of 
protein solution containing 10 µM of protein (either wild-type β2m, D76N or ΔN6) 
and 20 mM L-histidine in 10 mM potassium phosphate pH 7.4, to give a final H2O2 
concentration of 0.05 % v/v. The sample was then passed at a flowrate of 20 µl min-1, 
through a fused silica capillary (inner diameter: 100 µm) and exposed to UV 
irradiation (beam width ~3 mm) using a Compex 50 Pro KrF excimer laser operating 
at 248 nm (Coherent Inc., Ely, UK) with a firing frequency of 15 Hz and a pulse 
duration of 20 ns. Laser power was kept constant at 110 mJ. The outflow from the 
capillary was collected in an Eppendorf tube containing 20 µl quench solution (100 
mM L-methionine, 1 µM catalase in 10 mM potassium phosphate pH 7.4) and placed 
immediately on ice. 
Following UV irradiation and quenching, the single disulphide bond in β2m was 
reduced by incubation with 10 mM DTT for 1 hr at 55 °C, shaking at 500 rpm. The 
resulting free thiols were alkylated (incubation with 55 mM iodoacetamide for 45 
min, 20 °C at 500 rpm in the dark). A 1:50 w/w ratio of chymotrypsin:protein was 
then added, and left for 18 hours at 37 °C, shaking at 500 rpm, to digest the samples 
into peptides. 
The resulting chymotryptic peptides (1 µl at 0.5 µM peptide concentration) were 
injected onto a UPLC M-Class Acquity system equipped with a C18 column (75 µm x 
150 mm, Waters Ltd., Wilmslow, UK) and separated by gradient elution of 1-50% 
MeCN in H2O, over 60 min at 0.3 µl min-1, where both mobile phases contained 0.1% 
v/v formic acid. Peptides eluting from the UPLC were analysed using a Q-Exactive 
Plus orbitrap mass spectrometer (ThermoFisher, Bremen, Germany) operating in 
DDA mode with the following acquisition parameters: TopN = 5, max injection time 
= 300 ms, dynamic exclusion = 3 s. 
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3.5.2 Experimental procedures for the analysis of WFL and STT 
Immediately prior to UV irradiation, 3 µl of 5% v/v H2O2 was added to 100 µl of 
protein solution containing 0.1 mg ml-1 of either WFL or STT and 10 mM L-histidine 
in formulation buffer (125 mM L- arginine, 20 mM sodium succinate, pH 6.0), to give 
a final H2O2 concentration of 0.15 % v/v. The sample was then passed at a flowrate of 
20 µl min-1, through the FPOP experimental setup and quenched as described in 
Section 3.5.1. 
Following UV irradiation and quenching, disulphide bonds were reduced by 
incubation with 10 mM DTT for 1 hr at 65 °C, shaking at 500 rpm. The resulting free 
thiols were alkylated (incubation with 55 mM iodoacetamide for 45 min, 20 °C at 500 
rpm in the dark). A 1:50 w/w ratio of trypsin:protein was then added, and left for 18 
hours at 37 °C, shaking at 500 rpm, to digest the samples in to peptides. 
The resulting tryptic peptides (1 µl at 0.5 µM peptide concentration) were injected 
onto a UPLC M-Class Acquity system equipped with a C18 column (75 µm x 150 mm, 
Waters Ltd., Wilmslow, UK) and separated by gradient elution of 1-60% MeCN in 
H2O, over 90 min at 0.3 µl min-1, where both mobile phases contained 0.1% v/v formic 
acid. Peptides eluting from the UPLC were analysed using an Orbitrap Fusion mass 
spectrometer (ThermoFisher, Bremen, Germany) operating in orbitrap-iontrap mode 
where the orbitrap was operated at 240,000 resolution and the linear ion trap was 
operated in rapid mode. The following DDA acquisition parameters were used: TopN 
= 7, max injection time = 200 ms, dynamic exclusion = 3 s. 
 
3.5.3 Data processing and analysis 
Peptides were identified using PEAKS v8.5 (Bioinformatics Solution Inc., Waterloo, 
ON, Canada). Variable mass additions of +16 Da, +32 Da, +14 Da, +73 Da and +89 Da 
were searched to identify FPOP oxidations (the latter two being singly and doubly 
oxidised cys side chains following carbamidomethylation). MS/MS data were 
manually curated to identify and assign genuine FPOP oxidations. Data were then 
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quantified manually at the residue level using Xcalibur software (v4.0.27.19, 
ThermoFisher, Bremen, Germany) by integrating peaks in the extracted ion 
chromatograms (XICs) of each peptide ion, generated by extracting the m/z of the base 
peak of each peptide isotope distribution, for each charge state, for the modified and 
unmodified versions of each peptide using Equation 3.6.  
 
 
% 𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 =  
∑𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑃𝑒𝑎𝑘
𝑈𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 + ∑𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑
𝐴𝑙𝑙 𝑃𝑒𝑎𝑘𝑠
 
(3.6) 
Equation 3.6 Quantifying FPOP oxidations at residue level resolution.  The modified peak of interest, 
generated from using XIC analysis, is quantified against the ion counts of all other identifiable versions 
of the peptide, both modified and unmodified. 
 
3.5.4 Calculation of solvent accessible surface area 
Calculation of the solvent accessible surface area of side chains in the NMR structures 
of wild-type and ΔN6 was performed in Pymol using the “get_area” command. 
Dot_solvent was set to on. Dot_density was set to 4. 
 
3.6 Homology modelling of mAbs 
Homology models of the Fab and Fc domains of MEDI19129-WFL were generated 
using SWISS-MODEL [248]. The homology model for the Fab domain was generated 
using PDB: 5WKZ [249] and the homology model for the Fc domain was generated using 
PDB: 5K65 [250] which had sequence identities to WFL of 95.23% and 89.81% 
respectively. These homology models were then roughly aligned into the canonical 
‘Y’ shape of an IgG using PDB: 1IGY [251]. 
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4 IMS-MS and HDX-LC-IMS-MS/MS comparing β2m 
variants 
 
The three variants of β2m (wild-type, D76N and ΔN6, discussed in detail in Section 
2.2) provide an ideal model system to study both the structural and dynamical factors 
which make proteins amyloidogenic, and to develop methods which can provide 
unique insights in the characterisation of such factors. The D76N variant, for example, 
differs by only a single amino acid from the wild-type protein in sequence, but 
exhibits a significantly increased propensity to aggregate, thus offering an opportunity 
to study how this amino acid substitution affects the protein structure, and why these 
differences modulate the aggregation propensity of this, largely unstudied, β2m 
variant so significantly. Similarly, both ΔN6 and the wild-type protein are well-
characterised protein variants with known structures [78], and provide a useful 
benchmark to develop new methods or analysis techniques to study aggregation-
prone proteins. 
This chapter summarises the beginnings of the investigation into the structure and 
dynamics of the three variants of β2m with three main aims: 
1. Perform an initial characterisation of the recombinantly expressed β2m 
variants to ensure purity and correct folding. 
2. Perform a low resolution structural characterisation of the three variants using 
IMS, to establish any global effects of the D76N mutation, or global similarities 
to the ΔN6 truncation variant. 
3. Analyse the three variants using HDX to identify changes in structure or 
dynamics caused by the D76N mutation at higher resolution, and use the well-
characterised wild-type and ΔN6 variants to develop new HDX-MS analysis 
techniques. 
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Data for the wild-type protein and for the ΔN6 truncation variant shown in the HDX 
section of this chapter were subsequently published in Cornwell., et al., JASMS, 2019 
[252]. 
 
4.1 Protein preparation and initial characterisation 
Wild-type, D76N, and ΔN6 β2m were expressed recombinantly and purified as 
described in Section 3.1. The final gel filtration purification step showed all three 
proteins eluting as a single peak from the size exclusion column (an example of wild-
type β2m is shown in Figure 4.1). SDS-PAGE analysis of fractions collected from the 
gel filtration eluate show the elution peak to consist of pure protein with a band at 
approximately 12 kDa consistent with the mass of monomeric β2m (Figure 4.1b). For 
the wild-type protein, pooling fractions 4-7 (Figure 4.1b) generated a final yield of 
~40 mg L-1 (10 L total prepared volume), which was approximately consistent across 
all three variants. 
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Figure 4.1 Size exclusion purification of wild-type β2m.  a) The single peak at elution volume ~ 225 ml 
is found at a similar elution volume to the calibrant protein cytochrome c (dashed vertical lines) and 
corresponds to monomeric β2m. b) Fractions collected at nine different elution volumes (green vertical 
lines in a) analysed by SDS-PAGE showing a single band for each fraction at ~12 kDa corresponding to 
wild-type β2m. 
 
To ensure that the protein samples had refolded correctly from the preparation 
process, which was initiated from a urea unfolded state (see Section 3.1 for details), 
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far UV-CD was used to assess bulk protein secondary structure (Figure 4.2). For both 
the wild-type protein and the ΔN6 truncation variant, these data are consistent with 
previously published CD spectra [146, 159]. The D76N variant shows a remarkably similar 
CD spectrum to that of the wild-type protein which consistent with the observed 
similarity of their folded protein structures and β-sheet content [77, 157]. 
 
 
Figure 4.2 CD spectra for three variants of β2m.  Traces for the wild-type protein (blue), D76N (red) 
and ΔN6 (black) are shown. Detailed experimental conditions can be found in Section 3.1.1.2. Dr Hugh 
Smith of the Radford research laboratory is gratefully acknowledged for acquiring these data. 
 
For final characterisation of the β2m samples, accurate mass analysis was performed 
under denaturing conditions to determine the precise mass of each prepared protein 
sample (Figure 4.3). The data show masses of 11860.36 ± 0.02 Da, 11859.35 ± 0.05 Da 
and 11136.29 ± 0.98 Da for the wild-type protein, the D76N variant, and the ΔN6 
truncation variant, respectively. These match closely the theoretical average masses 
for each variant (11860.4 Da, 11859.4 Da and 11136.5 Da) indicating the presence of 
the intact disulphide bond in all three variants, and identifying the 1 Da difference in 
mass between the wild-type protein and the D76N variant, associated with the D→N 
amino acid substitution (Figure 4.3a and b). No significant impurities could be 
detected in samples from any of the three variants. 
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Together, these data indicate that the wild-type protein, the D76N variant, and the 
ΔN6 truncation variant, have all been expressed as the desired species with intact 
disulphide bonds, no detectable impurities, with the correct mass and associated 
native protein fold. 
 
 
Figure 4.3 Denatured ESI-MS analysis of three variants of β2m.  Wild-type (a), D76N (b) and ΔN6 β2m 
(c) analysed by ESI-MS under denaturing conditions. The intact MS method used to acquire these 
spectra can be found in Section 3.3. Annotations above each peak show the m/z and charge state. The 
mass and standard deviation calculated from each spectrum is shown in the top right hand corner. 
 
4.2 Native IMS-MS 
Native IMS-MS experiments were performed on the three variants of β2m for an 
initial, low resolution structural comparison of the three proteins to observe the effect, 
if any, of the D76N mutation on global protein structure by IMS-MS, and to identify 
any similarities to the aggregation-prone ΔN6 truncation variant. 
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Native ESI-MS analysis for the three variants showed narrow charge state 
distributions ranging from 5+ to 8+ charge states for the wild-type protein and the 
D76N variant, and 4+ to 7+ charge states for the truncation variant (Figure 4.4). The 
highest charge state observed in each spectrum (8+) is consistent with the largest 
predicted charge state for native globular proteins based on simplified Rayleigh 
equation modelling (Equation 4.1) [253]. This model estimates, based on the mass of the 
protein and assuming a globular, roughly spherical fold, the maximum number of 
charges a solvent droplet of equivalent size to the protein could accommodate before 
undergoing fission due to Coulombic repulsion (similar to ESI mechanisms described 
in Section 1.2.1). Thus, this model serves to assess the protein charge state above 
which Coulombic repulsion is likely to significantly affect protein conformation or, 
alternatively, determine the charge state above which increased surface area (i.e. 
protein unfolding) would likely be required to adopt further charges. 
For β2m, this model calculates ~8.5 charges would be needed to reach this threshold, 
consistent with the highest observable charge state (8+) observed in the spectra, 
indicating that the protein conformation is likely native-like. 
Other than a minor, but reproducible, reduction the in the intensity of the 6+ charge 
state of the D76N variant relative to the wild-type protein (Figure 4.4a and b), the 
native ESI mass spectra of the wild-type and D76N variants are largely 
indistinguishable and remain distinct to that of the ΔN6 truncation variant (Figure 
4.4c). 
 
 𝑍𝑅 = 0.078𝑀
0.5 (4.1) 
Equation 4.1 Simplified Rayleigh equation to model charges on the surface of globular, natively folded 
proteins.  In this equation, ZR is the number of charges on the protein, and M is the average mass of the 
protein in Da. Equation taken from [253]. 
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Figure 4.4 Native ESI-MS analysis of three variants of β2m.  Wild-type (a), D76N (b) and ΔN6 β2m (c) 
analysed by ESI-MS under non-denaturing solution conditions, 150 mM ammonium acetate pH 7.4. 
Instrument conditions are listed in Section 3.2.2. Annotations above each peak show the m/z and 
charge state. The mass calculated from each spectrum is shown in the top right hand corner. 
 
Native IMS-MS analysis of these samples identified multiple peaks within the arrival 
time distributions (ATDs) of different charge states for all three variants, consistent 
with the presence of multiple protein conformations (Figure 4.5). This was most 
obvious upon closer examination of the ATDs, after adjusting T-wave IMS conditions 
for optimal separation (Figure 4.6). 
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Figure 4.5 3D IMS-MS plots of three variants of β2m.  Plots were exported from Driftscope v3.0 with 
ion intensity on a logarithmic scale. Plots are for the wild-type protein (a), the D76N variant (b) and 
the ΔN6 truncation variant (c). T-wave conditions were ‘T-wave 1’ as described in Table 3.2. 
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Figure 4.6 Arrival time distributions from ESI-IMS-MS analysis of the 6+ charge state of three variants 
of β2m.  Black trace indicates the overall arrival time distribution, where red, green and blue traces 
show Gaussian fitted curves to the data for wild-type (a), D76N (b) and ΔN6 (c). R2 values for Gaussian 
fits were 0.998, 0.996 and 0.994 for wild-type, D76N and ΔN6, respectively. T wave conditions were 
‘T-wave 2’ as described in Table 3.2. Reference lines are shown at 5.0, 7.5 and 10.0 ms. 
 
Assuming the presence of either two or three conformers – an assumption made upon 
manual inspection of the ATDs, CCS values calculated for these conformers 
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(calibration plot shown in Figure 4.7) were similar for the wild-type protein and the 
D76N variant (Table 4.1) and the D76N amino acid substitution did not significantly 
or reproducibly affect the relative intensity of either conformer. This similarity in 
CCS and ATD is consistent with the known similarity between the two protein 
structures, when observed by X-ray crystallography (Figure 2.9) [77, 157]. 
Similar to the native ESI-MS data, the native ESI-IMS-MS data for the ΔN6 truncation 
variant was distinct from that of the wild-type protein and the D76N variant showing 
a significantly wider ATD and generally smaller CCS values than either of the other 
two variants (Table 4.1, Figure 4.6c). This is consistent with the removal of the six N-
terminal amino acids, and could indicate increased conformational flexibility of ΔN6 
relative to the wild-type protein and D76N.  
 
 
Figure 4.7 Linear calibration plot for native ESI-IMS-MS CCS values. Proteins and charge states used 
for calibration were: cytochrome c (6+), β-lactoglobulin monomer (7+, 8+, 9+), β-lactoglobulin dimer 
(11+, 12+, 13+), and alcohol dehydrogenase (23+, 24+, 25+, 26+). T wave conditions were ‘T-wave 1’ as 
described in Table 3.2. R2 value and the equation of the fitted linear trend line used for calibration are 
shown in the top left hand corner. 
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Table 4.1 Calculated CCS values for wild-type, D76N, and ΔN6 β2m.
 Rotationally averaged collision cross section (nm2) 
Charge State Wild-type D76N ΔN6 
4+ - - 11.63 
5+ 12.43 
13.30 
12.34 
13.16 
12.03 
6+ 12.44 
13.31 
12.41 
13.35 
12.07 
13.19 
14.53 
7+ 15.45 
15.51 
15.45 
16.04 
15.06 
15.76 
8+ 16.47 16.96 - 
 
Calculations of in silico CCS values from the X-ray crystal structures of both the wild-
type protein (PDB: 1LDS, Figure 4.8b) and the D76N variant (PDB: 4FXL, Figure 4.8c) 
showed similar calculated CCS values (14.52 nm2 vs 14.50 nm2 for wild-type and D76N 
β2m crystal structures, respectively) consistent with the known similarity in protein 
structure between the two variants [77, 157]. However, these CCS values, along with the 
in silico CCS values calculated for the NMR structures of the wild-type protein (PDB: 
2XKS, Figure 4.8a) and the ΔN6 truncation variant (PDB: 2XKU, Figure 4.8d), were 
consistently larger (~15%) compared with the measured CCS values from the IMS data 
(Table 4.1).  
In silico CCS calculations of these protein structures, following molecular dynamics 
simulations performed in vacuo, revealed slightly smaller cross sections (Figure 4.8) 
more consistent with those of the measured CCS values, suggesting a slight gas-phase 
compaction for each of the three β2m variants. The post MD structures of the wild-
type protein reveal that this partial gas-phase collapse likely results from compaction 
of the N-terminus, and partially also from the collapse of the A-B loop protrusion in 
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the crystal structure, a feature absent in the NMR structure (Figure 4.8a and b). 
Interestingly, despite this large protrusion that is absent in the NMR structure of the 
wild-type protein, the NMR structure of wild-type β2m undergoes significantly more 
gas phase reduction in CCS than the crystal structure (~14.5 % compared to 10%), 
with a much lower endpoint CCS value. This likely results from the significant shift 
in conformation of the flexible D-strand, a rigid element in the crystal structure, the 
collapse of which is the likely cause of the difference in CCS between the two post-
MD conformations. 
Interestingly, the measured CCS values for the compact and extended conformations 
observed for the lowest discernible charge state of the wild-type protein (5+) were 
found to be consistent with the post-MD CCS values of the NMR and crystal 
structures, respectively. Although curious, the data presented here are insufficient to 
determine the identity of the two conformations, and the CCS and relative abundance 
of neither is significantly affected by the D76N amino acid substitution. 
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Figure 4.8 Gas-phase molecular dynamics and CCS values for three variants of β2m.  Protein structures 
for the wild-type protein, a shows the NMR structure (PDB: 2XKS), b shows the crystal structure (PDB: 
1LDS), the D76N variant (c, PDB: 4FXL) and the NMR structure of the truncation variant (d, PDB: 
2XKU) before (dark colours) and after (pale colours) gas-phase molecular dynamics simulations. CCS 
values calculated for each structure using IMPACT (see Section 3.2.3) are shown. CCS values calculated 
from travelling wave ESI-IMS-MS data are shown in e as data points (blue = wild-type, red = D76N, 
black = ΔN6), and compared to the in silico CCS values, shown as horizontal lines.
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4.3 HDX-LC-IMS-MS 
Seeking alternative structural MS methods to characterise the three β2m variants 
further, HDX, followed by reduction of the central disulphide bond, proteolytic 
digestion under quench conditions, and LC-IMS-MS analysis of the resulting peptides, 
was used to determine whether any changes in the solvent accessibility or hydrogen 
bonding of backbone amide protons could be detected between the three proteins.  
To determine the reproducible sequence coverage from the proteolytic digestion, all 
three variants were first diluted directly into the low pH quench solution, with no 
deuteration, prior to online digestion via an immobilised pepsin column. The resulting 
peptides were separated by RP-LC and analysed using a Waters Synapt G2Si using an 
HDMSE workflow (Figure 4.9, detailed methods can be found in Section 3.4.1).  
 
 
Figure 4.9 Automated HDX-LC-IMS-MS/MS workflow using a Synapt G2Si.  I) Solution containing a 
low µM concentration of protein is diluted into deuterated buffer to begin deuterium exchange. II) 
After incubation periods of varying length, the deuterated sample is further diluted into a low 
temperature, low pH quench solution to unfold the protein and minimise further deuterium exchange. 
III) The quenched sample is passed through an immobilised protease column to digest the protein into 
peptides, which are subsequently passed through a trapping column for desalting and alignment prior 
to LC separation. IV) After valve switching, the trapped peptides, still under quench conditions, are 
separated by RP-LC, prior to ESI. V) Peptide ions are trapped, and separated by IMS prior to 
fragmentation in the transfer cell and ToF-MS analysis. Detailed methods can be found in Section 3.4.1. 
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A total of 51 peptides were identified that were present reproducibly in the peptic 
digests of both the wild-type protein and the D76N variant, achieving 100% sequence 
coverage. Of these, 46 were also present reproducibly in the digest of the ΔN6 
truncation variant, where the missing five peptides all included the six N-terminal 
residues, which are absent in ΔN6 β2m (Figure 4.10). 
 
 
Figure 4.10 Sequence coverage of wild-type, D76N and ΔN6 β2m from online pepsin digestion.  The 
annotated amino acid sequence is shown. Peptides coloured blue were found in all three variants. 
Peptides coloured orange were found in the wild-type protein and the D76N variant only. Peptide 
identification criteria can be found in Section 3.4.2. 
 
All three variants were then subjected to deuterium labelling at 4 °C for 30, 60, 120, 
1800 or 7200 seconds before quenching, peptic digestion and LC-IMS-MS analysis, as 
before. Assignment of the deuterated peptides was performed by automated 
alignment of their IMS drift time and LC retention time to those of the previously 
identified unlabelled peptides. 
As the incorporation of deuterium on to a peptide increases its mass by increments of 
1 Da, this overlaps with the mass differences associated with the natural abundance 
of 13C isotopes in organic molecules. As a consequence, deuterium uptake in proteins, 
under the most commonly observed EX2 exchange kinetics, results in an observable 
shift in peptide isotope distributions towards higher m/z values, where this increase 
is quantified by subtracting the weighted average mass of the deuterated peptide 
isotope distribution, from that of the undeuterated peptide (Figure 4.11a-c). These 
data were used to generate deuterium uptake plots, where mass increase versus time 
can be compared between variants for each peptide identified (Figure 4.11d). 
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Figure 4.11 Generating deuterium uptake plots for peptides of β2m variants.  Isotope distributions for 
the 2+ charge state of peptide 68-79 (Sequence: TEFTPTEK(D/N)EYA) for wild-type (a), D76N (b) and 
ΔN6 β2m (c). The weighted average m/z (dashed line) for the undeuterated sample (top three spectra in 
a-c) is compared to that of the deuterated samples. The increase in m/z (blue shaded region) is corrected 
for charge state to calculate mass increase in Da. Mass increase, or deuterium uptake, is then plotted 
against time to generate deuterium uptake plots for each peptide (d – coloured as in a-c), which can be 
used to compare deuterium uptake for the same peptide from different proteins. Error bars show 
standard deviation, n = 5. 
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The most obvious identifiable differences between the three variants were 
significantly increased deuterium uptake in the ΔN6 truncation variant, relative to the 
wild-type protein and the D76N variant, on peptides surrounding the D-E loop 
(residues 56-60), B-C loop (28-34) and the C-terminus (81-99), regions where 
deuterium uptake in the wild-type and D76N proteins were remarkably similar to 
each other (Figure 4.12). Multiple overlapping peptides covering the same regions 
were also identified, most of which showed similar trends of increased deuterium 
uptake in ΔN6. However, in some instances the overlapping peptides showed differing 
trends. For example, although peptide 81-99, covering the C-terminus of β2m, showed 
higher deuterium incorporation in the truncation variant relative to the other two 
proteins, peptides covering the final six residues in the C-terminus (94-99) showed no 
significant difference in uptake between any of the variants (Figure 4.12). Instances 
of this nature make data interpretation challenging, as multiple, sometimes 
contradictory, uptake plots of overlapping peptides covering the same region, with 
varying degrees of overlap, need to be interpreted simultaneously, across multiple 
different proteins, as well as multiple different time points, to determine the regions 
of most significant difference. 
 
IMS-MS and HDX-LC-IMS-MS/MS comparing β2m variants 
117 
 
 
Figure 4.12 Example deuterium uptake plots highlighting increases in uptake in the ΔN6 truncation 
variant.  Amino acid residues of β2m covered by each peptide are shown in the top left hand corner of 
each plot. Error bars show standard deviation, n = 5. 
 
4.4 Development of a new HDX-MS processing algorithm 
In an ideal scenario, comparisons between states in HDX-MS experiments would be 
between individual backbone amides of the protein structure, the highest resolution 
unit of the experiment, where a single deuterium uptake value per time point is 
obtained for each exchangeable backbone amide, in contrast to overlapping peptide 
level data which generates multiple uptake values per time point, for groups of 
backbones amides. This would allow for a simple, residue by residue comparison of 
deuterium uptake between states, which can be plotted readily onto protein structures 
for data interpretation and visualisation, avoiding the difficulties associated with 
developing robust data interpretation and presentation strategies for complex, 
overlapping peptide level data [254]. Indeed, HDX-MS experiments can be conducted 
to provide residue level resolution by fragmenting deuterated peptides using 
alternative fragmentation techniques, such as ETD, and quantifying deuterium 
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incorporation at each backbone amide by analysing the isotope distributions of the 
resulting fragment ions [216, 255]. However, these experiments are plagued by poor, 
charge dependent fragmentation efficiency, often requiring the addition of non-
volatile supercharging reagents to achieve adequate peptide fragmentation [255]. 
Similarly, MS source conditions must be carefully tuned to avoid transferring excess 
internal energy to peptide ions, and minimise gas phase scrambling of the non-
covalent and labile, deuterium label [216, 256]. This additional experimental complexity 
is such that, despite the problematic interpretation and visualisation, HDX-MS 
experiments are typically performed to peptide level resolution [206, 257]. 
Numerous efforts have been made to consolidate peptide level deuterium uptake data 
to attain a single uptake value per amino acid, and simplify comparisons between 
states. One popular approach is a subtraction analysis, whereby the deuterium content 
of the overlapped region between peptides is calculated from the difference in 
deuterium content of the two peptides which overlap [258]. In the example presented 
in Figure 4.12, this would mean the deuterium content, and any differences in uptake 
between the three variants of β2m, between residues 81-93 could be assessed by 
subtracting the deuterium content of peptide 94-99 from peptide 81-99. While 
conceptually appealing, there are several problems with this approach. Firstly, in cases 
where more than two peptides cover the same overlapped region, multiple subtraction 
analyses are possible, which can still result in multiple uptake values per exchangeable 
amide. For example, two additional peptides, that cover the C-terminal ~10 amino 
acids of β2m (other than the two listed above) were also identified (Figure 4.10), so a 
simple subtraction of peptides 81-99 and 94-99 would discard these, otherwise valid, 
data. Secondly, recent evidence suggests that, excepting cases where almost complete 
deuterium retention on the overlapped peptides can be achieved (i.e. no back 
exchange), subtraction analyses often provide unreliable results, as peptides of 
different lengths but similar sequence, can form different secondary structures, such 
as alpha helices, under quench conditions [257]. The resulting differential hydrogen 
bonds that form can change the back exchange behaviour of the peptide and, as such, 
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the deuterium uptake values for identical amide groups present on different peptides 
cannot be considered equivalent [257].  
Many commercial HDX-MS processing methods, such as those in the Waters DynamX 
software used in our studies, circumvent this issue entirely by plotting data for all 
observed peptides, ordered by amino acid starting position, next to one another on the 
x axis, against change in absolute mass on the y axis, for each time point [259]. These so 
called ‘butterfly plots’, have an advantage in that they present the raw data in a 
minimally processed form. However, as a result, they can be challenging to interpret 
and visualise, as peptide lengths, and the regions of the protein each peptides covers, 
are not readily identifiable. Similarly, a threshold for differences in absolute mass 
between peptides of different states is typically set as the determinant of statistically 
significant difference [260, 261]. This can be misleading, however, as the biological 
significance of that mass change is somewhat dependent on the length of the peptide, 
which is not typically taken into account when measuring only changes in absolute 
mass. For instance, a difference of 0.5 Da in the weighted average mass of a 20 amino 
acid long peptide between two states, would appear, on a butterfly plot, to be of equal 
significance to the same mass difference on a five amino acid long peptide, despite 
being four times more concentrated, in terms of mass increase per exchangeable site, 
in the latter example. 
One novel approach however, designed to consolidate peptide level data across 
multiple time points into a single plot, sums the mass increase for a given peptide 
across all measured time points, before correcting for the number of exchangeable 
sites in the peptide, generating a single, fractional mass increase value for each peptide 
observed [170, 262]. These values are then averaged across all peptides covering a 
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particular amino acid in the protein sequence, to generate a single uptake value for 
each residue in the protein (Equation 4.2). 
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(4.2) 
Equation 4.2 Previously published HDX-MS peptide level data consolidation approaches. Where ?̅?𝑗  is 
the mean mass increase at amino acid j, summed across all measured time points, n is the number of 
overlapping peptides covering amino acid j, 𝑞
𝑖
 is the number of exchangeable amides for peptide i, 𝑚𝑖
𝑡 
is the weighted average mass for peptide i at time t and 𝑚𝑖
0is the weighted average mass for peptide i 
at time 0. 
 
The advantage of this approach is not only that it corrects mass increase for peptide 
length, but it consolidates peptide level HDX-MS data into the desired, single value 
per amino acid, which can be easily compared between states. However, although the 
usefulness of this approach has been demonstrated in numerous publications [170, 262, 
263], there are, perhaps, three significant limitations to this method. Firstly, statistical 
significance of any differences identified cannot be calculated, as there is, at present, 
no way of propagating errors in the deuterium uptake measurements of the peptides, 
to the final uptake value obtained for each residue. Similarly, without statistical 
analysis, robust methods of data presentation and visualisation, such as heat maps on 
protein structures, are challenging to develop. Lastly, the summation of uptake 
measurements across time points is such that minor differences observed over 
multiple time points accumulate, and may appear significantly larger in the processed 
data than the peptide deuterium uptake plot would suggest [170]. 
To address these issues, the following algorithm was developed to provide the desired 
single uptake measurement per amino acid from the overlapped peptide level data, for 
processing, visualising and comparing the HDX-MS data for the β2m variants, using 
relative fractional uptake data exported from DynamX. This simple approach not only 
evaluates each time point independently, but also allows statistical analysis of the 
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processed data to determine significant differences between states, offering robust 
criteria for data visualisation and presentation between datasets. 
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(4.3) 
Equation 4.3 PAVED algorithm: calculating combined mean relative fractional uptake per residue.  
Where 𝑋𝐶 is the combined mean relative fractional uptake for a given residue at a given time point, 𝑛𝑖 
is the number of replicates for peptide 𝑖. 𝑋𝑖 is the mean relative fractional uptake for peptide 𝑖 at a 
given time point. Peptides 𝑖 to 𝑧 are all the peptides that cover an amino acid position, excluding the 
N-terminal residue of each due to back exchange. 
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(4.4) 
Equation 4.4 PAVED algorithm: calculating combined standard deviation per residue.  Where 𝑆𝑐 is the 
combined standard deviation for a given residue at a given time point, 𝑆𝑖 is the standard deviation of 
peptide 𝑖 at a given time point. 𝑋𝐶 is the combined mean relative fractional uptake for a given residue 
at a given time point, 𝑛𝑖 is the number of replicates for peptide 𝑖. 𝑋𝑖 is the mean relative fractional 
uptake for peptide 𝑖 at a given time point. Peptides 𝑖 to 𝑧 are all the peptides that cover an amino acid 
position, excluding the N-terminal residue of each due to back exchange. 
 
For a given time point and state, Equation 4.3 calculates the combined mean relative 
fractional uptake (deuterium uptake corrected for the number of exchangeable amides 
in the peptide) for each amino acid, by averaging the relative fractional uptake values 
for peptides which cover the amino acid in question. Equation 4.4 then uses this 
combined mean, and the standard deviations for each of the peptides, arising from 
replicate measurements, as well as variances between charge states from the same 
measurement, to calculate a combined standard deviation. This process is repeated for 
each residue in the sequence, for every measured time point, and all states (wild-type, 
ΔN6 and D76N in these experiments). Knowing the combined mean relative fractional 
uptake, combined standard deviation, and the total number of measurements for each 
residue (n = replicates x peptides covering the residue), statistical analysis can be 
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performed using one way ANOVA and post hoc Tukey tests, to determine significant 
differences, on a per residue basis, between states at equivalent time points [264].  
Although the presence of multiple charge states for a given peptide provides multiple 
measurements of deuterium uptake, and were included in the calculation of both the 
combined mean relative fractional uptake and the combined standard deviation of 
each residue, it was decided to exclude the number of charge states from the 
calculation of n, as this would weight larger peptides, offering lower structural 
resolution, more significantly than smaller ones in the final calculation of combined 
relative fractional uptake. Additionally, the N-terminal amide of each peptide has 
been observed to undergo rapid back exchange, within 1-2 minutes, under quench 
conditions, leaving no deuterium on this residue [221]. It was therefore decided to 
exclude the N-terminal residue of each peptide from our analysis, and the calculation 
of relative fractional uptake. 
This processing algorithm was designed to process output files from DynamX, and was 
initially written in R (original code can be found in Section 8.1) before being further 
developed by James Ault (MS facility manager) for faster processing speeds, and the 
inclusion of a graphical user interface (Figure 4.13). This software, named PAVED 
(Positional Averaging for Visualising Exchange Data) is now available for free 
download at:  
https://biologicalsciences.leeds.ac.uk/downloads/download/28/software_download 
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Figure 4.13 PAVED graphical user interface.  PAVED software for visualising and presenting peptide 
level HDX-MS data. Software and GUI created by James Ault. 
  
4.5 Evaluating the PAVED algorithm 
To evaluate the utility of the PAVED algorithm, the differences in HDX behaviour of 
wild-β2m and the ΔN6 truncation variant, being the two well-characterised variants 
of β2m, were first compared with previously published studies comparing the two 
proteins using NMR relaxation methods [78] as well as intact HDX-MS [134]. 
Despite the initial 100% sequence coverage (Figure 4.10), the removal of the N-
terminal residue of each peptide during processing results in the loss of coverage of 
two internal amides (Tyr 26 and Arg 81), as well as the N-terminal methionine (Figure 
4.14b). Figure 4.14c shows the PAVED processed HDX-MS data for wild-type β2m 
after 30 seconds of deuteration. As deuterium incorporation is dependent on both the 
primary sequence and the solvent accessibility and dynamics of each amide, factors 
which are unique to each protein, these combined relative fractional uptake plots 
provide a unique protein ‘fingerprint’ of deuterium uptake across the protein 
sequence, for a given peptide list. Indeed, this ‘fingerprint’ deuterium uptake pattern 
is remarkably similar for all three β2m variants after 30 seconds of labelling, likely 
reflective of their similar sequences and protein structures (Figure 4.15).  
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After processing, significant errors in the combined mean relative fractional uptake 
values are observed across all three variants between residues 35-40 and 65-70 (Figure 
4.14c, Figure 4.15). This is due to the positional averaging of peptides with minimal 
overlap, covering different regions of the protein, which have significantly different 
relative fractional uptake values, and accurately reflects the uncertainty of the 
deuterium uptake measurements in these regions (Figure 4.14a and b). The same effect 
is observed in ΔN6 at the C-terminal region (residues 90-99) where overlapping 
peptides discussed earlier (peptides 81-99 and 94-99, Figure 4.12) showed differing 
trends with regards to the deuterium uptake differences relative to the wild-type 
protein. Here, the positional averaging algorithm has reduced the combined mean 
relative fractional uptake at the extreme C-terminus to show no statistical significance 
to the wild-type protein, but significant differences are shown between residues 82-
90 (F-G loop), accurately reflecting the complex overlapping peptide level data for 
this region (Figure 4.12, Figure 4.15, Figure 4.17). 
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Figure 4.14 Consolidation of HDX-MS data using positional averaging.  Relative fractional uptake data 
taken from DynamX (a) is processed by removing the N-terminal residue from each peptide due to 
back exchange. Multiple uptake measurements for each residue can then be identified by evaluating 
the relative fractional uptake value for each peptide, and the residues each peptide covers (b). Finally, 
Equation 4.3 and Equation 4.4 are used to combine the mean and standard deviations for multiple 
measurements of the same residue, from the overlapping peptides, to achieve a single uptake 
measurements and error value, per residue, per time point, per state (c). Data are shown for wild-type 
β2m for the 30 second time point. Error bars shown in b) are standard deviations associated with 
replicate measurements (n=5) and variances between charge states of the same replicate. Error bars 
shown in c) are combined standard deviations calculated using Equation 4.4. 
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Figure 4.15 Comparing HDX-MS between three β2m variants data after 30 seconds deuteration.  
Combined mean relative fractional uptake per residue was calculated using the PAVED algorithm. 
Shaded regions show combined standard deviation. 
 
Similarly significant differences (p < 0.05, based on combined standard deviation and 
combined mean relative fractional uptake) between ΔN6 and the wild-type protein 
are observed in the B-C and D-E loop regions (residues 27-35 and 57-62, respectively), 
consistent with NMR relaxation experiments [78]. Including significant differences 
identified in the F-G loop (residues 82-90), these regions highlight a total of 24 
backbone amides with statistically significantly (p < 0.05) increased deuterium uptake 
in the ΔN6 truncation. This is remarkably close to the 22 ± 1 backbone amides 
estimated to have decreased protection in this variant from intact HDX-MS data [134]. 
Although these differences are largely consistent across all time points measured, at 
later labelling time points (1800 and 7200 seconds), both the ΔN6 truncation variant 
and the D76N variant show smaller increases in deuterium uptake (2-3%) relative to 
the wild-type protein, across the length of the β2m sequence (Figure 4.16). This is 
likely the result of decreased stability of the native fold in both proteins, and increased 
propensity of D76N and ΔN6 to populate the unfolded state, relative to the wild-type 
protein [146, 156], and effectively demonstrates the utility of evaluating each deuteration 
time point separately. 
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Figure 4.16 PAVED difference plots of HDX-MS data for wild-type, D76N and ΔN6 β2m. Shaded regions 
show combined standard deviation.Wild-type β2m has been set to zero for reference. Incubation time 
in deuterated buffer is shown in the bottom left hand corner of each plot. 
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Figure 4.17 Visualising differences in deuterium uptake relative to wild-type β2m.  Statistically 
significant differences (p < 0.05 based on PAVED processed data) are shown. Increases in deuterium 
uptake, relative to the wild-type protein, are shown in red. Decreases are shown in blue. Missing 
residues and the N-terminal truncation are shown in black. For reference, a detailed, annotated 
structure of b2m can be found in Figure 2.6 in Section 2.2. PDB: 4FXL [157]. 
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With a deuterium uptake value for each residue, and statistical analyses determining 
significant differences, the PAVED processing algorithm was then used to screen data 
for statistical significance as a robust method of data presentation and visualisation. 
Residues which show statistically significant differences between states were then 
coloured according to the magnitude of the difference in relative fractional uptake, 
and plotted on the β2m structure (Figure 4.17). Structurally, the differences observed 
between the wild-type and the ΔN6 truncation variant at the earliest labelling time 
points, are located proximal to the N-terminal truncation (Figure 4.17), consistent 
with earlier reports [78]. 
 
4.6 Deuterium uptake behaviour of the D76N variant of β2m 
Relative to both the wild-type protein, and the ΔN6 truncation variant, D76N shows 
remarkably increased deuterium uptake in the E-F loop (residues 65-80), directly 
surrounding the amino acid substitution. Indeed, uptake plots indicate that the 
deuterium uptake has largely plateaued from the earliest measured time point, for all 
peptides covering this region (Figure 4.18). However, as a consequence of the 
difference in amino acid sequence for these peptides between the wild-type protein 
and the D76N variant, it should be noted that the intrinsic deuterium exchange rate 
is also different.  
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Figure 4.18 Deuterium uptake plots for peptides covering the D76N substitution.  Amino acid residues 
of β2m covered by each peptide are shown in the top left hand corner of each plot. Error bars show 
standard deviation, n = 5. 
 
To determine whether these differences were a result of structural change in the 
protein, or differences associated with a change in chemical exchange rate, peptides 
including residues 68-80 from both the wild-type protein and the D76N variant were 
purchased from Peptide Synthetics and fully deuterated in label buffer for 24 hours. 
Following labelling, the fully deuterated peptides were quenched and analysed by LC-
MS, in the same fashion as peptides from the proteolytic digests. The wild-type 
peptide was found to have an average mass increase of 6.16 Da, compared with 6.80 
Da increase of the D76N peptide. These values can be considered the effective 
maximum possible exchange for these peptides, on our system, after back exchange 
and can therefore be used as a benchmark for back exchange correction, and the 
determination of fractional deuterium uptake for each time point. 
After back exchange correction, despite the naturally increased deuterium exchange 
rate of the D76N peptide relative to the wild-type peptide, the D76N variant still 
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shows ~20% increased deuterium uptake at the earliest labelling time points, relative 
to both the wild-type protein and the ΔN6 truncation variant, indicating that these 
changes are associated with a change in hydrogen bonding, solvent accessibility 
and/or dynamics in the D76N variant (Figure 4.19). 
 
 
Figure 4.19 Back exchange correction for peptides covering the D76N substitution.  Correction was 
performed using synthetic peptides purchased from Peptide Synthetics which were fully deuterated in 
label buffer. Peptide sequence is shown in the top left hand corner. Error bars show standard deviation, 
n = 5. 
 
Minor increases in deuterium uptake for the D76N variant, relative to the wild-type 
protein, were also observed in the A-B loop (residues 12-22, Figure 4.15, Figure 4.16, 
and Figure 4.20). Although, after PAVED processing, these differences proved not to 
be statistically significant, structurally the A-B loop is on the same side of the protein’s 
β-sandwich structure as the E-F loop and the D76N mutation. This proximity to the 
D-N substitution site, and the observed HDX differences surrounding the mutation, 
suggests that these minor changes in the A-B loop may be real, but insufficiently 
resolved by the comparatively long peptides which cover this region. 
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Figure 4.20 A-B loop hydrogen exchange uptake plots.  Amino acid residues of β2m covered by each 
peptide are shown in the top left hand corner of each plot. Error bars show standard deviation, n = 5. 
 
4.7 Discussion 
4.7.1 The PAVED algorithm 
The differences observed and characterised by the PAVED processing algorithm 
between the ΔN6 truncation variant and the wild-type protein are consistent with 
earlier reports [78] [134, 146] [156], and indicate changes in structure directly proximal to the 
N-terminal truncation, as well as a decreased stability of the native fold, relative to 
the wild-type protein. 
Due to the correction for peptides of different lengths, and the propagation or errors 
in the averaging calculations, the PAVED algorithm offers a useful method of 
visualising peptide level HDX-MS data, highlighting both the statistical and biological 
significance of the data. Similarly, by using all the available peptide data, this approach 
avoids bias in peptide selection for data presentation, either as uptake plots or as heat 
maps on protein structures, instead offering a robust, statistically driven method for 
data visualisation. 
However, the shortcomings of this approach must also be discussed. The minor 
differences in deuterium uptake between the wild-type protein and the ΔN6 
truncation variant, between residues 90-99 in the processed data (Figure 4.15), are in 
contradiction with the actual peptide level data, where data points in the uptake plot 
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overlay (Figure 4.12). Although processing with PAVED has correctly assigned 
differences in this region as not statistically significant, the combined average 
deuterium uptake in the processed data is higher in the ΔN6 variant than in the wild-
type protein in this region, as a result of a much longer, overlapping peptide where 
deuterium uptake in ΔN6 is increased relative to the wild-type protein. This 
‘smoothing’ effect on the data is to some extent unavoidable with this approach, and 
is a similar issue for the alternative processing method described in Equation 4.2. 
Clearly, shorter peptides provide higher structural resolution on changes in deuterium 
uptake, where overlap with longer peptides exacerbates the smoothing effect on the 
data during processing. The PAVED algorithm developed here lends itself to further 
development in this regard as, currently, peptides of all lengths are weighted equally 
in the calculation of the relative fractional uptake for each residue. In reality, the 
relative fractional uptake for a given residue is more likely to be represented 
accurately by shorter peptides than by longer peptides as, in the former case, an 
individual amide makes a larger relative contribution to the measured peptide level 
data. 
As such, a modelling approach, based on the PAVED processing algorithm, could be 
conceived whereby shorter peptides are weighted more heavily in the calculation of 
relative fractional uptake: 
 
 
𝑋𝐶 = 
∑ 𝑛𝑖?̅?𝑖𝑙𝑖
−1𝑧
𝑖=1
∑ 𝑛𝑖
𝑧
𝑖=1 𝑙𝑖
−1  
(4.5) 
Equation 4.5 Proposed modelling of HDX data based on PAVED processing.  Where 𝑋𝐶 is the combined 
mean relative fractional uptake for a given residue at a given time point, 𝑛𝑖 is the number of replicates 
for peptide 𝑖. 𝑋𝑖 is the mean relative fractional uptake for peptide 𝑖 at a given time point. 𝑙𝑖 is the 
number of exchangeable amides in peptide 𝑖 , excluding the N-terminal residue. Peptides 𝑖 to 𝑧 are all 
the peptides that cover an amino acid position, excluding the N-terminal residue of each. 
 
Although such a modelling approach would need to be tested on control proteins with 
precisely known deuterium uptake behaviour, weighting shorter peptides more 
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heavily may mitigate the smoothing effect of the algorithm, thus further simplifying 
data interpretation. 
 
4.7.2 HDX behaviour of the D76N variant 
The markedly increased deuterium uptake of the E-F loop in the D76N variant, 
observed here for the first time, is suggestive of a significant structural or dynamical 
change in this region. These observations are consistent with ssNMR experiments 
which identified structural changes between wild-type β2m and D76N at both the E-
F loop, and more minor differences at residues Arg 12 and His 13 in the A-B loop [164]. 
These findings could be consistent with the minor differences in deuterium exchange 
of the A-B loop observed by HDX-MS, where such minor differences are expectedly 
unresolved, both dynamically and spatially, by the comparatively long (> 11 residues) 
peptides identified which cover this region (Figure 4.10). 
Although increased solvent accessibility in the E-F loop of the D76N variant, relative 
to the wild-type protein, could account for the observed relative increase in 
deuterium uptake, this explanation seems unlikely, as the E-F loop extends out into 
bulk solvent, and is largely solvent exposed in both variants (Figure 2.9). In the NMR 
structure of wild-type β2m, Asp 76 is involved in an extensive hydrogen bonding 
network in the E-F loop involving residues Tyr 78, Thr 73 and Lys 75 (Figure 4.21). 
Three of these contacts are main-chain hydrogen bonds involving backbone amide 
protons, changes in which would be visible by HDX-MS experiments (Figure 4.21). 
While many of these hydrogen bonds are also present in the crystal structure of the 
D76N variant [157], static crystallographic structures are not necessarily representative 
of the solution phase conformational distribution of the protein. Indeed, MD 
simulations of the D76N variant have indicated that the D-N substitution disrupts 
hydrogen bonding in the E-F loop, causing the loss of molecular contact between 
hydrogen bonded residues [265]. These simulations are consistent with the observed de-
protection of backbone amides in the E-F loop of D76N and, given the central role 
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that residue 76 plays in the structure of the E-F loop in the wild-type protein, loss of 
hydrogen bonding in the E-F loop seems a plausible explanation for the increased 
deuterium uptake in this region observed here using HDX-MS. 
 
 
Figure 4.21 Hydrogen bonding in the E-F loop of wild-type β2m.  Side chains in the E-F loop (red) 
involved in hydrogen bonding are shown as sticks and coloured by element: oxygen = pink, nitrogen = 
blue, hydrogen = white. Polar contacts between atoms are shown as dashed yellow lines. The C-
terminus has been hidden for clarity. PDB: 2XKS [78]. 
 
4.7.3 Insights on the aggregation propensity of the D76N variant 
Analysis of both the IMS, and HDX data demonstrate that the D76N variant is distinct, 
in terms of protein structure and dynamics, from the aggregation-prone ΔN6 
truncation variant, with little similarity in terms of deuterium uptake behaviour or 
IMS ATDs. While the IMS data showed that the D76N variant was largely 
indistinguishable from the wild-type protein, as indeed most regions of the protein 
were using PAVED analysis of the HDX-MS data (Figure 4.16, Figure 4.17), the 
marked increase in deuterium uptake in the E-F loop of the D76N variant relative to 
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the wild-type protein, and hypothesised loss of hydrogen bonding, is an important 
observation regarding the increased aggregation propensity of this variant. The 
hydrogen bonding analysis in Section 4.7.2, coupled with previous studies 
demonstrating the critical nature of the D76 residue in preventing the aggregation of 
β2m [159] is highly suggestive that the structure of the E-F loop is a key factor in 
preventing oligomerisation and amyloid formation in β2m. Although considerably 
more research is needed before any firm conclusions can be drawn from these data, 
the clear distinction between D76N and the ΔN6 truncation variant, considered to be 
a structural mimic of the amyloidogenic IT state [78, 146], shown by these data and by 
others [161] could indicate an alternative, or additional route, to amyloid formation in 
β2m, not involving the IT state folding intermediate. If true, further analysis of the β2m 
model protein system could prove invaluable in studying the potential multiplicity of 
pathways available to amyloid formation from the native state of a protein structure. 
 
4.7.4 Attempted HDX-ETD single residue experiments 
In an effort to gain higher resolution structural information on the HDX behaviour of 
the E-F loop in D76N, and ascertain precisely which residues were responsible for the 
increased deuterium uptake in this region, single residue HDX-MS experiments using 
ETD peptide fragmentation were attempted. Although problems with method 
development meant these experiments ultimately failed to yield any useful results, 
the discussion of these data may help future research and, for the interested reader, 
are presented (briefly) in this section. 
With help from Malcolm Anderson (Principal applications chemist, Waters 
Corporation, Wilmslow, UK) the Synapt G2Si instrument was tuned to optimise ETD 
fragmentation and minimise deuterium scrambling, using the peptide P1 standard 
similar to earlier reports [266]. Good sequence coverage was obtained (Figure 4.22), and 
minimal deuterium scrambling was observed after incorporation of the peptide with 
deuterated buffer, as evidenced by the retention of deuterium at the C-terminal end 
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of the peptide, where the slower exchanging isoleucine and lysine side chains are 
located (Figure 4.23). 
 
Figure 4.22 ETD fragmentation of peptide P1.  a) Fragmentation spectrum of peptide P1 (sequence: 
HHHHHHIIKIIK) and a 400x y axis zoomed image (b). C and Z ions are shown in blue and pink, 
respectively, above each peak. 
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Figure 4.23 Deuterium scrambling analysis on peptide P1.  Deuterium content of peptide P1, following 
instrument tuning, matches that of the unscrambled values obtained from modelling equations found 
in [266]. 
 
Although the fragmentation efficiency was low, ETD fragmentation was successfully 
incorporated into the online LC-IMS-MS workflow (outlined in section 3.4.1) by 
combining multiple acquisitions to increase the total level of signal. This was 
successfully tested on the 3+ charge state of the N-terminal peptide of wild-type β2m 
where, after six combined LC-MS acquisitions, almost a complete fragment ion series 
could be observed (Figure 4.24). 
IMS-MS and HDX-LC-IMS-MS/MS comparing β2m variants 
139 
 
 
Figure 4.24 Online HDX-LC-ETD-MS of the N-terminal peptide of β2m. a) ETD fragmentation 
spectrum of peptide 0-9 of wild-type β2m (sequence : MIQRTPKIQV) from online LC-ETD-MS/MS 
experiments. b) 400x y axis zoomed image of the fragmentation spectrum. C and Z ions are annotated 
blue and pink, respectively. 
 
Despite these successes however, the peptides that were identified in the region of the 
E-F loop were all doubly charged, and yielded no identifiable fragment ions when 
subjected to ETD fragmentation, even after combining multiple acquisitions.  In 
accordance with earlier ETD methods [255], 0.05 % (v/v) supercharging reagent (M-
NBA) was added to the LC solvents to increase the charge states of identified peptides. 
Whilst this did produce a 3+ charge state of one peptide covering the desired region, 
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the intensity of this charge state was too low (~5e4) to identify any fragment ions 
following ETD, even after combining multiple acquisitions (Figure 4.25). 
Additionally, the added supercharging reagent, presumably due to its lack of 
volatility, frustrated the author (and the MS facility manager) to a great degree by 
fouling the front end of the mass spectrometer with brown goo. 
 
 
Figure 4.25 ETD fragmentation of the E-F loop of wild-type β2m. Fragmentation spectrum (top) and a 
400x y axis zoom (bottom) of peptide 67-78 (sequence YTEFTPTEKDEY) of wild-type β2m after six 
combined acquisitions. No ETD fragment ions could be identified. 
 
 
 
 
 
 
FULL ETD run wild-type b2m t=0
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
wil-type t=0 v2 24 (5.760) Cm (21:27) 4: TOF MSMS 508.20ES+ 
5.59e4508.2256
505.2191
508.5602
508.8949
761.8333
509.2298
511.1917
762.8336
763.3400
wil-type t=0 v2 24 (5.760) Cm (17:29) 4: TOF MSMS 508.20ES+ 
814508.2256
469.8646
467.8137
251.0715
131.1003
365.1955
405.1697
508.5602 761.8333682.0223
681.6918
668.0061
762.3394
1002.0049
887.7979
887.4338
767.2763
768.9820
826.7335
1001.5214
942.7509
1011.5192
1012.1857
1022.5017
1023.0461
1395.4998
1136.5590
1669.2717
1396.7229 1851.2004
IMS-MS and HDX-LC-IMS-MS/MS comparing β2m variants 
141 
 
Alternative digest strategies using two different acid proteases (other than pepsin) 
were similarly ineffective at providing an abundant, triply charged peptide in the 
region of the E-F loop (Figure 4.26). 
 
 
Figure 4.26 Alternative acid protease digests of wild-type β2m.  Digests using Nepenthesin (a) and 
Aspergillopepsin (b) both failed to provide abundant, triply charged peptides in the region of the E-F 
loop that would be conducive to successful ETD fragmentation. 
 
While these experiments were not successful in attaining the greater understanding 
of the E-F loop of D76N as desired, and certainly highlight the need for more 
orthogonal digestion methods, many experimental parameters were left unchanged, 
due to time constraints, which may have yielded better results. For example, 
alternative quench conditions or a re-optimisation of the digest protocol, as opposed 
to changing proteolytic enzyme, may provide more ETD compatible peptides in the 
preferred region. Alternatively, orthogonal fragmentation strategies, such as UV 
photodissociation, have been shown to successfully localise deuterium incorporation 
on peptides to residue level without adding internal energy sufficient to produce 
deuterium scrambling [267]. It has been proposed that this fragmentation technique also 
has higher fragmentation efficiency and a more limited dependence on the charge 
state of the peptide precursor. These characteristics could make this an ideal 
fragmentation method to suit the issued thus far encountered with these experiments. 
Given the stark difference in deuterium uptake between the, otherwise startlingly 
similar, wild-type protein and the D76N variant, and the time constraints limiting the 
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development time that was available for the above method, the importance of the 
continuation and further development of this, or similar, methods to further 
understand the E-F loop of D76N cannot be overstated. The implications of this are 
discussed further in section 7.2. 
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5 FPOP-LC-MS/MS comparing β2m variants  
As discussed earlier in Section 2.4.4, fast photochemical oxidation of proteins (FPOP) 
is an emerging technique frequently used in conjunction with MS analysis, used for 
the characterisation and understanding of protein structures, although the method 
itself, and the intricacies of how to analyse and interpret the resulting data, are poorly 
understood. This chapter aims to address some of these issues, with the following aims: 
1. Evaluate the current FPOP method used in our laboratory and determine the 
significance, and incidence, of structural artefacts created by FPOP labelling 
in these experiments. 
2. Use the well-characterised wild-type and ΔN6 truncation variants of β2m to 
develop the FPOP method, and gain a greater understanding of how to 
interpret and analyse FPOP-LC-MS/MS data. 
3. Use FPOP-LC-MS/MS to characterise the, poorly understood, D76N variant of 
β2m and identify any changes that may be associated with the increased 
propensity of this variant to aggregate. 
FPOP data for wild-type β2m and the ΔN6 truncation variant from this chapter were 
subsequently published in Cornwell., et al., JASMS, 2019 [252]. 
 
5.1 FPOP method validation 
In an ideal FPOP experiment, each protein, and the solution immediately surrounding 
it, would be irradiated no more than once. This is because once a protein has been 
irradiated, it has the possibility, although not certainty, of being labelled by a nearby 
hydroxyl radical, and the introduction of such non-native oxidations may shift the 
protein structure into a non-native conformation. As a result, continued oxidative 
labelling of the protein increases the chance of probing non-native structures 
generated as artefacts of FPOP labelling, rather than the protein in its native state. 
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However, the experimental setup typically used in FPOP, both in the literature and 
our laboratory (described in detail in Section 3.5), makes the determination of exactly 
how many irradiation events, or ‘shots’, a protein has undergone quite challenging. 
The FPOP analyte solution is passed, at a fixed flow rate, through a capillary that 
intersects orthogonally the beam of a UV excimer laser, necessary to liberate hydroxyl 
radicals from hydrogen peroxide. Due to the nature of the laser itself, this beam is not 
constant and is instead pulsed at a constant frequency, for a fixed duration of 20 ns 
(Figure 5.1). Although this extremely short pulse duration can be assumed as 
instantaneous, for most practical purposes, this setup is such that many other 
parameters are involved in determining how many times a protein molecule is 
irradiated including: laser firing frequency, beam width, diffusion of the protein in 
solution, and time spent in the irradiation window, the latter of which is directly 
proportional to the flowrate of the solvent in the capillary.  
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Figure 5.1 Schematic diagram of a typical FPOP experimental setup.  Solution containing the protein 
sample, hydrogen peroxide and a scavenger amino acid is passed through a capillary intersecting an 
irradiation window where 248 nm UV light causes photolysis of the hydrogen peroxide, generating 
hydroxyl radicals. These hydroxyl radicals then covalently label the protein sample, before the sample 
is diverted into a quench solution to prevent further radical oxidation. 
 
The beam width (~3 mm), firing frequency (15 Hz) and the flowrate (20 µl min-1) of 
the analyte solution have been optimised previously in our laboratory to approximate 
each bolus of liquid in the capillary experiencing a single shot, which can be 
demonstrated, knowing the inner radius of the capillary (50 µm), by showing that the 
irradiated volume per second is approximately equal to the flow rate used [231]. 
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 𝐼𝑟𝑟𝑎𝑑𝑖𝑎𝑡𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 𝑝𝑒𝑟 𝑠𝑒𝑐𝑜𝑛𝑑 =  𝜋𝑟2  × 𝑤 × 𝑓 
= 𝜋(50 × 10−6)2 × (3 × 10−3) × 15 
= 3.54 × 10−10 𝑚3𝑠−1 
= 21 µ𝑙 𝑚𝑖𝑛−1  
(5.1) 
Equation 5.1 Calculating irradiation volumes in FPOP capillary experimental setups assuming a plug 
flow model.  Area of the capillary (units = m2) multiplied by beam width (denoted w, units = m) 
multiplied by laser firing frequency (denoted f, units = s-1). Units of m3 s-1 converted to µl min-1 by 
multiplying by 109 (units = µl s-1) and multiplying again by 60 (µl min-1). 
 
Although others have used more conservative experimental parameters, opting for a 
brief exclusion volume with no irradiation between each shot [227], which has been 
achieved by increasing the flowrate or reducing the firing frequency, both of these 
calculations are flawed in that they assume a ‘plug flow’ model where all solvent across 
the radius of the capillary is flowing at the same rate. In reality, the flow regime in 
the capillary is more accurately described by a laminar flow model, where solvent 
travels faster at the centre of the capillary, and slower at the capillary walls, a scenario 
typically visualised as a series of concentric rings of varying flow rates around the 
capillary centre (Figure 5.2). The velocity of solvent at any given radius from the 
centre of the capillary can be calculated using Equation 5.2 [268]. 
 
 
𝑣(𝑟) = 2 (
𝑉
𝜋𝑟2
)(1 −
𝑟2
𝑅2
) 
(5.2) 
Equation 5.2 Calculating the velocity of solvent at different radii from the capillary centre in laminar 
flow.  Where v(r) is the velocity at a given radius (r) from the capillary centre (units = m s-1), V is flow 
rate (units = m3 s-1) and R is the capillary radius (units = m). 
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Figure 5.2 Visualising laminar flow in capillaries.  Side view (left) and end view (right) of laminar flow 
shows solvent flows faster at the capillary centre and slower at the capillary walls. R and r are annotated 
as in Equation 5.2. 
 
Laminar flow regimes have been described previously in the context of FPOP 
experiments by Konermann et al., where the authors concluded that diffusion of the 
protein both axially along the capillary, and laterally between flow regimes were 
negligible factors in the resulting number of irradiation events experienced by protein 
molecules in the sample. However, the authors also concluded that due to the slower 
moving proteins in solvent nearer the capillary walls, multiple shots for a certain 
proportion of the sample, and only minimal radiation exposure for proteins in faster 
flow regimes in the capillary centre, are inevitable consequences of laminar flow in 
these experiments [268]. Nevertheless, based on these findings, the FPOP method used 
previously in our laboratory was re-evaluated to determine the degree to which 
multiple exposure events were occurring under the present experimental conditions. 
Using Equation 5.2 and experimental parameters listed in Section 3.5, the velocity of 
solvent, and time spent inside the irradiation window, at various different radii from 
the capillary centre, were calculated (Figure 5.3). By assuming this velocity is 
consistent across short widths of the capillary, we can simplify the problem by 
splitting the flow in the capillary into multiple, smaller ‘plug flow’ models, where each 
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concentric ring of flow, of arbitrary width, is approximated to have the same average 
velocity. This approximation is most accurate closest to the capillary centre, where 
the dependence of velocity on radial position is the lowest (Figure 5.3). As such, the 
calculation was split into multiple 5 µm wide rings from the capillary centre (0-5 µm, 
5-10 µm etc…) where, smaller, 1 µm intervals were used after 45 µm from the 
capillary centre, where radial position affects velocity most significantly. 
 
 
Figure 5.3 Velocities and time spent in the irradiation zone calculated for different flow regimes in the 
FPOP capillary. Calculated using Equation 5.2 and experimental parameters listed in Section 3.5. A 
radius of 0 on the x axis is the capillary centre. The work of Prof. Nik Kapur (Applied Fluid Mechanics, 
School of Mechanical Engineering, University of Leeds) is gratefully acknowledged for his help in these 
calculations. 
 
Knowing the firing frequency of the laser (15 Hz) and the time spent in the irradiation 
window for each concentric ring of flow, or flow regime, we can determine the 
average number of shots and, consequently, the maximum and minimum number of 
shots, a protein could experience under each flow regime, maximum being a scenario 
where a protein is irradiated the instant it enters the beam width, and the minimum 
being a protein that follows one that was instantly irradiated (equivalent to one fewer 
than the maximum number of hits). As the proportion of protein receiving the 
maximum and minimum number of shots under each flow regime must sum to 1, we 
can determine the fraction of protein, under each flow regime, that receives the 
maximum and minimum number of shots (Equation 5.3, Table 5.1). 
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 𝑥 + 𝑦 = 1 
𝛼𝑥 + 𝛽𝑦 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠ℎ𝑜𝑡𝑠 
(5.3) 
Equation 5.3 Simultaneous equations calculating the maximum and minimum number of irradiation 
events for different flow regimes in FPOP. Where x and y are the proportions of protein receiving the 
maximum and minimum number of shots, and α and β are the maximum and minimum number of 
shots for a given flow regime. 
 
Calculating the cross sectional area of each flow regime ring, we can determine the 
mean flow rate of solvent in each regime, by multiplying by the mean velocity of the 
solvent at this radius (Table 5.1). Dividing this by the mean flow across the whole 
capillary, we can estimate the fraction of the sample subjected to each flow regime. 
Knowing how much of the sample is in each flow regime, and how much of each flow 
regime experiences different numbers of irradiation events, we can determine, 
overall, the proportion of the sample that is under the desired single exposure 
conditions (Figure 5.4). 
 
Table 5.1 Determining the number of irradiation events under different flow regimes of a laminar flow 
model in FPOP experiments. 
Radius 
(µm) 
Velocity 
(m s-1) 
Time in 
zone (s) 
Max 
hits 
Average 
hits 
Min hits 
fraction 
Max hits 
fraction 
Mean flow at this 
radius (m3 s-1) 
Fraction flow at 
this radius (%) 
0 0.084883 0.035343 1 0.530144 0.469856 0.530144 
  
0-5 0.084034 0.0357 1 0.535499 0.464501 0.535499 6.6E-12 2.210133 
5-10 0.081487 0.036816 1 0.552233 0.447767 0.552233 1.92E-11 6.429478 
10-15 0.077243 0.038838 1 0.582576 0.417424 0.582576 3.03E-11 10.15768 
15-20 0.071301 0.042075 1 0.631124 0.368876 0.631124 3.92E-11 13.12685 
20-25 0.063662 0.047124 1 0.706858 0.293142 0.706858 4.5E-11 15.06909 
25-30 0.054325 0.055223 1 0.82835 0.17165 0.82835 4.69E-11 15.7165 
30-35 0.04329 0.0693 2 1.039498 0.960502 0.039498 4.42E-11 14.8012 
35-40 0.030558 0.098175 2 1.472622 0.527378 0.472622 3.6E-11 12.05527 
40-45 0.016128 0.186015 3 2.79023 0.20977 0.79023 2.15E-11 7.210839 
45-46 0.013038 0.230097 4 3.451457 0.548543 0.451457 3.73E-12 1.248176 
46-47 0.00988 0.303633 5 4.5545 0.4455 0.5545 2.89E-12 0.966672 
47-48 0.006655 0.450803 7 6.762038 0.237962 0.762038 1.99E-12 0.665094 
48-49 0.003361 0.892498 14 13.38747 0.612531 0.387469 1.02E-12 0.343013 
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Figure 5.4 Exposure events per protein in the current FPOP experimental arrangement.  
 
Figure 5.4 indicates that ~two thirds (66%) of the sample is under single exposure 
conditions using these experimental parameters, just over 25% of the sample 
experiences no irradiation events at all, leaving less than 8% of the sample to 
experience multiple exposures. This is slightly more oxidation than was suggested as 
optimal by Konermann et al., [268] and as such, the effects of multiple exposure events 
on wild-type β2m were evaluated to determine the significance of these events with 
regards to their effect on protein conformation and downstream analysis. 
Native MS experiments showed no significant change in the charge state distribution 
following FPOP compared with the control protein, with the most notable change 
being a significant decrease in signal intensity for the FPOP sample, presumably due 
to signal splitting between the various different oxidised species (Figure 5.5).  
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Figure 5.5 Native MS of FPOP oxidised wild-type β2m.  (a) Wild-type β2m oxidised by FPOP (as per 
experimental procedures described in section 3.5.1) compared with (b) the control without FPOP or 
exposure to hydrogen peroxide. Inset shows a zoom of the 7+ charge state ions highlighting the 
observable +16 Da oxidations in the oxidised sample and no oxidations, although some salt adducts, on 
the non-oxidised sample. The ESI-MS solution was 150 mM ammonium acetate, pH 7.4. 
 
ESI-IMS-MS of the native protein showed identical ATDs for the unmodified and 
oxidised versions of the protein for up to three oxidations, which is the maximum 
number resolvable using native MS (Figure 5.6a), thus indicating no significant 
conformational changes result from FPOP oxidation for wild-type β2m under the 
conditions employed.  
To determine the effect, if any, of multiple oxidations on proteolytic digestion of the 
wild-type protein, samples of wild-type β2m contained in Eppendorf tubes, rather 
than the typical capillary flow setup, were irradiated between one and ten times, 
reduced, alkylated and digested with trypsin, before the tryptic peptides were 
analysed by LC-MS/MS. Figure 5.6b shows that as the number of irradiation events 
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increases, the percentage of the protein sequence covered from the peptides identified 
decreases. A likely explanation for this is that multiple irradiation events cause 
significant oxidation which splits the peptide signal among many different oxidised 
species eluting at different retention times, which fall below the limit of detection. 
 
 
Figure 5.6 The effect of FPOP oxidation on native IMS ATDs and sequence coverage in proteolytic 
digests of wild-type β2m.  a) ATD extracted from the 6+ charge state ions of wild-type β2m for the 
unmodified, and up to three oxidative FPOP modifications. b) Sequence coverage from tryptic digests 
of β2m following FPOP oxidation. 
 
Although some evidence suggests that FPOP oxidations can partially unfold proteins 
[269], others have found limited oxidation to be relatively benign [226, 270], with some 
evidence suggesting that certain enzymes can even retain activity following oxidation 
by FPOP [271]. This is consistent with the fact that FPOP labels primarily solvent 
exposed side chains, often hydrophilic structures with a high degree of 
conformational freedom, and thus are unlikely to be significantly structurally 
perturbed by the effect of a small, hydrophilic modification such as hydroxylation. 
Overall, these data suggest that the current FPOP experimental setup is unlikely to 
generate significant detectable structural artefacts, given only ~8% of the sample 
experiences multiple exposure events (Figure 5.4), and such exposure has no 
significant effect on the native protein conformation, to the resolution of an IMS 
experiment. Additionally, those molecules that do experience multiple exposure 
events contribute less to the analysis of oxidations in LC-MS/MS data, as the higher 
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levels of oxidation split the peptide signal further across multiple oxidised species, 
increasing the likelihood that such species fall below the limit of detection. 
 
5.2 FPOP LC-MS/MS of wild-type, D76N and ΔN6 β2m 
Wild-type, D76N, and ΔN6 β2m were subjected to FPOP oxidation under native 
conditions, prior to intact MS analysis under denaturing conditions. All three variants 
showed significant oxidation, observable as a series of +16 Da mass additions that were 
absent in the control samples (Figure 5.7). After quantification, no significant 
difference in the degree of oxidation was observed between the three variants. In each 
case, ~65% of the total protein signal was observed to be modified.  
 
FPOP-LC-MS/MS comparing β2m variants 
 
155 
 
 
Figure 5.7 Denatured ESI-MS of three β2m variants following FPOP.  (a) Wild-type, (b) D76N, and (c) 
ΔN6 before (black) and after (orange) FPOP. Annotations above each peak show m/z and charge state. 
Inset shows a zoom of the 10+ charge state ions. Calculated masses from each species in the spectra are 
shown in the top right hand corner. 
 
Although no global differences in oxidation could be detected between the three 
variants, to determine if any differences could be observed by FPOP at higher 
resolution, the three oxidised β2m variants were enzymatically digested with 
chymotrypsin and the resulting peptides were then analysed by LC-MS/MS using a 
Q-Exactive quadrupole orbitrap mass spectrometer operating in DDA mode 
(experimental details can be found in Section 3.5.1). The data were then searched 
automatically for peptide MS/MS data matching the wild-type β2m/D76N/ΔN6 amino 
acid sequences, along with possible variable mass additions of +16 Da, +32 Da, and +14 
Da, in order to identify oxidations generated from FPOP. Greater than 95% sequence 
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coverage was observed reproducibly in all three variants (Figure 5.8), where manual 
inspection of peptide coverage maps identified seven chymotryptic peptides for which 
both modified and unmodified peptides were present in all replicates for all three 
proteins (green peptides in Figure 5.8). An additional peptide at the N-terminus 
(absent in ΔN6) that fit these criteria for the wild-type protein and the D76N variant 
(orange peptide in Figure 5.8) was also identified. Thus, these eight peptides were used 
to assess differences in FPOP oxidation between the three variants. 
 
 
Figure 5.8 Peptide coverage of three variants of β2m following chymotrpyptic digest.  Bars represent 
identified peptides. The D76N modified site is identified with an asterisk. Blue = irreproducible 
peptides or peptides for which no oxidised products could be identified that were found in this 
representative coverage map. Orange = reproducible peptides found in all replicates of both wild-type 
and D76N β2m, for which both modified and unmodified versions could be identified. Green = 
reproducible peptides found in all replicates of all three variants for which modified and unmodified 
versions could be found. 
 
Manual inspection of tandem MS spectra for modified versions of these eight 
chymotryptic peptides could be used to assign 19 different modified sites 
(approximately 20% of the β2m sequence, summarised in Table 5.2), all but one of 
which could be localised to single amino acid resolution. The location of these 
modified sites are shown in the structure of β2m in Figure 5.9. 
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Table 5.2 Residues modified by FPOP in wild-type, D76N and ΔN6 β2m.
Peptide Sequence Modified residues 
0-10 (Wild-type and D76N 
only) 
MIQRTPKIQVY Met 0  
11-26 SRHPAENGKSNFLNCY His 13, Lys 19, Phe 22, 
Tyr 26,  
27-40 VSGFHPSDIEVDLL Val 27, Phe 30, His 31, Ile 
35 (wild-type and D76N 
only) 
41-54 KNGERIEKVEHSDL Lys 48, His 51 
55-63 SFSKDWSFY Trp 60 
67-78 YTEFTPTEK(D/N)EY Tyr 67, Phe 70, Tyr 78 
79-87 ACRVNHVTL His 84 
88-95 SQPKIVKW Lys 94, Trp 95, unknown 
(Pro 90 or Lys 91) 
 
 
Figure 5.9 Residues modified by FPOP in wild-type, D76N and ΔN6 β2m mapped onto the β2m 
structure.  Modified residues are shown as sticks. Green = modified in all three variants. Orange = 
modified in wild-type and D76N only. Β-sheets are shown as ribbons and coloured blue. PDB: 4FXL 
[157]. 
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To quantify and compare the degree of oxidation at each of these sites between the 
three variants of β2m, the LC elution profiles for m/z values corresponding to modified 
versions of each peptide were analysed individually by generating extracted ion 
chromatograms (XICs) (Figure 5.10). Tandem MS spectra which positively identified 
oxidised residues within modified peptides could then be assigned to peaks in the XIC 
based on the retention time (RT) at which the MS/MS data were acquired. 
Quantification of each modified species was then calculated by peak integration, and 
comparison of the peak area to that of the unmodified version of the same peptide, 
according to Equation 3.6 (Section 3.5.3). The results for the overall % modified for 
each site, for all three variants are shown in Figure 5.11.  
 
 
Figure 5.10 Analysis workflow for FPOP-LC-MS/MS experiments. Extracted ion chromatograms (XICs) 
are generated for the unmodified, and modified versions of each peptide m/z. The MS/MS acquired for 
each peak is used to identify the modification site. Integration of XICs is used to quantify levels of 
oxidation relative to the unmodified version of each peptide. Example shown here is that of peptide 0-
10 of β2m (sequence: MIQRTPKIQVY) where Met 0 was found to be the only oxidised side chain. 
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Figure 5.11 Residue level quantification of FPOP oxidations in three variants of β2m.  The residue, or 
amino acid sequence, to which the modification could be localised is shown on the x axis. Error bars 
show standard deviation. N = 3. 
 
Although methods for calculating the degree of modification at FPOP oxidised sites 
are established in the literature [231, 241], precisely how to interpret changes observed 
between states (in the case of these experiments: wild-type, D76N and ΔN6 β2m) is 
still poorly defined, with recent evidence suggesting that primary sequence may 
complicate the relationship between solvent accessible surface area (SASA) and the 
degree of modification [232]. Similarly, the complex, manual, and time consuming 
nature of data analysis is such that FPOP data are commonly quantified to peptide, 
rather than residue, level resolution [231, 234], thus hampering an in-depth analysis of 
data provided by these experiments. To that end, the differences in FPOP oxidation 
between the wild-type protein and the ΔN6 truncation variant, observed here at the 
residue level, were first compared to the differences associated with the solution phase 
NMR structures of the two proteins (currently no NMR structure is available for the 
D76N variant) [78], offering a rare opportunity to gain insight into the detailed 
interpretation of changes observed by FPOP, using these NMR structures as a point 
of reference. 
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5.2.1 Wild-type Vs ΔN6 
Seven of the nineteen oxidised sites were observed to have statistically significant (p 
< 0.05) differences in their degree of oxidation between the wild-type protein and the 
ΔN6 truncation variant: Phe 22, Val 27, Phe 30, Ile35, His 31, Trp 60 and His 84. 
Mapping these side chains onto the wild-type NMR structure (PDB: 2XKS, [78]), it can 
be observed that spatially, six of these seven sites are located proximal to the N-
terminal truncation in the D-E, B-C and F-G loops (Figure 5.12). This is expected 
given the substantial conformational changes localised to this region associated with 
the removal of the N-terminal hexapeptide, and is consistent with earlier reports [78, 
272]. 
 
 
Figure 5.12 Differences in FPOP oxidation between wild-type and ΔN6 β2m.  Residues with higher 
observed labelling in the truncation variant are shown in red. Residues with lower observed oxidation 
in the truncation variant are shown in blue. P < 0.05. PDB: 2XKS [78]. 
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The remaining residue, Phe 22, is located at the N-terminal end of the B-strand, on 
the opposite end of the β-sandwich structure to the N-terminal truncation (Figure 
5.12), Indeed, His 51, located at the N-terminal end of the D-strand, showed similarly 
increased labelling in the truncation variant (Figure 5.11). Although these changes 
proved not to be statistically significant (p = 0.505), likely caused by the considerable 
measurement error due to the low signal intensity of this peptide [273], Phe 22 and His 
51 are somewhat proximal in the NMR structure, and face each other in the wild-type 
crystal structure (Figure 5.13) [77], suggesting a possible, and subtle, long range 
conformational change in this region caused by the removal of the N-terminal six 
amino acids. 
 
 
Figure 5.13 Minor side chain rearrangements detected by FPOP between wild-type and ΔN6 β2m.  Side 
chains His 51 and Phe 22 both showed increased oxidation in the truncation variant and are annotated 
(red sticks). PDB: 1LDS [77]. 
 
From the NMR structures of each protein, the SASA for side chains modified by FPOP 
was calculated (see Section 3.5.4 for method details), and corrected for the maximal 
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possible solvent exposure for side chains of that type, based on their solvent 
accessibility in Gly-x-Gly tripeptides [274]. The fold change of these SASAs between 
the two proteins was then correlated with the changes in the levels of oxidation 
observed on these side chains. The results, shown in Figure 5.14, highlight that most 
of the modified side chains show minimal changes in SASA between the two variants, 
and minimal changes in FPOP oxidation (blue data points centred closet to the origin 
in Figure 5.14). Interestingly, the majority of side chains observed to have 
significantly different degrees of oxidation show a general positive correlation 
between calculated changes in SASA and measured changes in oxidation, where 
increases in SASA show increases in the extent of modification, and vice versa (Figure 
5.14).  
 
 
Figure 5.14 FPOP oxidation compared with SASA calculated from NMR structures.  Green boxes 
indicate regions of positive correlation between FPOP and SASA as calculated from NMR structures 
(i.e. more modified in the ΔN6 variant, and more solvent exposed, or less modified and less solvent 
exposed). Red areas indicate regions of negative correlation between NMR and FPOP data (i.e. more 
solvent exposed but less labelled). Statistically significant (p < 0.05) changes observed by FPOP are 
coloured orange and annotated. Ile 35 is not included in these data as this side chain was not observed 
to modify in the truncation variant. 
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A notable and obvious exception to this is the Val 27 side chain which, despite 
increasing in SASA by more than 20x in the truncation variant, oxidises by FPOP less 
than half as much as in the wild-type protein (Figure 5.11, Figure 5.14). In both 
variants, Val 27 is located at the C-terminal end of the B-strand, proximal to the N-
terminus of the protein. Closer inspection of this region reveals that the nearby Phe 
30 side chain, rotates almost 180° between the two variants. In the wild-type 
structure, Phe 30 is positioned in a largely solvent inaccessible position facing the D-
E loop, whereas in the truncation variant, this side chain is rotated to face bulk 
solvent, positioned directly adjacent to the Val 27 side chain (Figure 5.15). Given the 
relatively high reactivity to hydroxyl radicals of phenylalanine side chains compared 
with valine residues, it seems plausible that the proximity of Phe 30 to Val 27 causes 
increased competition for hydroxyl radicals in the region, resulting in lower labelling 
in the less reactive valine group, despite increased access to solvent. This is consistent 
with observations made by Xie et al., where increased competition for hydroxyl 
radicals was observed in unfolded proteins in FPOP experiments [232]. 
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Figure 5.15 The rotation of the Phe 30 side chain in the ΔN6 truncation variant of β2m.  The NMR 
structures of (a) the wild-type protein and (b) the truncation variant. Side chains proximal to the N-
terminal truncation which showed statistically different level of oxidation between the two variants 
are shows as sticks and coloured red and blue, respectively. PDB: 2XKS (wild-type), 2XKU (ΔN6) [78]. 
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5.2.2 Positional isomers in FPOP experiments 
When examining the XIC profiles of modified peptides, several species of the same 
m/z are observed frequently as different peaks in the XIC. Each peak corresponds to a 
different version of the modified peptide, where hydroxyl radical labelling has 
occurred on a different side chain in the peptide sequence. An example of this is 
shown in Figure 5.16a, where seven differently modified species of peptide 11-26 of 
the β2m sequence could be identified by use of MS/MS. However, certain residue 
types, when modified, appeared more than once in the XIC, with multiple peaks at 
different retention times. In the example shown in Figure 5.16a, both Phe 22 and Tyr 
26 were identified as the modified residue within the peptide, at multiple different 
retention times. 
Across all the modified residues in the experiment, peptides containing modified Phe 
side chains were observed to elute at three different retention times, peptides 
containing modified Tyr residues were observed to elute at two different retention 
times, and peptides which contained modified Trp side chains, were observed to elute 
at up to nine different retention times (summarised in Table 5.3). These peaks 
correspond to positional isomers formed by hydroxyl radical attack at different 
positions on the same aromatic side chain, based on well-established oxidation 
chemistries of aromatic amino acids, such as Trp [275], Phe [276, 277] and Tyr [228]. 
However, despite the fact that these positional isomers are a known and expected 
consequence of the hydroxyl radical-mediated oxidation of aromatic side chains, these 
products are, to date, seldom mentioned in the FPOP literature [241, 278]. To that end, 
the NMR structures of wild-type and ΔN6 β2m were again used to assess the properties 
of positional isomers in FPOP experiments, and to determine their utility in detecting 
conformational changes in proteins at higher structural resolution. 
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Figure 5.16 Identification of positional isomers in FPOP modified peptides.  a) XIC of peptide 11-26 of 
β2m (sequence: SRHPAENGKSNFLNCY) showing unmodified (black) and +16 Da modified (red) LC-
MS traces. Modified residues within the peptide are annotated above each peak. Tandem MS spectra 
for peaks 1, 2, 3, and 4 are shown in b). “b” and “y” ions are coloured blue and red, respectively. 
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Table 5.3 A summary of residues to which multiple mono-oxidised XIC peaks could be assigned. 
Residue Number of XIC Peaks observed 
Phe 22 3 
Tyr 26 2 
Phe 30 3 
Trp 60 9 
Tyr 67 2 
Phe 70 3 
Tyr 78 2 
Trp 95 4 
 
5.2.2.1 Phenylalanine isomers 
The three isomers observed for each of the modified Phe side chains are consistent 
with the three possible positional isomers caused by net incorporation of oxygen at 
the ortho, meta and para positions of the benzene ring (Figure 5.17). Although these 
products have the same m/z, with identical fragment ion spectra, it has been widely 
reported that such positional isomers, when separated by RP-LC, elute in a predictable 
retention time order of para < meta < ortho, both as free amino acids, and in peptide 
chains [279-283]. Assigning the observed positional isomers based on this retention time 
order, and quantifying each peak in the XICs separately, more detailed structural 
information can be extracted from the available data. 
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Figure 5.17 Positional isomers of +16 Da hydroxyl radical-mediated phenylalanine oxidation.  
 
Most notably, when quantifying isomers of Phe 30, a trend of increasing difference in 
the degree of modification between the wild-type protein and the truncation variant 
is observed, where ΔN6 β2m shows increasingly more modification, relative to the 
wild-type protein, for isomers at shorter retention times. Indeed, the para isomer 
shows >four-fold more modification in the truncation variant than in the wild-type 
protein, whereas the ortho isomer shows only a ~1.3-fold change (Figure 5.18b). The 
rotation of the Phe 30 side chain discussed earlier clearly shows the para position as 
undergoing the largest structural movement of the three possible isomeric positions 
(Figure 5.15). Calculation of the SASA of each of the positional isomers for this side 
chain from the NMR structures of both variants shows an increase in SASA in the 
truncation variant for the ortho, meta and para isomers of 1.51 Å2, 6.98 Å2 and 12.16 
Å2, respectively. This is in good agreement with the increasing trend of modification 
shown in the truncation variant and supports the assignment made for each isomer. 
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As free amino acids, Phe side chains oxidise with known ratios of para:meta:ortho 
products, with expected isomer ratios of 1.5:1:2 or 2.1:1:2.3, depending on solution 
conditions [228]. These expected isomer ratios are not matched by the measured isomer 
ratios from FPOP oxidation for either variant, for any of the Phe residues observed to 
modify (Table 5.4). However, as all of these side chains are, at least partially, buried 
in the NMR structures of both proteins, and given the observed changes in isomer 
ratio in Phe 30 upon structural rearrangement, it is reasonable to conclude that 
changes in SASA not only affect the overall oxidation of the residue, but also the 
observed isomer distribution. 
 
Table 5.4 A summary of Phenylalanine positional isomer ratios calculated from FPOP quantification 
data for Phe 22, Phe 30 and Phe 70 in the β2m protein sequence. 
Residue Phe 22 Phe 30 Phe 70 
Protein Wild-type ΔN6 Wild-type ΔN6 Wild-type ΔN6 
Isomer 
ratio 
(p:m:o) 
1.16:1:1.27 2.15:1:0.94 0.35:1:0.76 1.19:1:0.70 0.57:1:0.54 0.47:1:0.52 
SASA (Å2) ~88.3 ~105.2 ~2.2 ~48.8 ~11.0 ~5.7 
% solvent 
exposed 
~49 ~58.4 ~1.2 ~27.1 ~6.1 ~3.2 
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Figure 5.18 Quantification of positional isomers identified from Phe30.  a) XIC of peptide 27-40 of β2m 
(sequence: VSGFHPSDIEVLL) showing unmodified (black) and +16 Da modified (red) LC traces. The 
m/z values used to generate each XIC are shown in the top right hand corner. Modified residues 
identified by MS/MS within each peptide are annotated above each peak. The black cross indicates an 
overlapping and interfering isotope distribution from another peptide. Isomers of Phe 30 are denoted 
p, m, and o for para, meta, and ortho isomers, respectively. b) Quantification of positional isomers. 
Error bars show standard deviation. n = 3.  
 
5.2.2.2 Tryptophan isomers 
Tryptophan side chains, among the most highly reactive residues to hydroxyl radical 
oxidation, have complex oxidation chemistry generating multiple oxidation products 
across several masses [228]. Indeed, the peptide containing Trp 60, which showed a 
small but statistically significant decrease in oxidation upon the truncation of the N-
terminal six amino acids, was observed to have nine different oxidation products 
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present in the XIC of the modified peptide, all of which were identified by MS/MS to 
be present on the Trp 60 side chain (Figure 5.19a).  
 
 
Figure 5.19 Quantification of positional isomers identified from Trp 60.  a) XIC of peptide 55-63 of β2m 
(sequence: SFSKDWSFY) showing unmodified (black), +16 Da modified (red), and +32 Da modified 
(purple) LC traces. The m/z values used to generate each XIC are shown in the top right hand corner. 
Identified Trp 60 positional isomers are annotated above each peak in the XIC with numbers 1-9. 
Secondary peak identified as a possible tautomer oxidation product is highlighted with an asterisk. b) 
Quantification of isomers 1-9. Error bars show standard deviation. n = 3.  
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However, Trp 60, unlike Phe 30, is not well defined in the NMR structures of either 
variant, and occupies a variety of different positions in each state of the PDB file, 
likely reflective of the highly dynamic nature of the D-E loop in which Trp 60 is found 
(Figure 5.20). While this makes a direct comparison of the FPOP data to the NMR 
structure challenging, the well-established literature on tryptophan oxidation, and 
characteristics observed in the XIC of the modified peptides, permits some tentative 
positional isomer assignments to be made. 
 
 
Figure 5.20 Overlaid states in the NMR structures of wild-type and ΔN6 β2m.  30 different structural 
models from the NMR structures of (a) the truncation variant and (b) the wild-type protein are 
superimposed, highlighting the side chain orientations of the Trp 60 and Phe 30 side chains, coloured 
pink and green, respectively. PDB: 2XKU (ΔN6), 2XKS (wild-type) [78]. 
 
In hydroxyl radical-mediated oxidation of free tryptophan, hydroxyl radicals have 
been reported to attack preferentially the 5-membered pyrrole moiety, compared 
with the 6-membered benzene moiety of the indole group, with a ratio of ~60:40 [228, 
275]. Pyrrole ring oxidation of tryptophan yields two major products: the singly 
oxidised product, 2-hydroxytryptophan (+16 Da), and the doubly oxidised product, 
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N-formylkynurenine (+32 Da) (Figure 5.21). This is consistent with the two dominant 
oxidation products of Trp 60 for the wild-type protein (peaks 7 and 4, respectively in 
Figure 5.19a). Strikingly, comparing the ratio of modification for these two oxidation 
products with that of the remaining oxidation products observed for Trp 60, a ratio of 
60.4:39.6 is observed in favour of the dominant +16 Da and +32 Da products – 
remarkably close to that of the expected ratio for free tryptophan in solution [228, 275]. 
This can be rationalised by closer inspection of the wild-type NMR structure, which 
shows the Trp 60 side chain is, on average, ~80% solvent exposed and thus, can be 
expected to behave similarly to the free amino acid in solution. Similarly, the 2-
hydroxytryptophan product, tentatively assigned to peak 7 in Figure 5.19a, is known 
to undergo keto-enol tautomerism [284]. These tautomers interconvert during 
separation by RP-LC, and can be observed as a double peak [285]. A smaller shoulder 
peak is observed on peak 7 at ~30% relative intensity (denoted with an * in Figure 
5.19a). Examination of the full MS scan for this retention time revealed no interfering 
isotope distributions from other peptides (Figure 5.22a). Similarly, examination of the 
tandem MS spectra did not show any evidence of multiple species (Figure 5.22b), 
indicating that the shoulder peak is the same modified residue as the main peak. As 
the four other possible +16 Da positional isomers, caused by oxidation on the benzene 
ring of the indole group, can be reasonably assigned to the four other +16 Da oxidation 
products observed (peaks 5, 6, 8 and 9), this shoulder peak could be the alternative 
tautomer for the 2-hydroxytryptophan product, reinforcing the assignment made for 
this XIC peak. The remaining three +32 Da oxidised species are likely 
dihydroxytryptophan, where both aromatic rings of the indole group are oxidised 
(Figure 5.21). 
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Figure 5.21 Common oxidation products of the hydroxyl radical-mediated oxidation of tryptophan.  
 
In the case of ΔN6, peaks 7 and 4, (assigned as oxidation products resulting from 
hydroxyl radical attack on the pyrrole ring) both have significantly lower levels of 
modification than the wild-type protein, by up to 3-fold (Figure 5.19b). However, 
three of the four remaining +16 Da oxidation products, assigned as oxidation resulting 
from hydroxyl radical attack on the benzene ring, show the opposite trend, where the 
ΔN6 truncation variant shows increased labelling relative to the wild-type protein 
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(peaks 5, 8, and 9 in Figure 5.19b). Previous reports have shown that the Trp 60 side 
chain is less accessible to solvent in the truncation variant, as well as other 
amyloidogenic variants of β2m, both by partial proteolysis [134] and other covalent 
labelling MS methods [286]. These FPOP data, however, suggest a side chain 
rearrangement, rather than complete burial, where the 6-membered ring of the indole 
group becomes more solvent exposed in the truncation variant but the 5-membered 
ring becomes less solvent exposed.  
 
 
Figure 5.22 Full and tandem MS scans of the 2-hydroxytryptophan oxidation product of Trp 60. a) Full 
MS scan combined between retention times 35-36 min, encompassing the XIC peak proposed as the 2-
hydroxytryptophan oxidation product of Trp 60. Inset: zoomed image between m/z 590-600. Isotopic 
distribution of the Trp 60 modified peptide species is annotated in blue and shows no interferring 
isotope distributions from other peptides. b) Tandem MS spectra of peak 7 in Figure 5.19a. B and Y ions 
are annotated blue and red respectively. 
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5.2.3 FPOP behaviour of the D76N variant of β2m 
Of all the oxidations identified, only two show statistically significant differences 
between the wild-type and D76N variants of β2m: Lys 19, located in the A-B loop, and 
Tyr 78, located in the E-F loop, proximal to the D76N amino acid substitution (Figure 
5.11, Figure 5.23). As both of these changes only show minimal differences in the 
degree of oxidation (~ 1.4 fold change), these data are largely consistent with the 
crystal structures of the two proteins which show minimal structural differences 
between the two variants [77, 157]. 
 
 
Figure 5.23 Structural differences between wild-type and D76N β2m observed by FPOP.  Tyr 78 (red 
sticks) and Lys 19 (blue sticks) both show statistically significant (p < 0.05) differences between the 
wild-type (blue bars) and D76N (red bars) variants of β2m. Quantification of these modification sites is 
also included for the ΔN6 truncation variant (grey bars). The D76N amino acid substitution is shown 
in green on the protein structure. Error bars show standard deviation. N=3. PDB: 4FXL [157]. 
 
Closer examination of the Tyr 78 oxidation reveals two positional isomers, consistent 
with the two expected isomeric oxidation products of tyrosine (ortho and meta) [228], 
both of which show increased oxidation in the D76N variant (Figure 5.24). Although 
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these changes could be due to the D-N substitution itself, and the known effects of 
primary sequence on side chain oxidation in FPOP [232], these data could suggest a 
subtle rearrangement of the Tyr 78 side chain in the E-F loop, as well as Lys 19 in the 
nearby A-B loop, of the D76N variant. 
 
 
Figure 5.24 Positional isomers of oxidised Tyr 78 in three variants of β2m.  a) XIC of the unmodified 
(black) and modified (red) version of peptide 67-78 of β2m (sequence: YTEFTPTEK(D/N)EY). The m/z 
values used to generate each XIC are shown in the top right hand corner. Residues modified in each 
peptide in the XIC, identified by MS/MS, are annotated above each peak. b) Quantification of the two 
Tyr 78 positional isomers for wild-type (blue), D76N (red) and ΔN6 (grey). Error bars show standard 
deviation. N = 3.  
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5.3 Discussion 
5.3.1 Interpretation of FPOP data 
The suggestion made by others [232, 287, 288] that primary sequence, and proximity to 
reactive side chains, affects the degree to which side chains of a protein structure label 
in FPOP experiments is, to some extent, supported by observations made here in 
comparing the FPOP oxidation levels of wild-type β2m and the truncation variant. For 
example, Phe residues 56 and 62, despite both being highly reactive and largely 
solvent accessible in the NMR structures of both proteins, were not observed to label 
in either variant, presumably due to increased local competition for hydroxyl radicals, 
due to their close proximity to the significantly more reactive, Trp 60 side chain 
(Figure 5.25). 
 
 
Figure 5.25 Proximity of the Trp 60 side chain to nearby Phe side chains.  30 states of the NMR 
structures of (a) the truncation variant and (b) the wild-type protein are shown, highlighitng the side 
chain orientations of the Trp 60 side chain (red) as well as the Phe 56 and Phe 62 side chains (green). 
PDB: 2XKU (ΔN6), 2XKS (wild-type) [78]. 
 
However, in the case of the Phe 30 rearrangement, the effects of proximity to this 
reactive group were only observed on the nearby Val 27 residue, when the Phe 30 
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side chain rotated to the solvent exposed position, in place of the truncated N-
terminus. Given that, in both variants, Phe 30 and Val 27 are the same distance apart 
in sequence, these data could suggest an effect of nearby, reactive solvent accessible 
side chains on the degree of labelling of other groups, in space. Although this 
phenomenon requires further exploration, if true it raises a number of important 
questions regarding the interpretation of FPOP data: 
1. Over what distance, in 3D space, are the effects of nearby reactive side chains 
significant? 
2. Does this distance change for side chains of different reactivities? 
3. Does the solvent accessibility of either group, or the presence of multiple 
reactive side chains, change the significance of this effect? 
Indeed, the detailed comparison of FPOP data with calculated SASAs from the NMR 
structures in Figure 5.14, although finding a general positive correlation between 
SASA and the degree of oxidation for most of the changes which showed statistical 
significance, no definitive correlation was observed between the magnitude of 
changes in SASA and the magnitude of changes in FPOP oxidation, for equivalent side 
chains. This may be due to the complication of microenvironment factors discussed 
above, but could similarly be affected by differential sensitivity to changes in SASA 
for side chains of varying reactivities. That is to say, is a tryptophan side chain, for 
example, more or less sensitive to changes in SASA than a phenylalanine side chain? 
To the author’s knowledge, this factor has yet to be explored in the FPOP literature 
but, given the known and well-established differences in reactivity to hydroxyl 
radical oxidation of the different side chains, is certainly a plausible scenario which 
requires further study, before detailed interpretations of unknown protein structures 
can be made from FPOP data. 
That said, the examination of positional isomers following these FPOP experiments 
highlights the potential for achieving sub-amino acid level resolution on changes in 
protein structure using this technique. Although further study is required to 
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determine the usefulness of positional isomers in FPOP, which would no doubt 
benefit from a greater understanding of the effects of local microenvironment, it is 
important to note that side chain movements, at this level of detail, are largely 
invisible to other structural MS methods, such as HDX. Moreover, the propensity of 
FPOP to label large hydrophobic side chains, coupled with the immense detail 
provided by separate quantification of positional isomers, is of great significance in 
the study of aggregation-prone proteins, where solvent exposure of typically buried, 
hydrophobic groups is often implicated in the aggregation mechanism [170].  
 
5.3.2 FPOP method development 
Being a new method, multiple stages of the FPOP experiment lend themselves 
towards further development, including the oxidation process itself, as well as the 
associated LC-MS/MS workflows and data processing/analysis. 
 
5.3.2.1 Internal standards 
During sample oxidation, the inclusion of internal standards, or dosimetry 
experiments to assess the hydroxyl radical dose given to each sample, would be a 
useful tool to develop the robustness and reproducibility of the technique, and has 
been implemented successfully into the FPOP workflow elsewhere [289-291]. Although 
not used in the experiments described here due to the identical solution conditions 
between samples, internal standards such as leu-enkephalin have been used in FPOP 
to correct for changes in hydroxyl radical dose, thus allowing comparisons of samples 
at different concentration, or under different buffer conditions where the •OH 
scavenging ability of the solution may vary [291]. However, as discussed earlier, a deeper 
understanding of the reactivities of different side chains, and the effects of their 
relative solvent accessibilities, would be needed before the corrections applied from 
the oxidation of internal standards could be relied upon for detailed analyses. Namely, 
does side chain reactivity affect the sensitivity of side chains to change in •OH dose 
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(i.e. is a tryptophan side chain more or less sensitive to change in •OH dose than a 
phenylalanine?), and does the solvent accessibility of each side chain affect that 
sensitivity (is a buried tryptophan more or less sensitive to changes in •OH dose than 
an exposed tryptophan?). Considering the sensitivity to oxidation of the internal 
standard itself is of critical importance, such effects require further study before an 
optimal choice of internal standard can be made. 
 
5.3.2.2 LC-MS/MS development 
Although the assignments of FPOP isomers identified for the two β2m variants are 
consistent with the existing literature regarding known oxidation chemistries [228] and 
the affirmed elution orders of positional isomers by RP-LC [279-283], these assignments 
cannot be made with certainty, without retention time alignment of identical oxidised 
peptides with known, unique, positional isomers. Not only would this be prohibitively 
expensive, but the low throughput of this method makes this approach largely 
impractical. However, positional isomers of both Phe [292] and Trp [293] are 
distinguishable by differential UV absorbance spectra, and UV detectors are routinely 
implemented for online analysis in LC-MS/MS workflows. Indeed, Trp oxidation in 
heat stressed antibodies has been characterised previously in precisely this manner [294] 
and thus, make this an appealing development opportunity for the routine 
characterisation of positional isomers in FPOP experiments. 
With regards to MS/MS procedures, the DDA approach used in our experiments and 
most commonly in the literature, while effective, requires instrumentation capable of 
fast MS/MS acquisition and, due to the oxidised products frequently having the same 
m/z, partial or incomplete LC separation of different versions of a modified peptide, 
results in co-selection of the different modified peptides by the quadrupole, and the 
generation of difficult to interpret, chimeric MS/MS data (Figure 5.26). 
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Figure 5.26 Chimeric MS/MS data from co-isolation of overlapping oxidised peptides. Example shown 
is peptide 20-41 (sequence: SNFLNCYVSGFHPSDIEVDLLK) resulting from tryptic digestion of β2m 
following FPOP. Overlapping or partially separated oxidised peptides with the same m/z in the XIC 
result in co-selection by the quadrupole during DDA, and the generation of chimeric MS/MS data. A 
distinct pattern of dual fragment ion peaks is observed where the two peptides, modified on different 
amino acids, generate a mixed spectrum of both modified (yellow), and unmodified (purple) fragment 
ions for each b and y ion. 
 
A possible solution to this problem, largely unexplored in the current literature, could 
be to use DIA as an alternative mode of acquisition, as the assignment of fragment 
ions to their respective precursors is carried out by automated retention time 
alignment. Although control experiments would be required to ensure current DIA 
processing algorithms correctly assign fragment ions from co-eluting oxidised 
peptides with similar fragment ion spectra, this approach has the potential to allow 
for the identification and quantification of partially separated or overlapping modified 
peptides with the same m/z by generating XICs of unique fragment ions (Figure 5.27). 
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Figure 5.27 A schematic representation of DDA vs DIA MS/MS workflows for FPOP data acquisition.  
a) Acquisition of fragment ion spectra via DDA quadrupole selection of overlapping oxidised peptides 
with the same m/z can result in chimeric MS/MS with multiple fragment ion series present. b) By 
applying DIA workflows, reconstructed fragment ion spectra from retention time alignment allows 
deconvolution of overlapping species by examination of specific fragment ion XICs (blue and green 
MS/MS peaks) against the precursor m/z (orange). 
 
5.3.3 FPOP of the ΔN6 truncation variant of β2m 
Previous studies have observed that burial of the Trp 60 side chain is correlated with 
the propensity of β2m to form amyloid fibrils [134, 286]. In the truncation variant, 
previous reports have shown that the Trp 60 side chain is less accessible to proteases 
[134]. Similarly, copper ions, which have been implicated in the promotion of amyloid 
formation of β2m both in vitro and in DRA [140-144], have been shown to reduce the 
solvent accessibility of the Trp 60 side chain upon binding, using alternative MS based 
covalent labelling methods [286]. However, the covalent labelling reagent used in that 
study, dimethyl(2-hydroxy-5-nitrobenzyl)sulfonium bromide, usually shorthanded 
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to HNSB, is comparatively large, giving rise to a 151 Da mass addition upon 
modification of the tryptophan side chain [286]. The smaller size of the hydroxyl radical 
in FPOP labelling, and the identification of positional isomers has allowed 
experiments performed here to obtain a higher resolution analysis of Trp 60, 
suggesting only partial burial of this residue in the amyloidogenic truncation variant.  
The minor conformational changes observed for Phe 22 and His 51 are intriguing, as 
these are distant from the site of the N-terminal truncation. While the significance of 
these changes, with regards to the aggregation propensity of the truncation variant, 
are difficult to ascertain from these data without further study, the conformation of 
the D-strand in which His 51 is located has been implicated numerous times in the 
aggregation of β2m [295, 296], and could provide additional insight into the aggregation of 
the ΔN6 truncation variant.  
 
5.3.4 FPOP of the D76N variant of β2m 
For the most part, the wild-type protein and the D76N variant were largely 
indistinguishable by FPOP, exhibiting only minor differences in labelling on two side 
chains: Tyr 76 and Lys 19. While these changes are both located nearby to the D76N 
substitution, indicating the amino acid change has some effect on the solvent 
accessibility of nearby side chains, these data are largely consistent with the known 
similarity between the crystal structures of the two variants [77, 157], and suggest only 
minimal changes in protein structure caused by the D76N substitution. These data 
are, perhaps, unsurprising, as even considerable side chain movements nearby to the 
D-N substitution could easily remain undetectable by FPOP, assuming the residue 
adopts a similarly solvent exposed position in the D76N variant, a likely scenario given 
the solvent exposed nature of the E-F loop in which the D76N substitution is found. 
Curiously, these data are in contrast to the deuterium exchange behaviour of the E-F 
loop in this variant, relative to the wild-type protein, discussed earlier in Section 4.6 
and 4.7.2. These differences will be discussed in detail later in Section 7.2. 
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6 FPOP-LC-MS/MS of WFL and STT 
As discussed earlier in Section 2.3, protein aggregation in biopharmaceutical 
development is of critical importance to patient safety, and the future development of 
biopharmaceutical products. Given the minor, triple amino acid substitution made in 
the heavy chain CDRs (W30S, F31T, L57T), and subsequent drastic changes in the 
propensity to undergo reversible self-association, the two mAbs WFL and STT 
developed by Medimmune (discussed in detail in Section 2.3.1), provide an ideal 
model system by which to study aggregation in pharmaceutically relevant mAbs. 
Similarly, these proteins offer an opportunity to develop further the FPOP 
methodology for the study of larger, more complex protein systems, and assess the 
potential utility of this technique for probing conformational changes associated with 
aggregation propensity in mAbs. As such, the two mAb variants, WFL and STT, were 
subjected to FPOP-LC-MS/MS analysis, with the following aims:  
1. Identify differences in conformation and structure which may be associated 
with the propensity of WFL to undergo reversible self-association 
2. Develop the FPOP-LC-MS/MS methodology for more complex protein 
systems, and assess the utility of FPOP in the study of biopharmaceutical 
protein structure. 
Data in this chapter were subsequently published in Cornwell et al., Analytical 
Chemistry, 2019 [297]. 
 
6.1 Initial characterisation and overview 
Both WFL and STT were subjected to oxidation by FPOP as described in Section 3.5.2. 
Both proteins were oxidised in their formulation buffer (20 mM sodium succinate, 
125 mM L-arginine, pH 6.0 – optimised by Medimmune) at 0.1 mg ml-1, conditions at 
which both proteins are known to be predominantly monomeric [170]. 10 mM L-
histidine was added as a scavenger amino acid, and 3 µl of 5 % v/v H2O2 was added 
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immediately prior to oxidation. This is 3x the hydrogen peroxide used in the FPOP 
experiments performed with β2m (Section 5) and was necessary to overcome the •OH 
scavenging effect of the arginine excipient in the formulation buffer. 
Following FPOP, reduction of disulphide bonds, alkylation and proteolytic digestion 
using trypsin (detailed methods described in Section 3.5.2) yielded good sequence 
coverage for the heavy and light chains for both WFL and STT (an example coverage 
map is shown in Figure 6.1). A total of 19 peptides were used for quantification of 
identified FPOP oxidations (green lines in Figure 6.1), as these were found to be 
present in all replicates of both proteins, and had both modified, and unmodified 
versions. Of these 19 peptides, MS/MS data were used to identify 50 different modified 
sites (28 identified on the heavy chain, and 22 on the light chain), the majority of 
which could be localised to residue level resolution, and were observed in both 
variants (Table 6.1, Figure 6.2).  
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Figure 6.1 Example peptide coverage map of mAbs WFL and STT following FPOP and tryptic digestion.  
Coverage maps for the heavy chain (a) and light chain (b) are shown. The W30S, F31T and L57T 
modification sites are annotated with an *. Example shown is that of WFL. Blue bars show identified 
peptides. Green bars show peptides used for FPOP quantification (all were identified in all replicates 
of WFL and STT, and had both modified and unmodified versions).  
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Table 6.1 A summary of modifications observed following FPOP of the mAbs WFL and STT. 
Peptide Sequence Modified residues 
 24-38 (Heavy chain) ASGGTF(ST/WF)GAFTWVR Trp 36 
STT only: Phe 34, Phe 29 
WFL only: Trp 30, Phe 31 
53-67 (heavy chain) PIFG(T/L)TNLAQNFQGR Phe 55 
68-87 (Heavy chain) VTITADESTSTVYMELSSLR  Met 81 
117-132 (Heavy chain) VWGQGTMVTVSSASTK  Met 123 
133-144 (Heavy chain) GPSVFPLAPSSK  Pro 134, Val 136, Phe 137, Pro 138 
(STT only) 
145-158 (Heavy chain) STSGGTAALGCLVK  Leu 153, Ser 147, Cys 155 
286-299 (Heavy chain) FNWYVDGVEVHNAK  286-FNW-288, His 296 
313-328 (Heavy chain) VVSVLTVLHQDWLNGK  His 321, Trp 324 
367-381 (Heavy chain) EEMTKNQVSLTCLVK  Met 369 
372-381 (Heavy chain) NQVSLTCLVK  372-NQ-373, Cys 378 
404-420 (Heavy chain) TTPPVLDSDGSFFLYSK  Leu 409, Phe 415, 413-GSF-415, 
404-TTPPVLDS-411 
428-450 (Heavy chain) WQQGNVFSCSVMHEALHNHYTQK  428–WQQGNVFSCSVM-439 
18-46 (Light chain) VTISCSGSSSDIGNNYVSWYQQLPGTAPK  18–VTISCSGSSSDIGNNYV-34, Trp 
36, 40-LPGTA-44 
68-106 (Light chain) SGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFG
GGTK 
77–TGLQTGDEADYYCGTWDS-94 
107-114 (Light chain) LTVLGQPK  Leu 110, 114-PK-115 
134-153 (Light chain) ATLVCLISDFYPGAVTVAWK  Trp 152 
154-170 (Light chain) ADSSPVKAGVETTTPSK  154-ADSSP-158, Lys 160 
176-190 (Light chain) YAASSYLSLTPEQWK  Tyr 176, Leu 184, 186-PE-187, Trp 
189, 186-PEQWK-190  
194-208 (Light chain) SYSCQVTHEGSTVEK  194-SYSCQ-198, His 201, Cys 197 
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Figure 6.2 Modified residues identified following FPOP-LC-MS/MS of WFL and STT.  Modifications 
are shown as sticks and coloured by the protein variant (i.e. WFL or STT) on which they were 
identified. Green shows modifications identified in both WFL and STT, orange shows modifications 
identified only in STT, and pink shows modifications only idenitified in WFL. 
 
6.2 Regions surrounding the W30S and F31T mutations 
Perhaps the most obvious differences between WFL and STT, with regards to the 
identified oxidation sites, were observed directly proximal to the W30S and F31T 
amino acid substitutions in the VHCDR1 loop of the mAbs, nearby to which were four 
of the five modified sites not common to both WFL and STT (Table 6.1). XICs for the 
modified and unmodified versions of the peptide containing the W30 and F31 residues 
in WFL are shown in Figure 6.3a. Multiple modified species eluting at different 
retention times were observed for both W30 and F31 oxidation, corresponding to the 
multiple positional isomers expected from incorporation of oxygen at different 
positions on the aromatic groups of those side chains [228]. 
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Figure 6.3 XICs for modified and unmodified peptides covering the W30S and F31T mutations. XICs 
for the unmodified (black), as well as +16 Da (red) and doubly oxidised +32 Da (purple) modified 
peptides are shown. Peaks are annotated according to which modified residue was identified for each 
peak using MS/MS. Peptide 24-38 of WFL (sequence: ASGGTFWFGAFTWVR) is shown in a). Peptide 
24-38 of STT (sequence: ASGGTFWFGAFTWVR is shown in b).  
 
However, despite a dominant series of y type fragment ions in the tandem MS spectra 
of these modified species – not uncommon for tryptic peptides, typically basic at their 
C-terminus [298], MS/MS data for several oxidised products, for both WFL and STT, 
could only localise the modification site to between residues 35 and 37 (35-TWV-37) 
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(Figure 6.4). This can be further narrowed down to Trp 36 or Val 37, if water loss ions 
are used for assignment [299]. Given the significantly higher reactivity to hydroxyl 
radical oxidation of tryptophan than either threonine or valine, as well as the presence 
of multiple oxidation products and double (+32 Da) oxidations in this region, these 
modifications are most likely present on the Trp 36 side chain. Although this residue 
is present in the core of the VH domain, surprisingly, following quantification, Trp 36 
was found to be ~6-fold more oxidised in the WFL variant than in the STT variant 
(Figure 6.5a). This could suggest a marked difference in the conformation and solvent 
accessibility of side chains in the region of the VH domain caused by the WFL-STT 
substitutions. 
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Figure 6.4 Representative MS/MS for peptide 24-38 of WFL. The region, or residue, to which MS/MS 
could localise the +16 Da modification are shown underlined on the sequence of each peptide, shown 
in the top right hand corner of each spectrum. The assignment made for the modification site is shown 
in bold. The top spectrum shows the unmodified version of the peptide. 
 
This hypothesis is supported by a closer examination of other oxidised products in the 
region. The Phe 29 and Phe 34 side chains, located either side of the W30S and F31T 
substitutions, were only observed to modify in the STT variant (Figure 6.3b, Figure 
6.5a). Similarly, the Phe 55 side chain in the VHCDR2 loop, adjacent to the L57T 
substitution site and spatially proximal to the W30S and F31T substitutions, was 
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oxidised ~2x more in the STT mAb variant (Figure 6.5a). Taken together, these 
findings could suggest a structural rearrangement of the VH domain, where the solvent 
accessibility of all four of these side chains (Trp 36, Phe 29, Phe 35 and Phe 55) has 
been changed by the WFL-STT triple substitution. 
 
 
Figure 6.5 Quantification of FPOP modifications identified in WFL and STT.  Modification sites for 
WFL (green) and STT (cyan) for the heavy chain (a) and the light chain (b) are shown along the x axis 
of each plot. Modifications are localised to residue level or a short sequence of amino acids. Where 
resolution was >6 amino acids, the first and last three residues of the sequence to which the 
modification could be localised are shown. Inserts show zoomed in quantification of low abundance 
modifications. Mutation sites that were modified in either variant are annotated with an ‘M’. * = p < 
0.01. Error bars show standard deviation (N=3). 
 
However, although the effects of local microenvironment and sequence have yet to 
be fully established in FPOP experiments, these effects cannot be ruled out as a 
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potential cause of, or contributor to, the changes in oxidation observed in this region. 
For example, the W30S, F31T and L57T substitutions are expected to decrease the 
reactivity of these amino acid positions with regards to their susceptibility to hydroxyl 
radical oxidation, by factors of 40, 13 and 3, respectively [228]. While this likely explains 
the absence of any observed oxidation on Ser 30 and Thr 31 in STT (residue 57 labels 
in neither variant), the newly diminished competition for hydroxyl radicals in the 
region could explain the increased modification of the nearby Phe 55 side chain in 
STT, as well as the oxidation of Phe 29 and Phe 34 observed only in STT.  All three of 
these side chains are proximal to the site of the amino acid substitutions (~10 Å) and, 
as such, the removal of highly reactive groups in the region, and subsequent reduction 
in competition for hydroxyl radicals, could be expected to make hydroxyl radical 
attack on nearby, less solvent accessible, or less reactive, groups more likely. Similar 
effects regarding changing competition for hydroxyl radicals have been proposed 
previously in the context of unfolded proteins in FPOP experiments [232]. 
Alternatively, recent reports have suggested that hydrogen peroxide, from which 
hydroxyl radicals are liberated in FPOP, preferentially interacts with certain side 
chains, including a favoured hydrogen bond interaction with threonine side chains 
over leucine side chains [300, 301]. Thus, the L57T mutation could increase the local 
concentration of hydrogen peroxide in the region, offering an alternative explanation 
for the increased oxidation of the nearby Phe 55 side chain in the STT variant.  
 
6.3 Constant domains and the CL-CH1 interface 
The only remaining oxidation product that was not observed to be modified in both 
mAb variants was Pro 138, which was labelled only in STT, and is present in the CL 
domain, near to the interface of the CL and CH1 domains (Figure 6.5a, Figure 6.6). 
Remarkably, following quantification, only three other side chains across both the 
heavy and light chains, each with a p value < 0.01, showed a > 4-fold difference in the 
degree of labelling between the two variants: Val 136, Trp 152 and an unknown 
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modification between residues Pro 186 and Lys 190 (Figure 6.5a and b). All three of 
these side chains are similarly located proximal to the CL-CH1 interface and all show 
significantly lower levels of oxidation in the WFL variant (Figure 6.6). Minor (< 2-
fold), although statistically significant, changes in oxidation were also observed at the 
top of the nearby CH2 domain, with similarly decreased labelling in the WFL variant 
(Figure 6.6). These results are surprising, as these changes are a distance of > 60 Å from 
the WFL-STT triple substitution, and suggest a conformational change of the constant 
domains, or a change in orientation of the constant domains, particularly the CL and 
CH1 domains, relative to one another. 
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Figure 6.6 Differences in FPOP oxidation between WFL and STT. Modified sites which showed 
statistically significant differences (p < 0.01) are shown as spheres and coloured by the magnitude of 
the difference observed (dark red indicates ≥ 4 fold increase in labelling in WFL, dark blue indicates ≥ 
4 fold decrease in labelling in WFL). Amino acid substitution sites are shown as purple spheres. Heavy 
and light chains are shown in grey and green respectively. A model mAb structure is shown in the 
bottom left hand corner for clarity. The right hand side insert shows a zoomed image of the CL – CH1 
and CH1 – CH2 domain interfaces where modification sites are annotated in red showing either residue 
level resolution, or a short sequence of amino acids to which the modification could be localised. 
 
Perhaps the most striking difference in the degree of oxidative labelling between the 
two variants surrounding the CL-CH1 interface is observed for Trp 152 in the light 
chain, located on the edge of the CL domain (Figure 6.6). Although, at the residue 
level, this side chain showed ~5-fold less oxidation in WFL than in STT, examination 
of the XIC for peptides containing modified Trp 152 identified five different products 
using MS/MS, eluting at different retention times, where Trp 152 was the modified 
side chain in each case. These likely correspond positional isomers, four with a single 
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(+16 Da) oxidation and one doubly oxidised (+32 Da) species (Figure 6.7a). However, 
unlike the tryptophan isomers discussed earlier in Section 5.2.2.2, the data obtained 
here cannot feasibly be used to ascertain the precise identity of each positional isomer, 
and no robust, or routine, method of characterising positional isomers in FPOP has 
yet been developed. That said, separate quantification of these isomers can yield some 
additional information regarding the change in orientation of this side chain between 
the two mAb variants. Following quantification, only three isomer oxidation products 
showed statistically significant (p < 0.01) changes between the two variants, whereas 
two of the isomers, including the doubly oxidised product, show no significant change 
(Figure 6.7b). 
 
 
Figure 6.7 Identifying and quantifying positional isomers of oxidised Trp 152. a) XICs of the unmodified 
(black), +16 Da modified (red) and +32 Da modified (purple) versions of peptide 134-153 (sequence: 
ATLVCLISDFYPGAVTVAWK. Peaks are annotated 1-5 according to their quantification data shown 
b). Error bars show standard deviation (n=3). 
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As some of the isomer products of Trp 152 show differences in labelling by up to ~14-
fold, this could be suggestive of a significant change in the solvent accessibility of this 
side chain. However, the relationship between changing solvent accessible surface 
area and changes in oxidation has not been fully established in FPOP, and is likely 
complicated by various factors such as the reactivity of the side chain itself, and the 
effects of microenvironment [232, 300]. Alternatively, the observation that some of the 
oxidation products show no significant change between WFL and STT could indicate 
that part of the Trp 152 side chain remains largely unchanged between mAb variants, 
indicative of a more subtle side chain movement. Although establishing the utility of 
positional isomers in FPOP requires further research, this alternative explanation, 
involving more subtle conformational change in the region, is to some extent 
supported by other nearby side chains, where Phe 137, Trp 189 and Lys 160 all show 
no significant change between the two mAb variants (Figure 6.5). 
Despite the difficulty in establishing the significance of the conformational changes 
observed at the CL-CH1 interface, long range conformational changes of this type have 
been observed by other groups, where changes in the conformation of the CL-CH1 
interface thought to be related to antigen binding have been reported [302]. Similarly, 
one report identified a change in orientation of the CL-CH1 domains associated with 
changes in CDR loop structure, thus altering the surface exposed hydrophobicity of 
the region [303]. Interestingly, the changes observed in WFL and STT suggest a similar 
trend in reverse, whereby changes in surface exposed hydrophobicity of the CDR 
loops, as a result of the WFL-STT substitutions, illicit changes in the orientation of 
the CL-CH1 domains. Taken together, these data could suggest a long range 
conformational link between the antigen binding regions and the constant domains 
of the Fab arm. 
It has been suggested that conformational changes between the constant and variable 
domains of the Fab arm are mediated through the flexible ‘elbow’ angle between the 
two regions [304]. Although no modified residues were identified in the elbow region 
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between the VH and CH1 domains, one modified species was observed, localised to 
residues Pro 114 or Lys 115, in the elbow region linking the VL and CL domains (Figure 
6.6). This species was observed to be statistically significantly (p < 0.01) less oxidised 
in the WFL variant, highlighting a conformational change in this region between the 
two variants (Figure 6.5b, Figure 6.6), possibly mediating the changes observed in the 
CL-CH1 interface, caused by the WFL-STT triple substitution in the heavy chain CDRs. 
 
6.4 Analysis of retention time data 
Given the complexity of LC-MS/MS data obtained from proteolytic digests of protein 
samples oxidised by FPOP, any additional information that can be mined from such 
data to aid in interpretation offers a clear advantage. In particular, the task of 
identifying oxidised residues within modified peptides, and assigning those modified 
species to elution peaks in the XIC trace of each peptide is often a challenge, not least 
because of the manual nature of the data analysis, but also because these assignments, 
at present, rely solely on the MS/MS data obtained – the quality of which can suffer 
significantly owing to the inherent low abundance of oxidised peptides in the sample, 
and the possibility of chimeric fragmentation spectra from co-isolation in the 
quadrupole. 
Currently, LC separation is an essential part of the FPOP experimental workflow – 
used primarily to separate peptides over time, allowing more DDA cycles to occur, 
and the acquisition of more fragmentation spectra which can be used for assignment 
of oxidised residues. However, although changes in retention time for oxidised 
peptides, relative to the unmodified version of the peptide, is a well-established 
phenomenon [240], any relationship between changes in retention time and the nature 
of the modified peptide (i.e. which residue within the peptide is modified) has, thus 
far, not been explored or systematically investigated. Given the necessity of LC 
separation in the current FPOP workflow, these data are essentially ‘free’, requiring 
no additional experiments to be performed, or any changes to the current LC-MS/MS 
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experimental workflow. Using the abundance of data provided by FPOP-LC-MS/MS 
analysis of WFL and STT, combined with the β2m dataset discussed in Section 5.2, we 
sought to explore the utility of using the separation data itself, in conjunction with 
MS/MS, as an aid to assign modified residues in oxidised peptides. 
 
 
 
Figure 6.8 Analysis of the effect of FPOP oxidations on peptide retention time in RP-LC. Data included 
in this analysis consists only of modifications which could be unambiguously assigned to residue level 
resolution combined from the WFL/STT data set, as well as the FPOP data from Chapter 5. X axis shows 
change in MeCN concentration at which peptides eluted, relative to the unmodified version of the 
peptide (set as 0 on the x axis). Histograms binned every Δ1% are shown as shaded columns. Gaussian 
fits to raw data are shown as solid lines. 
 
Figure 6.8 shows a retention time analysis of the most commonly modified residues 
within oxidised peptides observed in this thesis, identified by MS/MS, and their 
subsequent change in retention time relative to the unmodified version of that 
peptide, by RP-LC. Nearly all the modified peptides observed elute at a lower aqueous 
concentration of organic solvent (i.e. shorter retention time) than their unmodified 
counterparts. This is expected, given the addition of oxygen and subsequent decrease 
in hydrophobicity of the peptide. Interestingly, peptides where lysine was the 
modified residue were observed to have a remarkably reproducible effect on the 
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retention time of the peptide, eluting at an MeCN concentration 0.05 – 0.1 % v/v 
lower than the unmodified version of the peptide (Figure 6.8). This minimal effect on 
retention time is largely consistent with the marginal change in hydrophobicity 
caused by incorporation of oxygen to lysine side chains. 
Another notable observation made from these data is that peptides where histidine 
was the modified residue elute reproducibly at higher MeCN concentrations (i.e. 
longer retention times) (Figure 6.8). The dominant +16 Da product generated from 
hydroxyl radical oxidation of histidine is 2-oxo histidine, the structure of which is 
shown in Figure 6.9. It has been reported previously that oxidation of histidine into 
2-oxo histidine renders protonation of the side chain significantly less favourable, 
likely due to the significantly lower proton affinity of the oxidised product [305, 306]. 
This suggests that the 2-oxo histidine product, unlike the unmodified histidine side 
chain, is likely to remain un-protonated under typical LC-MS conditions, likely 
resulting in increased hydrophobicity of the peptide, despite the incorporation of an 
oxygen atom. 
 
 
Figure 6.9 Chemical structures of histidine and 2-oxo histidine.  
 
This hypothesis is supported by the observation that histidine modifications 
frequently show a significant charge state bias towards lower charge states when 
ionised by ESI (Figure 6.10). In the experiments presented here, this observation was 
unique to histidine modifications, and was not found on any other type of modified 
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residue. However, this charge state bias was not observed on all peptides where 
histidine was the oxidised residue, and likely depends on the presence of other 
protonatable groups in the peptide. 
 
 
Figure 6.10 Histidine oxidations in peptides show charge state biases towards lower charge states. XIC 
of peptide 313-328 (sequence: VVSVLTVLHQDWLNGK) showing the unmodified version (black), and 
two charge states of the +16 Da modified version (2+ = green, 3+ = blue). Peptides where the oxidation 
was present on the histidine side chain show longer retention times and charge state biases towards 
lower charge states, whereas peptides where tryptophan was the oxidised side chain show shorter 
retention times and the XICs of the two charge states largely overlay. 
 
In several instances, examination of the XICs for modified and unmodified versions 
of a peptide revealed similar retention time profiles, where the oxidised peptide 
product eluted at the same retention time as the unmodified version of the peptide. 
An example of this is shown in Figure 6.11a, where MS/MS could reliably identify the 
modified residue as Tyr 94 (Figure 6.11b). Although it cannot be ruled out that some 
oxidations generated from hydroxyl radical attack during FPOP do not affect the 
retention time of the peptide, an alternative explanation is that such oxidations occur 
after LC separation during the ESI process [228, 307, 308]. As such, suspected ‘in-source’ 
oxidations generated from ESI were excluded from analysis and not quantified. This 
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observation further highlights the importance of performing comprehensive analyses 
of FPOP data, including careful examination of retention time profiles and LC 
separation data. 
 
 
Figure 6.11 Possible in-source oxidations observed during FPOP-LC-MS/MS experiments. a) XIC for 
peptide 88-98 (sequence: SEDTAVYYCAR) in the heavy chain of WFL showing the unmodified (black) 
and +14 Da modified (red) LC elution traces. Insert: expansion of the XIC between 29 and 33 minutes. 
MS/MS for the modified (bottom) and unmodified (top) are shown in b. 
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6.5 Discussion 
The changes in conformation observed between WFL and STT at the CL-CH1 interface 
support the view that long range changes in conformation can occur between the 
constant and variable domains of the Fab arm in mAbs. However, the significance of 
this conformational change, and indeed the changes in oxidation observed 
surrounding the WFL-STT substitutions in the CDR regions, cannot be reliably 
determined from these data. Interpretation of FPOP data in this regard would benefit 
greatly from a greater understanding of positional isomers, the effects of changing 
solvent accessibility for different side chains as well as changes in local 
microenvironment. 
Similarly, the significance of the observed changes in conformation between the two 
mAb variants, with regards to the poor pharmacological properties of WFL [170] cannot 
be established from these data. However, a recent report demonstrated that, for light 
chain dimers, structurally similar to that of the Fab domain [309], the CL domains were 
observed to modulate protein aggregation, and the interface between constant 
domains was suggested as a potential target for mitigating protein aggregation [310]. 
This could suggest a possible role of the CL domain in the aggregation of WFL, where 
the conformational changes observed, caused by the WFL-STT substitution, play a 
role in the reversible self-association of the WFL mAb variant. 
Critically, however, these data definitively show that amino acid substitutions in the 
variable domain of the Fab arm, can affect the conformation and positioning of side 
chains in the constant domains of the Fab arm. Typically, these two distinct regions 
are often assumed to be functionally independent [311, 312]. While the functionality of 
this conformational link cannot be established from these data, the observation itself 
may prove critical in the identification of aggregation-prone sites, or undesirable 
conformational changes, generated distal from the site of amino acid substitutions that 
may otherwise go overlooked. 
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6.5.1 Retention time analysis 
The retention time analysis of peptides oxidised by FPOP, from both the mAb data 
discussed here, and the β2m data discussed in Section 5, highlight the potential utility 
of using the LC separation data as an aid, not only to assign modified residues within 
oxidised peptides, but to avoid erroneous assignments of in-source oxidations 
generated from the ESI process. Undoubtedly, MS/MS remains the gold standard in 
determining oxidation sites in FPOP. However, as peptides in FPOP experiments 
often have the same m/z, are typically low abundance and sometimes only partially 
separated by LC, the resulting chimeric, or poor quality, tandem MS spectra, are such 
that finding alternative, or complementary methods of assignment offers a distinct 
advantage. Given the current necessity of using LC in FPOP experimental workflows, 
the LC separation data seems an obvious place to start, in looking for such alternatives. 
Although considerably more data would be needed to establish whether changes in 
retention time could be used as a predictive tool in FPOP assignments, even the small 
data set collated here demonstrates the potential utility of using changes in retention 
time to assign lysine and histidine oxidations within oxidised peptides, given their 
unique, and reproducible effect on the elution of the peptide. Indeed, retention time 
prediction tools have long been established in other peptide LC-MS workflows [313], 
and may prove to be a useful future tool in characterising positional isomers in FPOP. 
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7 Concluding remarks 
The work presented here has outlined several novel findings and advances that are of 
crucial importance to the field of structural MS, particularly with regards to the use 
of FPOP and other structural MS techniques in the study of aggregation-prone 
proteins.  
In this last section, the overall findings of this thesis are discussed in a broader 
scientific context, with regards to the thesis aims laid out in Section 2.5. 
 
7.1 A new understanding of FPOP 
The detailed comparison of FPOP data between wild-type β2m and the ΔN6 
truncation variant, outlined in Section 5.2.1, and subsequently published in 2018 [252], 
allowed for the first time a detailed characterisation of positional isomers in FPOP 
experiments. These data highlight the possibility, with further study, of utilising 
positional isomers in FPOP for more detailed analyses of protein structures. However, 
the well-characterised variants studied in these experiments also revealed a complex 
relationship between SASA, or change in SASA, and the degree to which side chains 
label in FPOP. While these data are in line with those of other studies [232, 287, 288], these 
combined observations begin to illustrate the true complexity of using FPOP to 
analyse protein structures, where nearby side chains in sequence or space, changing 
solution conditions, and the reactivity of the side chain itself, all likely play a role in 
the degree to which amino acid groups oxidise, and the sensitivity of the oxidation on 
these side chains to changes in protein structure and local microenvironment.  
Efforts to understand these effects in FPOP experiments should be considered 
amongst the highest priority tasks for future work in this field. In the immediate 
future, disentanglement of these factors would allow optimal design of internal 
standards in FPOP experiments [289-291], greatly improving the robustness and 
reproducibility of the technique, but would also widen the range of possible 
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experiments available to FPOP users. Similarly, a greater understanding of the 
interplay between different side chains, SASA and amino acid reactivity on the degree 
to which side chains label in FPOP would also release this technique from its current 
limitations with regards to data interpretation.  
These efforts would also likely benefit from a more detailed understanding of the 
precise reactivities of the different amino acids, specifically for oxidation induced by 
FPOP. Indeed, the general observations made from the FPOP data presented here 
show that tyrosine side chains modify considerably less, on average, than tryptophan 
side chains, even when similarly solvent exposed (section 5.2). Given that the 
reactivities of these two residue types are predicted to be precisely the same, from 
reactivity data produced by electron pulse radiolysis (Table 2.2), we must entertain 
the possibility that the reactivity of the amino acids in FPOP differs slightly from 
these data.  
In much the same way that the effects of pH, temperature and sequence have been 
largely unravelled with regards to deuterium incorporation in HDX, in the long term, 
achieving a near complete understanding of the factors described above in FPOP, 
particularly in the age of machine learning, seems largely feasible. Although 
challenging, the prize for such an endeavour: a known relationship between absolute 
SASA and the degree of labelling for a given amino acid type, under a given set of 
conditions, promises the establishment of low resolution protein structural models, 
derived de novo from MS data alone. With the already recognised possibility of 
expanding the FPOP platform to include alternative radical based labelling reactions 
[236, 237], as well as in vivo work [235], adding FPOP to the suite of well-established 
structural MS techniques already available, could yet prove to be a critical step 
forward in the advancement of structural MS as a field. 
7.1.1 How do HDX and FPOP compare? 
In addition to the findings outlined above, the comparison of wild-type β2m to the 
truncation variant using both FPOP and HDX highlights the similarity regarding the 
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identified regions of difference between the two proteins, where both techniques 
identified the region directly proximal to the N-terminal truncation as the site of most 
significant structural change. However, the closest agreement between the two 
methods was observed at the earliest labelling time points of the HDX experiment, 
prior to larger scale increases in deuterium uptake across the length of the protein, 
likely associated with the decreased stability of the native fold of the truncation 
variant, relative to the wild-type protein. These large scale changes were not observed 
by FPOP, and could indicate a time dependence of the agreement between the two 
methods, where faster HDX labelling time points show better correlation with FPOP 
data, than longer deuterium incubation times. Similarly, the trend in labelling 
between the two methods was not observed to be consistent, where, upon truncation 
of the N-terminus, both increased and decreased labelling of sites was observed using 
FPOP, but only increased labelling was observed using HDX. This is not entirely 
unexpected, given the different labelling targets (i.e. side chain vs backbone) of the 
two methods. Similarly, although the precise timescale of FPOP labelling is still 
currently disputed [233], the differing labelling timescales of the two methods, along 
with the broad/low resolution vs narrow/high resolution coverage of structural 
changes for HDX and FPOP, respectively, grant these two methods a high degree of 
complementarity when used together. Indeed, an increasing number of studies have 
utilised both HDX and FPOP in the characterisation of protein structural changes or 
binding events [217, 278, 314], further demonstrating the useful structural MS niche FPOP 
is beginning to occupy. 
 
7.2 The D76N variant 
Given its overwhelming structural similarity to the wild-type protein, the observation 
that the D76N variant of β2m has significantly increased deuterium uptake in the E-F 
loop surrounding the D-N amino acid substitution, is of notable importance. These 
changes could not be described solely by the changes in intrinsic exchange rate caused 
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by the change in amino acid sequence, and demonstrate a significant structural change 
in the D76N variant, with some evidence supporting minor changes in deuterium 
uptake in the nearby A-B loop as well. Although the differences between the wild-
type protein and D76N shown by FPOP were also in these regions, supporting both 
the minor changes observed by HDX in the A-B loop, and the observation that HDX 
and FPOP, as structural MS techniques, highlight similar regions of structural change, 
the differences in oxidation observed were minor, compared with the substantial 
differences in deuterium uptake between the two proteins.  
There are several possible explanations for this observation. One is that the differences 
are observed more significantly at timescales appropriate for HDX (sec – hours) than 
for FPOP (µs-ms). However, the most significant changes in deuterium uptake were 
observed at the earliest labelling time points of the HDX experiment and, as such, one 
might expect to observe larger differences with faster labelling techniques such as 
FPOP, as opposed to the minimal changes in oxidation which these data show. 
Alternatively, the difference in resolution and coverage between FPOP and HDX 
could explain the discrepancy, whereby residues in the E-F loop which significantly 
change in SASA are covered by the peptide level HDX data, but were not labelled in 
the FPOP experiment. Lastly, both the HDX and FPOP data could be explained by 
the difference in the protein structural factors each technique probes. For example, a 
significant loss of hydrogen bonding in residues of the E-F loop, a hypothesis outlined 
in Section 4.7.2, would likely dramatically increase the deuterium uptake of the 
region, in line with the observed uptake behaviour. However, such H-bond losses 
would not necessarily cause significant movement of the amino acid side chains 
involved and, indeed, given the largely solvent accessible nature of the E-F loop in 
both proteins, would likely only make minimal changes to the SASA of side chains in 
this region. Hydrogen bonding is not currently believed to significantly affect 
oxidation of amino acid side chains by FPOP. Therefore, the fact that oxidation by 
FPOP remained largely similar between the wild-type protein and the D76N variant, 
could support, or at least does not contradict, the hypothesis that the D76N 
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substitution has disturbed hydrogen bonding in the E-F loop, as opposed to having 
caused a wholesale structural rearrangement of the region. 
Although considerably more work is needed before a determination of how, or even 
if, the stability and structure of the E-F loop factor in to the increased aggregation 
propensity of this variant, given the stark similarity between the structure and 
dynamics of D76N and the wild-type protein when studied by other methods [157, 161], 
these large scale changes in HDX surrounding the D-N substitution are encouraging 
and worthy of further investigation. It would be wise for future work to be directed 
towards establishing precisely which residues cause the increase in deuterium uptake 
by, for example, continuing to develop the single residue HDX-MS experiments using 
ETD peptide fragmentation outlined in section 4.7.4. Additionally, utilising site 
directed mutagenesis to disrupt hydrogen bonding in this region by other means, will 
be useful to establish the significance of the E-F or A-B loops on aggregation 
propensity, before an aggregation mechanism can be elucidated. The observation by 
FPOP, HDX and IMS that the D76N variant is largely distinct from the aggregation-
prone ΔN6 truncation variant, considered to be a structural mimic of the 
amyloidogenic IT state folding intermediate, is consistent with the results of others 
[161]. Although this research is certainly in the early stages, these data could suggest an 
alternative, or additional, aggregation pathway for the D76N variant not involving the 
amyloidogenic IT state. If true, this would offer a remarkable opportunity to study the 
common factors which direct both the IT state, and the D76N variant towards amyloid 
formation and, more generally, gain insight into which factors lead proteins to form 
amyloid – an essential step in future disease prevention and treatment. 
 
7.3 What did we learn from studying biopharmaceuticals? 
The detailed characterisation of the mAbs WFL and STT by FPOP, subsequently 
published in 2019 [297], gave a unique insight into the effect of the triple CDR 
substitutions on the structure of these proteins. Although some studies have suggested 
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a functional allosteric link between the constant and variable domains of mAbs [315], it 
is generally considered that these two domains are functionally independent [311, 312]. 
Although the existence of a functional link between the constant and variable 
domains of the Fab arms in WFL/STT cannot be established from these data, the FPOP 
data clearly demonstrate that the structural features of the heavy chain CDR in these 
proteins significantly affect the structure of the interface between the CH1 and CL 
domains. Although these conformational changes are likely minor, as discussed in 
Section 6.3, these data highlight three key findings: 
1. Long range conformational changes in mAbs can be transmitted between the 
constant and variable domains of the Fab arm. 
2. FPOP, as a technique, is capable of distinguishing these minor conformational 
changes, which could be important for protein aggregation and reversible self-
association. 
3. FPOP could be a useful method for screening new biopharmaceuticals for long 
range interactions which may/may not be beneficial. 
Indeed, despite the significantly increased complexity of the sample compared with 
the FPOP study of the three variants of β2m (Section 5), sub-amino acid level 
resolution on some of the oxidised products identified was still achievable, and could 
be used to gain additional insight on the long range conformational changes observed. 
Similarly, the large data set obtained from LC-MS/MS analysis of the oxidised mAb 
samples provided a useful starting point for the comprehensive analysis of RT data 
from oxidised peptides. Although limited, the LC RT data obtained here demonstrate, 
for the first time, that changes in RT may be useful as an aid in determining the 
oxidised site within the peptide. Given that LC separation is, at present, an essential 
part of the FPOP experimental workflow, the utility of analysing and compiling these 
data cannot be overstated, and future work should continue to compile LC RT data 
from FPOP experiments in an effort to expand and assess the predictability of RT 
changes for specific types of oxidation. 
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However, the limitations of this work must also be discussed. Firstly, the difficulty in 
the interpretation of changes surrounding the site of the amino acid substitutions 
would greatly benefit from an increased understanding of the effects of local 
microenvironment and sequence, discussed earlier in Section 7.1. Secondly, following 
FPOP-LC-MS/MS analysis, only ~2.5x the number of oxidised sites were identified in 
WFL and STT (50 in total) than in the FPOP data for the β2m variants (19 in total), 
despite WFL and STT being ~12x larger. Although, the interfaces between domains 
of the antibody reduce the available surface area per Ig subunit, when compared with 
monomeric β2m, this is considerably lower than one might expect, for a protein 
consisting of multiple Ig domains of similar structure to β2m. Undoubtedly, further 
optimisation of the LC-MS/MS method used would yield more confidently identified 
modifications. However, a comprehensive analysis of such large proteins following 
FPOP oxidation and ‘bottom-up’ LC-MS sample prep, with hundreds, if not 
thousands, of low abundance, modified peptides with the same m/z and similar 
fragmentation spectra, may be asking too much of even the most capable MS/MS 
instrumentation. 
Although the current experimental workflow is largely effective and provides an 
enormous quantity of data for each sample, with regards to optimising FPOP for larger 
molecules such as biopharmaceuticals, it would be unwise to rule out alternative 
experimental strategies to that of the traditional LC-MS/MS workflow, especially 
given the early stage of method development FPOP currently occupies. 
For example, could a ‘top-down’ approach be considered? Modern orbitrap MS 
instruments are capable of utilising multiple ion activation techniques, and have been 
used successfully for top-down sequencing of mAbs previously [316]. While this may 
complicate quantification of oxidised sites and likely remove the possibility of 
characterising positional isomers, this method would subvert other issues with the 
traditional bottom-up LC-MS/MS approach. For example, issues with failing 
enzymatic digestion at oxidised lysine residues, and signal splitting from multiple 
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oxidised species eluting at different retention times. Alternatively, a ‘Middle-down’ 
approach could be used, using enzymatic digestion or reduction of disulphide bonds 
to generate smaller subunits of the protein for subsequent top-down analysis [317, 318]. 
Regardless, these data demonstrate that, although significantly more work is required 
to optimise FPOP for the study of larger, more complex molecules, this method has 
the potential to characterise the structure of mAbs, in great detail, and may prove to 
be a useful additional tool to study the reversible self-association of biotherapeutics. 
7.4 Final thoughts 
The study of aggregation-prone proteins, and the development of methods which 
make their characterisation possible, is of critical importance to the prevention and 
treatment of disease in the modern era. The work presented in this thesis 
demonstrates a modest step forward in the understanding and development of several 
MS based techniques ideally suited to this purpose, as well as an increased 
understanding of the protein systems studied. 
The lessons learned during this project however, stretch much further than those 
outlined above. With each research project, the subtleties of each obstacle stumbled 
across provide a valuable insight to those involved, as to how future work might be 
streamlined for faster research progression. While many of the issues encountered 
during the course of this PhD project could easily be attributed to any eager young 
scientist with a limited experience pool, most others could be attributed to challenges 
in appropriate data interpretation, usually arising from a multitude of different, 
plausible explanations. Hindered by a fledgling scientific career, or perhaps because 
of it, the author has often resorted to searching for answers to these problems from 
outside of the scientific realm. 
During his time in the military, the famous comic, writer and poet, Spike Milligan, 
was once asked by a fellow serviceman where, in the UK, he was from. Although he 
had been born in India, Spike responded by saying that he was from London, where 
he had lived from the age of twelve, having moved there with his parents in 1931. 
Concluding remarks 
 
216 
 
“Which part?” remarked the serviceman - London being a rather large place. 
“… Well, all of me.” Said Spike. 
Although likely not the intention of either man, this exchange demonstrates, quite 
effectively, that such difficulties in the interpretation of data can arise, even when not 
really asking the wrong question, by asking the right question, imprecisely. 
Given that protein aggregation and FPOP are both, independently, incredibly 
complex, multi-faceted subjects for study, moving forward, a high degree of precision 
in the research questions posited will undoubtedly prove beneficial in the further 
implementation and development of FPOP, as well as other methods in the structural 
MS toolbox, to study the aggregation of amyloidogenic proteins like D76N, or 
biopharmaceuticals like WFL and STT. While this thesis outlines some of the 
questions, and suggests some new avenues of research to begin this effort, there is, 
unquestionably, a long way to go, where - to paraphrase the great, Douglas Adams - 
making progress will require us to think the unthinkable, to do the undoable, and to 
“grapple with the ineffable itself, and see if we may not eff it after all.” 
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8 Appendices 
The following appendices contain raw data, figures and information relating to each 
chapter. 
8.1 Related information for Chapter 4 
Table 8.1 Raw state data (as exported from DynamX) for HDX-MS experiments.
 
Start 
End Sequence MaxUptake Protein Exposure Centre Centre SD Uptake Uptake SD 
1 10 MIQRTPKIQV 8 Wild-type 0 1214.649 0.104704 0 0 
1 10 MIQRTPKIQV 8 Wild-type 0.5 1217.23 0.0247 2.580781 0.107578 
1 10 MIQRTPKIQV 8 Wild-type 1 1217.36 0.045922 2.711117 0.114332 
1 10 MIQRTPKIQV 8 Wild-type 2 1217.506 0.025463 2.857303 0.107756 
1 10 MIQRTPKIQV 8 Wild-type 30 1217.582 0.046735 2.933384 0.114661 
1 10 MIQRTPKIQV 8 Wild-type 120 1217.785 0.065008 3.136351 0.123243 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 Wild-type 0 2703.133 0.167672 0 0 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 Wild-type 0.5 2708.3 0.129742 5.167058 0.212006 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 Wild-type 1 2708.628 0.175295 5.495531 0.242574 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 Wild-type 2 2708.786 0.10498 5.652998 0.197824 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 Wild-type 30 2709.109 0.202872 5.97659 0.263193 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 Wild-type 120 2709.453 0.142575 6.320577 0.220094 
2 10 IQRTPKIQV 7 Wild-type 0 1083.224 0.05378 0 0 
2 10 IQRTPKIQV 7 Wild-type 0.5 1085.7 0.037933 2.475867 0.065812 
2 10 IQRTPKIQV 7 Wild-type 1 1085.83 0.030087 2.606238 0.061624 
2 10 IQRTPKIQV 7 Wild-type 2 1085.99 0.045149 2.765807 0.070219 
2 10 IQRTPKIQV 7 Wild-type 30 1086.224 0.08209 2.9998 0.098138 
2 10 IQRTPKIQV 7 Wild-type 120 1086.312 0.041402 3.088398 0.067871 
4 10 RTPKIQV 5 Wild-type 0 841.915 0.024333 0 0 
4 10 RTPKIQV 5 Wild-type 0.5 843.9773 0.041792 2.062316 0.04836 
4 10 RTPKIQV 5 Wild-type 1 844.0443 0.017357 2.129315 0.029889 
4 10 RTPKIQV 5 Wild-type 2 844.1681 0.044022 2.253073 0.0503 
4 10 RTPKIQV 5 Wild-type 30 844.2945 0.036671 2.379467 0.04401 
4 10 RTPKIQV 5 Wild-type 120 844.3475 0.04001 2.432472 0.046828 
6 10 PKIQV 3 Wild-type 0 584.6948 0.007523 0 0 
6 10 PKIQV  3 Wild-type 0.5 585.8201 0.012492 1.125356 0.014582 
6 10 PKIQV 3 Wild-type 1 585.8903 0.007017 1.195543 0.010288 
6 10 PKIQV 3 Wild-type 2 585.9739 0.013561 1.279155 0.015508 
6 10 PKIQV 3 Wild-type 30 586.048 0.013962 1.353241 0.01586 
6 10 PKIQV 3 Wild-type 120 586.1986 0.024513 1.503808 0.025642 
11 23 YSRHPAENGKSNF 11 Wild-type 0 1507.565 0.030325 0 0 
11 23 YSRHPAENGKSNF 11 Wild-type 0.5 1510.365 0.074444 2.800139 0.080383 
11 23 YSRHPAENGKSNF 11 Wild-type 1 1510.492 0.051381 2.926296 0.059663 
11 23 YSRHPAENGKSNF 11 Wild-type 2 1510.505 0.023414 2.940129 0.038312 
11 23 YSRHPAENGKSNF 11 Wild-type 30 1510.611 0.087883 3.04557 0.092968 
11 23 YSRHPAENGKSNF 11 Wild-type 120 1510.732 0.037683 3.166781 0.04837 
11 26 YSRHPAENGKSNFLNC 14 Wild-type 0 1837.935 0.086961 0 0 
11 26 YSRHPAENGKSNFLNC 14 Wild-type 0.5 1840.497 0.03678 2.562254 0.094419 
11 26 YSRHPAENGKSNFLNC 14 Wild-type 1 1840.589 0.078763 2.653526 0.117328 
11 26 YSRHPAENGKSNFLNC 14 Wild-type 2 1840.617 0.047244 2.682016 0.098966 
11 26 YSRHPAENGKSNFLNC 14 Wild-type 30 1840.717 0.103526 2.782132 0.135203 
11 26 YSRHPAENGKSNFLNC 14 Wild-type 120 1840.758 0.086924 2.822377 0.122955 
27 35 YVSGFHPSD 7 Wild-type 0 1008.961 0.027743 0 0 
27 35 YVSGFHPSD 7 Wild-type 0.5 1009.936 0.034714 0.974845 0.044438 
27 35 YVSGFHPSD 7 Wild-type 1 1010.045 0.054767 1.083407 0.061393 
27 35 YVSGFHPSD 7 Wild-type 2 1010.199 0.111729 1.237752 0.115122 
27 35 YVSGFHPSD 7 Wild-type 30 1010.56 0.052192 1.598825 0.059107 
27 35 YVSGFHPSD 7 Wild-type 120 1010.712 0.050249 1.750528 0.057399 
27 37 YVSGFHPSDIE 9 Wild-type 0 1251.238 0.044765 0 0 
27 37 YVSGFHPSDIE 9 Wild-type 0.5 1251.879 0.038914 0.640529 0.059314 
27 37 YVSGFHPSDIE 9 Wild-type 1 1251.965 0.023498 0.726735 0.050557 
27 37 YVSGFHPSDIE 9 Wild-type 2 1252.065 0.037962 0.82654 0.058694 
27 37 YVSGFHPSDIE 9 Wild-type 30 1252.77 0.063106 1.532005 0.07737 
27 37 YVSGFHPSDIE 9 Wild-type 120 1253.012 0.060228 1.774184 0.075042 
27 38 YVSGFHPSDIEV 10 Wild-type 0 1350.069 0.015799 0 0 
27 38 YVSGFHPSDIEV 10 Wild-type 0.5 1350.945 0.045757 0.876329 0.048408 
27 38 YVSGFHPSDIEV 10 Wild-type 1 1351.146 0.071398 1.077086 0.073125 
27 38 YVSGFHPSDIEV 10 Wild-type 2 1351.368 0.029131 1.299108 0.033139 
27 38 YVSGFHPSDIEV 10 Wild-type 30 1352.07 0.055107 2.001372 0.057327 
27 38 YVSGFHPSDIEV 10 Wild-type 120 1352.373 0.141616 2.304499 0.142495 
29 35 SGFHPSD 5 Wild-type 0 746.7241 0.028105 0 0 
29 35 SGFHPSD 5 Wild-type 0.5 747.4501 0.026492 0.725981 0.038623 
29 35 SGFHPSD 5 Wild-type 1 747.5174 0.020176 0.793253 0.034597 
29 35 SGFHPSD 5 Wild-type 2 747.6198 0.014116 0.895645 0.031451 
29 35 SGFHPSD 5 Wild-type 30 747.8446 0.024055 1.120448 0.036993 
29 35 SGFHPSD 5 Wild-type 120 747.9613 0.028167 1.237126 0.03979 
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36 39 IEVD 3 Wild-type 0 475.4448 0.023089 0 0 
36 39 IEVD 3 Wild-type 0.5 475.553 0.048904 0.108264 0.054081 
36 39 IEVD 3 Wild-type 1 475.6176 0.040733 0.172778 0.046821 
36 39 IEVD 3 Wild-type 2 475.7806 0.044417 0.335846 0.050059 
36 39 IEVD 3 Wild-type 30 476.0594 0.025927 0.614595 0.034717 
36 39 IEVD 3 Wild-type 120 476.0687 0.054696 0.623888 0.059369 
36 40 IEVDL 4 Wild-type 0 588.586 0.011613 0 0 
36 40 IEVDL 4 Wild-type 0.5 588.8798 0.014841 0.293809 0.018844 
36 40 IEVDL 4 Wild-type 1 588.9283 0.01735 0.342316 0.020877 
36 40 IEVDL 4 Wild-type 2 588.9982 0.028759 0.412221 0.031015 
36 40 IEVDL 4 Wild-type 30 589.3154 0.0204 0.729424 0.023473 
36 40 IEVDL 4 Wild-type 120 589.4759 0.021141 0.889905 0.02412 
36 41 IEVDLL 5 Wild-type 0 701.8437 0.018952 0 0 
36 41 IEVDLL 5 Wild-type 0.5 702.0775 0.021814 0.233829 0.028897 
36 41 IEVDLL 5 Wild-type 1 702.1788 0.035366 0.335057 0.040125 
36 41 IEVDLL 5 Wild-type 2 702.2346 0.029955 0.390876 0.035447 
36 41 IEVDLL 5 Wild-type 30 702.4983 0.020631 0.654582 0.028015 
36 41 IEVDLL 5 Wild-type 120 702.6459 0.016583 0.802174 0.025183 
36 56 IEVDLLKNGERIEKVEHSDLS 20 Wild-type 0 2424.7 0.080807 0 0 
36 56 IEVDLLKNGERIEKVEHSDLS 20 Wild-type 0.5 2430.141 0.094319 5.44138 0.124201 
36 56 IEVDLLKNGERIEKVEHSDLS 20 Wild-type 1 2430.354 0.110033 5.654528 0.136518 
36 56 IEVDLLKNGERIEKVEHSDLS 20 Wild-type 2 2430.493 0.081614 5.793608 0.11485 
36 56 IEVDLLKNGERIEKVEHSDLS 20 Wild-type 30 2430.79 0.069179 6.090295 0.106375 
36 56 IEVDLLKNGERIEKVEHSDLS 20 Wild-type 120 2431.362 0.100432 6.662527 0.128905 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 Wild-type 0 2571.858 0.083893 0 0 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 Wild-type 0.5 2577.55 0.081021 5.692236 0.116629 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 Wild-type 1 2577.795 0.075574 5.937171 0.112914 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 Wild-type 2 2577.974 0.098131 6.115651 0.129103 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 Wild-type 30 2578.21 0.098929 6.351619 0.129711 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 Wild-type 120 2578.718 0.08745 6.859912 0.121183 
38 55 VDLLKNGERIEKVEHSDL 17 Wild-type 0 2095.454 0.156101 0 0 
38 55 VDLLKNGERIEKVEHSDL 17 Wild-type 0.5 2100.174 0.085673 4.720057 0.178065 
38 55 VDLLKNGERIEKVEHSDL 17 Wild-type 1 2100.303 0.12088 4.849235 0.197432 
38 55 VDLLKNGERIEKVEHSDL 17 Wild-type 2 2100.352 0.155914 4.898328 0.220628 
38 55 VDLLKNGERIEKVEHSDL 17 Wild-type 30 2100.392 0.116166 4.938038 0.194582 
38 55 VDLLKNGERIEKVEHSDL 17 Wild-type 120 2100.908 0.113463 5.453825 0.19298 
38 56 VDLLKNGERIEKVEHSDLS 18 Wild-type 0 2182.409 0.107436 0 0 
38 56 VDLLKNGERIEKVEHSDLS 18 Wild-type 0.5 2187.891 0.157287 5.482425 0.190477 
38 56 VDLLKNGERIEKVEHSDLS 18 Wild-type 1 2188.157 0.203902 5.747961 0.230474 
38 56 VDLLKNGERIEKVEHSDLS 18 Wild-type 2 2188.224 0.123916 5.815004 0.164005 
38 56 VDLLKNGERIEKVEHSDLS  18 Wild-type 30 2188.234 0.151841 5.824919 0.186006 
38 56 VDLLKNGERIEKVEHSDLS 18 Wild-type 120 2188.769 0.145229 6.360423 0.180648 
39 57 DLLKNGERIEKVEHSDLSF 18 Wild-type 0 2230.32 0.069108 0 0 
39 57 DLLKNGERIEKVEHSDLSF 18 Wild-type 0.5 2236.133 0.097198 5.813481 0.119261 
39 57 DLLKNGERIEKVEHSDLSF 18 Wild-type 1 2236.223 0.072818 5.903107 0.100391 
39 57 DLLKNGERIEKVEHSDLSF 18 Wild-type 2 2236.413 0.078956 6.093021 0.104928 
39 57 DLLKNGERIEKVEHSDLSF 18 Wild-type 30 2236.471 0.069825 6.151945 0.098242 
39 57 DLLKNGERIEKVEHSDLSF 18 Wild-type 120 2236.782 0.086729 6.462497 0.110895 
40 55 LLKNGERIEKVEHSDL 15 Wild-type 0 1881.099 0.108406 0 0 
40 55 LLKNGERIEKVEHSDL 15 Wild-type 0.5 1885.058 0.083856 3.95827 0.137054 
40 55 LLKNGERIEKVEHSDL 15 Wild-type 1 1885.169 0.141897 4.069735 0.178569 
40 55 LLKNGERIEKVEHSDL 15 Wild-type 2 1885.184 0.174013 4.084348 0.205018 
40 55 LLKNGERIEKVEHSDL 15 Wild-type 30 1885.228 0.161414 4.128637 0.194438 
40 55 LLKNGERIEKVEHSDL 15 Wild-type 120 1885.379 0.138553 4.279747 0.175923 
40 56 LLKNGERIEKVEHSDLS 16 Wild-type 0 1968.041 0.059337 0 0 
40 56 LLKNGERIEKVEHSDLS 16 Wild-type 0.5 1972.986 0.089191 4.945505 0.107126 
40 56 LLKNGERIEKVEHSDLS 16 Wild-type 1 1973.224 0.123681 5.183197 0.137178 
40 56 LLKNGERIEKVEHSDLS 16 Wild-type 2 1973.324 0.165952 5.282796 0.176241 
40 56 LLKNGERIEKVEHSDLS 16 Wild-type 30 1973.322 0.109178 5.281705 0.12426 
40 56 LLKNGERIEKVEHSDLS 16 Wild-type 120 1973.513 0.117593 5.471807 0.131716 
40 57 LLKNGERIEKVEHSDLSF 17 Wild-type 0 2115.183 0.033729 0 0 
40 57 LLKNGERIEKVEHSDLSF 17 Wild-type 0.5 2120.779 0.127769 5.596368 0.132146 
40 57 LLKNGERIEKVEHSDLSF 17 Wild-type 1 2120.875 0.115587 5.692133 0.120407 
40 57 LLKNGERIEKVEHSDLSF 17 Wild-type 2 2120.941 0.096867 5.75843 0.102571 
40 57 LLKNGERIEKVEHSDLSF 17 Wild-type 30 2121.031 0.090115 5.848536 0.096221 
40 57 LLKNGERIEKVEHSDLSF 17 Wild-type 120 2121.171 0.093805 5.988472 0.099684 
41 55 LKNGERIEKVEHSDL 14 Wild-type 0 1767.991 0.058232 0 0 
41 55 LKNGERIEKVEHSDL 14 Wild-type 0.5 1771.792 0.088348 3.800837 0.105813 
41 55 LKNGERIEKVEHSDL 14 Wild-type 1 1771.816 0.117883 3.824241 0.131481 
41 55 LKNGERIEKVEHSDL 14 Wild-type 2 1771.824 0.107219 3.832733 0.122012 
41 55 LKNGERIEKVEHSDL 14 Wild-type 30 1771.834 0.125103 3.842438 0.137991 
41 55 LKNGERIEKVEHSDL 14 Wild-type 120 1772.053 0.093791 4.061388 0.110398 
41 56 LKNGERIEKVEHSDLS 15 Wild-type 0 1854.994 0.058292 0 0 
41 56 LKNGERIEKVEHSDLS 15 Wild-type 0.5 1859.382 0.126264 4.387788 0.13907 
41 56 LKNGERIEKVEHSDLS 15 Wild-type 1 1859.485 0.173958 4.491089 0.183465 
41 56 LKNGERIEKVEHSDLS 15 Wild-type 2 1859.592 0.171771 4.597704 0.181393 
41 56 LKNGERIEKVEHSDLS 15 Wild-type 30 1859.536 0.219089 4.541573 0.226711 
41 56 LKNGERIEKVEHSDLS 15 Wild-type 120 1859.779 0.194701 4.784412 0.20324 
41 57 LKNGERIEKVEHSDLSF 16 Wild-type 0 2002.222 0.099094 0 0 
41 57 LKNGERIEKVEHSDLSF 16 Wild-type 0.5 2007.382 0.103249 5.159903 0.143108 
41 57 LKNGERIEKVEHSDLSF 16 Wild-type 1 2007.552 0.079292 5.329351 0.126913 
41 57 LKNGERIEKVEHSDLSF 16 Wild-type 2 2007.575 0.124392 5.352889 0.159038 
41 57 LKNGERIEKVEHSDLSF 16 Wild-type 30 2007.594 0.081441 5.371251 0.128266 
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41 57 LKNGERIEKVEHSDLSF 16 Wild-type 120 2007.704 0.078509 5.481297 0.126425 
56 63 SFSKDWSF 7 Wild-type 0 1004.179 0.040787 0 0 
56 63 SFSKDWSF 7 Wild-type 0.5 1006.203 0.058805 2.024336 0.071566 
56 63 SFSKDWSF 7 Wild-type 1 1006.394 0.062525 2.214566 0.074652 
56 63 SFSKDWSF 7 Wild-type 2 1006.59 0.035866 2.410775 0.054313 
56 63 SFSKDWSF 7 Wild-type 30 1006.803 0.026759 2.623998 0.048781 
56 63 SFSKDWSF 7 Wild-type 120 1006.802 0.020354 2.623154 0.045583 
57 61 FSKDW 4 Wild-type 0 682.7389 0.034363 0 0 
57 61 FSKDW 4 Wild-type 0.5 683.7629 0.019432 1.023997 0.039477 
57 61 FSKDW 4 Wild-type 1 683.9297 0.016582 1.190741 0.038155 
57 61 FSKDW 4 Wild-type 2 684.0549 0.013217 1.31596 0.036817 
57 61 FSKDW 4 Wild-type 30 684.2023 0.023405 1.463416 0.041576 
57 61 FSKDW 4 Wild-type 120 684.2281 0.01184 1.489208 0.036345 
57 63 FSKDWSF 6 Wild-type 0 917.0544 0.033516 0 0 
57 63 FSKDWSF 6 Wild-type 0.5 918.7138 0.024238 1.659342 0.041362 
57 63 FSKDWSF 6 Wild-type 1 918.8735 0.025493 1.819125 0.04211 
57 63 FSKDWSF 6 Wild-type 2 919.0168 0.029862 1.962417 0.04489 
57 63 FSKDWSF 6 Wild-type 30 919.2065 0.027549 2.152097 0.043385 
57 63 FSKDWSF 6 Wild-type 120 919.2342 0.03474 2.179745 0.048272 
58 62 SKDWS 4 Wild-type 0 622.5009 0.019386 0 0 
58 62 SKDWS 4 Wild-type 0.5 623.4123 0.029885 0.911366 0.035622 
58 62 SKDWS 4 Wild-type 1 623.5272 0.035785 1.026264 0.040699 
58 62 SKDWS 4 Wild-type 2 623.6677 0.031186 1.166819 0.03672 
58 62 SKDWS 4 Wild-type 30 623.7645 0.031362 1.263533 0.03687 
58 62 SKDWS 4 Wild-type 120 623.8083 0.028379 1.3074 0.034368 
58 63 SKDWSF 5 Wild-type 0 769.8156 0.016578 0 0 
58 63 SKDWSF 5 Wild-type 0.5 771.0771 0.019898 1.261503 0.025899 
58 63 SKDWSF 5 Wild-type 1 771.2769 0.025342 1.461355 0.030283 
58 63 SKDWSF 5 Wild-type 2 771.4586 0.02425 1.643 0.029375 
58 63 SKDWSF 5 Wild-type 30 771.6542 0.016102 1.838629 0.023111 
58 63 SKDWSF 5 Wild-type 120 771.6739 0.03316 1.858345 0.037073 
59 63 KDWSF 4 Wild-type 0 682.7111 0.036858 0 0 
59 63 KDWSF 4 Wild-type 0.5 684.0453 0.014384 1.334227 0.039565 
59 63 KDWSF 4 Wild-type 1 684.1448 0.027562 1.4337 0.046023 
59 63 KDWSF 4 Wild-type 2 684.2457 0.021238 1.534621 0.042539 
59 63 KDWSF 4 Wild-type 30 684.3661 0.037837 1.654985 0.052822 
59 63 KDWSF 4 Wild-type 120 684.3644 0.01269 1.653264 0.038981 
60 63 DWSF 3 Wild-type 0 554.4942 0.015262 0 0 
60 63 DWSF 3 Wild-type 0.5 555.422 0.012195 0.927757 0.019536 
60 63 DWSF 3 Wild-type 1 555.5664 0.030893 1.072245 0.034457 
60 63 DWSF 3 Wild-type 2 555.6644 0.006733 1.170183 0.016681 
60 63 DWSF 3 Wild-type 30 555.7901 0.022097 1.295879 0.026856 
60 63 DWSF 3 Wild-type 120 555.8 0.029092 1.30585 0.032852 
63 67 FYLLY 4 Wild-type 0 718.7383 0.021872 0 0 
63 67 FYLLY 4 Wild-type 0.5 718.7994 0.024491 0.061098 0.032836 
63 67 FYLLY 4 Wild-type 1 718.8011 0.021443 0.062717 0.03063 
63 67 FYLLY 4 Wild-type 2 718.7885 0.023216 0.050115 0.031897 
63 67 FYLLY 4 Wild-type 30 718.8295 0.014193 0.091151 0.026074 
63 67 FYLLY 4 Wild-type 120 718.9046 0.011066 0.166217 0.024512 
64 67 YLLY 3 Wild-type 0 571.6766 0.014298 0 0 
64 67 YLLY 3 Wild-type 0.5 571.7411 0.015292 0.064561 0.020935 
64 67 YLLY 3 Wild-type 1 571.7512 0.016326 0.074592 0.021702 
64 67 YLLY 3 Wild-type 2 571.7374 0.018958 0.060809 0.023745 
64 67 YLLY 3 Wild-type 30 571.7082 0.01982 0.031637 0.024439 
64 67 YLLY 3 Wild-type 120 571.8033 0.012071 0.126712 0.018712 
64 68 YLLYY 4 Wild-type 0 734.7492 0.021619 0 0 
64 68 YLLYY 4 Wild-type 0.5 734.7782 0.027171 0.028983 0.034722 
64 68 YLLYY 4 Wild-type 1 734.7996 0.022469 0.050381 0.03118 
64 68 YLLYY 4 Wild-type 2 734.7826 0.02301 0.033351 0.031573 
64 68 YLLYY 4 Wild-type 30 734.849 0.030814 0.099714 0.037641 
64 68 YLLYY 4 Wild-type 120 734.9274 0.038254 0.178153 0.04394 
65 68 LLYY 3 Wild-type 0 571.6098 0.005148 0 0 
65 68 LLYY 3 Wild-type 0.5 571.6372 0.014922 0.027446 0.015785 
65 68 LLYY 3 Wild-type 1 571.6266 0.023175 0.016771 0.023739 
65 68 LLYY 3 Wild-type 2 571.6295 0.005174 0.019661 0.007299 
65 68 LLYY 3 Wild-type 30 571.6238 0.008409 0.014009 0.00986 
65 68 LLYY 3 Wild-type 120 571.6561 0.009061 0.046313 0.010421 
66 71 LYYTEF 5 Wild-type 0 835.8 0.021728 0 0 
66 71 LYYTEF 5 Wild-type 0.5 836.2815 0.020505 0.481524 0.029876 
66 71 LYYTEF 5 Wild-type 1 836.3913 0.02516 0.591292 0.033243 
66 71 LYYTEF 5 Wild-type 2 836.4463 0.03084 0.646286 0.037726 
66 71 LYYTEF 5 Wild-type 30 836.4681 0.013879 0.668112 0.025783 
66 71 LYYTEF 5 Wild-type 120 836.4616 0.008243 0.661659 0.023239 
67 70 YYTE 3 Wild-type 0 575.5419 0.021735 0 0 
67 70 YYTE 3 Wild-type 0.5 576.0215 0.007024 0.479649 0.022842 
67 70 YYTE 3 Wild-type 1 576.1379 0.00799 0.59599 0.023158 
67 70 YYTE 3 Wild-type 2 576.1921 0.017942 0.650198 0.028184 
67 70 YYTE 3 Wild-type 30 576.1485 0.003639 0.60662 0.022038 
67 70 YYTE 3 Wild-type 120 576.1772 0.00432 0.63529 0.022161 
67 71 YYTEF 4 Wild-type 0 722.7504 0.008058 0 0 
67 71 YYTEF 4 Wild-type 0.5 723.2127 0.011071 0.46227 0.013693 
67 71 YYTEF 4 Wild-type 1 723.2947 0.015834 0.544315 0.017766 
67 71 YYTEF 4 Wild-type 2 723.33 0.011098 0.579632 0.013715 
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67 71 YYTEF 4 Wild-type 30 723.2908 0.017073 0.54043 0.018879 
67 71 YYTEF 4 Wild-type 120 723.3096 0.013159 0.559216 0.015431 
67 79 YYTEFTPTEKDEY 11 Wild-type 0 1686.698 0.038113 0 0 
67 79 YYTEFTPTEKDEY 11 Wild-type 0.5 1689.379 0.035484 2.681019 0.052074 
67 79 YYTEFTPTEKDEY 11 Wild-type 1 1689.737 0.079747 3.039339 0.088386 
67 79 YYTEFTPTEKDEY 11 Wild-type 2 1690.052 0.057253 3.354169 0.068779 
67 79 YYTEFTPTEKDEY 11 Wild-type 30 1690.427 0.046935 3.728623 0.060461 
67 79 YYTEFTPTEKDEY 11 Wild-type 120 1690.471 0.043514 3.772836 0.057845 
68 71 YTEF 3 Wild-type 0 559.5784 0.015936 0 0 
68 71 YTEF 3 Wild-type 0.5 559.9933 0.035481 0.414868 0.038895 
68 71 YTEF 3 Wild-type 1 560.0963 0.014391 0.517897 0.021472 
68 71 YTEF 3 Wild-type 2 560.1499 0.00957 0.57151 0.018588 
68 71 YTEF 3 Wild-type 30 560.1157 0.011267 0.537321 0.019516 
68 71 YTEF 3 Wild-type 120 560.1106 0.014284 0.53217 0.0214 
68 78 YTEFTPTEKDE 9 Wild-type 0 1360.344 0.106569 0 0 
68 78 YTEFTPTEKDE 9 Wild-type 0.5 1362.739 0.035781 2.395582 0.112415 
68 78 YTEFTPTEKDE 9 Wild-type 1 1363.006 0.046428 2.662683 0.116243 
68 78 YTEFTPTEKDE 9 Wild-type 2 1363.184 0.070815 2.840493 0.127952 
68 78 YTEFTPTEKDE 9 Wild-type 30 1363.374 0.055382 3.029884 0.120101 
68 78 YTEFTPTEKDE 9 Wild-type 120 1363.437 0.019504 3.093667 0.108339 
68 80 YTEFTPTEKDEYA 11 Wild-type 0 1594.649 0.042436 0 0 
68 80 YTEFTPTEKDEYA 11 Wild-type 0.5 1597.019 0.125935 2.370042 0.132893 
68 80 YTEFTPTEKDEYA 11 Wild-type 1 1597.226 0.106183 2.576974 0.114349 
68 80 YTEFTPTEKDEYA 11 Wild-type 2 1597.657 0.105206 3.007809 0.113442 
68 80 YTEFTPTEKDEYA 11 Wild-type 30 1597.964 0.053511 3.315008 0.068296 
68 80 YTEFTPTEKDEYA 11 Wild-type 120 1597.994 0.04661 3.344791 0.063034 
68 81 YTEFTPTEKDEYAC 12 Wild-type 0 1697.844 0.169876 0 0 
68 81 YTEFTPTEKDEYAC 12 Wild-type 0.5 1700.461 0.073725 2.616891 0.185185 
68 81 YTEFTPTEKDEYAC 12 Wild-type 1 1700.694 0.084463 2.850218 0.189716 
68 81 YTEFTPTEKDEYAC 12 Wild-type 2 1700.94 0.108224 3.096801 0.201421 
68 81 YTEFTPTEKDEYAC 12 Wild-type 30 1701.394 0.107374 3.550778 0.200965 
68 81 YTEFTPTEKDEYAC 12 Wild-type 120 1701.411 0.098699 3.567592 0.196468 
69 78 TEFTPTEKDE 8 Wild-type 0 1196.973 0.013275 0 0 
69 78 TEFTPTEKDE 8 Wild-type 0.5 1199.363 0.054871 2.39007 0.056454 
69 78 TEFTPTEKDE 8 Wild-type 1 1199.643 0.053923 2.669759 0.055533 
69 78 TEFTPTEKDE 8 Wild-type 2 1199.768 0.072229 2.795043 0.073439 
69 78 TEFTPTEKDE 8 Wild-type 30 1199.939 0.051623 2.966071 0.053303 
69 78 TEFTPTEKDE 8 Wild-type 120 1199.939 0.080987 2.965905 0.082068 
69 80 TEFTPTEKDEYA 10 Wild-type 0 1431.381 0.027154 0 0 
69 80 TEFTPTEKDEYA 10 Wild-type 0.5 1433.662 0.041045 2.281274 0.049214 
69 80 TEFTPTEKDEYA 10 Wild-type 1 1433.942 0.025286 2.561441 0.037104 
69 80 TEFTPTEKDEYA 10 Wild-type 2 1434.21 0.034059 2.829133 0.043558 
69 80 TEFTPTEKDEYA 10 Wild-type 30 1434.572 0.070446 3.191361 0.075499 
69 80 TEFTPTEKDEYA 10 Wild-type 120 1434.631 0.038041 3.250817 0.046738 
69 81 TEFTPTEKDEYAC 11 Wild-type 0 1534.514 0.028031 0 0 
69 81 TEFTPTEKDEYAC 11 Wild-type 0.5 1536.848 0.083577 2.333675 0.088152 
69 81 TEFTPTEKDEYAC 11 Wild-type 1 1537.142 0.057711 2.628267 0.064158 
69 81 TEFTPTEKDEYAC 11 Wild-type 2 1537.384 0.074591 2.869776 0.079684 
69 81 TEFTPTEKDEYAC 11 Wild-type 30 1537.775 0.081868 3.260855 0.086534 
69 81 TEFTPTEKDEYAC 11 Wild-type 120 1537.838 0.044611 3.323974 0.052687 
82 100 RVNHVTLSQPKIVKWDRDM 17 Wild-type 0 2323.565 0.035898 0 0 
82 100 RVNHVTLSQPKIVKWDRDM 17 Wild-type 0.5 2327.509 0.110425 3.944402 0.116114 
82 100 RVNHVTLSQPKIVKWDRDM 17 Wild-type 1 2327.776 0.08834 4.211121 0.095355 
82 100 RVNHVTLSQPKIVKWDRDM 17 Wild-type 2 2327.977 0.105686 4.4125 0.111616 
82 100 RVNHVTLSQPKIVKWDRDM 17 Wild-type 30 2328.121 0.056432 4.555759 0.066882 
82 100 RVNHVTLSQPKIVKWDRDM 17 Wild-type 120 2328.558 0.119209 4.992804 0.124497 
91 100 PKIVKWDRDM 8 Wild-type 0 1288.379 0.039091 0 0 
91 100 PKIVKWDRDM 8 Wild-type 0.5 1290.231 0.062899 1.852006 0.074057 
91 100 PKIVKWDRDM 8 Wild-type 1 1290.339 0.076685 1.959608 0.086074 
91 100 PKIVKWDRDM 8 Wild-type 2 1290.395 0.068407 2.015696 0.078788 
91 100 PKIVKWDRDM 8 Wild-type 30 1290.467 0.068597 2.088125 0.078953 
91 100 PKIVKWDRDM 8 Wild-type 120 1290.529 0.069089 2.150282 0.079381 
94 100 VKWDRDM 6 Wild-type 0 949.9624 0.019987 0 0 
94 100 VKWDRDM 6 Wild-type 0.5 951.2677 0.064491 1.305274 0.067517 
94 100 VKWDRDM 6 Wild-type 1 951.3227 0.024772 1.360305 0.03183 
94 100 VKWDRDM 6 Wild-type 2 951.4715 0.062699 1.509127 0.065808 
94 100 VKWDRDM 6 Wild-type 30 951.4607 0.040988 1.498313 0.045601 
94 100 VKWDRDM 6 Wild-type 120 951.4885 0.047423 1.526095 0.051463 
95 100 KWDRDM 5 Wild-type 0 850.8711 0.039349 0 0 
95 100 KWDRDM 5 Wild-type 0.5 852.2357 0.056807 1.364618 0.069104 
95 100 KWDRDM 5 Wild-type 1 852.3595 0.036966 1.48835 0.053989 
95 100 KWDRDM 5 Wild-type 2 852.3744 0.049272 1.50328 0.063056 
95 100 KWDRDM 5 Wild-type 30 852.42 0.028675 1.548889 0.048689 
95 100 KWDRDM 5 Wild-type 120 852.4299 0.048849 1.558744 0.062726 
1 10 MIQRTPKIQV 8 D76N 0 1214.573 0.067792 0 0 
1 10 MIQRTPKIQV 8 D76N 0.5 1217.253 0.032829 2.679976 0.075323 
1 10 MIQRTPKIQV 8 D76N 1 1217.426 0.033249 2.852556 0.075507 
1 10 MIQRTPKIQV 8 D76N 2 1217.525 0.053099 2.952003 0.086112 
1 10 MIQRTPKIQV 8 D76N 30 1217.603 0.068468 3.02958 0.096352 
1 10 MIQRTPKIQV 8 D76N 120 1217.887 0.043425 3.314023 0.080508 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 D76N 0 2703.118 0.125231 0 0 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 D76N 0.5 2708.725 0.121379 5.606965 0.1744 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 D76N 1 2709.061 0.163565 5.94378 0.206 
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1 23 MIQRTPKIQVYSRHPAENGKSNF 20 D76N 2 2709.273 0.137202 6.155132 0.185761 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 D76N 30 2709.46 0.261306 6.342915 0.289765 
1 23 MIQRTPKIQVYSRHPAENGKSNF 20 D76N 120 2709.857 0.188388 6.739016 0.226214 
2 10 IQRTPKIQV 7 D76N 0 1083.259 0.02496 0 0 
2 10 IQRTPKIQV 7 D76N 0.5 1085.741 0.03257 2.482787 0.041034 
2 10 IQRTPKIQV 7 D76N 1 1085.854 0.042696 2.594848 0.049457 
2 10 IQRTPKIQV 7 D76N 2 1086.025 0.050398 2.766048 0.056241 
2 10 IQRTPKIQV 7 D76N 30 1086.114 0.04448 2.854963 0.051005 
2 10 IQRTPKIQV 7 D76N 120 1086.361 0.038038 3.102603 0.045496 
4 10 RTPKIQV 5 D76N 0 841.9159 0.013515 0 0 
4 10 RTPKIQV 5 D76N 0.5 844.0246 0.031648 2.108745 0.034412 
4 10 RTPKIQV 5 D76N 1 844.103 0.030681 2.187142 0.033526 
4 10 RTPKIQV 5 D76N 2 844.2297 0.034826 2.313846 0.037356 
4 10 RTPKIQV 5 D76N 30 844.3057 0.036339 2.389851 0.038771 
4 10 RTPKIQV 5 D76N 120 844.4603 0.026876 2.544403 0.030083 
6 10 PKIQV 3 D76N 0 584.6648 0.014043 0 0 
6 10 PKIQV 3 D76N 0.5 585.8118 0.018717 1.147042 0.0234 
6 10 PKIQV 3 D76N 1 585.8841 0.010758 1.219249 0.017691 
6 10 PKIQV 3 D76N 2 585.949 0.013569 1.284219 0.019528 
6 10 PKIQV 3 D76N 30 586.052 0.013941 1.387178 0.019788 
6 10 PKIQV 3 D76N 120 586.2373 0.024839 1.572488 0.028534 
11 23 YSRHPAENGKSNF 11 D76N 0 1507.559 0.032641 0 0 
11 23 YSRHPAENGKSNF 11 D76N 0.5 1510.642 0.042634 3.082214 0.053694 
11 23 YSRHPAENGKSNF 11 D76N 1 1510.81 0.050408 3.250812 0.060053 
11 23 YSRHPAENGKSNF 11 D76N 2 1510.881 0.068237 3.321196 0.075642 
11 23 YSRHPAENGKSNF 11 D76N 30 1510.894 0.066178 3.334292 0.07379 
11 23 YSRHPAENGKSNF 11 D76N 120 1511.106 0.031438 3.546851 0.045319 
11 26 YSRHPAENGKSNFLNC 14 D76N 0 1837.955 0.092234 0 0 
11 26 YSRHPAENGKSNFLNC 14 D76N 0.5 1840.801 0.129421 2.846175 0.158924 
11 26 YSRHPAENGKSNFLNC 14 D76N 1 1840.82 0.099579 2.864586 0.135731 
11 26 YSRHPAENGKSNFLNC 14 D76N 2 1840.87 0.113566 2.915365 0.146303 
11 26 YSRHPAENGKSNFLNC 14 D76N 30 1840.97 0.099934 3.014697 0.135993 
11 26 YSRHPAENGKSNFLNC 14 D76N 120 1841.078 0.058547 3.123201 0.109247 
27 35 YVSGFHPSD 7 D76N 0 1008.939 0.064844 0 0 
27 35 YVSGFHPSD 7 D76N 0.5 1010.08 0.044142 1.140295 0.078443 
27 35 YVSGFHPSD 7 D76N 1 1010.167 0.05298 1.228129 0.083735 
27 35 YVSGFHPSD 7 D76N 2 1010.227 0.05793 1.287529 0.086952 
27 35 YVSGFHPSD 7 D76N 30 1010.645 0.034703 1.705458 0.073546 
27 35 YVSGFHPSD 7 D76N 120 1010.805 0.045229 1.865792 0.079059 
27 37 YVSGFHPSDIE 9 D76N 0 1251.227 0.036886 0 0 
27 37 YVSGFHPSDIE 9 D76N 0.5 1251.92 0.036407 0.692901 0.051827 
27 37 YVSGFHPSDIE 9 D76N 1 1252.063 0.02709 0.83658 0.045765 
27 37 YVSGFHPSDIE 9 D76N 2 1252.143 0.055579 0.915842 0.066705 
27 37 YVSGFHPSDIE 9 D76N 30 1252.875 0.057019 1.647859 0.067909 
27 37 YVSGFHPSDIE 9 D76N 120 1253.203 0.035328 1.975954 0.051074 
27 38 YVSGFHPSDIEV 10 D76N 0 1350.047 0.02207 0 0 
27 38 YVSGFHPSDIEV 10 D76N 0.5 1350.944 0.106963 0.897149 0.109216 
27 38 YVSGFHPSDIEV 10 D76N 1 1351.173 0.057426 1.125995 0.061521 
27 38 YVSGFHPSDIEV 10 D76N 2 1351.357 0.067824 1.310359 0.071325 
27 38 YVSGFHPSDIEV 10 D76N 30 1352.139 0.084097 2.092369 0.086945 
27 38 YVSGFHPSDIEV 10 D76N 120 1352.391 0.048147 2.344108 0.052964 
29 35 SGFHPSD 5 D76N 0 746.7026 0.053272 0 0 
29 35 SGFHPSD 5 D76N 0.5 747.4112 0.031135 0.708644 0.061703 
29 35 SGFHPSD 5 D76N 1 747.5083 0.039117 0.805663 0.066091 
29 35 SGFHPSD 5 D76N 2 747.5792 0.028927 0.876586 0.060619 
29 35 SGFHPSD 5 D76N 30 747.869 0.025569 1.166365 0.05909 
29 35 SGFHPSD 5 D76N 120 748.0476 0.075141 1.345056 0.092109 
36 39 IEVD 3 D76N 0 475.5109 0.045347 0 0 
36 39 IEVD 3 D76N 0.5 475.7004 0.045225 0.189565 0.064044 
36 39 IEVD 3 D76N 1 475.7344 0.038981 0.22358 0.059798 
36 39 IEVD 3 D76N 2 475.8323 0.073035 0.321386 0.085968 
36 39 IEVD 3 D76N 30 476.0918 0.025153 0.580927 0.051856 
36 39 IEVD 3 D76N 120 476.1075 0.016073 0.596622 0.048111 
36 40 IEVDL 4 D76N 0 588.588 0.017301 0 0 
36 40 IEVDL 4 D76N 0.5 588.8683 0.013641 0.280311 0.022032 
36 40 IEVDL 4 D76N 1 588.9702 0.014879 0.382186 0.022819 
36 40 IEVDL 4 D76N 2 589.0569 0.024847 0.468858 0.030277 
36 40 IEVDL 4 D76N 30 589.3521 0.006357 0.764118 0.018432 
36 40 IEVDL 4 D76N 120 589.4953 0.01733 0.907255 0.024488 
36 41 IEVDLL 5 D76N 0 701.802 0.040287 0 0 
36 41 IEVDLL 5 D76N 0.5 702.0781 0.009985 0.276047 0.041506 
36 41 IEVDLL 5 D76N 1 702.1281 0.028744 0.326075 0.04949 
36 41 IEVDLL 5 D76N 2 702.2047 0.040219 0.40271 0.056926 
36 41 IEVDLL 5 D76N 30 702.5231 0.01376 0.721072 0.042572 
36 41 IEVDLL 5 D76N 120 702.6589 0.01 0.856891 0.04151 
36 56 IEVDLLKNGERIEKVEHSDLS 20 D76N 0 2424.632 0.088187 0 0 
36 56 IEVDLLKNGERIEKVEHSDLS 20 D76N 0.5 2430.226 0.09881 5.594392 0.13244 
36 56 IEVDLLKNGERIEKVEHSDLS 20 D76N 1 2430.576 0.112375 5.943935 0.142846 
36 56 IEVDLLKNGERIEKVEHSDLS 20 D76N 2 2430.781 0.084861 6.149406 0.122386 
36 56 IEVDLLKNGERIEKVEHSDLS 20 D76N 30 2431.384 0.104342 6.751901 0.136617 
36 56 IEVDLLKNGERIEKVEHSDLS 20 D76N 120 2431.952 0.153837 7.319607 0.177321 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 D76N 0 2571.86 0.103524 0 0 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 D76N 0.5 2577.656 0.087186 5.796469 0.135346 
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36 57 IEVDLLKNGERIEKVEHSDLSF 21 D76N 1 2578.041 0.114704 6.181188 0.154513 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 D76N 2 2578.166 0.120698 6.306813 0.159013 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 D76N 30 2578.833 0.095937 6.973582 0.141142 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 D76N 120 2579.295 0.146062 7.435163 0.179029 
38 55 VDLLKNGERIEKVEHSDL 17 D76N 0 2095.42 0.13714 0 0 
38 55 VDLLKNGERIEKVEHSDL 17 D76N 0.5 2100.242 0.090379 4.822237 0.164243 
38 55 VDLLKNGERIEKVEHSDL 17 D76N 1 2100.459 0.083853 5.039241 0.160744 
38 55 VDLLKNGERIEKVEHSDL 17 D76N 2 2100.556 0.09622 5.135591 0.167528 
38 55 VDLLKNGERIEKVEHSDL 17 D76N 30 2100.916 0.097287 5.495687 0.168143 
38 55 VDLLKNGERIEKVEHSDL 17 D76N 120 2101.423 0.073753 6.003079 0.155714 
38 56 VDLLKNGERIEKVEHSDLS 18 D76N 0 2182.436 0.112589 0 0 
38 56 VDLLKNGERIEKVEHSDLS 18 D76N 0.5 2187.918 0.104534 5.481722 0.153635 
38 56 VDLLKNGERIEKVEHSDLS 18 D76N 1 2188.226 0.129085 5.789975 0.171287 
38 56 VDLLKNGERIEKVEHSDLS 18 D76N 2 2188.326 0.141021 5.889302 0.180453 
38 56 VDLLKNGERIEKVEHSDLS 18 D76N 30 2188.855 0.090413 6.418506 0.144398 
38 56 VDLLKNGERIEKVEHSDLS 18 D76N 120 2189.269 0.084091 6.83231 0.140526 
39 57 DLLKNGERIEKVEHSDLSF 18 D76N 0 2230.253 0.074887 0 0 
39 57 DLLKNGERIEKVEHSDLSF 18 D76N 0.5 2236.25 0.08537 5.996274 0.113561 
39 57 DLLKNGERIEKVEHSDLSF 18 D76N 1 2236.489 0.073074 6.236207 0.104632 
39 57 DLLKNGERIEKVEHSDLSF 18 D76N 2 2236.558 0.082704 6.304549 0.11157 
39 57 DLLKNGERIEKVEHSDLSF 18 D76N 30 2236.876 0.100226 6.623086 0.125113 
39 57 DLLKNGERIEKVEHSDLSF 18 D76N 120 2237.328 0.031028 7.075112 0.08106 
40 55 LLKNGERIEKVEHSDL 15 D76N 0 1881.048 0.099721 0 0 
40 55 LLKNGERIEKVEHSDL 15 D76N 0.5 1885.059 0.084147 4.010852 0.13048 
40 55 LLKNGERIEKVEHSDL 15 D76N 1 1885.183 0.050975 4.134851 0.111995 
40 55 LLKNGERIEKVEHSDL 15 D76N 2 1885.348 0.144835 4.300298 0.175845 
40 55 LLKNGERIEKVEHSDL 15 D76N 30 1885.579 0.069173 4.531026 0.121364 
40 55 LLKNGERIEKVEHSDL 15 D76N 120 1885.976 0.068893 4.928047 0.121204 
40 56 LLKNGERIEKVEHSDLS 16 D76N 0 1968.115 0.070604 0 0 
40 56 LLKNGERIEKVEHSDLS 16 D76N 0.5 1972.882 0.146943 4.767532 0.163024 
40 56 LLKNGERIEKVEHSDLS 16 D76N 1 1973.094 0.065851 4.979841 0.096547 
40 56 LLKNGERIEKVEHSDLS 16 D76N 2 1973.198 0.099481 5.083375 0.121989 
40 56 LLKNGERIEKVEHSDLS 16 D76N 30 1973.359 0.074173 5.244672 0.102404 
40 56 LLKNGERIEKVEHSDLS 16 D76N 120 1973.688 0.119276 5.573226 0.138606 
40 57 LLKNGERIEKVEHSDLSF 17 D76N 0 2115.204 0.037369 0 0 
40 57 LLKNGERIEKVEHSDLSF 17 D76N 0.5 2120.762 0.091456 5.558762 0.098796 
40 57 LLKNGERIEKVEHSDLSF 17 D76N 1 2120.848 0.132432 5.644276 0.137603 
40 57 LLKNGERIEKVEHSDLSF 17 D76N 2 2121.039 0.09516 5.834874 0.102235 
40 57 LLKNGERIEKVEHSDLSF 17 D76N 30 2121.152 0.043065 5.948531 0.057018 
40 57 LLKNGERIEKVEHSDLSF 17 D76N 120 2121.4 0.039449 6.196491 0.054338 
41 55 LKNGERIEKVEHSDL 14 D76N 0 1767.968 0.048341 0 0 
41 55 LKNGERIEKVEHSDL 14 D76N 0.5 1771.688 0.079894 3.720359 0.09338 
41 55 LKNGERIEKVEHSDL 14 D76N 1 1771.873 0.084116 3.904612 0.097017 
41 55 LKNGERIEKVEHSDL 14 D76N 2 1771.931 0.101508 3.962466 0.112431 
41 55 LKNGERIEKVEHSDL 14 D76N 30 1772.115 0.113608 4.14691 0.123466 
41 55 LKNGERIEKVEHSDL 14 D76N 120 1772.465 0.04531 4.496725 0.066256 
41 56 LKNGERIEKVEHSDLS 15 D76N 0 1854.965 0.045304 0 0 
41 56 LKNGERIEKVEHSDLS 15 D76N 0.5 1859.413 0.189525 4.44759 0.194864 
41 56 LKNGERIEKVEHSDLS 15 D76N 1 1859.567 0.139585 4.601586 0.146753 
41 56 LKNGERIEKVEHSDLS 15 D76N 2 1859.67 0.160673 4.705046 0.166938 
41 56 LKNGERIEKVEHSDLS 15 D76N 30 1859.9 0.174812 4.934937 0.180587 
41 56 LKNGERIEKVEHSDLS 15 D76N 120 1860.158 0.161214 5.192442 0.167458 
41 57 LKNGERIEKVEHSDLSF 16 D76N 0 2002.18 0.055875 0 0 
41 57 LKNGERIEKVEHSDLSF 16 D76N 0.5 2007.367 0.073585 5.186809 0.092394 
41 57 LKNGERIEKVEHSDLSF 16 D76N 1 2007.502 0.103799 5.321543 0.117883 
41 57 LKNGERIEKVEHSDLSF 16 D76N 2 2007.624 0.054743 5.444177 0.078223 
41 57 LKNGERIEKVEHSDLSF 16 D76N 30 2007.683 0.118471 5.50292 0.130986 
41 57 LKNGERIEKVEHSDLSF 16 D76N 120 2007.958 0.136745 5.777713 0.14772 
56 63 SFSKDWSF 7 D76N 0 1004.11 0.049095 0 0 
56 63 SFSKDWSF 7 D76N 0.5 1006.275 0.053962 2.164997 0.072953 
56 63 SFSKDWSF 7 D76N 1 1006.489 0.04302 2.378996 0.065276 
56 63 SFSKDWSF 7 D76N 2 1006.71 0.051318 2.600274 0.07102 
56 63 SFSKDWSF 7 D76N 30 1006.899 0.051641 2.78934 0.071254 
56 63 SFSKDWSF 7 D76N 120 1006.969 0.028458 2.859684 0.056746 
57 61 FSKDW 4 D76N 0 682.675 0.020621 0 0 
57 61 FSKDW 4 D76N 0.5 683.7655 0.019166 1.090536 0.028152 
57 61 FSKDW 4 D76N 1 683.948 0.004372 1.273035 0.021079 
57 61 FSKDW 4 D76N 2 684.0808 0.014076 1.405753 0.024967 
57 61 FSKDW 4 D76N 30 684.2476 0.034603 1.572547 0.040282 
57 61 FSKDW 4 D76N 120 684.2878 0.014246 1.612744 0.025063 
57 63 FSKDWSF 6 D76N 0 917.0146 0.035469 0 0 
57 63 FSKDWSF 6 D76N 0.5 918.7162 0.019237 1.70165 0.04035 
57 63 FSKDWSF 6 D76N 1 918.9272 0.045801 1.912645 0.057929 
57 63 FSKDWSF 6 D76N 2 919.0802 0.026995 2.065674 0.044573 
57 63 FSKDWSF 6 D76N 30 919.3166 0.031263 2.302087 0.04728 
57 63 FSKDWSF 6 D76N 120 919.3376 0.033707 2.323077 0.048931 
58 62 SKDWS 4 D76N 0 622.4948 0.016934 0 0 
58 62 SKDWS 4 D76N 0.5 623.4009 0.037982 0.906099 0.041586 
58 62 SKDWS 4 D76N 1 623.5592 0.040241 1.064395 0.043659 
58 62 SKDWS 4 D76N 2 623.6663 0.036673 1.171486 0.040393 
58 62 SKDWS 4 D76N 30 623.8551 0.043555 1.360279 0.046731 
58 62 SKDWS 4 D76N 120 623.8362 0.052092 1.34135 0.054775 
58 63 SKDWSF 5 D76N 0 769.7661 0.143677 0 0 
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58 63 SKDWSF 5 D76N 0.5 771.1094 0.02229 1.343312 0.145395 
58 63 SKDWSF 5 D76N 1 771.3225 0.019541 1.556418 0.144999 
58 63 SKDWSF 5 D76N 2 771.4906 0.034204 1.724512 0.147692 
58 63 SKDWSF 5 D76N 30 771.7158 0.046722 1.949724 0.151082 
58 63 SKDWSF 5 D76N 120 771.7471 0.019096 1.981024 0.14494 
59 63 KDWSF 4 D76N 0 682.6851 0.036611 0 0 
59 63 KDWSF 4 D76N 0.5 683.9717 0.02751 1.286639 0.045794 
59 63 KDWSF 4 D76N 1 684.1382 0.014104 1.453152 0.039233 
59 63 KDWSF 4 D76N 2 684.2738 0.032235 1.58874 0.048779 
59 63 KDWSF 4 D76N 30 684.4337 0.047875 1.748623 0.060269 
59 63 KDWSF 4 D76N 120 684.531 0.025572 1.845919 0.044657 
60 63 DWSF 3 D76N 0 554.4967 0.007193 0 0 
60 63 DWSF 3 D76N 0.5 555.4145 0.032827 0.917848 0.033606 
60 63 DWSF 3 D76N 1 555.5461 0.016035 1.049419 0.017574 
60 63 DWSF 3 D76N 2 555.6707 0.030686 1.174058 0.031518 
60 63 DWSF 3 D76N 30 555.7916 0.022079 1.294924 0.023221 
60 63 DWSF 3 D76N 120 555.8365 0.013391 1.339862 0.015201 
63 67 FYLLY 4 D76N 0 718.7342 0.030732 0 0 
63 67 FYLLY 4 D76N 0.5 718.7971 0.021714 0.062944 0.037629 
63 67 FYLLY 4 D76N 1 718.7858 0.012726 0.051674 0.033263 
63 67 FYLLY 4 D76N 2 718.7852 0.018822 0.051042 0.036038 
63 67 FYLLY 4 D76N 30 718.8094 0.012167 0.075276 0.033053 
63 67 FYLLY 4 D76N 120 718.8836 0.025436 0.149393 0.039893 
64 67 YLLY 3 D76N 0 571.6159 0.027193 0 0 
64 67 YLLY 3 D76N 0.5 571.6945 0.015253 0.078604 0.031179 
64 67 YLLY 3 D76N 1 571.6971 0.015628 0.081246 0.031364 
64 67 YLLY 3 D76N 2 571.6934 0.0254 0.077512 0.03721 
64 67 YLLY 3 D76N 30 571.7246 0.016654 0.108778 0.031887 
64 67 YLLY 3 D76N 120 571.7824 0.022867 0.166547 0.035529 
64 68 YLLYY 4 D76N 0 734.7674 0.047698 0 0 
64 68 YLLYY 4 D76N 0.5 734.7922 0.016275 0.02477 0.050398 
64 68 YLLYY 4 D76N 1 734.851 0.050173 0.083661 0.069227 
64 68 YLLYY 4 D76N 2 734.8304 0.063469 0.063017 0.079394 
64 68 YLLYY 4 D76N 30 734.9056 0.122127 0.13825 0.131111 
64 68 YLLYY 4 D76N 120 734.9946 0.062856 0.227201 0.078905 
65 68 LLYY 3 D76N 0 571.5809 0.017939 0 0 
65 68 LLYY 3 D76N 0.5 571.6404 0.024848 0.059453 0.030646 
65 68 LLYY 3 D76N 1 571.6274 0.014384 0.046411 0.022993 
65 68 LLYY 3 D76N 2 571.633 0.019115 0.052051 0.026214 
65 68 LLYY 3 D76N 30 571.6414 0.018816 0.060413 0.025997 
65 68 LLYY 3 D76N 120 571.6635 0.012547 0.082607 0.021892 
66 71 LYYTEF 5 D76N 0 835.7851 0.020451 0 0 
66 71 LYYTEF 5 D76N 0.5 836.3528 0.032404 0.567695 0.038318 
66 71 LYYTEF 5 D76N 1 836.4703 0.041127 0.685143 0.045932 
66 71 LYYTEF 5 D76N 2 836.4683 0.017341 0.683179 0.026813 
66 71 LYYTEF 5 D76N 30 836.4964 0.02462 0.711232 0.032006 
66 71 LYYTEF 5 D76N 120 836.5325 0.046764 0.747393 0.05104 
67 70 YYTE 3 D76N 0 575.5297 0.022386 0 0 
67 70 YYTE 3 D76N 0.5 576.0941 0.020144 0.564391 0.030115 
67 70 YYTE 3 D76N 1 576.1961 0.005963 0.666453 0.023167 
67 70 YYTE 3 D76N 2 576.2223 0.009666 0.692642 0.024384 
67 70 YYTE 3 D76N 30 576.182 0.017427 0.652332 0.02837 
67 70 YYTE 3 D76N 120 576.1926 0.013201 0.662876 0.025989 
67 71 YYTEF 4 D76N 0 722.7329 0.019331 0 0 
67 71 YYTEF 4 D76N 0.5 723.2749 0.003933 0.541972 0.019727 
67 71 YYTEF 4 D76N 1 723.376 0.005878 0.64314 0.020205 
67 71 YYTEF 4 D76N 2 723.3921 0.020415 0.659224 0.028115 
67 71 YYTEF 4 D76N 30 723.3496 0.010948 0.616702 0.022216 
67 71 YYTEF 4 D76N 120 723.3705 0.011296 0.637609 0.02239 
67 79 YYTEFTPTEKNEY 11 D76N 0 1685.631 0.025989 0 0 
67 79 YYTEFTPTEKNEY 11 D76N 0.5 1689.815 0.077915 4.184076 0.082135 
67 79 YYTEFTPTEKNEY 11 D76N 1 1689.971 0.11578 4.340902 0.118661 
67 79 YYTEFTPTEKNEY 11 D76N 2 1690.128 0.11722 4.497766 0.120067 
67 79 YYTEFTPTEKNEY 11 D76N 30 1690.011 0.055539 4.380104 0.061319 
67 79 YYTEFTPTEKNEY 11 D76N 120 1690.13 0.076695 4.499557 0.080979 
68 71 YTEF 3 D76N 0 559.5725 0.022797 0 0 
68 71 YTEF 3 D76N 0.5 560.0789 0.01781 0.506453 0.028929 
68 71 YTEF 3 D76N 1 560.1414 0.011622 0.568951 0.025589 
68 71 YTEF 3 D76N 2 560.1585 0.013741 0.586045 0.026618 
68 71 YTEF 3 D76N 30 560.1404 0.01417 0.567922 0.026842 
68 71 YTEF 3 D76N 120 560.1732 0.009051 0.600715 0.024528 
68 78 YTEFTPTEKNE 9 D76N 0 1359.357 0.061159 0 0 
68 78 YTEFTPTEKNE 9 D76N 0.5 1363.033 0.033066 3.675727 0.069526 
68 78 YTEFTPTEKNE 9 D76N 1 1363.128 0.035155 3.770896 0.070543 
68 78 YTEFTPTEKNE 9 D76N 2 1363.103 0.036571 3.746284 0.071259 
68 78 YTEFTPTEKNE 9 D76N 30 1362.947 0.041304 3.590029 0.0738 
68 78 YTEFTPTEKNE 9 D76N 120 1363.143 0.047118 3.785875 0.077205 
68 80 YTEFTPTEKNEYA 11 D76N 0 1593.542 0.060625 0 0 
68 80 YTEFTPTEKNEYA 11 D76N 0.5 1597.608 0.070345 4.06616 0.092865 
68 80 YTEFTPTEKNEYA 11 D76N 1 1597.607 0.110306 4.064482 0.125868 
68 80 YTEFTPTEKNEYA 11 D76N 2 1597.774 0.090496 4.231597 0.108926 
68 80 YTEFTPTEKNEYA 11 D76N 30 1597.659 0.118325 4.117409 0.132952 
68 80 YTEFTPTEKNEYA 11 D76N 120 1597.754 0.063329 4.211859 0.08767 
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68 81 YTEFTPTEKNEYAC 12 D76N 0 1696.717 0.030187 0 0 
68 81 YTEFTPTEKNEYAC 12 D76N 0.5 1700.871 0.052499 4.154027 0.060559 
68 81 YTEFTPTEKNEYAC 12 D76N 1 1701.057 0.112346 4.3396 0.116331 
68 81 YTEFTPTEKNEYAC 12 D76N 2 1701.141 0.095837 4.423755 0.100479 
68 81 YTEFTPTEKNEYAC 12 D76N 30 1701.028 0.073206 4.310272 0.079185 
68 81 YTEFTPTEKNEYAC 12 D76N 120 1701.129 0.098385 4.411646 0.102912 
69 78 TEFTPTEKNE 8 D76N 0 1196.023 0.012761 0 0 
69 78 TEFTPTEKNE 8 D76N 0.5 1199.633 0.034685 3.610346 0.036958 
69 78 TEFTPTEKNE 8 D76N 1 1199.663 0.037894 3.64014 0.039985 
69 78 TEFTPTEKNE 8 D76N 2 1199.592 0.091284 3.569292 0.092171 
69 78 TEFTPTEKNE 8 D76N 30 1199.393 0.071473 3.369751 0.072603 
69 78 TEFTPTEKNE 8 D76N 120 1199.606 0.057044 3.58259 0.058454 
69 80 TEFTPTEKNEYA 10 D76N 0 1430.322 0.042827 0 0 
69 80 TEFTPTEKNEYA 10 D76N 0.5 1434.048 0.129707 3.726412 0.136594 
69 80 TEFTPTEKNEYA 10 D76N 1 1434.223 0.091209 3.900798 0.100763 
69 80 TEFTPTEKNEYA 10 D76N 2 1434.276 0.131614 3.954575 0.138407 
69 80 TEFTPTEKNEYA 10 D76N 30 1434.186 0.058812 3.863939 0.072754 
69 80 TEFTPTEKNEYA 10 D76N 120 1434.245 0.088715 3.923276 0.098512 
69 81 TEFTPTEKNEYAC 11 D76N 0 1533.436 0.027766 0 0 
69 81 TEFTPTEKNEYAC 11 D76N 0.5 1537.255 0.084483 3.819046 0.088928 
69 81 TEFTPTEKNEYAC 11 D76N 1 1537.435 0.027826 3.998879 0.039309 
69 81 TEFTPTEKNEYAC 11 D76N 2 1537.482 0.085727 4.045802 0.090111 
69 81 TEFTPTEKNEYAC 11 D76N 30 1537.405 0.092964 3.968517 0.097022 
69 81 TEFTPTEKNEYAC 11 D76N 120 1537.47 0.071504 4.033793 0.076706 
82 100 RVNHVTLSQPKIVKWDRDM 17 D76N 0 2323.559 0.036512 0 0 
82 100 RVNHVTLSQPKIVKWDRDM 17 D76N 0.5 2327.626 0.117442 4.066652 0.122987 
82 100 RVNHVTLSQPKIVKWDRDM 17 D76N 1 2327.992 0.081892 4.432753 0.089663 
82 100 RVNHVTLSQPKIVKWDRDM 17 D76N 2 2328.183 0.063839 4.62351 0.073543 
82 100 RVNHVTLSQPKIVKWDRDM 17 D76N 30 2328.129 0.196082 4.56983 0.199452 
82 100 RVNHVTLSQPKIVKWDRDM 17 D76N 120 2328.539 0.141636 4.98007 0.146267 
91 100 PKIVKWDRDM 8 D76N 0 1288.393 0.037954 0 0 
91 100 PKIVKWDRDM 8 D76N 0.5 1290.255 0.116675 1.861692 0.122693 
91 100 PKIVKWDRDM 8 D76N 1 1290.558 0.115179 2.164236 0.121271 
91 100 PKIVKWDRDM 8 D76N 2 1290.703 0.094827 2.309773 0.102141 
91 100 PKIVKWDRDM 8 D76N 30 1290.808 0.265519 2.414757 0.268218 
91 100 PKIVKWDRDM 8 D76N 120 1290.891 0.222585 2.497556 0.225797 
94 100 VKWDRDM 6 D76N 0 949.958 0.029286 0 0 
94 100 VKWDRDM 6 D76N 0.5 951.1507 0.066865 1.192707 0.072997 
94 100 VKWDRDM 6 D76N 1 951.3044 0.067611 1.346384 0.073681 
94 100 VKWDRDM 6 D76N 2 951.3407 0.095715 1.382741 0.100095 
94 100 VKWDRDM 6 D76N 30 951.3046 0.019364 1.346591 0.035109 
94 100 VKWDRDM 6 D76N 120 951.6492 0.023426 1.69123 0.037502 
95 100 KWDRDM 5 D76N 0 850.8568 0.064341 0 0 
95 100 KWDRDM 5 D76N 0.5 852.2432 0.040685 1.386415 0.076125 
95 100 KWDRDM 5 D76N 1 852.3555 0.067351 1.498793 0.093145 
95 100 KWDRDM 5 D76N 2 852.3943 0.04514 1.537557 0.078596 
95 100 KWDRDM 5 D76N 30 852.4941 0.042827 1.637341 0.077291 
95 100 KWDRDM 5 D76N 120 852.5511 0.023912 1.694373 0.068641 
11 23 YSRHPAENGKSNF 11 ΔN6 0 1507.495 0.037201 0 0 
11 23 YSRHPAENGKSNF 11 ΔN6 0.5 1510.484 0.095233 2.989718 0.102241 
11 23 YSRHPAENGKSNF 11 ΔN6 1 1510.659 0.075175 3.164558 0.083876 
11 23 YSRHPAENGKSNF 11 ΔN6 2 1510.72 0.070509 3.224995 0.079721 
11 23 YSRHPAENGKSNF 11 ΔN6 30 1511.07 0.045306 3.575224 0.058622 
11 23 YSRHPAENGKSNF 11 ΔN6 120 1511.364 0.05075 3.869537 0.062925 
11 26 YSRHPAENGKSNFLNC 14 ΔN6 0 1837.884 0.057194 0 0 
11 26 YSRHPAENGKSNFLNC 14 ΔN6 0.5 1840.399 0.094384 2.514222 0.110361 
11 26 YSRHPAENGKSNFLNC 14 ΔN6 1 1840.624 0.051517 2.739648 0.076975 
11 26 YSRHPAENGKSNFLNC 14 ΔN6 2 1840.72 0.075712 2.835142 0.094886 
11 26 YSRHPAENGKSNFLNC 14 ΔN6 30 1841.11 0.15855 3.225593 0.16855 
11 26 YSRHPAENGKSNFLNC 14 ΔN6 120 1841.317 0.14138 3.432686 0.152511 
27 35 YVSGFHPSD 7 ΔN6 0 1008.995 0.058462 0 0 
27 35 YVSGFHPSD 7 ΔN6 0.5 1010.913 0.032352 1.917408 0.066817 
27 35 YVSGFHPSD 7 ΔN6 1 1010.978 0.062263 1.982236 0.085408 
27 35 YVSGFHPSD 7 ΔN6 2 1011.081 0.042597 2.085801 0.072335 
27 35 YVSGFHPSD 7 ΔN6 30 1011.075 0.005145 2.080008 0.058688 
27 35 YVSGFHPSD 7 ΔN6 120 1011.144 0.087233 2.14811 0.105011 
27 37 YVSGFHPSDIE 9 ΔN6 0 1251.252 0.031903 0 0 
27 37 YVSGFHPSDIE 9 ΔN6 0.5 1252.663 0.030503 1.411797 0.044139 
27 37 YVSGFHPSDIE 9 ΔN6 1 1252.729 0.056784 1.476987 0.065133 
27 37 YVSGFHPSDIE 9 ΔN6 2 1252.821 0.039326 1.569772 0.050639 
27 37 YVSGFHPSDIE 9 ΔN6 30 1253.211 0.091449 1.959106 0.096854 
27 37 YVSGFHPSDIE 9 ΔN6 120 1253.527 0.045852 2.275289 0.055859 
27 38 YVSGFHPSDIEV 10 ΔN6 0 1350.364 0.08177 0 0 
27 38 YVSGFHPSDIEV 10 ΔN6 0.5 1351.898 0.096883 1.533954 0.126778 
27 38 YVSGFHPSDIEV 10 ΔN6 1 1352.214 0.134442 1.849836 0.157357 
27 38 YVSGFHPSDIEV 10 ΔN6 2 1352.145 0.086814 1.780851 0.11926 
27 38 YVSGFHPSDIEV 10 ΔN6 30 1352.811 0.064228 2.447229 0.103979 
27 38 YVSGFHPSDIEV 10 ΔN6 120 1353.015 0.108172 2.650374 0.1356 
29 35 SGFHPSD 5 ΔN6 0 746.7365 0.027362 0 0 
29 35 SGFHPSD 5 ΔN6 0.5 748.3017 0.020828 1.565132 0.034387 
29 35 SGFHPSD 5 ΔN6 1 748.3254 0.033508 1.588852 0.043261 
29 35 SGFHPSD 5 ΔN6 2 748.3577 0.012021 1.621219 0.029887 
29 35 SGFHPSD 5 ΔN6 30 748.3617 0.048549 1.625206 0.055729 
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29 35 SGFHPSD 5 ΔN6 120 748.3875 0.009498 1.650938 0.028964 
36 39 IEVD 3 ΔN6 0 475.4701 0.035276 0 0 
36 39 IEVD 3 ΔN6 0.5 475.7984 0.040038 0.328274 0.053361 
36 39 IEVD 3 ΔN6 1 475.8742 0.030837 0.40406 0.046854 
36 39 IEVD 3 ΔN6 2 475.9847 0.032541 0.514582 0.047993 
36 39 IEVD 3 ΔN6 30 476.1166 0.021223 0.646466 0.041168 
36 39 IEVD 3 ΔN6 120 476.2061 0.037354 0.73596 0.051378 
36 40 IEVDL 4 ΔN6 0 588.6323 0.020651 0 0 
36 40 IEVDL 4 ΔN6 0.5 589.0045 0.012121 0.372164 0.023945 
36 40 IEVDL 4 ΔN6 1 589.0805 0.019481 0.448178 0.02839 
36 40 IEVDL 4 ΔN6 2 589.1649 0.023085 0.5326 0.030974 
36 40 IEVDL 4 ΔN6 30 589.3289 0.023588 0.696544 0.031351 
36 40 IEVDL 4 ΔN6 120 589.4364 0.029406 0.804076 0.035933 
36 41 IEVDLL 5 ΔN6 0 701.8469 0.042 0 0 
36 41 IEVDLL 5 ΔN6 0.5 702.1927 0.031013 0.345709 0.052209 
36 41 IEVDLL 5 ΔN6 1 702.3147 0.019003 0.467714 0.046099 
36 41 IEVDLL 5 ΔN6 2 702.3922 0.02093 0.545223 0.046926 
36 41 IEVDLL 5 ΔN6 30 702.5182 0.014515 0.671255 0.044438 
36 41 IEVDLL 5 ΔN6 120 702.5966 0.022083 0.749627 0.047452 
36 56 IEVDLLKNGERIEKVEHSDLS 20 ΔN6 0 2424.69 0.103566 0 0 
36 56 IEVDLLKNGERIEKVEHSDLS 20 ΔN6 0.5 2430.389 0.098329 5.698412 0.14281 
36 56 IEVDLLKNGERIEKVEHSDLS 20 ΔN6 1 2430.612 0.124062 5.922076 0.161608 
36 56 IEVDLLKNGERIEKVEHSDLS 20 ΔN6 2 2430.851 0.148246 6.161086 0.18084 
36 56 IEVDLLKNGERIEKVEHSDLS 20 ΔN6 30 2431.245 0.166662 6.554392 0.19622 
36 56 IEVDLLKNGERIEKVEHSDLS 20 ΔN6 120 2431.93 0.168612 7.239599 0.197879 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 ΔN6 0 2571.912 0.122433 0 0 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 ΔN6 0.5 2577.922 0.103046 6.009414 0.160026 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 ΔN6 1 2578.066 0.137453 6.154019 0.184074 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 ΔN6 2 2578.303 0.129946 6.390176 0.178538 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 ΔN6 30 2578.828 0.202865 6.915885 0.236947 
36 57 IEVDLLKNGERIEKVEHSDLSF 21 ΔN6 120 2579.345 0.131415 7.432613 0.17961 
38 55 VDLLKNGERIEKVEHSDL 17 ΔN6 0 2095.459 0.153392 0 0 
38 55 VDLLKNGERIEKVEHSDL 17 ΔN6 0.5 2100.232 0.115158 4.772982 0.191809 
38 55 VDLLKNGERIEKVEHSDL 17 ΔN6 1 2100.356 0.083879 4.896946 0.174828 
38 55 VDLLKNGERIEKVEHSDL 17 ΔN6 2 2100.523 0.096812 5.063317 0.181389 
38 55 VDLLKNGERIEKVEHSDL 17 ΔN6 30 2100.811 0.098702 5.351916 0.182404 
38 55 VDLLKNGERIEKVEHSDL 17 ΔN6 120 2101.383 0.12286 5.923269 0.196529 
38 56 VDLLKNGERIEKVEHSDLS 18 ΔN6 0 2182.43 0.131256 0 0 
38 56 VDLLKNGERIEKVEHSDLS 18 ΔN6 0.5 2188.049 0.136536 5.618854 0.189394 
38 56 VDLLKNGERIEKVEHSDLS 18 ΔN6 1 2188.198 0.11668 5.767554 0.17562 
38 56 VDLLKNGERIEKVEHSDLS 18 ΔN6 2 2188.337 0.289046 5.907259 0.317452 
38 56 VDLLKNGERIEKVEHSDLS 18 ΔN6 30 2188.658 0.227036 6.227771 0.262247 
38 56 VDLLKNGERIEKVEHSDLS 18 ΔN6 120 2189.127 0.166516 6.696594 0.212028 
39 57 DLLKNGERIEKVEHSDLSF 18 ΔN6 0 2230.31 0.059031 0 0 
39 57 DLLKNGERIEKVEHSDLSF 18 ΔN6 0.5 2236.391 0.098665 6.080458 0.114976 
39 57 DLLKNGERIEKVEHSDLSF 18 ΔN6 1 2236.473 0.036446 6.163007 0.069375 
39 57 DLLKNGERIEKVEHSDLSF 18 ΔN6 2 2236.674 0.087614 6.363807 0.105644 
39 57 DLLKNGERIEKVEHSDLSF 18 ΔN6 30 2236.95 0.150785 6.639726 0.161928 
39 57 DLLKNGERIEKVEHSDLSF 18 ΔN6 120 2237.445 0.076215 7.134648 0.096402 
40 55 LLKNGERIEKVEHSDL 15 ΔN6 0 1881.042 0.161818 0 0 
40 55 LLKNGERIEKVEHSDL 15 ΔN6 0.5 1885.207 0.122782 4.164452 0.203127 
40 55 LLKNGERIEKVEHSDL 15 ΔN6 1 1885.304 0.044111 4.26167 0.167723 
40 55 LLKNGERIEKVEHSDL 15 ΔN6 2 1885.576 0.235433 4.533469 0.285682 
40 55 LLKNGERIEKVEHSDL 15 ΔN6 30 1885.953 0.118055 4.911043 0.200305 
40 55 LLKNGERIEKVEHSDL 15 ΔN6 120 1886.326 0.100349 5.283235 0.190408 
40 56 LLKNGERIEKVEHSDLS 16 ΔN6 0 1968.121 0.041546 0 0 
40 56 LLKNGERIEKVEHSDLS 16 ΔN6 0.5 1973.04 0.13443 4.918831 0.140704 
40 56 LLKNGERIEKVEHSDLS 16 ΔN6 1 1973.04 0.1013 4.919315 0.109488 
40 56 LLKNGERIEKVEHSDLS 16 ΔN6 2 1973.236 0.090027 5.114837 0.099151 
40 56 LLKNGERIEKVEHSDLS 16 ΔN6 30 1973.575 0.07571 5.454575 0.086361 
40 56 LLKNGERIEKVEHSDLS 16 ΔN6 120 1973.962 0.084953 5.841557 0.094568 
40 57 LLKNGERIEKVEHSDLSF 17 ΔN6 0 2115.138 0.061011 0 0 
40 57 LLKNGERIEKVEHSDLSF 17 ΔN6 0.5 2120.931 0.095615 5.793206 0.113422 
40 57 LLKNGERIEKVEHSDLSF 17 ΔN6 1 2120.994 0.096624 5.856394 0.114274 
40 57 LLKNGERIEKVEHSDLSF 17 ΔN6 2 2121.149 0.075141 6.011397 0.096791 
40 57 LLKNGERIEKVEHSDLSF 17 ΔN6 30 2121.263 0.027103 6.125103 0.06676 
40 57 LLKNGERIEKVEHSDLSF 17 ΔN6 120 2121.617 0.083632 6.479149 0.103521 
41 55 LKNGERIEKVEHSDL 14 ΔN6 0 1767.961 0.06078 0 0 
41 55 LKNGERIEKVEHSDL 14 ΔN6 0.5 1771.973 0.087124 4.012766 0.10623 
41 55 LKNGERIEKVEHSDL 14 ΔN6 1 1772.065 0.069286 4.104435 0.092167 
41 55 LKNGERIEKVEHSDL 14 ΔN6 2 1772.169 0.071673 4.208147 0.093975 
41 55 LKNGERIEKVEHSDL 14 ΔN6 30 1772.454 0.105741 4.492958 0.121965 
41 55 LKNGERIEKVEHSDL 14 ΔN6 120 1772.711 0.041097 4.749984 0.07337 
41 56 LKNGERIEKVEHSDLS 15 ΔN6 0 1855.001 0.052737 0 0 
41 56 LKNGERIEKVEHSDLS 15 ΔN6 0.5 1859.643 0.140975 4.641197 0.150516 
41 56 LKNGERIEKVEHSDLS 15 ΔN6 1 1859.796 0.061655 4.794553 0.081132 
41 56 LKNGERIEKVEHSDLS 15 ΔN6 2 1859.815 0.061743 4.813912 0.081199 
41 56 LKNGERIEKVEHSDLS 15 ΔN6 30 1860.143 0.072389 5.141865 0.089562 
41 56 LKNGERIEKVEHSDLS 15 ΔN6 120 1860.417 0.087071 5.415649 0.101797 
41 57 LKNGERIEKVEHSDLSF 16 ΔN6 0 2002.221 0.118496 0 0 
41 57 LKNGERIEKVEHSDLSF 16 ΔN6 0.5 2007.423 0.093867 5.202024 0.15117 
41 57 LKNGERIEKVEHSDLSF 16 ΔN6 1 2007.601 0.136472 5.379632 0.180738 
41 57 LKNGERIEKVEHSDLSF 16 ΔN6 2 2007.616 0.100131 5.394805 0.155137 
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41 57 LKNGERIEKVEHSDLSF 16 ΔN6 30 2007.891 0.144454 5.669797 0.186837 
41 57 LKNGERIEKVEHSDLSF 16 ΔN6 120 2008.211 0.129402 5.989759 0.17546 
56 63 SFSKDWSF 7 ΔN6 0 1004.145 0.040328 0 0 
56 63 SFSKDWSF 7 ΔN6 0.5 1006.977 0.054058 2.831453 0.067444 
56 63 SFSKDWSF 7 ΔN6 1 1006.94 0.051208 2.795049 0.065182 
56 63 SFSKDWSF 7 ΔN6 2 1006.973 0.075171 2.828144 0.085306 
56 63 SFSKDWSF 7 ΔN6 30 1006.806 0.058217 2.660634 0.070821 
56 63 SFSKDWSF 7 ΔN6 120 1006.917 0.067924 2.771412 0.078994 
57 61 FSKDW 4 ΔN6 0 682.7149 0.004597 0 0 
57 61 FSKDW 4 ΔN6 0.5 684.511 0.041409 1.796157 0.041663 
57 61 FSKDW 4 ΔN6 1 684.5186 0.025934 1.80376 0.026339 
57 61 FSKDW 4 ΔN6 2 684.5564 0.025077 1.841538 0.025495 
57 61 FSKDW 4 ΔN6 30 684.4484 0.021662 1.733552 0.022145 
57 61 FSKDW 4 ΔN6 120 684.5282 0.023931 1.81332 0.024369 
57 63 FSKDWSF 6 ΔN6 0 917.06 0.051501 0 0 
57 63 FSKDWSF 6 ΔN6 0.5 919.3813 0.044549 2.321359 0.068095 
57 63 FSKDWSF 6 ΔN6 1 919.3732 0.029473 2.313251 0.059338 
57 63 FSKDWSF 6 ΔN6 2 919.3798 0.034736 2.319861 0.06212 
57 63 FSKDWSF 6 ΔN6 30 919.2255 0.027314 2.165511 0.058296 
57 63 FSKDWSF 6 ΔN6 120 919.3143 0.016631 2.254379 0.054119 
58 62 SKDWS 4 ΔN6 0 622.5054 0.0138 0 0 
58 62 SKDWS 4 ΔN6 0.5 623.8879 0.019832 1.38247 0.024161 
58 62 SKDWS 4 ΔN6 1 623.867 0.022414 1.361531 0.026322 
58 62 SKDWS 4 ΔN6 2 623.8597 0.023874 1.354306 0.027576 
58 62 SKDWS 4 ΔN6 30 623.7683 0.039157 1.262871 0.041517 
58 62 SKDWS 4 ΔN6 120 623.8018 0.032126 1.296329 0.034964 
58 63 SKDWSF 5 ΔN6 0 769.8086 0.01995 0 0 
58 63 SKDWSF 5 ΔN6 0.5 771.9618 0.119249 2.153236 0.120906 
58 63 SKDWSF 5 ΔN6 1 771.9575 0.120859 2.148932 0.122495 
58 63 SKDWSF 5 ΔN6 2 771.8986 0.15124 2.090048 0.15255 
58 63 SKDWSF 5 ΔN6 30 771.6846 0.011063 1.876034 0.022812 
58 63 SKDWSF 5 ΔN6 120 771.7189 0.009604 1.910388 0.022141 
59 63 KDWSF 4 ΔN6 0 682.7736 0.042265 0 0 
59 63 KDWSF 4 ΔN6 0.5 684.3386 0.008836 1.564963 0.043178 
59 63 KDWSF 4 ΔN6 1 684.3053 0.023513 1.531719 0.048365 
59 63 KDWSF 4 ΔN6 2 684.3138 0.010615 1.540193 0.043577 
59 63 KDWSF 4 ΔN6 30 684.2117 0.018175 1.438044 0.046007 
59 63 KDWSF 4 ΔN6 120 684.2581 0.017624 1.484498 0.045792 
60 63 DWSF 3 ΔN6 0 554.5122 0.007954 0 0 
60 63 DWSF 3 ΔN6 0.5 555.9015 0.022384 1.389337 0.023755 
60 63 DWSF 3 ΔN6 1 555.8708 0.023179 1.358663 0.024505 
60 63 DWSF 3 ΔN6 2 555.8867 0.024228 1.374465 0.0255 
60 63 DWSF 3 ΔN6 30 555.7531 0.004202 1.240912 0.008996 
60 63 DWSF 3 ΔN6 120 555.8124 0.041775 1.300204 0.042526 
63 67 FYLLY 4 ΔN6 0 718.7455 0.016955 0 0 
63 67 FYLLY 4 ΔN6 0.5 718.787 0.017806 0.041526 0.024587 
63 67 FYLLY 4 ΔN6 1 718.8076 0.011743 0.062055 0.020624 
63 67 FYLLY 4 ΔN6 2 718.8255 0.035517 0.079979 0.039356 
63 67 FYLLY 4 ΔN6 30 718.9799 0.037351 0.234444 0.041019 
63 67 FYLLY 4 ΔN6 120 719.3594 0.019683 0.613899 0.025978 
64 67 YLLY 3 ΔN6 0 571.5967 0.016427 0 0 
64 67 YLLY 3 ΔN6 0.5 571.6622 0.011286 0.065513 0.01993 
64 67 YLLY 3 ΔN6 1 571.6436 0.008514 0.04694 0.018502 
64 67 YLLY 3 ΔN6 2 571.6494 0.006526 0.052766 0.017676 
64 67 YLLY 3 ΔN6 30 571.6745 0.022676 0.0778 0.028001 
64 67 YLLY 3 ΔN6 120 571.7076 0.021448 0.110904 0.027016 
64 68 YLLYY 4 ΔN6 0 734.7599 0.018045 0 0 
64 68 YLLYY 4 ΔN6 0.5 734.7809 0.02354 0.020967 0.029661 
64 68 YLLYY 4 ΔN6 1 734.7814 0.02304 0.021449 0.029266 
64 68 YLLYY 4 ΔN6 2 734.7913 0.006247 0.031363 0.019096 
64 68 YLLYY 4 ΔN6 30 734.8819 0.035136 0.121995 0.039499 
64 68 YLLYY 4 ΔN6 120 735.1289 0.033438 0.368951 0.037997 
65 68 LLYY 3 ΔN6 0 571.717 0.016407 0 0 
65 68 LLYY 3 ΔN6 0.5 571.7889 0.019613 0.071858 0.025571 
65 68 LLYY 3 ΔN6 1 571.7944 0.02106 0.077376 0.026697 
65 68 LLYY 3 ΔN6 2 571.7845 0.02952 0.067512 0.033773 
65 68 LLYY 3 ΔN6 30 571.8397 0.022066 0.12268 0.027497 
65 68 LLYY 3 ΔN6 120 571.9526 0.013694 0.235568 0.02137 
66 71 LYYTEF 5 ΔN6 0 835.8105 0.025642 0 0 
66 71 LYYTEF 5 ΔN6 0.5 836.2956 0.008616 0.485084 0.027051 
66 71 LYYTEF 5 ΔN6 1 836.4342 0.037385 0.623623 0.045333 
66 71 LYYTEF 5 ΔN6 2 836.516 0.020011 0.705425 0.032526 
66 71 LYYTEF 5 ΔN6 30 836.5731 0.027405 0.762518 0.03753 
66 71 LYYTEF 5 ΔN6 120 836.7264 0.02282 0.915828 0.034326 
67 70 YYTE 3 ΔN6 0 575.5851 0.024345 0 0 
67 70 YYTE 3 ΔN6 0.5 576.0136 0.008559 0.428432 0.025806 
67 70 YYTE 3 ΔN6 1 576.1114 0.017037 0.526223 0.029715 
67 70 YYTE 3 ΔN6 2 576.1742 0.020636 0.589065 0.031915 
67 70 YYTE 3 ΔN6 30 576.2036 0.01719 0.618418 0.029803 
67 70 YYTE 3 ΔN6 120 576.2814 0.014579 0.696243 0.028377 
67 71 YYTEF 4 ΔN6 0 722.7584 0.018961 0 0 
67 71 YYTEF 4 ΔN6 0.5 723.2214 0.025812 0.462979 0.032027 
67 71 YYTEF 4 ΔN6 1 723.3115 0.028226 0.553114 0.034003 
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67 71 YYTEF 4 ΔN6 2 723.3721 0.016624 0.613663 0.025217 
67 71 YYTEF 4 ΔN6 30 723.4249 0.015121 0.666525 0.024252 
67 71 YYTEF 4 ΔN6 120 723.5133 0.017945 0.75485 0.026106 
67 79 YYTEFTPTEKDEY 11 ΔN6 0 1686.65 0.044152 0 0 
67 79 YYTEFTPTEKDEY 11 ΔN6 0.5 1689.286 0.05584 2.635969 0.071186 
67 79 YYTEFTPTEKDEY 11 ΔN6 1 1689.626 0.058447 2.97572 0.07325 
67 79 YYTEFTPTEKDEY 11 ΔN6 2 1689.956 0.068171 3.305485 0.08122 
67 79 YYTEFTPTEKDEY 11 ΔN6 30 1690.496 0.075218 3.846173 0.087219 
67 79 YYTEFTPTEKDEY 11 ΔN6 120 1690.872 0.026228 4.222168 0.051355 
68 71 YTEF 3 ΔN6 0 559.5779 0.035117 0 0 
68 71 YTEF 3 ΔN6 0.5 559.9831 0.026257 0.40524 0.043848 
68 71 YTEF 3 ΔN6 1 560.1154 0.031236 0.537525 0.046999 
68 71 YTEF 3 ΔN6 2 560.1844 0.033099 0.606511 0.048257 
68 71 YTEF 3 ΔN6 30 560.185 0.029289 0.60717 0.045728 
68 71 YTEF 3 ΔN6 120 560.2372 0.031687 0.659286 0.0473 
68 78 YTEFTPTEKDE 9 ΔN6 0 1360.345 0.037326 0 0 
68 78 YTEFTPTEKDE 9 ΔN6 0.5 1362.824 0.08063 2.478761 0.08885 
68 78 YTEFTPTEKDE 9 ΔN6 1 1363.115 0.053888 2.770399 0.065553 
68 78 YTEFTPTEKDE 9 ΔN6 2 1363.351 0.072288 3.005703 0.081356 
68 78 YTEFTPTEKDE 9 ΔN6 30 1363.799 0.091174 3.453553 0.098519 
68 78 YTEFTPTEKDE 9 ΔN6 120 1363.928 0.084319 3.583091 0.092212 
68 80 YTEFTPTEKDEYA 11 ΔN6 0 1594.649 0.021002 0 0 
68 80 YTEFTPTEKDEYA 11 ΔN6 0.5 1596.968 0.121651 2.318666 0.12345 
68 80 YTEFTPTEKDEYA 11 ΔN6 1 1597.351 0.068164 2.702078 0.071326 
68 80 YTEFTPTEKDEYA 11 ΔN6 2 1597.676 0.084889 3.027049 0.087448 
68 80 YTEFTPTEKDEYA 11 ΔN6 30 1598.25 0.163031 3.601 0.164378 
68 80 YTEFTPTEKDEYA 11 ΔN6 120 1598.491 0.075076 3.842102 0.077958 
68 81 YTEFTPTEKDEYAC 12 ΔN6 0 1697.832 0.079241 0 0 
68 81 YTEFTPTEKDEYAC 12 ΔN6 0.5 1700.347 0.071951 2.514766 0.107033 
68 81 YTEFTPTEKDEYAC 12 ΔN6 1 1700.686 0.086959 2.853831 0.117648 
68 81 YTEFTPTEKDEYAC 12 ΔN6 2 1701.077 0.110461 3.244538 0.135944 
68 81 YTEFTPTEKDEYAC 12 ΔN6 30 1701.811 0.179361 3.978263 0.196086 
68 81 YTEFTPTEKDEYAC 12 ΔN6 120 1701.947 0.034483 4.114371 0.086419 
69 78 TEFTPTEKDE 8 ΔN6 0 1197.22 0.068069 0 0 
69 78 TEFTPTEKDE 8 ΔN6 0.5 1199.44 0.044805 2.219443 0.081492 
69 78 TEFTPTEKDE 8 ΔN6 1 1199.605 0.047295 2.384024 0.082887 
69 78 TEFTPTEKDE 8 ΔN6 2 1199.858 0.042894 2.637304 0.080457 
69 78 TEFTPTEKDE 8 ΔN6 30 1200.269 0.03069 3.04833 0.074668 
69 78 TEFTPTEKDE 8 ΔN6 120 1200.402 0.040803 3.181874 0.079362 
69 80 TEFTPTEKDEYA 10 ΔN6 0 1431.369 0.04311 0 0 
69 80 TEFTPTEKDEYA 10 ΔN6 0.5 1433.644 0.0381 2.274996 0.057533 
69 80 TEFTPTEKDEYA 10 ΔN6 1 1433.873 0.056143 2.504343 0.070784 
69 80 TEFTPTEKDEYA 10 ΔN6 2 1434.174 0.079457 2.805079 0.090398 
69 80 TEFTPTEKDEYA 10 ΔN6 30 1434.813 0.103746 3.443753 0.112346 
69 80 TEFTPTEKDEYA 10 ΔN6 120 1435.003 0.046748 3.633929 0.063591 
69 81 TEFTPTEKDEYAC 11 ΔN6 0 1534.458 0.018855 0 0 
69 81 TEFTPTEKDEYAC 11 ΔN6 0.5 1536.799 0.021758 2.341039 0.028791 
69 81 TEFTPTEKDEYAC 11 ΔN6 1 1537.088 0.079899 2.629423 0.082094 
69 81 TEFTPTEKDEYAC 11 ΔN6 2 1537.411 0.046283 2.952472 0.049976 
69 81 TEFTPTEKDEYAC 11 ΔN6 30 1538.154 0.11245 3.69519 0.114019 
69 81 TEFTPTEKDEYAC 11 ΔN6 120 1538.331 0.123583 3.873121 0.125013 
82 100 RVNHVTLSQPKIVKWDRDM 17 ΔN6 0 2323.531 0.053418 0 0 
82 100 RVNHVTLSQPKIVKWDRDM 17 ΔN6 0.5 2328.85 0.118535 5.3189 0.130015 
82 100 RVNHVTLSQPKIVKWDRDM 17 ΔN6 1 2329.158 0.153269 5.627 0.162311 
82 100 RVNHVTLSQPKIVKWDRDM 17 ΔN6 2 2329.574 0.106082 6.042988 0.118772 
82 100 RVNHVTLSQPKIVKWDRDM 17 ΔN6 30 2329.83 0.21345 6.299611 0.220033 
82 100 RVNHVTLSQPKIVKWDRDM 17 ΔN6 120 2330.169 0.177698 6.63818 0.185553 
91 100 PKIVKWDRDM 8 ΔN6 0 1288.419 0.021031 0 0 
91 100 PKIVKWDRDM 8 ΔN6 0.5 1290.04 0.043555 1.620705 0.048367 
91 100 PKIVKWDRDM 8 ΔN6 1 1290.198 0.06479 1.778596 0.068117 
91 100 PKIVKWDRDM 8 ΔN6 2 1290.327 0.086882 1.907464 0.089391 
91 100 PKIVKWDRDM 8 ΔN6 30 1290.393 0.018091 1.973686 0.027741 
91 100 PKIVKWDRDM 8 ΔN6 120 1290.687 0.035386 2.267943 0.041163 
94 100 VKWDRDM 6 ΔN6 0 950.0268 0.053029 0 0 
94 100 VKWDRDM 6 ΔN6 0.5 951.4433 0.038685 1.416455 0.06564 
94 100 VKWDRDM 6 ΔN6 1 951.5949 0.065723 1.568028 0.084448 
94 100 VKWDRDM 6 ΔN6 2 951.6546 0.043516 1.627736 0.068598 
94 100 VKWDRDM 6 ΔN6 30 951.8932 0.066203 1.866411 0.084823 
94 100 VKWDRDM 6 ΔN6 120 952.0252 0.005004 1.998399 0.053265 
95 100 KWDRDM 5 ΔN6 0 850.9581 0.050067 0 0 
95 100 KWDRDM 5 ΔN6 0.5 852.2467 0.052306 1.28858 0.072406 
95 100 KWDRDM 5 ΔN6 1 852.3529 0.083326 1.394813 0.09721 
95 100 KWDRDM 5 ΔN6 2 852.4617 0.048027 1.503583 0.069378 
95 100 KWDRDM 5 ΔN6 30 852.5842 0.02992 1.626101 0.058326 
95 100 KWDRDM 5 ΔN6 120 852.6869 0.04392 1.728786 0.066601 
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Table 8.2 PAVED processed data for D76N β2m. 
 Residue D76N 
Combined relative fractional uptake (%) Combined standard deviation 
 
0.5 1 2 30 120 0.5 1 2 30 120 
1 30.76726 32.68793 33.83785 34.79216 37.56018 2.879176 3.129053 3.222989 3.353562 4.010618 
2 32.3343 34.14837 35.73022 36.78984 39.81442 3.248417 3.310514 3.781857 3.956762 4.58556 
3 32.3343 34.14837 35.73022 36.78984 39.81442 3.248417 3.310514 3.781857 3.956762 4.58556 
4 34.79445 36.54699 38.3669 39.54163 42.58283 5.117576 5.058866 5.632276 5.882978 6.233241 
5 34.79445 36.54699 38.3669 39.54163 42.58283 5.117576 5.058866 5.632276 5.882978 6.233241 
6 35.48251 37.36592 39.25498 40.88116 44.54952 4.792393 4.819319 5.349534 5.912012 6.8363 
7 35.48251 37.36592 39.25498 40.88116 44.54952 4.792393 4.819319 5.349534 5.912012 6.8363 
8 35.48251 37.36592 39.25498 40.88116 44.54952 4.792393 4.819319 5.349534 5.912012 6.8363 
9 35.48251 37.36592 39.25498 40.88116 44.54952 4.792393 4.819319 5.349534 5.912012 6.8363 
10 28.03483 29.7189 30.77566 31.71458 33.69508 0.872 1.03 0.928805 1.448825 1.13107 
11 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
12 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
13 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
14 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
15 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
16 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
17 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
18 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
19 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
20 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
21 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
22 25.46159 26.57769 27.26413 27.85329 29.41592 3.73229 4.413142 4.647929 4.632685 5.127771 
23 20.32982 20.46133 20.82404 21.53355 22.30858 1.135171 0.969507 1.045021 0.971379 0.780336 
24 20.32982 20.46133 20.82404 21.53355 22.30858 1.135171 0.969507 1.045021 0.971379 0.780336 
25 20.32982 20.46133 20.82404 21.53355 22.30858 1.135171 0.969507 1.045021 0.971379 0.780336 
26 NA NA NA NA NA NA NA NA NA NA 
27 10.98677 12.69999 13.89096 21.19897 24.01677 3.906197 3.614997 3.525742 2.637495 2.114723 
28 10.98677 12.69999 13.89096 21.19897 24.01677 3.906197 3.614997 3.525742 2.637495 2.114723 
29 11.7833 13.55331 14.80115 21.73106 24.73785 3.705115 3.524542 3.489404 2.532939 2.40049 
30 11.7833 13.55331 14.80115 21.73106 24.73785 3.705115 3.524542 3.489404 2.532939 2.40049 
31 11.7833 13.55331 14.80115 21.73106 24.73785 3.705115 3.524542 3.489404 2.532939 2.40049 
32 11.7833 13.55331 14.80115 21.73106 24.73785 3.705115 3.524542 3.489404 2.532939 2.40049 
33 11.7833 13.55331 14.80115 21.73106 24.73785 3.705115 3.524542 3.489404 2.532939 2.40049 
34 11.7833 13.55331 14.80115 21.73106 24.73785 3.705115 3.524542 3.489404 2.532939 2.40049 
35 8.335195 10.27764 11.63981 19.61662 22.69806 1.080316 1.132898 1.634531 1.539831 0.923773 
36 13.01316 14.74829 16.36394 22.72699 25.3009 9.4576 9.536167 9.080963 7.110521 7.100681 
37 13.89887 15.65711 17.39526 23.46323 25.85854 9.940184 10.01349 9.416527 7.422726 7.5228 
38 19.03455 20.64169 22.02796 26.83451 29.28281 11.13412 11.1991 10.44605 8.217897 8.354223 
39 22.89081 24.5264 25.50116 29.32461 31.84371 10.7018 10.62898 10.08867 8.196102 7.985709 
40 26.67246 27.99311 28.68518 31.57186 33.86274 7.98514 8.085498 7.863651 6.377809 6.271573 
41 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
42 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
43 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
44 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
45 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
46 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
47 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
48 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
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49 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
50 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
51 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
52 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
53 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
54 29.48154 30.71099 31.35221 33.33081 35.51685 2.398672 2.292757 2.261731 2.207845 2.094788 
55 30.37174 31.66162 32.30711 34.31046 36.34122 2.164647 1.912229 1.856618 1.541183 1.660565 
56 31.27829 32.86231 34.0844 35.84696 37.61774 2.22233 2.076128 2.629048 2.427767 2.243344 
57 28.85092 32.56298 35.57283 39.1765 39.96306 1.742661 1.305983 1.407483 1.124585 1.1808 
58 27.2143 31.08544 34.09918 38.10619 38.60868 3.085914 2.874018 3.017 2.657765 3.057541 
59 28.03958 31.95933 35.03573 39.04109 39.86523 3.399942 3.295771 3.495534 3.261129 3.986574 
60 28.40463 32.39095 35.62138 39.6301 40.55049 3.299556 3.236842 3.562135 3.358994 4.059133 
61 28.59483 32.48512 35.70097 39.68283 40.58914 3.516501 3.480656 3.833318 3.602058 4.375702 
62 29.7833 33.66017 36.98374 40.818 42.00022 2.479512 2.4526 2.74888 2.750478 3.264082 
63 1.5736 1.29185 1.27605 1.8819 3.734825 0.940725 0.831575 0.90095 0.826325 0.997325 
64 1.604328 2.030525 1.811736 2.988028 4.988806 1.360853 1.389047 1.552262 2.191351 1.69857 
65 1.698688 1.909652 1.79256 2.744463 4.429996 1.294811 1.279756 1.413903 1.991788 1.798274 
66 3.62973 4.268294 4.166764 5.040498 6.533569 4.046528 4.871526 4.919775 4.933847 4.527197 
67 14.05905 15.03538 16.23858 16.11262 16.23131 12.49426 12.36971 13.50268 12.71575 11.91278 
68 25.52424 27.40051 28.82687 27.92195 28.57057 11.59341 10.89045 11.03534 10.65014 10.92394 
69 29.42225 31.11798 31.95971 30.83322 31.80893 11.79163 11.08475 10.86123 10.48613 10.80828 
70 30.55089 32.06509 32.84688 31.76065 32.80006 11.8524 11.24948 11.00179 10.57348 10.86524 
71 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
72 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
73 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
74 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
75 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
76 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
77 38.34272 39.47898 39.82711 38.62963 39.78363 3.660608 3.345134 2.795264 2.237637 2.897134 
78 36.23243 37.56019 38.50965 37.63966 38.26688 1.722451 1.680244 1.891717 1.711794 1.7422 
79 35.70166 37.13741 37.91486 37.06612 37.73924 1.560735 1.48623 1.551307 1.428499 1.365106 
80 34.66775 36.25839 36.82232 35.98938 36.71728 0.675804 0.736736 0.829387 0.770629 0.782961 
81 NA NA NA NA NA NA NA NA NA NA 
82 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
83 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
84 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
85 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
86 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
87 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
88 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
89 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
90 23.92148 26.07502 27.19712 26.88135 29.29453 0.723453 0.527429 0.432606 1.173247 0.860394 
91 23.59632 26.56398 27.94158 28.53291 30.15005 1.242371 1.235774 1.233391 3.006039 2.206068 
92 23.59632 26.56398 27.94158 28.53291 30.15005 1.242371 1.235774 1.233391 3.006039 2.206068 
93 23.59632 26.56398 27.94158 28.53291 30.15005 1.242371 1.235774 1.233391 3.006039 2.206068 
94 22.35703 25.18923 26.19305 26.503 29.44902 2.143373 2.302312 2.734076 3.792014 2.037826 
95 23.69985 26.38589 27.39254 28.06395 30.61703 3.071566 3.023085 3.191692 4.323385 2.715836 
96 23.69985 26.38589 27.39254 28.06395 30.61703 3.071566 3.023085 3.191692 4.323385 2.715836 
97 23.69985 26.38589 27.39254 28.06395 30.61703 3.071566 3.023085 3.191692 4.323385 2.715836 
98 23.69985 26.38589 27.39254 28.06395 30.61703 3.071566 3.023085 3.191692 4.323385 2.715836 
99 23.69985 26.38589 27.39254 28.06395 30.61703 3.071566 3.023085 3.191692 4.323385 2.715836 
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Table 8.3 Paved processed data for wild-type β2m. 
 Residue Wild-type 
Combined relative fractional uptake (%) Combined standard deviation 
 
0.5 1 2 30 120 0.5 1 2 30 120 
1 29.04753 30.68331 31.99064 33.27513 35.40364 3.432847 3.468858 3.908552 3.660581 4.029622 
2 31.15486 32.8662 34.4976 36.46818 38.30908 4.127063 4.220227 4.805171 5.475362 5.293564 
3 31.15486 32.8662 34.4976 36.46818 38.30908 4.127063 4.220227 4.805171 5.475362 5.293564 
4 33.67773 35.29622 37.13857 39.24847 40.89417 5.665942 5.582307 6.204381 6.772623 6.425241 
5 33.67773 35.29622 37.13857 39.24847 40.89417 5.665942 5.582307 6.204381 6.772623 6.425241 
6 34.44455 36.20726 38.23855 40.42038 42.74072 5.299214 5.317258 5.97401 6.499551 6.841938 
7 34.44455 36.20726 38.23855 40.42038 42.74072 5.299214 5.317258 5.97401 6.499551 6.841938 
8 34.44455 36.20726 38.23855 40.42038 42.74072 5.299214 5.317258 5.97401 6.499551 6.841938 
9 34.44455 36.20726 38.23855 40.42038 42.74072 5.299214 5.317258 5.97401 6.499551 6.841938 
10 25.83529 27.47766 28.26499 29.88295 31.60289 1.06003 1.21287 0.98912 1.315965 1.10047 
11 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
12 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
13 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
14 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
15 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
16 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
17 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
18 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
19 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
20 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
21 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
22 23.19764 25.17408 24.7169 25.81411 27.32845 3.565489 3.549078 4.047397 4.425161 4.763569 
23 18.30181 18.95376 19.15726 19.87237 20.15984 0.674421 0.838057 0.7069 0.965736 0.87825 
24 18.30181 18.95376 19.15726 19.87237 20.15984 0.674421 0.838057 0.7069 0.965736 0.87825 
25 18.30181 18.95376 19.15726 19.87237 20.15984 0.674421 0.838057 0.7069 0.965736 0.87825 
26 NA NA NA NA NA NA NA NA NA NA 
27 9.935545 11.44098 13.28568 19.95878 22.58856 2.961796 3.145945 3.627734 2.497345 2.430764 
28 9.935545 11.44098 13.28568 19.95878 22.58856 2.961796 3.145945 3.627734 2.497345 2.430764 
29 11.08156 12.547 14.44248 20.57133 23.12705 3.266256 3.348472 3.7395 2.437217 2.336599 
30 11.08156 12.547 14.44248 20.57133 23.12705 3.266256 3.348472 3.7395 2.437217 2.336599 
31 11.08156 12.547 14.44248 20.57133 23.12705 3.266256 3.348472 3.7395 2.437217 2.336599 
32 11.08156 12.547 14.44248 20.57133 23.12705 3.266256 3.348472 3.7395 2.437217 2.336599 
33 11.08156 12.547 14.44248 20.57133 23.12705 3.266256 3.348472 3.7395 2.437217 2.336599 
34 11.08156 12.547 14.44248 20.57133 23.12705 3.266256 3.348472 3.7395 2.437217 2.336599 
35 7.940139 9.422847 11.08743 18.518 21.37907 1.005939 1.497425 1.972676 1.664636 2.03424 
36 12.26052 13.7727 15.65471 21.36386 23.97491 9.592874 9.322289 8.640776 6.1512 6.16166 
37 13.11778 14.72234 16.7332 22.08746 24.68521 10.10662 9.748019 8.882229 6.352571 6.37544 
38 18.30948 19.71732 21.2182 24.84557 27.49761 11.47936 11.1423 10.06689 6.975545 7.113573 
39 22.40781 23.57957 24.45466 26.80142 29.65568 10.56672 10.27279 9.947914 7.376331 7.008377 
40 26.64198 27.7232 28.33296 29.28526 31.47765 8.215107 7.812559 7.671941 6.256803 5.907006 
41 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
42 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
43 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
44 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
45 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
46 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
47 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
48 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
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49 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
50 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
51 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
52 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
53 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
54 29.48361 30.30661 30.78752 31.10297 32.94723 2.446 2.56948 2.659614 2.597978 2.502521 
55 30.29979 31.30002 31.90542 32.29417 34.09958 2.26057 2.204612 2.100783 1.876235 1.550401 
56 30.69826 31.8991 32.94812 33.97649 35.00673 2.415168 2.068305 2.071775 2.39783 1.69422 
57 27.39157 30.57464 33.34853 36.64646 36.97792 1.643933 1.208713 1.127414 1.06496 0.943649 
58 26.03778 29.32153 32.41521 35.66005 36.12293 2.276212 2.187992 1.915227 2.245055 1.975759 
59 27.25743 30.40836 33.40693 36.61248 37.02098 3.452302 3.180574 2.857056 3.004408 2.695451 
60 27.7814 31.17023 34.20681 37.55298 37.97794 3.453059 3.513133 3.298437 3.627488 3.418315 
61 28.14498 31.40385 34.42478 37.71424 38.10687 3.580952 3.723632 3.495597 3.871651 3.666626 
62 29.21715 32.5533 35.47564 38.93943 39.23642 2.88652 2.916171 2.805109 2.968373 2.948054 
63 1.52745 1.567925 1.252875 2.278775 4.155425 0.8209 0.76575 0.797425 0.65185 0.6128 
64 1.468019 1.771283 1.371206 1.942064 4.277661 0.989693 0.918685 0.934211 1.029313 0.8206 
65 1.329731 1.468221 1.192246 1.57329 3.594188 0.92801 1.03202 0.874895 1.108874 1.391622 
66 2.989881 3.539745 3.538941 3.93108 4.851447 3.432893 4.255033 4.770128 4.824268 3.500029 
67 10.53131 12.45816 13.5119 13.99167 14.89156 8.308508 9.63424 10.68423 11.2034 11.24521 
68 18.08193 20.80416 22.80452 24.03657 24.82424 5.996327 6.109455 6.71196 8.227444 8.208621 
69 19.90212 22.67675 24.74014 26.44784 27.25955 6.216411 6.468965 6.808228 8.217053 8.066016 
70 20.30149 22.9695 25.05308 27.07055 27.9067 6.387902 6.725779 7.066399 8.363758 8.219997 
71 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
72 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
73 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
74 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
75 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
76 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
77 24.10859 26.94094 29.27255 32.27455 32.74465 3.137593 3.580982 3.266313 2.760763 2.67572 
78 22.38437 24.96802 27.61548 31.03611 31.50328 1.517789 1.878255 1.998373 1.922089 1.903374 
79 21.86107 24.22848 26.85838 30.321 30.7677 1.239557 1.346343 1.47993 1.409099 1.380661 
80 21.51133 23.81471 25.94777 29.61698 30.00105 1.264724 1.24287 1.300378 1.308621 1.173714 
81 NA NA NA NA NA NA NA NA NA NA 
82 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
83 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
84 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
85 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
86 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
87 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
88 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
89 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
90 23.20236 24.7713 25.95588 26.79858 29.36944 0.683024 0.560912 0.656565 0.393424 0.732335 
91 23.17622 24.64854 25.57604 26.41135 28.26236 0.813889 0.8415 0.919121 0.854319 1.50584 
92 23.17622 24.64854 25.57604 26.41135 28.26236 0.813889 0.8415 0.919121 0.854319 1.50584 
93 23.17622 24.64854 25.57604 26.41135 28.26236 0.813889 0.8415 0.919121 0.854319 1.50584 
94 22.70234 23.94255 25.47821 25.96844 27.39238 1.145788 1.205368 0.979461 1.06038 1.870607 
95 23.84984 25.4753 26.75249 27.35992 28.44307 2.326472 2.82055 2.314402 2.471774 2.415501 
96 23.84984 25.4753 26.75249 27.35992 28.44307 2.326472 2.82055 2.314402 2.471774 2.415501 
97 23.84984 25.4753 26.75249 27.35992 28.44307 2.326472 2.82055 2.314402 2.471774 2.415501 
98 23.84984 25.4753 26.75249 27.35992 28.44307 2.326472 2.82055 2.314402 2.471774 2.415501 
99 23.84984 25.4753 26.75249 27.35992 28.44307 2.326472 2.82055 2.314402 2.471774 2.415501 
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Table 8.4 Paved processed data for ΔN6 β2m. 
 Residue ΔN6 
Combined relative fractional uptake (%) Combined standard deviation 
 
0.5 1 2 30 120 0.5 1 2 30 120 
1 NA NA NA NA NA NA NA NA NA NA 
2 NA NA NA NA NA NA NA NA NA NA 
3 NA NA NA NA NA NA NA NA NA NA 
4 NA NA NA NA NA NA NA NA NA NA 
5 NA NA NA NA NA NA NA NA NA NA 
6 NA NA NA NA NA NA NA NA NA NA 
7 NA NA NA NA NA NA NA NA NA NA 
8 NA NA NA NA NA NA NA NA NA NA 
9 NA NA NA NA NA NA NA NA NA NA 
10 NA NA NA NA NA NA NA NA NA NA 
11 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
12 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
13 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
14 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
15 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
16 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
17 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
18 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
19 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
20 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
21 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
22 23.08124 24.67991 24.78458 28.29666 29.8484 4.663502 4.621169 4.587535 4.786274 5.399766 
23 17.95873 19.56891 20.25101 23.03995 24.51919 0.788293 0.549821 0.677757 1.203929 1.089364 
24 17.95873 19.56891 20.25101 23.03995 24.51919 0.788293 0.549821 0.677757 1.203929 1.089364 
25 17.95873 19.56891 20.25101 23.03995 24.51919 0.788293 0.549821 0.677757 1.203929 1.089364 
26 NA NA NA NA NA NA NA NA NA NA 
27 19.47257 21.07566 21.68253 25.04508 27.49067 5.682848 5.333445 5.820789 3.45466 2.617218 
28 19.47257 21.07566 21.68253 25.04508 27.49067 5.682848 5.333445 5.820789 3.45466 2.617218 
29 22.43009 23.75101 24.36799 27.11703 28.87269 7.111965 6.556965 6.865541 4.486244 3.309263 
30 22.43009 23.75101 24.36799 27.11703 28.87269 7.111965 6.556965 6.865541 4.486244 3.309263 
31 22.43009 23.75101 24.36799 27.11703 28.87269 7.111965 6.556965 6.865541 4.486244 3.309263 
32 22.43009 23.75101 24.36799 27.11703 28.87269 7.111965 6.556965 6.865541 4.486244 3.309263 
33 22.43009 23.75101 24.36799 27.11703 28.87269 7.111965 6.556965 6.865541 4.486244 3.309263 
34 22.43009 23.75101 24.36799 27.11703 28.87269 7.111965 6.556965 6.865541 4.486244 3.309263 
35 15.51309 17.45466 17.62521 22.96982 25.89236 0.976736 1.60911 0.950282 1.711679 1.218915 
36 16.47075 18.26457 19.69392 23.44676 26.14322 8.235128 7.695631 7.358809 6.951353 7.166828 
37 16.60143 18.5735 20.06926 23.73623 26.28693 8.885977 8.266669 7.882799 7.4755 7.727563 
38 20.50875 21.97002 23.60134 26.31041 29.0377 10.0806 9.372413 8.784167 8.086154 8.439125 
39 23.77131 24.66362 25.93238 28.25499 31.19555 10.13258 9.482065 9.154093 8.55413 8.906932 
40 27.74205 28.36805 29.61105 31.43904 34.21211 7.752652 7.259242 7.063117 6.794115 7.090681 
41 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
42 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
43 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
44 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
45 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
46 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
47 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
48 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
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49 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
50 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
51 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
52 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
53 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
54 30.43828 31.12032 31.96205 33.87885 36.43915 2.384808 2.30413 2.192405 1.87311 1.789351 
55 31.26619 31.97114 32.72792 34.53208 37.07429 2.151729 2.044226 1.982977 1.626655 1.51714 
56 33.94452 34.31195 35.09788 35.80695 38.03411 3.965058 3.553334 3.462061 2.013664 1.799852 
57 41.34752 41.19248 41.70162 39.14657 40.83253 2.817921 2.947139 3.30077 3.187169 3.409643 
58 40.33381 40.11887 40.15269 37.54538 38.88165 3.844257 4.027451 4.289778 3.757862 4.109958 
59 40.13219 39.81456 39.87805 37.2705 38.57662 3.56549 3.771428 3.988749 3.503932 3.827788 
60 41.01491 40.59659 40.72626 37.87245 39.27713 3.957445 3.994554 4.249376 3.547789 3.954613 
61 40.36674 39.84702 39.84089 36.92997 38.23302 3.892289 3.822386 3.938517 2.943458 3.29517 
62 41.52773 41.00877 41.03754 37.78728 39.16499 3.16535 3.057481 3.150784 2.132881 2.485181 
63 1.03815 1.551375 1.999475 5.8611 15.34748 0.614675 0.5156 0.9839 1.025475 0.64945 
64 1.248697 1.217422 1.514139 3.834769 9.422683 0.96827 0.791127 0.889112 1.747486 4.832652 
65 1.53534 1.557867 1.698204 3.89841 9.030079 1.063618 1.007522 1.005668 1.585072 4.255016 
66 3.168608 3.740785 4.180263 6.1688 10.57783 3.41084 4.476273 5.053336 4.768786 5.20997 
67 10.40667 12.33475 13.69499 15.11014 19.34345 7.808869 8.98722 10.06079 10.33279 10.30818 
68 17.82569 20.90079 23.30793 26.28205 28.68594 6.082761 6.232902 6.738303 8.690364 8.524522 
69 19.45595 22.35783 24.96848 28.80873 31.11528 6.092494 6.035405 6.488383 8.514978 8.222354 
70 19.984 22.85961 25.51267 29.64493 31.95647 6.149728 6.119594 6.563628 8.50005 8.206409 
71 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
72 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
73 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
74 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
75 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
76 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
77 23.68515 26.55067 29.46427 35.05409 37.10456 2.870304 2.799015 2.740086 2.474581 2.308435 
78 22.0363 24.92433 27.91542 33.72727 35.93577 1.415726 1.434863 1.442162 1.500272 1.641778 
79 21.52917 24.33331 27.35373 33.47968 35.25588 1.089536 0.94908 0.984521 1.485746 1.1213 
80 21.10118 23.83611 26.93924 33.37241 34.79963 0.706139 0.886119 0.868688 1.385915 1.076454 
81 NA NA NA NA NA NA NA NA NA NA 
82 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
83 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
84 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
85 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
86 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
87 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
88 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
89 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
90 31.28765 33.1 35.54699 37.05654 39.04812 0.764794 0.954771 0.698659 1.294312 1.091488 
91 25.77323 27.66623 29.69514 31.55189 33.6987 5.557339 5.508557 5.925573 6.233826 5.417037 
92 25.77323 27.66623 29.69514 31.55189 33.6987 5.557339 5.508557 5.925573 6.233826 5.417037 
93 25.77323 27.66623 29.69514 31.55189 33.6987 5.557339 5.508557 5.925573 6.233826 5.417037 
94 25.05135 27.15542 28.83974 31.39294 33.56802 4.693668 4.627271 5.030648 5.073565 4.456424 
95 25.23141 27.34063 29.14772 31.69007 33.81994 4.140582 4.136014 4.443698 4.424069 3.940654 
96 25.23141 27.34063 29.14772 31.69007 33.81994 4.140582 4.136014 4.443698 4.424069 3.940654 
97 25.23141 27.34063 29.14772 31.69007 33.81994 4.140582 4.136014 4.443698 4.424069 3.940654 
98 25.23141 27.34063 29.14772 31.69007 33.81994 4.140582 4.136014 4.443698 4.424069 3.940654 
99 25.23141 27.34063 29.14772 31.69007 33.81994 4.140582 4.136014 4.443698 4.424069 3.940654 
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Figure 8.1 R code for the original PAVED algorithm. 
 
desired_p_value<- 0.05  
Residue_number <- 100  
pdb_file<- "4fxl"  
## Hi Nick! i've annotated this code as best i can, the Packages you need are: datasets, 
graphics, grDevices, methods, plyr, readr, stats and utils.  
##All of the following are just lines to set up how the progress bars work - they're basically 
just tick counters which count up every time a loop is passed  
plot.progress <- function(...) {  
  vectOfBar <- c(...)*100  
  numOfBar <- length(vectOfBar)  
  plot(c(0,100), c(0,numOfBar), type='n', xlab='', ylab='', yaxt='n', mar=c(3,3,3,3))  
  for(i in 1:numOfBar) {  
    rect(0, 0.1+i-1, vectOfBar[i], 0.9+i-1, col=rainbow(numOfBar)[i])  
    text(0.5, 0.5+i-1, paste('Status ', i, ': ', round(vectOfBar[i],2), '%', sep=''), adj=0)  
  }  
  title('Calculating Mean Relative Fractional Uptake per residue')  
}  
plot.progress2 <- function(...) {  
  vectOfBar <- c(...)*100  
  numOfBar <- length(vectOfBar)  
  plot(c(0,100), c(0,numOfBar), type='n', xlab='', ylab='', yaxt='n', mar=c(3,3,3,3))  
  for(i in 1:numOfBar) {  
    rect(0, 0.1+i-1, vectOfBar[i], 0.9+i-1, col=rainbow(numOfBar)[i])  
    text(0.5, 0.5+i-1, paste('Status ', i, ': ', round(vectOfBar[i],2), '%', sep=''), adj=0)  
  }  
  title('Calculating N per residue')  
}  
plot.progress3 <- function(...) {  
  vectOfBar <- c(...)*100  
  numOfBar <- length(vectOfBar)  
  plot(c(0,100), c(0,numOfBar), type='n', xlab='', ylab='', yaxt='n', mar=c(3,3,3,3))  
  for(i in 1:numOfBar) {  
    rect(0, 0.1+i-1, vectOfBar[i], 0.9+i-1, col=rainbow(numOfBar)[i])  
    text(0.5, 0.5+i-1, paste('Status ', i, ': ', round(vectOfBar[i],2), '%', sep=''), adj=0)  
  }  
  title('Calculating Standard Deviation per residue')  
}  
plot.progress4 <- function(...) {  
  vectOfBar <- c(...)*100  
  numOfBar <- length(vectOfBar)  
  plot(c(0,100), c(0,numOfBar), type='n', xlab='', ylab='', yaxt='n', mar=c(3,3,3,3))  
  for(i in 1:numOfBar) {  
    rect(0, 0.1+i-1, vectOfBar[i], 0.9+i-1, col=rainbow(numOfBar)[i])  
    text(0.5, 0.5+i-1, paste('Status ', i, ': ', round(vectOfBar[i],2), '%', sep=''), adj=0) 
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  }  
  title('Calculating N per peptide')  
}  
plot.progress5 <- function(...) {  
  vectOfBar <- c(...)*100  
  numOfBar <- length(vectOfBar)  
  plot(c(0,100), c(0,numOfBar), type='n', xlab='', ylab='', yaxt='n', mar=c(3,3,3,3))  
  for(i in 1:numOfBar) {  
    rect(0, 0.1+i-1, vectOfBar[i], 0.9+i-1, col=rainbow(numOfBar)[i])  
    text(0.5, 0.5+i-1, paste('Status ', i, ': ', round(vectOfBar[i],2), '%', sep=''), adj=0)  
  }  
  title('Assigning N values to main data frame')  
}  
#Read in the data from Dynamx - requires state data.csv and cluster data.csv  
# After reading in data - bottom two lines of code re-arrange that data accoridng to State (eg: 
Wild-type, D76N etc..)  
library(readr)  
main_data_frame <- read.csv("state data.csv", header=TRUE)  
main_data_frame2<- read.csv("cluster data.csv", header=TRUE)  
main_data_frame <- arrange(main_data_frame, State)  
main_data_frame2 <- arrange(main_data_frame2, State)  
#The block of code below creates lots of vectors that are needed later - a list of unique 
peptides and uniqe timepoints, caluclating the  
#relative fractional uptake from the imported data etc... nothing complicated here.  
Sequence <- c(1:Residue_number)  
Unique_peptides <- (as.character(unique(paste(main_data_frame[,2],main_data_frame[,3],sep = 
','))))  
Unique_timepoints <-unique(main_data_frame[,10])  
Number_of_timepoints <- length(unique(main_data_frame[,10]))  
Number_of_states <- length(unique(main_data_frame[,9]))  
Unique_states <- (as.character(unique(main_data_frame[,9])))  
Relative_fractional_uptake <- (main_data_frame$Uptake/main_data_frame$MaxUptake)*100  
RFU_SD<-(main_data_frame$Uptake.SD/main_data_frame$MaxUptake)*100  
All_Peptides<-(paste(main_data_frame[,2],main_data_frame[,3],sep = ','))  
All_Peptides_MDF2 <- (paste(main_data_frame2[,2],main_data_frame2[,3],sep = ','))  
main_data_frame2$Unique_start_and_end <-All_Peptides_MDF2  
#The Nested loop below calculated the number of rows in cluster data that every unique peptide 
appears, separately, for every time point and every state.  
## this is essentially N for each peptide per TP per state (including charge states) because 
the cluster data is almost the raw data  
## when the base loop (for v in 1:..) finishes it bins the data to a vector (n_for_peptides). 
This is a single column with each row corresponding to n at that timepoint at that state for 
each peptides (nrow = n unqiue peptides)  
## outside the base loop ive then column bound this vector to a new empty vector 
(n_for_peptides_timepoints). The second loop up then changes the timepoint and the base loop 
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runs again. This occurs until all the tps for the first state have been run, then that whole 
vector gets binned out to  
## another vector (n_for_peptides_timepoints_and_states) the top loop switches to the next 
state and the base loop runs again. This happens until all the tps for all the states are 
finished.  
## i have made all my nested loops this way - i didn't know how else to do it - but i suspect 
this is why everything goes so slowly... any adivce?  
n_for_peptides_timepoints_and_states<-c()  
n_for_peptides_timepoints<-c()  
n_for_peptdies<-c()  
for (x in 1:(length(Unique_states))) {  
for (w in 1:(length(Unique_timepoints))) {  
for (v in 1:(length(Unique_peptides))) {n_for_peptdies[v] <- sum(All_Peptides_MDF2 == 
Unique_peptides[v] & main_data_frame2$Exposure == Unique_timepoints[w] & main_data_frame2$State 
== Unique_states[x])}  
n_for_peptides_timepoints<-cbind(n_for_peptides_timepoints, n_for_peptdies)}  
n_for_peptides_timepoints_and_states<-cbind(n_for_peptides_timepoints_and_states, 
n_for_peptides_timepoints)  
n_for_peptides_timepoints<-c()}  
## the next block finds the number of unique charge states for each peptide at each tp at each 
state and uses it to find the actual value of n (closest integer) for each peptide  
charge_states<- ddply(main_data_frame2,c("State", "Unique_start_and_end", 
"Exposure"),summarise,charge_states_per_peptide=length(unique(z)))  
n_for_peptides_timepoints_and_states_without_charge_states <- c()  
n_for_peptides_timepoints_and_states_without_charge_states2 <- c()  
n_for_peptides_timepoints_and_states_without_charge_states3 <- c()  
for(K in 1:(length(Unique_states))){  
for(J in 1:(length(Unique_timepoints))){  
for(I in 1:(length(Unique_peptides))){  
for(H in 1: (nrow(charge_states))){  
if (charge_states[H,1] == Unique_states[K] & charge_states[H,2] == Unique_peptides[I] & 
charge_states[H,3] == Unique_timepoints[J]) 
n_for_peptides_timepoints_and_states_without_charge_states[I] = 
(n_for_peptides_timepoints_and_states[I,(J+((K-
1)*(length(Unique_timepoints))))]/charge_states[H,4])}  
  plot.progress4((I/(length(Unique_peptides))), ((J-1)/(length(Unique_timepoints))), ((K-
1)/length(Unique_states)))}  
  for(L in 
((nrow(as.matrix(n_for_peptides_timepoints_and_states_without_charge_states))+1):((length(Uniqu
e_peptides))+1))){  
    n_for_peptides_timepoints_and_states_without_charge_states[L] = NA}  
    
  n_for_peptides_timepoints_and_states_without_charge_states2<- 
cbind(n_for_peptides_timepoints_and_states_without_charge_states2, 
n_for_peptides_timepoints_and_states_without_charge_states)  
  n_for_peptides_timepoints_and_states_without_charge_states<-c()} 
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  n_for_peptides_timepoints_and_states_without_charge_states3<- 
cbind(n_for_peptides_timepoints_and_states_without_charge_states3, 
n_for_peptides_timepoints_and_states_without_charge_states2)  
  n_for_peptides_timepoints_and_states_without_charge_states2<-c()}  
n_for_peptides_timepoints_and_states_without_charge_states3<- 
head(n_for_peptides_timepoints_and_states_without_charge_states3,-1)  
n_for_peptides_timepoints_and_states_without_charge_states3<- 
round(n_for_peptides_timepoints_and_states_without_charge_states3,digits=0)  
main_matrix_frame <-(main_data_frame[,2])  
main_matrix_frame <-cbind(main_matrix_frame, main_data_frame[,3])  
main_matrix_frame <-cbind(main_matrix_frame, main_data_frame[,10])  
main_matrix_frame<- as.matrix(main_matrix_frame)  
main_data_frame_subset_peptides<-main_data_frame[,4]  
main_data_frame_subset_states <-main_data_frame[,9]  
#to save the script running through every single row of each data frame when processing each 
state, i wrote the next block of code to calcuate how many rows there were in the dataframe for 
each state and created start and end points for the script to start and finish dat, based on 
which state it was processing at the time.  
##this alonse makes the script run 3X faster  
main_data_frame_subset_nrow_states <-c()  
main_data_frame_subset_nrow_states2 <-c()  
for(M in 1:(length(Unique_states))){  
main_data_frame_subset_nrow_states<- nrow(subset(main_data_frame,State == (Unique_states[M])))  
main_data_frame_subset_nrow_states2<- rbind(main_data_frame_subset_nrow_states2, 
main_data_frame_subset_nrow_states)}  
startpositions<-c()  
for (N in 1: (length(Unique_states))){startpositions[N]<- nrow(main_data_frame) - 
(sum(main_data_frame_subset_nrow_states2[N:(length(main_data_frame_subset_nrow_states2))]))+1}  
endpositions<-c()  
for (P in 1:(length(Unique_states))){endpositions[P]<- nrow(main_data_frame) - 
((sum(main_data_frame_subset_nrow_states2[P:(length(main_data_frame_subset_nrow_states2))])))+m
ain_data_frame_subset_nrow_states2[P]}  
#This nested loop works as before - but now it calculated n for each residue based on each tp, 
state and the whole peptide list  
 
  
n.total5<-c()  
n.total4<-c()  
n.total3<-c()  
n.total2<-c()  
n.total<-c()  
for (C in 1:(length(Unique_states))){  
for (B in 1:(length(Unique_timepoints))){  
for (A in 1:Residue_number){  
for (z in 1:(length(Unique_peptides))) {  
for (y in (startpositions[C]):(endpositions[C])){ 
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if (Sequence[A] >= (main_matrix_frame[y,1]+1) & Sequence[A] <= main_matrix_frame[y,2] & 
main_matrix_frame[y,3] == Unique_timepoints[B] & main_data_frame_subset_states[y] == 
Unique_states[C] & All_Peptides[y] == Unique_peptides[z]) n.total[z] = 
n_for_peptides_timepoints_and_states_without_charge_states3[z,(B+(C-
1)*(length(Unique_timepoints)))]}}  
n.total2<-sum(n.total, na.rm=TRUE)  
n.total3<-rbind(n.total3,n.total2)  
n.total<-c()  
n.total2<-c()  
plot.progress2((A/Residue_number), ((B-1)/(length(Unique_timepoints))), ((C-
1)/length(Unique_states)))  
Sys.sleep(0.05)}  
n.total4<-cbind(n.total4, n.total3)  
n.total3<-c()}  
n.total5<-cbind(n.total5, n.total4)  
n.total4<-c()}  
#add n for each residue to main dataframe (makes later scripting easier)  
n_main_data_frame<-c()  
for (G in 1:(length(Unique_states))){  
for (F in 1:(length(Unique_peptides))){  
for (E in 1:(length(Unique_timepoints))) {  
for (D in (startpositions[G]):(endpositions[G])) {  
if(All_Peptides[D] == Unique_peptides[F] & main_matrix_frame[D,3] == Unique_timepoints[E] & 
main_data_frame[D,9] == Unique_states[G]) n_main_data_frame[D] = 
n_for_peptides_timepoints_and_states_without_charge_states3[F,(E+((G-
1)*(length(Unique_timepoints))))]}  
  plot.progress5((E/(length(Unique_timepoints))), ((F-1)/(length(Unique_peptides))), ((G-
1)/length(Unique_states)))  
  Sys.sleep(0.05)  }}}  
main_data_frame$n<-n_main_data_frame  
#calculate mean RFU for each residue  
uptake.total<-c()  
data.out<-c()  
Timepoints.out <- c()  
alldata.out<-c()  
for (q in 1:Number_of_states){  
  for (p in 1:Number_of_timepoints){  
    for (m in 1:Residue_number){  
      for (n in (startpositions[q]):(endpositions[q])){ if (Sequence[m] >= 
(main_matrix_frame[n,1]+1) & Sequence[m] <= main_matrix_frame[n,2] & main_matrix_frame[n,3] == 
Unique_timepoints[p] & main_data_frame[n,9] == Unique_states[q]) uptake.total[n] = 
(Relative_fractional_uptake[n]*main_data_frame[n,17])}  
      subset<- sum(uptake.total, na.rm=TRUE)/(n.total5[m,(p+((q-
1)*(length(Unique_timepoints))))])  
      data.out<-rbind(data.out,subset)  
      uptake.total<-c() 
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      plot.progress((m/Residue_number), ((p-1)/Number_of_timepoints), ((q-1)/Number_of_states))  
      Sys.sleep(0.05)}  
    Timepoints.out<-cbind(Timepoints.out,data.out)  
    data.out<-c()}  
  alldata.out<-cbind(alldata.out,Timepoints.out)  
  Timepoints.out<-c()}  
#Calculate SD for every residue  
stdev.total<-c()  
data.out2<-c()  
Timepoints.out2 <- c()  
alldata.out2<-c()  
for (u in 1:Number_of_states){  
  for (t in 1:Number_of_timepoints){  
    for (s in 1:Residue_number){  
      for (r in (startpositions[u]):(endpositions[u])){ if (Sequence[s] >= 
(main_matrix_frame[r,1]+1) & Sequence[s] <= main_matrix_frame[r,2] & main_matrix_frame[r,3] == 
Unique_timepoints[t] & main_data_frame[r,9] == Unique_states[u]) stdev.total[r] = 
main_data_frame[r,17]*((RFU_SD[r]^2)+((Relative_fractional_uptake[r]-alldata.out[s,(t+(u-
1)*(length(Unique_timepoints)))])^2))}  
      subset2<- sqrt(sum(stdev.total, na.rm=TRUE)/(n.total5[s,(t+((u-
1)*(length(Unique_timepoints))))]))  
      data.out2<-rbind(data.out2,subset2)  
      stdev.total<-c()  
      plot.progress3((s/Residue_number), ((t-1)/Number_of_timepoints), ((u-
1)/Number_of_states))  
      Sys.sleep(0.05)}  
    Timepoints.out2<-cbind(Timepoints.out2,data.out2)  
    data.out2<-c()}  
  alldata.out2<-cbind(alldata.out2,Timepoints.out2)  
  Timepoints.out2<-c()}  
#p values iterate by: 1 vs 2, 1 vs 3, 1vs 4 etc... then 2vs3, 2vs4 etc...  
all_p_values4<-c()  
all_p_values3<-c()  
all_p_values2 <-c()  
all_p_values<-c()  
for (T in 0:(((length(Unique_states)))-2)){  
  for (S in (T+1):(((length(Unique_states)))-1)){  
    for (R in 1:(length(Unique_timepoints))){  
      for (Q in 1:Residue_number){  
        all_p_values[Q] <-
(tsum.test(alldata.out[Q,(R+((length(Unique_timepoints))*T))],alldata.out2[Q,(R+((length(Unique
_timepoints))*T))], 
n.total5[Q,(R+((length(Unique_timepoints))*T))],alldata.out[Q,(R+((length(Unique_timepoints))*S
))],alldata.out2[Q,(R+((length(Unique_timepoints))*S))], 
n.total5[Q,((R+(length(Unique_timepoints))*S))],alternative="two.sided", mu=0, 
var.equal=FALSE,conf.level = (1-(desired_p_value))))$p.value} 
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8.2 Related information for Chapter 5 
 
 
Figure 8.2 XIC of peptide 79-87.  Sequence: ACRVNHVTL. Unmodified = black. Modified (+16 Da) = 
red. Modified residues are annotated above each peak in the XIC. 
 
      all_p_values2<-cbind(all_p_values2,all_p_values)  
      all_p_values<-c()}  
    all_p_values3<-cbind(all_p_values3,all_p_values2)  
    all_p_values2<-c()}  
  all_p_values4<-cbind(all_p_values4, all_p_values3)  
  all_p_values3<-c()  
}  
#Difference plot calculations  
difference_plot3<-c()  
difference_plot2<-c()  
difference_plot<-c()  
for(V in 1:((length(Unique_states))-1)){  
for(U in 1:(length(Unique_timepoints))){  
difference_plot<- alldata.out[,(U+(V*(length(Unique_timepoints))))]-alldata.out[,U]  
difference_plot2<-cbind(difference_plot2,difference_plot)  
difference_plot<-c()}  
  difference_plot3<-cbind(difference_plot3,difference_plot2)  
  difference_plot2<-c()}  
write.csv(alldata.out, "RFU.csv")  
write.csv(alldata.out2, "SD.csv")  
write.csv(all_p_values4, "p values.csv")  
write.csv(difference_plot3, "differenceplot.csv") 
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Figure 8.3 XIC of peptide 88-95. Sequence: SQPKIVKW. Unmodified = black. Modified (+16 Da) = 
red. Modified residues are annotated above each peak in the XIC.
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Table 8.5 Quantification and assignment data for FPOP of wild-type, D76N and ΔN6 β2m. 
 Unmodified Modified 
Peptide m/z Δmass 
(Da) 
m/z ΔRT (± S.D) 
(min) 
Wild-type 
(% Modified ± S.D) 
D76N 
(% Modified ± S.D) 
ΔN6  
(% Modified ±S.D) 
Assignment Assignment Criteria 
MIQRTPKIQVY (0-10 688.89 (2+) 
459.59 (3+) 
+16 696.88 (2+) 
464.93 (3+) 
-1.48 ± 0.04 96.48 ± 1.81 95.99 ± 0.75 N/A Met 0 MS/MS 
SRHPAENGKSNFLNCY 
(11-26) 
947.43 (2+) 
631.96 (3+) 
474.22 (4+) 
+16 478.21 (4+) +2.67 ± 0.08 1.41 ± 0.29 1.23 ± 0.22 1.89 ± 0.45 His 13 MS/MS 
  +16 478.21 (4+) 
637.28 (3+) 
+0.65 ± 0.04 0.23 ± 0.04 0.19 ± 0.08 0.23 ± 0.02 Phe 22 MS/MS 
  +16 478.21 (4+) 
637.28 (3+) 
+0.24 ± 0.07 0.21 ± 0.04 0.16 ± 0.05 0.18 ±0.05 Tyr 26 MS/MS 
  +16 478.21 (4+) 
637.28 (3+) 
-0.064 ± 0.04 0.51 ± 0.04 0.43 ± 0.01 0.56 ± 0.04 Lys 19 MS/MS 
  +16 478.21 (4+) 
637.28 (3+) 
-1.06 ± 0.06 0.47 ± 0.08 0.53 ± 0.07 0.66 ± 0.05 Tyr 26 MS/MS 
  +16 478.21 (4+) 
637.28 (3+) 
-2.46 ± 0.07 0.18 ± 0.00 0.16 ± 0.04 0.24 ± 0.04 Phe 22 MS/MS 
  +16 478.21 (4+) 
637.28 (3+) 
-3.27 ± 0.06 0.21 ± 0.02 0.25 ± 0.09 0.52 ± 0.14 Phe 22 MS/MS 
VSGFHPSDIEVDLL 
(27-40) 
764.38 (2+) + 16 772.38 (2+) +6.55 ± 0.26  0.39 ± 0.04 0.31 ± 0.10 0.26 ± 0.02 His 31 MS/MS 
  +16 772.38 (2+) -1.98 ± 0.18 0.15 ± 0.02 0.13 ± 0.04 0.20 ± 0.01 Phe 30 MS/MS 
  +16 772.38 (2+) -3.26 ± 0.28 0.20 ± 0.02 0.19 ± 0.09 0.28 ± 0.00 Phe 30 1. MS/MS narrows modification site to 
GFH 
2. Phe is >405X more reactive than Gly 
3. Although His and Phe have similar 
reactivities – His on this peptide was 
already assigned and has only ever 
observed here as one +16 Da peak 
4. All other +16 Da His modifications 
identified have retention times longer 
than the unmodified peak 
  +16 772.38 (2+) -4.20 ± 0.29 0.07 ± 0.01 0.06 ± 0.03 0.34 ± 0.03 Phe 30 MS/MS 
  +16 772.38 (2+) -5.06 ± 0.46 0.05 ± 0.01 0.03 ± 0.02 Not detected Ile 35 MS/MS 
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  +16 772.38 (2+) -6.14 ± 0.32 0.13 ± 0.01 0.10 ± 0.06 0.06 ± 0.02 Val 27 MS/MS 
KNGERIEKVEHSDL 
(41-54) 
827.43 (2+) 
551.96 (3+) 
414.22 (4) 
+16 557.29 (3+) +1.86 ± 0.05 0.96 ± 0.62 0.81 ± 0.33 2.27 ± 0.23 His 51 MS/MS 
  +16 557.29 (3+) - 0.06 ± 0.04 0.19 ± 0.05 0.19 ± 0.03 0.17 ± 0.11 Lys 48 MS/MS 
SFSKDWSFY 
(55-63) 
583.76 (2+) +16 591.76 (2+) -2.74 ± 0.05 4.32 ± 0.95 6.29 ± 2.49 13.58 ± 2.63 Trp 60 MS/MS 
  +16 591.76 (2+) -3.58 ± 0.15 5.51 ± 1.02 8.86 ± 3.05 16.93 ± 3.05 Trp 60 MS/MS 
  +16 591.76 (2+) -4.08 ± 0.11 29.31 ± 2.63 28.83 ± 2.30 8.65 ± 1.29 Trp 60 MS/MS 
  +16 591.76 (2+) -6.61 ± 0.07 5.57 ± 2.83 2.08 ± 0.65 3.36 ± 2.01 Trp 60 MS/MS 
  +16 591.76 (2+) -7.02 ± 0.06 5.90 ± 0.32 4.33 ± 0.15 10.82 ± 0.09 Trp 60 MS/MS 
  +32 599.75 (2+) -2.99 ± 0.05 29.65 ± 2.04 29.44 ± 7.54 18.71 ± 6.23 Trp 60 MS/MS 
  +32 599.75 (2+) -6.20 ± 0.05 7.03 ± 1.48 6.44 ± 0.44 7.48 ± 1.85 Trp 60 MS/MS 
  +32 599.75 (2+) -7.77 ± 0.08 6.20 ± 0.75 7.14 ± 0.07 8.58 ± 2.92 Trp 60 MS/MS 
  +32 599.75 (2+) -9.21 ± 0.09 4.16 ± 0.64 4.09 ± 0.32 3.55 ± 0.91 Trp 60 1. MS/MS identifies modification site to WSFY 
2. Trp is the most reactive residue on the peptide 
3. All 8 other modified peaks in the XIC were Trp 60 
YTEFTPTEKDEY 
(67-78) 
761.83 (2+) +16 769.82 (2+) -0.26 ± 0.04 0.35 ± 0.01 0.31 ± 0.02 0.30 ± 0.07 Tyr 67 1. MS/MS narrows modification site to 
YTE 
2. Tyr is >25X more reactive than Thr and 
> 56X more reactive than Glu 
  +16 769.82 (2+) -0.74 ± 0.04 0.78 ± 0.13 1.04 ± 0.08 0.94 ± 0.02 Tyr 78 MS/MS 
  +16 769.82 (2+) -1.16 ± 0.04 0.06 ± 0.01 0.06 ± 0.02 0.06 ± 0.01 Tyr 67 1. MS/MS narrows modification site to YT 
2. Tyr is 25X more reactive than Thr 
  +16 769.82 (2+) -1.34 ± 0.05 0.09 ± 0.01 0.14 ± 0.01 0.08 ± 0.01 Tyr 78 1. MS/MS narrows modification site to 
KDEY 
2. Tyr is >34X more reactive than Lys, 56X 
more reactive than Glu and >173X more 
reactive than Asp 
 
  +16 769.82 (2+) -2.65 ± 0.06 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 Phe 70 MS/MS 
  +16 769.82 (2+) -3.17 ± 0.06 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 Phe 70 MS/MS 
  +16 769.82 (2+) -3.36 ± 0.07 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 Phe 70 MS/MS 
ACRVNHVTL 
(79-87) 
535.28 (2+) 
357.19 (3+) 
+16 362.52 (3+) +4.37 ± 0.07 0.12 ± 0.03 0.13 ± 0.01 0.45 ± 0.07 His 84 MS/MS 
SQPKIVKW 
(88-95) 
493.29 (2+) +16 501.29 (2+) -0.07 ± 0.07 0.18 ± 0.01 0.19 ± 0.01 0.21 ± 0.01 Lys 94 MS/MS 
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  +16 501.29 (2+) -0.44 ± 0.12 0.39 ± 0.01 0.37 ± 0.04 0.32 ± 0.03 Unassigned 1. MS/MS narrows modification to Pro 90 
or Lys 91 
2. Both have similar reactivities (approx. 2 
fold difference) 
3. Pro can have >1 structural isomer 
  +16 501.29 (2+) -0.79 ± 0.11 0.35 ± 0.03 0.31 ± 0.02 0.32 ± 0.01 Unassigned 1. MS/MS narrows modification to Pro 90 
or Lys 91 
2. Both have similar reactivities (approx. 2 
fold difference) 
3. Pro can have >1 structural isomer 
  +16 501.29 (2+) -2.54 ± 0.14 0.35 ± 0.01 0.40 ± 0.04 0.35 ± 0.11 Trp 95 MS/MS 
  +16 501.29 (2+) -2.94 ± 0.14 0.43 ± 0.07 0.44 ± 0.12 0.39 ± 0.08 Trp 95 MS/MS 
  +16 501.29 (2+) -3.46 ± 0.14 0.17 ± 0.07 0.25 ± 0.05 0.36 ± 0.02 Trp 95 MS/MS 
  +16 501.29 (2+) -4.73 ± 0.13 0.15 ± 0.08 0.15 ± 0.03 0.16 ± 0.04 Trp 95 MS/MS 
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8.3 Related information for Chapter 6 
 
Figure 8.4 XIC of peptide 53-67 from the heavy chain of STT.  Sequence: PIFGTTNLAQNFQGR. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC. 
 
 
Figure 8.5 XIC of peptide 53-67 from the heavy chain of WFL. Sequence: PIFGLTNLAQNFQGR. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC. 
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Figure 8.6 XIC of peptide 68-87 from the heavy chain.Sequence: VTITADESTSTVYMELSSLR. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC. 
 
 
Figure 8.7 XIC of peptide 117-132 from the heavy chain.Sequence: VWGQGTMVTVSSASTK. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC. 
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Figure 8.8 XIC of peptide 133-144 from the heavy chain. Sequence: GPSVFPLAPSSK. Unmodified = 
black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the XIC. 
 
 
Figure 8.9 XIC of peptide 145-158 from the heavy chain. Sequence: STSGGTAALGCLVK. 
Unmodified = black. Modified (+16 Da) = red. Modified (+32 Da) purple. Modified residues are 
annotated above each peak in the XIC. 
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Figure 8.10 XIC of peptide 286-289 from the heavy chain. Sequence: FNWYVDGVEVHNAK. 
Unmodified = black. Modified (+16 Da) = red. Modified (+32 Da) = purple. Modified residues are 
annotated above each peak in the XIC.  
 
 
Figure 8.11 XIC of peptide 313-328 from the heavy chain.Sequence: VVSVLTVLHQDWLNGK. 
Unmodified = black. Modified (+16 Da) = red. Modified (+32 Da) = purple. Modified residues are 
annotated above each peak in the XIC.  
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Figure 8.12 XIC of peptide 367-381 from the heavy chain.  Sequence: EEMTKNQVSLTCLVK. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC.  
 
 
Figure 8.13 XIC of peptide 372-381 from the heavy chain.  Sequence: NQVSLTCLVK. Unmodified = 
black. Modified (+16 Da) = red. Modified (+32 Da = purple). Modified residues are annotated above 
each peak in the XIC. 
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Figure 8.14 XIC of peptide 404-420 from the heavy chain. Sequence: TTPPVLDSDGSFFLYSK. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC. 
 
 
Figure 8.15 XIC of peptide 428-450 from the heavy chain.Sequence: 
WQQGNVFSCSVMHEALHNHYTQK. Unmodified = black. Modified (+16 Da) = red. Modified 
residues are annotated above each peak in the XIC. 
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Figure 8.16 XIC of peptide 18-46 from the light chain. Sequence: 
VTISCSGSSSDIGNNYVSWYQQLPGTAPK. Unmodified = black. Modified (+16 Da) = red. Modified 
(+32 Da) = purple. Modified residues are annotated above each peak in the XIC. 
 
 
Figure 8.17 XIC of peptide 68-106 from the light chain. Sequence: 
SGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTK. Unmodified = black. Modified (+16 Da) 
= red. Modified residues are annotated above each peak in the XIC. 
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Figure 8.18 XIC for peptide 107-114 from the light chain. Sequence: LTVLGQPK. Unmodified = black. 
Modified (+16 Da) = red. Modified residues are annotated above each peak in the XIC. 
 
 
Figure 8.19 XIC for peptide 154-170 from the light chain. Sequence: ADSSPVKAGVETTTPSK. 
Unmodified = black. Modified (+16 Da) = red. Modified residues are annotated above each peak in the 
XIC. 
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Figure 8.20 XIC for peptide 176-190 from the light chain. Sequence: YAASSYLSLTPEQWK. 
Unmodified = black. Modified (+16 Da) = red. Modified (+32 Da) = purple. Modified residues are 
annotated above each peak in the XIC. 
 
 
Figure 8.21 XIC for peptide 194-208 from the light chain. Sequence: SYSCQVTHEGSTVEK. 
Unmodified = black. Modified (+16 Da) = red. Modified (+32 Da) = purple. Modified residues are 
annotated above each peak in the XIC.
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Table 8.6 Raw data table for WFL and STT FPOP data.
 Peptide m/z Δmass 
(Da) 
m/z ΔRT (± 
S.D) (min) 
MEDI1912_STT 
(% Modified ± S.D) 
MEDI1912_WFL 
(% Modified ± S.D) 
Assignment 
ASGGTFSTGAFTWVR (24-38) (Heavy chain) 772.88 (2+) +16 780.88 (2+) -7.47 ± 0.12 0.04 ± 0.00  Phe 34 
  +16 780.88 (2+) -6.07 ± 0.17 0.35 ± 0.16  Trp 36 
  +16 780.88 (2+) -5.3 ± 0.18 0.03 ± 0.01  Phe 34 
  +16 780.88 (2+) -4.97 ± 0.15 0.43 ± 0.06  Trp 36 
  +16 780.88 (2+) -2.34 ± 0.15 0.26 ± 0.04  Trp 36 
  +16 780.88 (2+) -1.89 ± 0.16 0.04 ± 0.03  Phe 34 
  +16 780.88 (2+) -1.52 ± 0.17 0.13 ± 0.03  Phe 29 
  +32 788.87 (2+) -8.32 ± 0.13 0.06 ± 0.01  Trp 36 
  +32 788.87 (2+) -3.55 ± 0.16 0.13 ± 0.03  Trp 36 
ASGGTFWFGAFTWVR (24-38) (Heavy chain) 845.41 (2+) +16 853.41 (2+) -6.83 ± 0.02  1.05 ± 0.16 Trp 30 
  +16 853.41 (2+) -6.22 ± 0.02  1.13 ± 0.24 Phe 31 
  +16 853.41 (2+) -5.19 ± 0.02  5.42 ± 1.16 Trp 36 
  +16 853.41 (2+) -4.84 ± 0.03  0.70 ± 0.13 Phe 31 
  +16 853.41 (2+) -3.79 ± 0.03  18.52 ± 1.34 Trp 30 
  +16 853.41 (2+) -3.40 ± 0.03  14.46 ± 5.81 Trp 30 
  +16 853.41 (2+) -1.91 ± 0.03  1.22 ± 0.17 Trp 36 
  +16 853.41 (2+) -1.56 ± 0.02  0.92 ± 0.15 Phe 31 
  +32 861.41 (2+) -7.50 ± 0.04  1.08 ± 0.32 Trp 30 
  +32 861.41 (2+) -7.24 ± 0.03  0.86 ± 0.11 Trp 30 
  +32 861.41 (2+) -6.13 ± 0.02  0.83 ± 0.20 Trp 36 
  +32 861.41 (2+) -4.29 ± 0.01  4.61 ± 0.86 Trp 30 
PIFGTTNLAQNFQGR (53-67) (Heavy chain) 832.43 (2+) +16 840.43 (2+) -6.80 ± 0.03 1.7 ± 0.26  Phe 55 
  +16 840.43 (2+) -1.7 ± 0.07 1.47 ± 0.28  Phe 55 
PIFGLTNLAQNFQGR (53-67) (Heavy chain) 838.45 (2+) +16 846.45 (2+) -1.48 ± 0.02  1.56 ± 0.16 Phe 55 
VTITADESTSTVYMELSSLR (68-87) (Heavy chain) 1102.05 (2+) 
735.04 (3+) 
+16 1110.04 (2+) 
740.36 (3+) 
-1.91 ± 0.02 54.36 ± 7.53 66.23 ± 15.79 Met 81 
VWGQGTMVTVSSASTK (117-132) (Heavy chain) 819.92 (2+) +16 827.91 (2+) -6.68 ± 0.04 100 ± 0.00 100.0 ± 0.00 Met 123 
GPSVFPLAPSSK (133-144) (Heavy chain) 593.83 (2+) +16 601.83 (2+) -9.34 ± 0.15 0.97 ± 0.04 0.84 ± 0.07 Phe 137 
   601.83 (2+) -7.20 ± 0.16 0.02 ± 0.00 0.00 ± 0.00 Pro 138 
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   601.83 (2+) -6.58 ± 0.17 0.27 ± 0.10 0.38 ± 0.02 Phe 137 
   601.83 (2+) -4.55 ± 0.09 0.05 ± 0.01 0.01 ± 0.00 Val 136 
   601.83 (2+) -3.61 ± 0.19 0.22 ± 0.08 0.20 ± 0.04 Phe 137 
   601.83 (2+) -2.23 ± 0.09 0.00 ± 0.00 0.00 ± 0.00 Pro 138 
   601.83 (2+) -0.80 ± 0.09 0.05 ± 0.01 0.06 ± 0.00 Pro 134 
STSGGTAALGCLVK (145-158) (Heavy chain) 661.35 (2+) +16 669.34 (2+) -9.63 ± 0.51 0.01 ± 0.00 0.00 ± 0.00 Leu 153 
  +16 669.34 (2+) -0.16 ± 0.09 0.06 ± 0.00 0.07 ± 0.01 Ser 147 
  +32 677.34 (2+) 0.63 ± 0.12 0.16 ± 0.04 0.16 ± 0.04 Cys 155 
FNWYVDGVEVHNAK (286-299) (Heavy chain) 839.41 (2+) 
559.94 (3+) 
+16 847.41 (2+) 
565.27 (3+) 
-8.60 ± 0.09 0.50 ± 0.11 0.36 ± 0.03 286 – FNW - 288 
  +16 847.41 (2+) 
565.27 (3+) 
-4.75 ± 0.06 0.48 ± 0.06 0.25 ± 0.02 286 – FNW - 288 
  +16 847.41 (2+) 
565.27 (3+) 
-3.81 ± 0.06 0.71 ± 0.13 0.43 ± 0.05 286 – FNW - 288 
  +16 847.41 (2+) 
565.27 (3+) 
-2.99 ± 0.08 0.07 ± 0.02 0.05 ± 0.01 286 – FNW - 288 
  +16 847.41 (2+) 4.23 ± 0.09 0.14 ± 0.04 0.19 ± 0.05 His 296 
  +32 855.40 (2+) 4.81 ± 0.08 0.16 ± 0.03 0.08 ± 0.02 His 296 
VVSVLTVLHQDWLNGK (313-328) (Heavy chain) 904.51 (2+) 
603.34 (3+) 
+16 912.51 (2+) 
608.68 (3+) 
-7.68 ± 0.09 0.08 ± 0.01 0.14 ± 0.06 Trp 324 
  +16 912.51 (2+) 
608.68 (3+) 
-5.02 ± 0.07 0.97 ± 0.16 1.26 ± 0.14 Trp 324 
  +16 912.51 (2+) 
608.68 (3+) 
-4.35 ± 0.07 0.51 ± 0.02 0.76 ± 0.05 Trp 324 
  +16 912.51 (2+) 
608.68 (3+) 
-3.22 ± 0.07 0.23 ± 0.11 0.31 ± 0.04 Trp 324 
  +16 912.51 (2+) 7.01 ± 0.09 0.05 ± 0.03 0.15 ± 0.04 His 321 
  +32 920.51 (2+) 
614.00 (3+) 
-6.01 ± 0.55 0.02 ± 0.01 0.00 ± 0.00 Trp 324 
EEMTKNQVSLTCLVK (367-381) (Heavy chain) 593.97 (3+) +16 599.31 (3+) -2.09 ± 0.55 86.65 ± 0.98 90.66 ± 3.90 Met 369 
NQVSLTCLVK (372-381) (Heavy chain) 581.32 (2+) +16 589.32 (2+) -0.65 ± 0.11 0.01 ± 0.00 0.02 ± 0.01 372 – NQ - 373 
  +32 597.31 (2+) 1.91 ± 0.13 0.13 ± 0.04 0.12 ± 0.03 Cys 378 
TTPPVLDSDGSFFLYSK (404-420) (Heavy chain) 937.47 (2+) +16 945.46 (2+) -6.33 ± 0.09 0.08 ± 0.01 0.07 ± 0.01 Leu 409 
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625.32 (3+) 
  +16 945.46 (2+) -5.58 ± 0.09 0.11 ± 0.01 0.08 ± 0.01 404 – TTPPVLDS - 411 
  +16 945.46 (2+) -5.25 ± 0.08 0.46 ± 0.01 0.48 ± 0.02 Phe 415 
  +16 945.46 (2+) -4.05 ± 0.08 0.17 ± 0.01 0.28 ± 0.05 413 – GSF - 415 
  +16 945.46 (2+) -1.42 ± 0.07 0.08 ± 0.00 0.06 ± 0.01 404 – TTPPVLDS - 411 
  +16 945.46 (2+) -1.12 ± 0.08 0.31 ± 0.02 0.32 ± 0.02 404 – TTPPVLDS - 411 
  +16 945.46 (2+) -0.48 ± 0.06 0.04 ± 0.01 0.06 ± 0.02 404 – TTPPVLDS - 411 
  +16 945.46 (2+) -0.25 ± 0.05 0.32 ± 0.05 0.35 ± 0.06 404 – TTPPVLDS - 411 
  +16 945.46 (2+) 1.36 ± 0.09 0.10 ± 0.01 0.12 ± 0.01 404 – TTPPVLDS - 411 
WQQGNVFSCSVMHEALHNHYTQK (428-450) (Heavy chain) 701.08 (4+) +16 705.07 (4+) -7.28 ± 0.11 60.62 ± 6.54 67.85 ± 4.60 428 – WQQGNVFSCSVM - 439 
   705.07 (4+) -7.02 ± 0.11 37.79 ± 6.01 31.34 ± 4.20 428 – WQQGNVFSCSVM - 439 
VTISCSGSSSDIGNNYVSWYQQLPGTAPK (18-46) (Light chain) 1558.74 (2+) 
1039.50 (3+) 
779.88 (4+) 
+16 1044.83 (3+) -5.82 ± 0.08 0.23 ± 0.09 0.20 ± 0.03 Trp 36 
  +16 1044.83 (3+) -5.14 ± 0.09 0.15 ± 0.05 0.17 ± 0.05 Trp 36 
  +16 1044.83 (3+) -4.96 ± 0.09 0.22 ± 0.01 0.33 ± 0.05 Trp 36 
  +16 1044.83 (3+) -3.39 ± 0.10 0.06 ± 0.02 0.06 ± 0.01 18 – VTISCSGSSSDIGNNYV - 34 
  +16 1044.83 (3+) -2.53 ± 0.09 0.30 ± 0.12 0.20 ± 0.02 Trp 36 
  +16 1044.83 (3+) -2.04 ± 0.08 0.03 ± 0.01 0.02 ± 0.00 40 – LPGTA – 44 
  +16 1044.83 (3+) -1.58 ± 0.09 0.66 ± 0.09 0.94 ± 0.05 Tyr 33 
  +32 1050.17 (3+) -7.16 ± 0.09 0.02 ± 0.01 0.02 ± 0.01 Trp 36 
  +32 1050.17 (3+) -6.00 ± 0.11 0.05 ± 0.01 0.04 ± 0.00 Trp 36 
  +32 1050.17 (3+) -3.13 ± 0.09 0.05 ± 0.02 0.05 ± 0.01 Trp 36 
SGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTK (68-106) (Light 
chain) 
1339.62 (3+) 
1004.96 (4+) 
+16 1344.95 (3+) 
1008.96 (4+) 
-3.49 ± 0.04 1.26 ± 0.33 1.00 ± 0.17 87 – TGLQTGDEADYYCGTWD - 
93 
  +16 1344.95 (3+) 
1008.96 (4+) 
-2.96 ± 0.06 0.33 ± 0.22 0.25 ± 0.08 87 – TGLQTGDEADYYCGTW - 
92 
  +16 1344.95 (3+) 
1008.96 (4+) 
-2.63 ± 0.05 0.44 ± 0.04 0.63 ± 0.11 87 – TGLQTGDEADYYCGTWDS 
- 94 
  +16 1344.95 (3+) 
1008.96 (4+) 
-1.88 ± 0.07 0.66 ± 0.11 0.89 ± 0.07 91 – TGDEADYYCGTW - 92 
LTVLGQPK (107-114) (Light chain) 428.27 (2+) +16 436.27 (2+) -9.53 ± 0.18 0.04 ± 0.00 0.04 ± 0.01 Leu 110 
   436.27 (2+) -1.88 ± 0.09 0.04 ± 0.00 0.04 ± 0.00 114 – PK - 115 
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   436.27 (2+) -0.55 ± 0.29 0.11 ± 0.02 0.02 ± 0.01 114 – PK - 115 
ATLVCLISDFYPGAVTVAWK (134-153) (Light chain) 1106.09 (2+) 
737.73 (3+) 
+16 1114.08 (2+) 
743.06 (3+) 
-5.06 ± 0.03 3.86 ± 1.24 0.27 ± 0.06 Trp 152 
  +16 1114.08 (2+) 
743.06 (3+) 
-2.20 ± 0.06 3.92 ± 1.11 0.79 ± 0.30 Trp 152 
  +16 1114.08 (2+) 
743.06 (3+) 
-1.80 ± 0.05 0.39 ± 0.16 0.21 ± 0.05 Trp 152 
  +16 1114.08 (2+) 
743.06 (3+) 
-1.47 ± 0.05 0.87 ± 0.08 0.18 ± 0.05 Trp 152 
  +32 1122.08 (2+) 
748.39 (3+) 
-0.87 ± 0.08 0.32 ± 0.20 0.36 ± 0.29 Trp 152 
ADSSPVKAGVETTTPSK (154-170) (Light chain) 837.94 (2+) 
558.96 (3+) 
+16 845.94 (2+) 
564.29 (3+) 
-3.59 ± 0.09 0.03 ± 0.01 0.03 ± 0.00 154 – ADSSP - 158 
  +16 845.94 (2+) 
564.29 (3+) 
-0.14 ± 0.07 0.20 ± 0.04 0.15 ± 0.01 Lys 160 
YAASSYLSLTPEQWK (176-190) (Light chain) 872.44 (2+) 
581.96 (3+) 
+16 800.43 (2+) -7.07 ± 0.20 0.11 ± 0.08 0.13 ± 0.02 Trp 189 
  +16 800.43 (2+) -6.27 ± 0.14 0.04 ± 0.01 0.02 ± 0.00 186 – PEQWK - 190 
  +16 800.43 (2+) -5.79 ± 0.16 0.03 ± 0.01 0.02 ± 0.01 Leu 184 
  +16 800.43 (2+) -5.30 ± 0.15 0.04 ± 0.02 0.00 ± 0.00 186 – PEQWK - 190 
  +16 800.43 (2+) -4.61 ± 0.17 0.36 ± 0.08 0.23 ± 0.02 Trp 189 
  +16 800.43 (2+) -3.58 ± 0.19 0.21 ± 0.12 0.23 ± 0.14 Trp 189 
  +16 800.43 (2+) -3.23 ± 0.16 0.31 ± 0.24 0.24 ± 0.03 Trp 189 
  +16 800.43 (2+) -1.87 ± 0.16 0.02 ± 0.02 0.03 ± 0.01 186 – PE - 187 
  +16 800.43 (2+) -0.61 ± 0.15 0.05 ± 0.02 0.09 ± 0.06 Tyr 176 
  +32 888.43 (2+) -6.43 ± 2.72 0.04 ± 0.01 0.04 ± 0.01 Trp 189 
  +32 888.43 (2+) -2.33 ± 0.17 0.07 ± 0.01 0.10 ± 0.01 Trp 189 
SYSCQVTHEGSTVEK (194-208) 856.38 (2+) 
571.26 (3+) 
+16 576.59 (3+) -3.40 ± 0.16 0.01 ± 0.00 0.01 ± 0.00 194 – SYSCQ - 198 
  +16 576.59 (3+) -2.94 ± 0.15 0.01 ± 0.01 0.01 ± 0.01 203 - GSTVEK - 208 
  +16 576.59 (3+) -2.18 ± 0.06 0.00 ± 0.00 0.00 ± 0.00 194 – SYSCQ - 198 
  +16 576.59 (3+) -0.58 ± 0.08 0.01 ± 0.01 0.02 ± 0.00 194 – SYSCQ - 198 
  +16 864.38 (2+) 3.90 ± 0.13 0.01 ± 0.01 0.03 ± 0.01 His 201 
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576.59 (3+) 
  +32 872.38 (2+) 
581.92 (3+) 
-0.38 ± 0.08 0.11 ± 0.02 0.12 ± 0.04 Cys 197 
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